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Abstract
Glycosylation is a very common post-translational modification and the glycans can
be attached to oxygen (O-linked), nitrogen (N-linked) or carbon (C-linked). N-linked
glycosylation has implications for protein folding and is also essential in viral infectiv-
ity and cell-cell signalling. Endo-α-1,2-mannosidase from family GH99 is a unique en-
zyme within the N-glycosylation pathway as it is the only one which does not cleave
the terminal sugar from the reducing end of the glycan, but instead releases an α-
Glc-1,3-Man disaccharide, with overall retention of stereochemistry at the anomeric
carbon. Previously it was proposed that GH99 endo-acting mannosidases and man-
nanases proceed through a neighbouring group participation mechanism with a 1,2-
anhydrosugar as a reaction intermediate. This Thesis contains evidence supporting
this hypothesis. Chapter 2 presents structures of the bacterial GH99 with its substrate,
with mimics of the reaction intermediate and with the products of the reaction. Ki-
netic and structural data on various intermediate mimics show that the compound
whose structure is the closest to the intermediate is turned over by the enzyme. In
Chapter 3, analysis of different designs of GH99 inhibitors and their conformation
on-enzyme is presented. Chapter 4 presents purification and solution of the crystal
structure of the catalytic domain of the human endomannosidase (MANEA). Multi-
ple crystal forms were obtained, which made it possible to look at the conformation of
a feature present in the eukaryotic but not bacterial GH99: a loop spanning residues
191–201. This loop was disordered when no ligand was present in the  – 2/– 1 sites,
and ordered when these sites were occupied. Chapter 5 explores attempts at pro-
ducing MANEAL, a paralog of MANEA which is found in bony vertebrates. The
Thesis concludes with an analysis of the phylogeny of endomannosidase genes and
perspectives for future research: studies of endomannosidase in mammalian model
organisms are needed to understand its significance.
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Chapter 1
Introduction
1.1 Why are sugars and glycans interesting? Carbohy-
drates, their roles and diversity
Carbohydrates are a ubiquitous group of biomolecules, found in all of the known
life forms. They share this status with nucleic acids, proteins and lipids1 (nucleic
acids themselves incorporate carbohydrates, ribose or deoxyribose, as a part of their
backbone structure). The specific roles of carbohydrates are too numerous to quote
here, but four general categories have been proposed2 and are depicted in Figure 1.1.
Below I will list the categories and explain them briefly. The field of science that is
concerned with biological roles of sugars is glycobiology. The rate of progress in the
field of glycobiology means that new roles are discovered frequently, but they are
likely to belong these broad categories. The detailed definition of a carbohydrate will
be presented in Section 1.2. For the purpose of this Section, a working definition of
“organic compounds with a formula CnH2nOn and the oligo- and polymers of these
compounds” will suffice.
• Structural and modulatory roles – these encompass functions relating to the
physical structure of a life form and the consequences of this structure, such as
its resistance to shear stress, viscosity, diffusion, protection from degradation by
enzymes, acquisition and storage of nutrients, promotion of protein folding,3
developmental gradient generation,4 histone modifications and others.
• Interspecies recognition roles – glycans in a host organism might be recognized
by other organisms. A host can in turn protect itself by taking advantage of the
1
Structural and
modulatory roles
Recognition roles
Interspecies Intraspecies
Host mimicry
Biological roles of carbohydrates
Figure 1.1: Biological roles of carbohydrates – a diagram.
information about its parasite and producing carbohydrate-based “decoys” (for
example, the surface of erythrocytes, which do not have the machinery to repli-
cate viruses).5,6 Milk oligosaccharides are another example of host-protective
carbohydrates.7 Glycans can also be recognized as antigens.8
• Intraspecies recognition roles – processes like intra- and intercellular signaling,
interactions with the extracellular matrix and fertilization are often mediated by
glycans. The ABO blood group system is an effect of genetic polymorphisms
leading to various glycans present on erythrocytes9.
• Molecular mimicry of the host – bacteria in the gut or pathogens can evolve to
synthesize host glycans in order to influence the host immune system.10 Viruses,
as they reproduce through selfish utilization of the host glycan synthesis ma-
chinery, commonly contain glycoproteins with glycans similar to these of a
host.
In addition to the multiplicity of their roles, carbohydrates are a structurally diverse
group of biomolecules (see the inset in Figure 1.2). Some monosugars, such as d-
glucose, are more common than others. But the structures of monosaccharides from
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various organisms are not as evolutionarily conserved as those of nucleotides and
amino acids. DNA is a polymer of four nucleotides and only two more are encoun-
tered ubiquitously (uracil in RNA, and nicotinamide in NAD (nicotinamide adenine
dinucleotide)). As few as 20 amino acids make up most proteins. In contrast, the num-
ber of monosaccharides encountered is higher and constantly growing. The primary
sequence of nucleic acids and polypeptides is encoded genetically, but the sequence
of polysaccharides is an effect of the concerted action of enzymes specific towards
different substrates. This adds to glycan diversity.
Figure 1.2: The number of human glycosylation disorders known in the years stated
and the processes they relate to. Inset: A representation of the diversity, conservation
and the knowledge base of different biomolecules. Glossary: GPI – glycosylphos-
phatidylinositol, GalNAc – N-acetylgalactosamine, GlcNAc – N-acetylglucosamine.
Figure adapted from Ref. 2.
In living organisms, it is proteins that play the roles of recognition sensors of glycans
and catalyze the reactions involving glycans. Interspecies recognition of glycans is
mediated by proteins such as adhesins, viral agglutinins, toxic lectins11 or pathogen
glycosidases. Host killer proteins recognize the xenosugars that are present on a
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parasite.12 In the process of N-glycosylation (which will be discussed in detail in Sec-
tion 1.4), chaperone lectins, glycosidases and glycosyltransferases recognize specific
glycan structures. This is an example of intraspecies recognition. The proteins that
recognize sugars have various functions: lectins bind to glycan “epitopes” but do not
catalyze the cleavage of any bonds, glycoside hydrolases hydrolyze bonds between
sugars (glycosidic bonds), and glycosyltransferases elongate the sugar chain using
sugar donor molecules. These and other categories will be explained in more detail
in Section 1.3. Many of the drugs that are produced using biotechnology are glyco-
proteins, which reflects the importance of glycan recognition.
Each of the multiple copies of a protein molecule in a single organism can have differ-
ent N-glycans attached after full processing inside the cell. Apart from the variation
in their sequence, oligo- and polymers of saccharides are often branched or function-
alized at their OH groups. In 2002, 41 different types of linkages between a glycoside
moiety and a polypeptide chain were known.13 Over a hundred human disorders
have been linked to aberrations in glycosylation (Figure 1.2).2 It is evident that glyco-
biology is a broad field of study, in which it is only feasible to track progress in the
narrower areas of one’s interest. Carbohydrates have been called “the last frontier of
cell and molecular biology” which is “rapidly being conquered”.14
The following Introduction will focus on the area of glycobiology relevant to work pre-
sented in this Thesis. First, carbohydrates and the ways to analyze their conformation
will be introduced (Section 1.2), followed by the classification system of carbohydrate
active enzymes into families and other categories (Section 1.3). These concepts are
crucial for understanding why a structural, mechanistic and functional characteriza-
tion of glycoside hydrolases of family GH99 was conducted, and the significance of
the obtained results. An in-depth look at the process on N-glycosylation in the ER
(endoplasmic reticulum), the Golgi apparatus and related organelles will follow (Sec-
tion 1.4). Family GH99 glycoside hydrolases participate in this pathway, and the cur-
rent state of knowledge about GH99 enzymes will be presented in Section 1.4.5. The
Introduction will close with a discussion of the potential relevance of GH99-targeting
therapies on human health (Section 1.5), and a summary of project aims (Section 1.6).
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1.2 Chemistry and conformation of carbohydrates
Carbohydrates as biomolecules have unique properties that stem from their chemical
structure. Some of these properties are specific to and stem from a sugar being in a
ring form. The sugar ring can assume different shapes, called conformations. Carbo-
hydrate active enzymes take advantage of the changes in the chemical properties of
sugars that stem from changes in their conformations. This is often the basis of their
mechanism of catalysis. Here, the various effects that give rise to certain conforma-
tions, and general theory of the sugar ring conformation.
Carbohydrates were originally defined as hydrates of carbon, i.e. compounds with the
formula CnH2nOn.15 The definition has evolved, now encompassing structures with
a slightly different general formula, such as deoxy sugars, unsaturated sugars, sugar
acids and derivatives such as N-acetylglucosamine, with at least three carbon atoms.
In their chemical structure, sugars are polychiral molecules: more than one carbon
in their structure has four different substituents. A convention for numbering the
carbon atoms in carbohydrates exists. The numbering of atoms in the sugar chain is
such that the carbon with an attached aldehydo or keto group has the lowest number
(1 or ≥2, respectively). The absolute configuration at the chiral carbon assigned the
highest number determines whether the sugar is d- or l-. If the OH group is on the
right when the structure is drawn in the Fischer projection it is a d-sugar and if on
the left, an l-sugar (see Figure 1.3). The majority of sugars in biology are d-sugars.
ᴅ-mannose
- -mannopyranoseα ᴅ - -mannopyranoseβ ᴅ
69.3% 30.7%
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- -mannopyranoseα ᴅ
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Figure 1.3: Structure of mannose, an example of a monosaccharide, in acyclic and
cyclic forms. The equivalent Fischer and Haworth projections of α-d-mannopyranose
are shown. The percentages refer to anomeric equilibrium in water at 20 °C.16
Most sugars can exist in a linear form or a cyclic form. When an OH group from
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another carbon in the chain performs a nucleophilic attack at the carbonyl carbon,
the product of this reaction is formation of a hemiacetal/hemiketal and a new chiral
centre at the former carbonyl carbon. Biologically, the most important sugar rings
are five-membered (furanoses) and six-membered (pyranoses). The new chiral centre
determines the anomer of the sugar, which can be α or β. When drawn in the Fischer
projection the α-anomer has the OH1 on the same side as the reference OH describing
the sugar absolute configuration, and the β-anomer on the opposite side. Cyclization
is reversible – the anomeric configuration can flip in a process called mutarotation.
A temperature-dependent equilibrium between anomers is achieved after the cyclic
sugar spends enough time in solution.17
Other effects of cyclization relate to the characteristics of the five- and six-membered
rings. As with cyclohexane, the conformation of the ring is constrained by prefer-
ence for ideal bond angles. Another contributor to sugar ring conformation is the
bulkiness of substituents. Large substituents (OH, CH2OH groups) usually prefer
the equatorial (close to the mean sugar plane) position, and small substituents (hydro-
gens) prefer the axial position. For example, in β-d-glucopyranose all the OH groups
are in equatorial positions when the sugar assumes a 4C1 chair conformation. When
α-d-mannopyranose is in the same 4C1 chair conformation, only OH1 and OH2 are
in axial positions. This preference of equatorial over axial position is partly a conse-
quence of varying energetic minima when substituents of different size are bound to
two adjacent carbons (they can be eclipsed or staggered).18 An unusual property of
pyranoses and furanoses is that, counterintuitively, the OH group connected to the
anomeric carbon often prefers the axial position. This is called the anomeric effect.
Traditionally, the anomeric effect was explained by dipole moment repulsion.19 Re-
cent computational studies point out that most of the anomeric effect can be explained
by steric hindrance and classical electrostatic interactions.20,21 As shown in Figure 1.3,
in standard conditions d-mannopyranose prefers the axial α-anomer. Anomers can
differ in surprising ways, for example the taste of α-d-mannose is perceived as sweet
by humans and the taste of β-d-mannose as bitter.22 The anomeric carbon, bound to
two oxygen atoms, is the most reactive part of a cyclic sugar. Nature takes advantage
of this by linking sugar moieties together through the OH1 group and thus creating
disaccharides, trisaccharides and higher order oligosaccharides, as well as polysac-
charides. The catalysis of these reactions is performed by glycosyltransferases. In
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some cases, glycoside hydrolases can be engineered to catalyze formation, not hy-
drolysis, of glycosidic bonds. These enzymes are referred to as glycosynthases.23 Ex-
amples of the mechanisms of reactions catalyzed by these enzymes are presented in
Figure 1.4.
Nucleophile mutant
A
B Inverting glycosynthase
Inverting glycosyltranferase
Figure 1.4: Reaction mechanisms of inverting, metal-dependent glycosyltranferases
(A) and engineered, inverting glycosynthases (B). Glossary: LG – leaving group, R –
radical. Figures adapted from references 24 and 25.
Conformation of the sugar ring is of interest to enzymologists, because CAZymes of-
ten rely on making conformations other than those which are favoured in solution
more energetically favourable when the sugar is bound to the enzyme. This lowers
the activation energy of certain reactions and makes catalysis possible. The pyra-
noses of perhaps the greatest scientific interest due to their abundance, d-glucose
and d-mannose, both prefer the 4C1 conformation in aqueous solutions. The alter-
native chair conformation, 1C4, puts most bulky substituents in these sugars in the
axial positions, making them energetically unfavourable. Certain intermediate pyra-
nose conformations are also possible, at least theoretically: boats B, skew-boats S,
half-chairs H and envelopes E (Figure 1.5A). For a more detailed explanation of the
so-called Cremer–Pople sphere and a guide to sugar conformations, see Appendix B.
The conformation of a pyranose ring can be described using only three parameters,
called puckering coordinates: the angles ϕ (phi) and θ (theta) and the total pucker-
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ing amplitude Q.26 In this system, 4C1 is the “North pole” (θ=0°), boat conformations
lie on the “equator” (θ=90°) and 1C4 is the “South pole” (θ=180°). Angle ϕ points to
the direction of ring puckering. This simple description makes it possible to visual-
ize the conformational landscape on projections similar to that used for the globe: θ
is the longitude and ϕ the latitude. The Stoddart projection (Figure 1.5B) is usually
used to visualize the poles, and the Mercator (Figure 1.5B) projection for the whole
“globe”. Depending on the chemical environment of a sugar, different conformations
will have different free energies, with those with lower free energies being more com-
monly observed: when bound to the enzyme, the free energy of a 4H5 conformation
may not be the same as when in solution. Computationally derived free energy land-
scape can be plotted on the projection, which constitutes a powerful tool for studying
enzyme mechanisms, especially when combined with structural data obtained from
crystallography.27,28
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Figure 1.5: Sugar conformations, projections and their free energy. (A) Examples
of theoretical α-d-mannopyranose conformations and their transitions. Note the in-
verted equatorial and axial positions in 4C1 and 1C4. (B) An example of conforma-
tional free energy landscape (FEL) plotted on the Stoddart projection (β-d-mannose)
– the northern hemisphere. Figure from Ref. 28. The numbers in white corre-
spond to the conformations of various saccharides at the – 1 subsite of various β-
mannosidases. (C) An example of conformational FEL plotted on the Mercator pro-
jection (α-d-mannose bound to GH47 from Caulobacter strain K31). Figure adapted
from Ref. 29, originally published in 30. ΔG: Gibbs free energy of a conformation.
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1.3 CAZy – a database classifying carbohydrate active
enzymes
Classification of proteins according to their fold can be useful for establishing deep
evolutionary links between them, but it is not very informative with respect to their
biochemistry. For this, special interest databases are more practical. One of such
databases, probably most relevant to this Thesis is the CAZy (Carbohydrate Active
EnZymes) database. The principle behind it was elaborated in a 1989 publication31.
Initially,32 31 families were described and the database was accessible on the Inter-
net under a different name. CAZy was set up in 1999 and described in the Nucleic
Acids Research journal in 2009.33,34 The curators categorize proteins into Families, Clans
and sometimes Subfamilies. In addition to enzymes, carbohydrate-binding modules
(CBMs) with no enzymatic activity have their own category (see Table 1.1). A CAZy
family is defined whenever a carbohydrate active enzyme or a CBM is biochemically
described, its sequence cannot be categorized into other families and a number of
uncategorizable homologues exist. The impetus to set up the database was that the
EC classification based on the activity was not specific enough for CAZymes: it is
based on the substrate, thus cannot detect divergence or convergent evolution, and is
inadequate for enzymes with broad specificity. The number of sequences and activi-
ties is increasing rapidly, and tools for sequence analysis coevolve, enabling sophisti-
cated alignment and prediction. At the beginning, hydrophobic cluster analysis was
used in addition to sequence alignment.31 The tools used by CAZy today also include
HMMer (which uses hidden Markov models) and BLAST similarity searches.33 1-5%
of the predicted coding sequences from any organism codes for CAZymes.34 With
such an abundance of sequencing information, the number of sequences to catego-
rize is considerable but the database seems to remain manageable. In this Thesis,
both the conventional single-letter and three-letter amino acid name abbreviations
will be used, according to the IUPAC-IUB (International Union of Pure and Applied
Chemistry-International Union of Biochemistry) Joint Commission on Biochemical
Nomenclature guidelines.35
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Table 1.1: CAZy classification system at the time of writing (excluding deleted fami-
lies).
Family Count Meaning Description
GH 143 Glycoside
Hydrolases
Enzymes hydrolyzing the glycosidic
bond.
GT 104 Glycosyltransfe-
rases
Enzymes transferring sugar moieties
from activated donors to acceptors,
forming glycosidic bonds.
PL 26 Polysaccharide
Lyases
Enzymes acting on polysaccharide chain
using an elimination mechanism and
produce an unsaturated product and a
new reducing end.
CE 16 Carbohydrate
Esterases
Enzymes catalyzing removal of ester
sugar decorations (de-O-acetylation or
de-N-acetylation).
AA 14 Auxilliary
Activities
Redox enzymes which degrade
saccharides.
CBM 81 Carbohydrate-
Binding
Modules
Polypeptides that bind carbohydrates
but do not alter their covalent bonds.
Polypeptides active towards carbohydrates can have broad activity, and single pro-
teins can possess multiple modules that are categorized into different CAZy fami-
lies. In some cases, subfamilies are defined within a CAZy family, in order to cluster
together polypeptides with closer sequence identity. The overall approach showed
good predictive value in identifying active residues.36 This makes CAZy an extremely
useful resource for research into these proteins.
1.4 N-glycosylation and its implications
N-linked glycosylation is an abundant post-translational modification. The N refers
both to the nitrogen atom to which sugars are linked, and the amino acid asparagine,
which is the site of the modification. Other types of protein-linked glycosylation
exist: O-linked glycosylation, which is a modification of the serine and threonine
side chains, and C-linked mannosylation,37,38 where tryptophan residues are modi-
fied. It will be presented below in order to contextualize the research presented in
later chapters. N-glycosylation is relevant to family GH99 enzymes, and plays a cen-
tral role in eukaryotes as an intricate mechanism of protein folding quality control.
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N-glycosylation itself promotes protein folding,3,39 is essential in quality control,40
protein stability, immune responses and other cellular processes.
In eukaryotes, the process of N-glycosylation starts in the ER lumen with the
transfer of the glycan Glc3Man9GlcNAc2 from Glc3Man9GlcNAc2-PP-dolichol to
an asparagine residue, catalyzed by an enzyme complex oligosaccharyltransferase
(OST).41 The glycan is then trimmed in the ER while the protein folds. When
folded, the protein is transported to the Golgi, where the smallest structure observed
is GlcNAcMan3GlcNAc2 and it is later readorned with various saccharides and
non-saccharide groups. The pathway is well-studied and has been reviewed many
times, but unanswered questions still exist.13,42–48
1.4.1 N-glycan assembly and transfer
The association of proteins with saccharides has been recognized in late 19th
century.49 Initially an obscure phenomenon, the discovery opened many questions
about the structure of proteins: why are the sugars and proteins linked? How are
the sugars attached to the protein? What may their function be? Many of these
questions, especially about the function of specific glycan structures, are still awaiting
an answer, but much progress has been made. Initial studies of the chemistry of
glycosylated peptides obtained from digesting ovalbumin led a conclusion that
the aspartate side chain must be the site of glycan attachment,50 and later the
Asn-glycan linkage was proposed, although first without direct evidence.51 The
structure of the Asn-linked precursor glycan (shown is Figure 1.6) was elucidated
in 1970s and shown to be conserved among eukaryotes from yeast to mammals52–54
as Glc3Man9GlcNAc2. This conservation reflects the functional importance of the
pathway.
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Figure 1.6: Structure of the precursor N-glycan bound to the protein, its link nomen-
clature and branch naming conventions. The lines representing bonds will convey
the linkage type as pictured only for sugar moieties present in the precursor glycan.
Synthesis of the glycan is achieved by a tandem of monomeric enzymes and enzyme
complexes, both in the cytoplasm and the ER lumen (see Figure 1.7 for a scheme).
In the cytosol, UDP-Glc (uridine diphosphate glucose) and GDP-Man (guanosine
diphosphate mannose) derived from primary metabolism serve as building blocks
for specific transferases. Dolichol kinase DOLK produces dolichyl phosphate (Dol-P)
at the ER membrane. The first step of the oligosaccharide assembly is DPAGT1-
(dolichyl-phosphate N-acetylglucosaminephosphotransferase 1-) catalyzed con-
version of Dol-P to α-GlcNAc-PP-Dol. DPAGT1 is a multipass transmembrane
protein formerly categorized in family GT4, now uncategorized. Subsequently a
GT1 transferase adds a GlcNAc molecule, and a complex of three GT33 and GT4
transferases adds five mannose residues, yielding Man5GlcNAc2-PP-Dol. The glycan
is then flipped from the cytoplasmic side of the ER to the lumenal side. The protein
responsible for this is thought to be RFT1 (RFT1 (requiring fifty three 1) homolog),
although the data are inconsistent.55 From then on, the building of the oligosaccha-
ride is achieved by the action of six inverting transferases from families GT58, GT22,
GT57 and GT59. They all are multi-pass transmembrane proteins with catalytic
machinery on the side of the ER lumen, and their donor substrates are Man-P-Dol
and Glc-P-Dol. These donors are synthesized on the cytosolic side of the ER56 from
GDP-Man, UDP-Glc and P-Dol by, respectively, DPM (dolichol-P-mannose synthase)
complex whose catalytic subunit is DPM1 (dolichyl-phosphate mannosyltransferase
subunit 1, catalytic) and ALG5 (asparagine-linked glycosylation 5 homolog) from
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family GT2. The products are then transported to the lumenal side by MPDU1
(mannose-P-dolichol utilization defect 1) flippase belonging to the lysosomal cystine
transporter family.57,58 Mutations in many of the genes involved in the precursor
glycan synthesis pathway result in congenital disorders of glycosylation (CDG).59
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Figure 1.7: Synthesis and transfer of the lipid-linked precursor N-glycan. The initial
steps of this process occur in the cytosol, and the later steps take place in the ER. The
names of enzymes catalyzing each step are above the reaction arrows. If known, the
CAZy family of each protein is shown. Linkages as in Figure 1.6.
The transfer of the oligosaccharide to Asn residues is performed by OST. OST in hu-
mans and yeast is a protein complex, while in bacteria it is monomeric. Structures
of exemplary OSTs have been solved and confirmed initial hypotheses about the re-
action mechanism.60–64 The recognition site of OST in eukaryotes is a sequon N-X-
T/S/(C)-X, where X is any amino acid other than proline. Bioinformatics and map-
ping studies in mice indicate that two thirds of all possible sites are glycosylated.65,66
The NXTX motifs are the best substrates for OST, followed by NXSX and NXCX. A
motif with cysteine can be thought of as non-canonical for the reaction, as it con-
stitutes only 1% of all glycosylated loci. 75% of the glycosylation occurred in pre-
dicted loop regions, 15% in β-strands and only 5% in α-helices.66 Proteins STT3A and
STT3B (from: staurosporin and temperature sensitive 3 A/B, current name: catalytic
subunit of the oligosaccharyltransferase complex) were recognized as the catalytic
subunits in mammalian OST and assigned to family GT66. In Saccharomyces cerevisiae
only one isoform, Stt3p, exists and also is catalytic.61 The roles of STT3A an STT3B are
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partially non-overlapping: complexes with STT3A are more efficient in glycosylating
the N-terminal recognition sites, while STT3B works on C-terminal sites. OST with
STT3A works co-translationally close to the growing polypeptide chain, while OST
with STT3B glycosylates its substrates after translation. The OST complex in yeast
was found to associate with the outlet of the ribosome.67 These catalytic subunits
arose from a gene duplication, and then developed different specificities. The bound-
ary between STT3A and STT3B OST specificity is 50–55 C-terminal residues.68,69 The
α-1,2-linked terminal glucose residue in the precursor glycan is the most important
moiety for recognition of an oligosaccharide as a substrate by OST, but it was found
that the minimal substrate that can be used is as small as GlcNAc-PP-Dol.70
The STT3B complex contains proteins MagT1 (magnesium transporter 1) and Tusc3
(tumor suppressor candidate 3), which are oxidoreductases. The environment of
the ER lumen is oxidizing which makes disulfide bond formation energetically
favourable. It has been proposed that when the STT3B-contaning OST associates
with the protein, MagT1 and Tusc3 may form transient disulfide bridges with
the protein or reduce those already formed, facilitating a situation in which the
polypeptide can fold first and form correct disulfide bridges later.71,72 When the
protein is folded, the recognition sequons are inaccessible to OST, as shown early on
using ovalbumin as a model.73
1.4.2 N-glycan trimming in the ER and quality control vesicles
Glycoside hydrolases can be broadly classified as exo and endo-acting, with some pro-
teins presenting semiprocessive* activity.74 Exoglycosidases release carbohydrates one
by one acting at the terminal end of an oligo/polysaccharide, and endoglycosidases
cleave non-terminal glycosidic bonds. In the ER, exomannosidases, exoglucosidases
and a glucosyltransferase is responsible for glycan processing. The ER N-glycan pro-
cessing pathway is instrumental for assuring correct protein folding in higher eu-
karyotes. It is interesting to note that the optimal pH for ER glycosidases is neu-
tral. The first enzyme to process the N-glycan is ER glucosidase I, an inverting α-1,2-
*Semiprocessive activity refers to enzymes that attack an internal bond and proceed by hydrolyzing
a number of consecutive moieties before initiating an attack at another internal position.
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glycosidase from family GH63. It is a type II† transmembrane protein75 encoded in
humans by the gene MOGS (mannosyl-oligosaccharide glucosidase). The structure
of yeast ER glucosidase I, which is kinetically similar to the mammalian enzyme,76,77
has been solved.78 The minimal substrate for the enzyme is a glucotriose with linkages
which are configured as in the native substrate, Glc3Man9GlcNAc2-Asn(…) (see Fig-
ure 1.6). Due to crystal packing issues, it was impossible to investigate ligand binding
experimentally, but docking efforts supported the view that Asp568 and Glu771 are
the catalytic acid/base residues. The glucotriose molecule recognized by ER glucosi-
dase I has a unique shape: the + 1 Glc has glycosidic bonds at adjacent groups, OH1
and OH2. This type of linked glycan structure occurs nowhere else in biology. This is
probably relevant to the function of N-glycosylation, which depends on enzymes in
the pathway catalyzing only specific reactions. The structure of GH63 from Thermus
thermophilus and enzymologic NMR studies were used to elucidate its reaction mech-
anism (shown in Figure 1.8A).79,80 Cleavage by ER glucosidase I is a rapid reaction
and the enzyme does not recognize the folding state of the protein.81
‡B
A
Figure 1.8: Two common reaction mechanisms of glycosidases. (A) The single dis-
placement, inverting mechanism of GH63 enzymes which act on the α-1,2-glucosidic.
Figure from Ref. 80. (B) The double displacement mechanism of GH31-catalyzed hy-
drolysis of α-1,3-glucosidic bond. The anomeric configuration is retained. Figure
adapted from Ref. 82.
†Type II membrane proteins are single-pass transmembrane proteins with their C-terminus facing
the ER lumen.
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After the first glucose moiety is trimmed, the glycan becomes a substrate for ER glu-
cosidase II and a ligand for malectin, a chaperone protein (see Section 1.4.3 for dis-
cussion of the latter and Figure 1.9 for an overview of glycan trimming and recogni-
tion in the ER). ER glucosidase II is a GH31 retaining α-1,3-glucosidase that is able
to cleave both α-1,3-linked glucoses from the N-glycan. In mammals and yeast it is
a heterodimer composed of a catalytic subunit encoded by GANAB (glucosidase II
alpha subunit) gene and a regulatory subunit encoded by PRKCSH (protein kinase
C substrate 80K-H).83 Mechanistically, GH31 proteins follow a classical Koshland84
double displacement reaction coordinate with one residue acting as an acid/base
and one as a nucleophile, as presented in Figure 1.8B.82,85 The enzyme is key to the
first level of ER quality control (ERQC). ER glucosidase II recognizes its substrates
by interacting with the C branch (see Figure 1.6 on page 13 for reference) of the gly-
can, as removing the C branch-linked mannose decreases the rate of the deglucosy-
lation reactions in vitro.86 Cleavage of the first glucose moiety results in oligosaccha-
ride Glc1Man9GlcNAc2 (G1M9Gn2), which is recognized by calnexin and calreticulin,
molecular chaperone lectins. The lectins can bind cotranslationally when the protein
chain is as short as 50 aa87 (amino acids) and two N-glycans are necessary for the
lectins to associate with the glycoprotein.81 The second cleavage of glucose yields
glycoproteins with Man9GlcNAc2 (M9), a structure for which the lectins have low
affinity and dissociate. However, another key enzyme, UDP-glucose:glycoprotein
glucosyltransferase (UGGT), which has a folding sensing domain88 can recognize
Man9GlcNAc2 and reglucosylate it, letting the chaperones bind again. UGGT belongs
to the GT24 CAZy family and there are two genes with associated protein products
of similar length in the human genome (UGGT1 and UGGT2). Structural analysis of
full-length eukaryotic UGGT89 revealed considerable conformational flexibility. The
fold of the protein is complex: its seven domains act like a clamp around the un-
folded protein and the GT24 domain is located inside the clamp, facing the folding
sensing machinery. Expression of UGGT is higher when cells undergo ER stress and
the protein plays an important role in response to an increase in unfolded proteins.90
UGGT1 was found to be essential for embryonic development: UGGT1-/- mouse mu-
tant embryos do not develop.91 This deglucosylation-reglucosylation cycle continues
until the protein is folded and no longer a UGGT substrate, or misfolded, which is
sensed by the EDEM (ER degradation enhancing alpha-mannosidase like) proteins.
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At this point the glycan has all mannose termini exposed and mannosidases step onto
the stage. The yeast and mammalian pathways are substantially different and be-
low the human pathway will be described, however there is still controversy about
particular steps. There are several genes in the human genome known to encode
N-glycosylation-associated α-1,2-mannosidases: EDEM1, EDEM2, EDEM3, MAN1A1
(mannosidase alpha class 1A member 1),MAN1A2 (mannosidase alpha class 1A mem-
ber 2), MAN1B1 (etc.) and MAN1C1. They all belong to the GH47 family and their
catalysis results in overall inversion of stereochemistry at the anomeric carbon,92 but
their specificities are different. ER mannosidase I (MAN1B1 product) contains a short
N-terminal cytoplasmic tail and a transmembrane domain while EDEMs are resident
in the ER lumen. In addition to a GH47 domain, EDEM3 also contains an N-terminal
protease-associated domain.93 The conventional names of the MAN1A1, MAN1A2
and MAN1C1 gene products, accordingly, Golgi mannosidase IA, IB and IC and all
are type II transmembrane proteins. A landmark study93 revealed that it is EDEM2
which is responsible for most of the conversion of M9Gn2 to Man8GlcNAc2 with the
α-1,2-mannose removed from the B branch of the precursor glycan (M8B). ER man-
nosidase I, contrary to its accepted name, is resident in the quality control vesicles
(QCVs).94 Due to a particular experimental and imaging procedure, previously it was
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thought the enzyme is localized to the ERQC because QCVs congregate in ERQC-like
clusters when cells are under stress. Golgi mannosidase IA was also found to localize
to QCVs and not the Golgi,95 after many years of controversy and conflicting data.96 To
avoid confusion, these will be referred to as QCVManI (ER mannosidase I) and QCV-
ManIA (Golgi mannosidase IA). Substrate specificity studies revealed that QCVManI,
like EDEM2, prefers to cleave the mannose on the B branch of the M9Gn2 glycan,
but the preference is not strict.97,98 QCVManIA prefers the A branch of M9Gn2 while
mannosidase IB prefers the C branch.99 This is substantiated by a later comparison of
mammalian structures of these two enzymes.100 Mannosidase IC is the only enzyme
that can remove the last α-1,2-linked mannose from M8AGn2 producing M7AAGn2,
and then proceed to cleave the C branch making M6AACGn2.101 Hypotheses about
their localization are discussed in Section 1.4.4. The picture is complicated by EDEM1
and EDEM3 proteins, which are specific towards the A and C arms of M8BGn2 and
act downstream of EDEM2. EDEM3 activity is more pronounced than EDEM1 ac-
tivity and mammalian cells with EDEM3 knocked out (ko) accumulate 10–20% more
M8BGn2 (~5% more for EDEM1 ko).93 A 2008 study102 reported that most EDEM1
is localized to EDEMosomes coated with LC3-I‡, and high turnover of this protein
(t1/2=1 h) was observed. No structural data on EDEM proteins exists, but structures of
QCVManI and QCVManIA were solved. Curiously, in addition to M9Gn2, cells with
QCVManI knocked down (kd) also accumulated proteins with G1M9Gn2 glycans
in a pulse-chase experiment.105 This happens in cells treated with kifunensine (KIF),
a selective29 GH47 inhibitor, as well. It can be explained by accumulation of M9Gn2
and its subsequent reglucosylation to G1M9Gn2 by UGGT. Cultured EDEM2-ko cells
also show an increased amount of G1M9Gn2.93 It is important to note that QCVManI
can process glucosylated N-glycans at the same rate as non-glucosylated glycans.106
It preferentially removes mannose moieties from unfolded proteins and very slowly
from native proteins.106,107 Coupled with its localization in mammalian cells outside
the Golgi, it seems to play a role of a post-translational quality check enzyme. An
overview of the current understanding of glycan processing in QCVs and the ERGIC
is presented in Figure 1.10.
‡LC3 is a canonical name for the protein products of the gene MAP1LC3A and MAP1LC3B
(microtubule associated protein 1 light chain 3 alpha/beta). LC3-I is nonlipidated and LC3-II is
lipidated.103,104 LC3-I is cytosolic and also associated with EDEMosomes, while LC3-II is associated
with authophagosomes.
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In summary, the only initial mannosyl residue cleavage reaction in the ER can occur
at the B branch of the N-glycan (catalyzed by EDEM2), and this makes the glycan
vulnerable to further cleavage of the C branch by EDEM3 and EDEM1. This process
often leads to the commencement of ERAD (ER-associated degradation). It is possible
that in rapidly and correctly folding proteins, no mannose residues are cleaved, and
an α-1,3-linked glucose can be still present on the glycan A branch. The most likely
situation is that GH47 mannosidases resident in the QCVs cleave off the mannoses
from the B and C branch of (G)M7-9, leaving proteins with (G)M5-7 glycans as they
enter the Golgi. Glycans are then processed further by unique Golgi mannosidases,
described in Section 1.4.4. Golgi processing involves subsequent readorning of the
N-glycan with other oligosaccharides, performed by various glycosyltransferases.
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1.4.3 ER quality control and ER-associated degradation
The quality control mechanism in the ER depends on lectins that recognize different
high-mannose glycans. The first one in the pathway is malectin, which recognizes
the G1M9Gn2 glycan and is upregulated under conditions of cellular stress.108,109 It
is a type I transmembrane protein and acts upstream of calnexin, calreticulin and BiP
(binding immunoglobulin protein) as it does not compete with them for substrates.
Overexpression of the gene encoding for malectin causes a reduction in folding-
incompetent protein secretion and less deglucosylation by ER glucosidase II.109 Two
lectins have been identified as major contributors to the regulation of this pathway.
Lectin OS9 (OS9, endoplasmic reticulum lectin, abbreviation from: osteosarcoma
amplified 9), the structure of whose sugar-binding domain is solved (PDB (Protein
Data Bank) code: 3AIH),110 has been shown to promote ERAD. OS9 binds with a
high affinity to M7AGn2 structures (where two mannose molecules from the B and
C branches were removed, see Figure 1.9 on page 18). Crucially, the OS9 must bind
after the EDEM3/1 cleavage, which produces this glycan. Two isoforms of OS9 are
produced in humans owing to alternative splicing and both are often overexpressed
in tumours. OS9 isoform 2 with an inactivated carbohydrate-binding module was
still competent at binding to a folding-defective protein, but when the glycosylation
site was removed, the interaction did not target it to ERAD.111 Therefore, the exact
function of this domain remains unclear. The other of the two is XTP3-B (XTP3-
transactivated gene B protein;), which has an opposite regulatory activity to OS9.
XTP3-B is a lectin which specifically binds to M9Gn2 oligosaccharides and makes
their degradation through ERAD less likely.112 As such, its binding activity would
compete with that of UGGT and EDEM2. However, conflicting reports exist that
assign the role of XTP3-B as essentially redundant with that of OS9.113
The function of EDEM proteins is important in ERAD. In Drosophila melanogaster, dE-
DEM1 is a homolog of human EDEM2, and dEDEM2 is homologous to EDEM1 and
EDEM3. Under the model described in Ref. 93, dEDEM1 would function upstream of
dEDEM2 in the fly. A recent study found that overexpression of either of the EDEM
genes protects against age-related proteinopathy and the mannosidase activity is not
essential for this effect.114 However, the same study found that the mannosidase ac-
tivity is essential to degrade the culprit protein, αβ42, in neurons. This suggests that
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EDEMs may possess chaperone-like qualities independent of their mannosidase ac-
tivity. Earlier115 it was proposed that EDEM proteins release folding-incompetent
proteins from the calnexin/calreticulin cycle, although only EDEM1 was known at
that time and its role is less important than that of EDEM2 or EDEM3, as described
above.
HSPA5 (heat shock protein family A member 5) encoding BiP was found as one of the
genes upregulated in conditions of stress. It belongs to the HSP70 family116 and is
constitutively expressed at a moderately high level. It has multiple roles in the ER,
and one of them is to keep polypeptides in a folding-competent state directly after
translation. As a member of the HSP70 (70-kDa (kilodalton) heat shock protein) fam-
ily it has an ATPase domain and a substrate binding domain. It may have a foldase
activity as upon binding the substrate, the rate of ATP hydrolysis increases. BiP is
thought to be stored in an inactive oligomeric form that is post-translationally modi-
fied and released in a monomeric form when needed, providing a reservoir for rapid
response to conditions of stress.117,118 It is possible that in QCVs, where QCVManI and
QCVManIA reside, there are lectins that recognize the oligosaccharides produced by
these enzymes. Such colocalization would provide a basis for another quality control
mechanism. Overexpression of MAN1A1 has been shown to enhance ERAD, whereas
its knockdown suppresses the degradation.95
The overall logic of the ERAD pathway, to which OS9-tagged proteins are directed,
is well understood. Terminally misfolded proteins are transported to the cytosol and
polyubiquitinylated. There is controversy about the exact mechanism, but in certainty
the ubiquitinylation machinery is located in the cytosol. N-linked glycans are cleaved
by PNGase (peptide:N-glycosidase) in the cytosol and then degraded by lysosomal
glycosidases. Polyubiquitinylated proteins are then degraded inside the proteasome
complex into 7-9 aa long peptides, and ubiquitin molecules are recycled for further
use.119–121 Free oligosaccharides (FOS) are generated during ERAD: overexpression
of EDEM1 in CHO-K1 cells increases the total amount of FOS resident in the cytosol
but not in the ER lumen.122 Due to the presence of PNGase, fully functional proteins
resident in the cytosol are in general deglucosylated (although at various rates).123,124
Folded glycoproteins are transported from the ER to the Golgi through QCVs or
ER-Golgi intermediate compartment (ERGIC). The cargo from the ER to ERGIC is
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packaged into vesicles coated by COPII (coat protein II).125 A marker for ERGIC is a
d-mannose-specific lectin ERGIC-53,126,127 whose another characteristic is a long half-
life. The identity of ERGIC-53 cargo is not clear, but it probably interacts with the
mannose “epitopes” on the high-mannose N-glycans. There is dispute about the role
of the ERGIC, but the prevailing understanding is that it plays a sorting role.128 The
glycoproteins are then packed in vesicles again and transported to the Golgi.
1.4.4 N-glycan processing in the Golgi
In the Golgi, glycoproteins encounter at least two enzymes with mannosidase
activity: the endo-α-1,2-mannosidase (ERGIC/cis-Golgi)129 and Golgi mannosi-
dase II (medial/trans-Golgi).96 The endomannosidase from family GH99 is the
main focus of this work and will reviewed separately in Section 1.4.5. It catalyzes
the removal of Glc3-1Man from the A branch of Glc3-1Man9-7GlcNAc2 glycans,
leaving Man8-6GlcNAc2 glycosylation.130 Golgi mannosidase II cleaves α-1,3- and
α-1,6-linked mannoses, converting GnM5Gn2 (GlcNAcMan5GlcNAc2) to GnM3Gn2
glycans.
The report about QCVManIA not being localized to the Golgi95 casts doubt on the
subcellular localization of related GH47 enzymes: “Golgi” mannosidases IB and IC.
Below, the possibility of both Golgi and QCV localization of them will be discussed.
In living cells, Golgi mannosidase II acts only after GlcNAc transferase I (MGAT1,
mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase) adds
a GlcNAc residue to the A branch of the glycan, which first must be free of α-1,2-
linked mannoses. For an overview of processing of N-glycan in the Golgi, refer to
Figure 1.11.
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Under the assumption that the glycan is still glucosylated and there are only two
QCV mannosidases, they would remove moieties from the B and C branch and mostly
GM7AGn2 glycans enter the Golgi. After the cleavage by the endomannosidase the
glycan would still possess one α-1,2-linked mannose (on the A branch), which implies
that at least one α-1,2-mannosidase resides in the Golgi. The best candidate would
be Golgi mannosidase IC, which is capable of catalyzing the removal of the α-1,2-
linked mannose from the A branch irrespective of the structure of other branches.101
Golgi mannosidase IB would serve as a backup Golgi mannosidase, trimming the B
and C branches. If Golgi mannosidases IB and IC were also localized to the QCVs,
the endomannosidase would need to be in these vesicles as well because there would
be no backup mechanism for cleaving the A branch in the Golgi. The data on en-
domannosidase localization is, however, entirely consistent with Golgi/ERGIC (see
Section 1.4.5.3 on page 31).
Golgi mannosidase II belongs to the CAZy family GH38, was first isolated from rat
liver Golgi and is a type II membrane protein.131,132 A crystal structure of Drosophila
melanogaster Golgi mannosidase II in complex with its substrate has been solved.133
The model suggests that the enzyme cleaves two mannose residues sequentially with-
out dissociating from the oligosaccharide, and that considerable movement in the ac-
tive site is needed to achieve this: only one subsite is catalytic. The first mannose
to be removed is the α-1,3-linked moiety (branch B), followed by the α-1,6-linked
Man (branch C). In humans and other mammals, there also exists an isozyme, Golgi
mannosidase IIx,134 whose role is largely complementary but it is essential for some
processes, such as spermatogenesis.135 Golgi mannosidase II/IIx double null mutant
mice completely lack complex-type N-glycans and fail to thrive.136 Single null mu-
tant mice are viable, demonstrating that the presence of one of these enzymes can
compensate for the lack of the other.
Subsequent processing of N-glycans occurs in cis, medial, trans-Golgi and trans-Golgi
network (TGN) and involves action of a vast array of enzymes. It is outside the scope
of this introduction to characterize them all. Much non-homogeneity exists in ma-
ture glycoproteins, even within a single glycosylation site, although some sites are
essential for the function of a particular protein.137 Three main classes of N-glycans
observed on mature proteins can be distinguished: high-mannose (in which the A,
B and C mannose branches of the precursor glycan are found), hybrid (only branch
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A removed and subsequently modified) and complex (all three branches removed
and modified, see Figure 1.11).138 One common modification is branching (up to 6
times) via the action of various GlcNAc transferases. Their specificities are tuned so
that they act in tandem, i.e. one branch must be created before another Golgi trans-
ferase recognizes the glycan as its substrate and creates another branch. The activ-
ities of some branching enzymes prevent others from recognizing the glycan as a
substrate.139,140 Other common saccharide-based modifications include fucosylation,
sialylation and galactosylation.45 Glycans can also be phosphorylated (for example,
phosphorylated high-mannose structures are tags for delivery of enzymes to lyso-
somes, see Figure 1.11),141 and sulfated. When the processing completes, proteins
are packaged into secretory vesicles and exported.142
1.4.5 Endo-α-1,2-mannosidase: a review
1.4.5.1 The enzymatic activity of endo-α-1,2-mannosidase
The endo-α-1,2-mannosidase, or endomannosidase for short, is the only endo-acting
mannosidase in the N-glycan trimming pathway. It was first isolated from rat
Golgi membranes by Lubas and Spiro.130 Before its discovery it was postulated
that more complex processing of mannoses may take place in the Golgi.143 The first
report established that the endomannosidase is active against GM9Gn2 glycans,
has a neutral (7.0–7.2) pH optimum and its activity is the highest in the Golgi
fractions. It also provided the explanation for an incomplete blockage of synthesis
of complex-type N-glycans in conditions of ER glucosidase II inhibition.144,145 The
enzyme was tested in presence of EDTA and had full activity in presence, lead-
ing to a conclusion that it does not depend on any metal ions as cofactors. The
enzyme also retained full activity when tested with and 1-deoxynojirimycin (DNJ,
a glucosidase II inhibitor) in solution. The novel activity was 69 times higher in
the Golgi extract than in the ER. The second report about the enzyme by the same
authors146 has shown no activity against M9Gn2 glycans, high activity against
monoglucosylated glycans and low (~7-8%) activity with di- and triglucosylated
substrates. Interestingly, the fewer mannose molecules the glycans possessed, the
higher the endomannosidase activity (2.3 times higher for Glc1Man4GlcNAc2 than
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for Glc1Man9GlcNAc2). Despite the lower activity of this enzyme with di- and
triglucosylated free oligosaccharides, the predominant products from its process-
ing of lipid-linked precursor glycan were Glc3Man and Glc2Man. A suggestion
was made that the additional glucose moieties may sterically inhibit the enzyme.
Buffers HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), HEPPS
(3-[4-(2-Hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid) and Tris (2-amino-2-
(hydroxymethyl)propane-1,3-diol) were inhibitory towards the enzyme, but HEPES
and HEPPS were uniquely inhibiting the endomannosidase while Tris inhibited exo
glucosidase and exomannosidase activity as well. Other exoglucosidase inhibitors,
such as castanospermine (CST), bromoconduritol (BCD), 1-deoxymannojirimycin
(DMJ) or swainsonine (SW) had no effect on the endomannosidase (for structures
of some of these compounds, see Appendix A). The minimal substrate for en-
domannosidase is a tetrasaccharide mimicking the linkages on the A-branch of
the N-glycan: α-Glc-1,3-α-Man-1,2-α-Man-1,2-Man147 (see Figure 1.12). Bacterial
GH99, a model for endomannosidase studies, was shown to retain the anomeric
configuration of its substrates. The reaction mechanism was proposed to be a unique
neighbouring group participation mechanism with a 1,2-anhydrosugar intermediate
(see Figure 2.1 on page 45 for details).148 Evidence of OH-catalyzed hydrolysis of
4-para-nitrophenyl α-d-mannopyranoside through such an intermediate has been
made available recently, but no enzymology-related proof has been published.149
The activity-based EC classification of endo-α-1,2-mannosidase is 3.2.1.130.
-Asn-
Minimal GH99 substrate
Scissile bond
Figure 1.12: Substrate specificity of the GH99 endomannosidase.
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Inhibition of mannosidases through the use of DMJ and KIF in a cell line lacking ER
glucosidase II results in production of glycoproteins with a specific high-mannose
oligosaccharide M8AGn2 attached. This result is exactly what one would expect if
the endomannosidase was the only enzyme at work downstream of ER glucosidase I.
Without this inhibition a product characteristic of the endomannosidase, G2M, was
released into the media. When CST, an ER glucosidase I inhibitor, was added to the
cocktail, the sugar released was G3M, again exactly as expected.150 These findings
helped define the specificity of the endomannosidase activity. Usage of the enzyme
as a tool for assessing glycosylation state of proteins was proposed151 and applied.152
1.4.5.2 Inhibition of GH99 through use of small molecules
The first inhibitors of GH99 were reported by Hiraizumi and Spiro,153 and shortly
after that more inhibitors were synthesized by Ardron et al.154 The backbone of en-
domannosidase inhibitors is an α-1,3-linked disaccharide which mimics the natural
substrate bound in the  – 2/– 1 subsites. Various – 1 “warheads” were surveyed and
DMJ without modifications was the most potent (see Figure 1.13A and C). The – 2
sugars tried included Glc, 2-, 3-, 4- and 6- (methyl- or deoxy-) glucose, Gal, Man
and Xyl (see Figure 1.13B). Of interest, the  – 2/– 1 endomannosidase cleavage prod-
uct, α-Glc-1,3-Man, was 130 times less potent than GlcDMJ, but two inhibitors were
approaching GlcDMJ affinity: Glc-d-glucal (1.3 × less potent) and Glc-ddMan (Glc-
dideoxymannose, 2.2 × less potent). Modifications and different substituents around
the DMJ ring were tried, but none toppled GlcDMJ affinity.
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Figure 1.13: The pioneering work on GH99 inhibition. (A) Various Glc-linked – 1 sub-
site compounds and their IC50 values. IC50 is the inhibitor concentration at which an
enzyme catalyzes the reaction at 50% of the rate of the uninhibited reaction. (B) Vari-
ous – 2 subsite compounds linked to DMJ and their IC50 values. (C) Modifications on
Glc-linked DMJ and their effects on the IC50 values. Abbreviations used: d – deoxy,
dd – dideoxy, Me – methyl, ND – not determined. The magnitude of IC50 depend on
the substrate concentration,155. As they cannot be directly compared, the values from
Ref. 153 are given without parentheses, and from Ref. 154 with parentheses.
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GlcDMJ was inhibiting 92-100% of the endomannosidase activity when tested at
80 µm (micromolar) with cultured cell membrane extract in vitro.153 GlcDMJ was
cleaved by the enzymes of mouse membrane extract, but remained intact when CST
was added to the extract.153 A report of the synthesis of Glc- and Man-linked α-
and β-homomannojirimycin was published, but there are no reports of testing their
potency.156 An alternative approach to GlcDMJ synthesis was published in 2004.157 It
was not until 2012 that reports of new GH99 inhibitors were published: Fleetamine
(GlcSW) was a potentially powerful inhibitor, originally proposed in 1993,154 but its
synthesis was not attempted. When produced, however, the compound did not bind
to bacterial GH99, which by then had become a more convenient testing platform.158
By contrast, Glc-isofagomine (GlcIFG) was found to be a better GH99 inhibitor than
GlcDMJ by a factor of 38.148 After that, a 4.5-fold improvement in binding to the
bacterial GH99 was made by synthesizing and testing ManIFG.159. Structures of
these inhibitors are shown in Figure 1.14.
GlcDMJ GlcIFG ManIFG Fleetamine
3
2
4
Figure 1.14: Different designs of actual and potential inhibitors of the endomannosi-
dase activity. The numbering on Fleetamine represents the – 1 subsite pyranose atom
mimicked by the fused five- and six-membered ring.
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1.4.5.3 An “alternative” pathway for complex glycans processing?
The third pioneering study of the endomannosidase concerned its activity in liver
(hepatocellular carcinoma) cell line HepG2. Inhibition of glucosidases by DNJ and
CST resulted in endomannosidase activity markers G1-3M being produced in the
growth media, although in a different pattern160 consistent with CST being more ef-
fective than DNJ at inhibiting ER glucosidase I. About 50% of theN-glycans produced
by the cells were complex-type, confirming previous observations and providing ev-
idence that the endomannosidase was responsible for this effect. Endomannosidase
activity was then detected in the brain and purification of a protein that was its source
was reported.161 The isolated enzyme had a pH optimum of 6.2–6.8. It is now known
that mammals have two genes encoding endomannosidase enzymes: MANEA (man-
nosidase endo-alpha) and MANEAL (mannosidase endo-alpha-like). MANEAL is ex-
pressed predominantly in the central nervous system (see Figure 4.1 in Section 4.2)
and MANEA in other tissues. Tulsiani et al. might have, unknowingly, described an
an isozyme of the one discovered by Lubas and Spiro.
In ER glucosidase II-deficient cells treated with CST, the predominant (91% molar)
N-glycans were complex-type, showing that endomannosidase can process glycans
on most proteins that are made in cells.150 Subsequent results showed that endoman-
nosidase does not discriminate between folded and unfolded proteins.162–164
Some results led the scientists to believe that a proportion proteins do not reach
the compartment in which endomannosidase resides.165 Rabouille and Spiro162
found that the susceptibility of glycoproteins to endomannosidase cleavage is
probably time-constrained, as fewer glycans were processed with increasing number
of glycosylation sites in CST+DMJ-treated cells. As the GH99 activity towards
triglucosylated glycans is low, in heavily N-glycosylated proteins many glycans
remained uncleaved. The same study162 is the first to describe the technique of
investigating endomannosidase activity by comparing the electrophoretic mobility
of glycoproteins treated or untreated with endo-β-N-acetylglucosaminidase H (endo
H).
Once endomannosidase inhibitors became available, it became apparent that Chinese
hamster ovary (CHO) cells do not have active mannosidase in their enzyme repertoir,
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and they can be used as a convenient control to investigate the effectiveness of GH99
inhibition. Without GlcDMJ, the endo H-cleavable glycans produced by BW5147
cells (mouse lymphoma) were mostly M9Gn2 and M8Gn2. When exomannosidases
and glucosidases were inhibited, G3M9-7Gn2 and M8Gn2 became the predominant
species, and M8Gn2 corresponded to endomannosidase product. With GlcDMJ, only
G3M9-8Gn2 were detected, suggesting that some demannosylation (consistent with
Golgi mannosidase IB activity) still took place. In CHO cells, G3M9Gn2 was detected
in conditions of exoglycosidase inhibition.153 The lack of endomannosidase in CHO
cells was a finding that added another layer of consideration for researchers when
choosing a cell line in which to conduct glycobiology research.
The products of endomannosidase activity are rapidly processed by Golgi mannosi-
dases (IB and IC under the current understanding) and cannot be observed with-
out the use of exomannosidase inhibitor. It was confirmed that the endomannosi-
dase pathway functions without a glucosidase blockade.166 In a seminal publication,
Karaivanova et al. determined that the G protein§ from vesicular stomatitis virus
(VSV) and influenza haemagglutinin is processed by endomannosidase, the extent
of which was host-cell dependent.168 HepG2, PtK1 (Potorous tridactylus kidney) and
BHK (baby hamster kidney) cells were found to utilize the endomannosidase path-
way heavily, while MDBK (Madin-Darby bovine kidney) and MDCK (Madin-Darby
canine kidney) not at all. The utilization level did not correspond to enzymatic ac-
tivity in postnuclear membrane extracts. Rather, it seemed to depend on which cel-
lular components proteins are trafficked through while their glycans are assembled
(MDCK cells were shown earlier153 to make use of the endomannosidase pathway).
Differential mobility of uncleaved, endo-H-treated and PNGase F-treated proteins
was used to establish differences in the level of utilization of the endomannosidase
pathway by each cell line. Incubation of HepG2 cells with GlcDMJ caused all VSV
glycans to be susceptible to endo-H cleavage, showing that this cell line uses the en-
domannosidase pathway heavily.
Subsequent research established that the low activity of endomannosidase in MDBK
and MDCK cells was determined genetically and not physiologically. When bovine
and canince MANEA were overexpressed, the protein products had an altered speci-
§G protein (glycoprotein) from VSV and related viruses are essential for the processes of cell at-
tachment and membrane fusion. These viruses (enveloped viruses) enter the by fusion of the viral
membrane with the host cell membrane.167
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ficity and lower activity than the human version. The bovine enzyme strictly pro-
cessed monoglucosylated and not di- or triglucosylated glycans; this result pointed
to the physiological significance of endomannosidase pathway.169 The canine enzyme
showed a preference towards monoglucosylated glycans more pronounced than the
human enzyme, but – unlike the bovine enzyme – it was not restricted in its process-
ing. Shortly after, a study in B16 mice melanoma cells showed that the endomannosi-
dase pathway is preferentially utilized by the cell when it produces tyrosinase-related
protein-1, but less so with tyrosinase.170
FOS that are by-products of ERAD (and molecular markers of ERAD having taken
place) are transported to the Golgi and processed by MANEA there. When cells are
treated with brefeldin A (BFA), which causes fusion of parts of the ER and Golgi,
endomannosidase activity can also be detected in the ER.171 The trafficking of the
enzyme to the Golgi is COPII-mediated.172 Endomannosidase knockdown increases
the total amount of FOS produced and ERAD can occur downstream of the cleavage
of glycans by this enzyme. When MANEA was overexpressed, small FOS, which im-
plied endomannosidase cleavage before ERAD, were observed during glucosidase
inhibition.173 In a later study, Alonzi et al.122 showed that in addition to total FOS, glu-
cosylated FOS accumulating in the ER lumen in cells lacking the endomannosidase
activity can serve as a marker for ERAD. Only non-glucosylated FOS are substrates for
a transporter that trafficks them across the membrane (from the ER to the cytosol),174
and they accumulate in the ER in cells lacking an active form of endomannosidase.
This model, however, necessitates the existence of ER-resident PNGase, which has not
been confirmed yet, although some data suggest it is ER membrane-associated.175
Expression of endomannosidase genes is tissue-specific and cell-specific. The high-
est level of the enzyme mRNA was found in the lung and the liver, moderate in the
brain and kidney and low in spleen, muscles and kidneys. This did not directly trans-
late to the level of enzymatic activity, which was the highest in lungs and the liver,
and moderate in all other cells.176 Immunofluorescence showed the protein colocal-
izes with Golgi mannosidase II, but is not present in endothelial liver cells, unlike
the other, ubiquitous enzyme. It was also not detected in other epithelia and adrenal
cortex and medullar cells.177 The general but not definitive pattern was that endoman-
nosidase is expressed in cells that need to secrete high amounts of glycoproteins. A
later study confirmed the Golgi localization using both immunofluorescence and im-
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munogold labelling.129 In particular, 84% of gold particles were found over cis/medial
Golgi, 15% over ERGIC and 1% over the rough ER. Trans-Golgi and TGN were not
labelled. Presence of DTT (1,4-dithiothreitol) arrests trafficking of proteins from the
ER.178 It was shown that when this process is halted, glycans do not undergo cleavage
by endomannosidase, again providing evidence of Golgi localization.179
In some cases, endomannosidase activity was directly observed in humans. In an
individual with an incredibly rare CDG-IIb¶ (ER glucosidase I deficiency), Glc3Man
tetrasaccharide, the product of endomannosidase activity, accumulated in urine.
This unusual FOS could not be detected at all in control urine.181 Tissue samples
showed no increase in the activity of the enzyme. The patient died at 74 days of
age. A follow-up report which used cultured fibroblasts from the infant showed a
dramatically altered pattern of endo H-released oligosaccharides which was normal
in the father and only slightly altered in the mother. ~80% of total glycans were
correctly processed and only ~16% were G3M9Gn2, showing the extent of rescuing
capability of endomannosidase in humans. As in cell culture studies during glucosi-
dase blockade,160 about 50% of all N-glycans were complex-type. The procedure for
measuring MANEA activity was refined and showed that in the child cell extract
it was 2.5 times more active than in controls (1.8 × in parents’ cells). This led the
authors to speculate that ER glucosidase I and endo-α-1,2-mannosidase pathways
do not operate independently, but their capacity may be tuned depending on the
situation.182 A pair of siblings with CDG-IIb were alive at ages of 6 and 11.183 There
are no reports of CDG caused by endomannosidase deficiency.
No evidence of endomannosidase activity was detected in the protozoan Trypanosoma
cruzi (incidentally, one of the earliest reports of observation of UGGT activity).184 Lit-
erature produced before the invention of Next-Generation Sequencing (NGS) sug-
gests this pathway of N-glycan processing is limited to chordates with one exception:
it was also detected in mollusks. Interestingly, the most active endomannosidase
seemed to come from a species of frog, Rana catesbeiana.185 Currently available data
are reanalyzed in Section 6.1.
A number of studies found MANEA genetic variants associated with with various
¶Congenital disorders of glycosylation are separated into two types: type I – “referring to defects in
the initial steps of N-linked protein glycosylation”, and type II – “defects in the processing of protein-
bound glycans or the addition or [sic] other glycans to the protein”.180
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ailments. The allele rs1133503 C was a top-ranked SNP (single-nucleotide polymor-
phism) associated with cocaine-induced paranoia (CIP).186 It is located in the 3’ UTR
(untranslated region) of the MANEA gene. The discovered allele had an overall fre-
quency of 41% in the surveyed population. A study that was prompted by this find-
ing detected another SNP, whose association with CIP was even higher: rs9387522 A,
also in the 3’-UTR. A number of other CIP risk-associated SNPs were also found in the
coding and promoter regions, as well as an association of eight markers with cocaine
dependence.187 In another study that was sparked by the discovery of rs1133503, as-
sociation of the C allele with panic disorder and generalized social anxiety disorder
was found to be statistically significant. In cells with both C and T alleles present
(heterozygous), 45% less T-allele mRNA was present, and the overall level of mRNA
in TT homozygotes was 67% of that in CC and CT cells.188 In the Han population in
mainland China, a SNP close to MANEA was found to be associated with sporadic
Parkinson’s disease.189 Using a novel approach of integrative genome-wide associa-
tion (iGWAS, integrative genome-wide association study), MANEA was identified as
a susceptibility gene for asthma.190 It was also discovered that MANEA expression
was decreased in response to androgens.191 Androgen-responsive genes are poten-
tial targets for anticancer medication, as high level of androgens is associated with a
higher incidence of prostate cancer.
Two general conclusions can be drawn from the body of knowledge about the enzyme.
First, endomannosidase cleavage is an event that ultimately prevents proteins from
re-entering the calnexin/calreticulin cycle. Second, the enzyme has probably evolved
in order to cleave monoglucosylated substrates irrespective of the folding state and
not act upon non-glucosylatedN-glycans. What seems to be often missed in literature
is the consideration that when proteins have multiple N-glycosylation sites, it is likely
that not all N-glycans will be processed in the same way before the protein exits from
the ER. Only some glycosylation sites may serve as binding sites for chaperone lectins.
The presence of the endomannosidase pathway ensures that all N-glycans will be
available for processing by the Golgi machinery: its localization within ERGIC and
cis/medial Golgi strongly points to such a function in vivo. As such, the pathway does
not look as an alternative, but an integrated part of N-glycosylation machinery in
animals, which ensures glycans can be processed further.
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1.4.5.4 Sequence, domain organization and 3D structure of endomannosidase
An affinity-based method of purifying endomannosidase was described in 1994.192
The group used a non-cleavable derivative of the  – 2/– 1 subsite ligand, GlcMan,
which was previously found to be weakly inhibitory.153 The purified rat liver endo-
mannosidase migrated as two bands and had an apparent molecular weight (Mw) of
56 and 60 kDa. This was followed up and the 60 kDa turned out to be the chaperone
calreticulin.193 Another study isolated the enzyme from pig liver and again it was
observed as two bands of mobility corresponding to an Mw of 48 and 50 kDa and
not glycosylated (which was also confirmed for rat enzyme in Ref. 172). Enzymes
from both bands were active, leading the authors to a conclusion that the enzyme
undergoes nonspecific proteolysis.194
The gene encoding the rat endomannosidase was cloned and expressed in E. coli in
1997 and the sequence of the protein product was not homologous to any other pro-
tein known at the time.176 The enzyme was found to be 451 aa long and have an
Mw of 52 kDa. It was claimed that a 8 kDa C-terminal peptide cleaved by E. coli
proteases was not a part of the active site, which is dubious as the proposed active
residues would be within this fragment. Most likely the sequence was cleaved but
did not dissociate from the protein, which would destabilize the fold. That first rat
endomannosidase sequence was shown to be an artifact of cloning seven years later.
The N-terminal sequence preceding aa 55 came from a different chromosome.195 Full-
length, C-terminally GFP-tagged (green fluorescent protein-tagged) human and rat
MANEA proteins were localized to the Golgi when produced in CHO-K1 cells, and
an N-terminally truncated human protein was mislocalized. When a protein compris-
ing residues 1–59 with a C-terminal GFP tag was produced, fluorescence was seen in
the Golgi. This established that it is the N-terminal signal sequence that targets the
protein to the Golgi, and that the enzyme is a typical type II membrane protein.195
When N-terminally tagged with GFP before the signal sequence, the enzyme also
localized to the Golgi.196
MANEA from CHO cells is inactive.153 Cloning, sequencing and translation of CHO
MANEA mRNA revealed two cysteines found in no other endomannosidases known
at the time: C177 and C188. In the human gene, these residues are, respectively, R
and W. The authors of a study published in 2007197 looked at “restoring” both of
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these residues from the CHO sequence to the human sequence. Whether residue 177
was C or R had no effect, rescuing or detrimental, to the activity of the enzyme (the
enzyme used for these substitution studies was CHO MANEA). Indeed, it was later
found that residue 177 in the wild-type chinese hamster MANEA protein sequence
is a cysteine when its genome was sequenced, annotated and the coding sequences
translated (see Figure 1.15).198 The C188 variants had no activity and localized to the
ER, while the C188W variants were active and localized to the Golgi.197 The ER mis-
localization was caused by formation of an intracellular disulfide bridge between the
residues. MANEA does not have any N-glycosylation sites and therefore its cysteines
might be less likely to be shielded by the lectin-based ER chaperoning machinery. An-
other sequence feature that was investigated was a positively charged patch found in
the cytoplasmic tail of endomannosidases from many species. Only the length of the
tail was found to influence the Golgi localization of the enzyme, not the identity of
amino acids: proteins with shortened tails were retained in the ER.199
Hs MANEA
Cg MANEA
CHO MANEA
177 188
Figure 1.15: An excerpt of multiple sequence alignment of Homo sapiens (Hs), Chi-
nese hamster (Cricetulus griseus, Cg) and CHO-K1 cells MANEA proteins. Amino acid
residues are coloured by similarity (BLOSUM62 score matrix with a similarity thresh-
old of 1, black background: 100% similar, light grey: 60–80% similar, white: less than
60% similar; for details of the BLOSUM score matrix see Ref.200). Residues 177 and
188, talked about in the text, are in red boxes. Figure made in Geneious201; sequences
aligned using the MUSCLE algorithm.202
Endomannosidase is post-translationally modified. Phosphorylation of the luminal
domain of MANEA in the Golgi was detected after the protein found its way into
the Golgi.172 The PhosphoSitePlus database203 lists experimentally confirmed post-
translational modifications (PTMs). In the human MANEA, 12 phosphorylation sites
(1 in the cytoplasmic tail), 4 O-glycosylation sites and 1 ubiquitinylation site were ob-
served. Torossi et al.172 could not, however, detect anyO-glycosylation on their variant
of the protein. They speculated that phosphorylation might be used in order to reg-
ulate its activity or its half-life, but also that it can be inconsequential. All potential
O-glycosylation sites are situated at the C-terminal part of the stem domain of endo-
mannosidase, which is a linker between the transmembrane helix and the catalytic
domain.
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Figure 1.16: Structure of Bacteroides xylanisolvens GH99 endo-α-1,2-mannanase in com-
plex with GlcIFG and α-1,2-mannobiose (PDB code 4AD4, Ref. 148). (A) Electrostatic
surface and ligands. Subsites annotated next to the sugar moieties. (B) Ribbon depic-
tion showing the (β ∕ α)8 barrel fold of the protein. Assembled in ccp4mg.204
Expression of a Shewanella amazonensis (prokaryote) gene encoding a GH99 protein
and the finding that it had endomannosidase activity was reported in 2011.205
3-dimensional structures of two bacterial GH99 endomannosidases whose natural
substrate is yeast mannan (and were therefore dubbed endo-α-1,2-mannanases)
were published by Thompson et al. in 2012.148 Bacteroides thetaiotaomicron (Bt) and
Bacteroides xylanisolvens (Bx) that live inside the human gastrointestinal tract were
source organisms, and the genes were expressed in E. coli. These proteins differ
from the endomannosidase by not having a type II membrane protein topology,
but instead being fully soluble. The structure revealed a new fold: a modified
(β ∕ α)8 barrel (Figure 1.16B) and a groove-like binding site typical of endo-acting
enzymes.206 Ligand soaking experiments helped define four subsites, from – 2 to
+2, within the groove (Figure 1.16A). Most amino acids that directly coordinated
the ligand were conserved between the bacterial and the mammalian enzymes,
implying similar modes of action. The only exception was a tryptophan residue
close to the – 2 sugar moiety, which in yeast mannan would be Man, and in the
N-linked glycan, Glu. In mammalian endomannosidases this is a tyrosine residue.
The bacterial endomannanases take part in “selfish” utilization of the yeast glycan
by gut endosymbionts.207
Of particular importance, the catalytic amino acid residues were discovered. These
are two Glu residues 333 and 336 (BxGH99 numbering) that correspond to E329 and
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E332 in BtGH99, E404 and E407 in the human MANEA and E406 and E409 in the
human MANEAL. The BtGH99 E329A had no activity, and the E332A mutant was 50-
fold slower than the WT (wild-type) enzyme. The structure of a Michaelis complex of
the inactive BxGH99 mutant with ManMan-4-methylumbelliferone (ManManMUF)
was published in 2015, but the ligand was bound in an unorthodox position, which
prevented the authors from drawing sweeping conclusions about the real structure of
substrate-bound GH99. Its catalyzed hydrolysis with the WT enzyme was remarkably
slow, as would be expected from the unorthodox positioning of ManManMUF (the
hydrogen bonding of bound ManManMUF was unlike any other BxGH99 structures
in complex with ligands; this will be elaborated further in Section 2.2).159
A structure of a GH99 family protein from the marine flavobacterium Ochrovirga paci-
fica without the catalytic residues has been published recently, but it bears resem-
blance to Bt/BxGH99 proteins only in its overall fold. The residues in the marine
GH99 corresponding to the catalytic residues in GH99 endomannosidases are not
likely to catalyze the hydrolysis of a glycosidic bond, and its binding cleft is deeper,
wider and longer. The authors of the study speculate that this protein might bind,
but not degrade, a mannose-rich glycan.208
1.5 Implications of glycosylation in health and disease
1.5.1 Glycosylation and viral diseases
Many viruses are known to depend on their glycans for retaining infectivity. A well-
known example is HIV (human immunodeficiency virus), which can lose its ability to
infect cells if some of its glycosylation sites are erased. The envelope protein gp120 is
glycosylated at approximately 25 sites.209 The removal of any one of six specific sites
within its V1/V2 and C1/C2 domains causes a complete loss of infectivity of HIV, and
when others are mutated it can become more infective.210 The glycosylation was found
to be dispensable for proper folding of this protein, but important for the virus to
evade antibody-mediated neutralization.209 Surprisingly, gp120 viral coat contains a
large number of hardly processed, high-mannose N-glycans, mainly Man9–8GlcNAc2
(a “mannose patch”,). This is caused by a high local density of glycosylation of this
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protein (see Figure 1.17), which sterically prevents mannosidases from accessing the
sites.211–213
Figure 1.17: Identity of N-glycans at various sites on HIV Env (envelope) trimer. Fig-
ure adapted from Ref. 212.
Inhibition of glucosidases using N-butyl-deoxynojirimycin (NB-DNJ) caused
G3M9Gn2 glycans to be present on SARS-CoV (severe acute respiratory syndrome
coronavirus) spike glycoprotein,‖ and changed its overall glycosylation pattern. As
would be expected, some glycans on the spike glycoprotein were processed due to
the action of endomannosidase.215 Viral proteins are dependent upon ER chaperones
for their correct folding and it was speculated that misfolding might have been
responsible for the previously observed observed reduction in infectivity.216 NB-DNJ
inhibits HIV entry into the immune cells by disrupting the shedding of its envelope
after it binds to the CD4 (cluster of differentiation 4) glycoprotein at the cell surface,
as well as lowering the amount of viruses released from cells. The inhibitor also
increases binding of antibodies to a loop region V3 (variable 3).216,217 The drug
was tested in HIV-infected people. It showed some antiviral activity, especially in
patients with previous exposure to a second tested drug zinovudine, but NB-DNJ
had unpleasant gastrointestinal side effects (osmotic diarrhoea, weight loss).218
The drug, at lower concentrations (100 mg 3 times per day vs 1500–3000 mg per
day in the antiviral therapy study) is approved to treat Gaucher disease type I, a
lysosomal storage disease.219 Due to a potential for broad-range antiviral activity
but unpleasant side effects, it was proposed that glucosidase inhibitors are better
suited to be used for acute, rather than chronic viral infections.220 Cells from the
‖The SARS-CoV spike glycoprotein, similarly to the G protein, mediates attachment and membrane
fusion. SARS-CoV is an enveloped virus.214
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two siblings with CDG-IIb, mentioned in context of endomannosidase activity being
observed in humans, were less susceptible to infections by viruses that depend on
glycosylation for cell entry.183 These cells mimic the effects of glucosidase inhibitors.
1.5.2 Glycosylation in cancer and other diseases
Glycans present on the cell surface are important in signaling to other cells. For ex-
ample, tumour cells show a decrease in high-mannose glycans and a corresponding
increase in branched, highly processed glycans. Their surface glycoprotein glycosy-
lation patterns are reminiscent of those of cells undergoing mitosis – in fact, they
are stuck in this part of the cell cycle.221 In particular, the presence of tetraanten-
nary, branched glycans with the core structure of a GlcNAc α-1,6-linked to the α-
1,6-linked mannose was observed as the cause.222,223 This particular branch can be
extended in order to form poly-N-lactosamine-type glycans (Figure 1.11, page 24),
which are recognized by galectin 3, a protein intimately involved in cell signalling,
mediating inflammation and transition to chronic inflammation.224 The branch can
form only when enzyme MGAT5 attaches the α-1,6-linked GlcNAc to a previously tri-
antennary glycan (previously acted upon by a sequence of enzymes: MGAT1, Golgi
mannosidase II, MGAT2 and MGAT4) and is associated with tumours. The level of
MGAT5 is elevated in neoplastic cells, and lower levels of MGAT5 reduce metastatic
potential.225–227 Remarkably, Mgat5-/- knockout mice show less metastases and live
longer when tumours are induced in them while appearing otherwise healthy.228
Later these mice were shown to be more susceptible to a number of automimmune
disorders.229 Galectin signalling activates a cascade of intracellular reactions, and
blocking MGAT5 prevents this process.230 Inhibitors of MGAT5 were developed,231,232
but have not yet been tested clinically and better binding compounds are needed (the
Ki of the best one was about 10 µm). The metastatic potential of a tumour is depen-
dent on the length of the glycopolymers (mimics of the heavily glycosylated protein
mucin) present on its surface, strongly suggesting that overproduction of mucin has
a similar effect.233
Inhibiting key branching transferases shows anti-cancer activity,234 but so do in-
hibitors of earlier steps of N-glycosylation. Tunicamycin, which inhibits DPAGT1235
(see Figure 1.7 on page 14) has an antiproliferative effect236. CST appeared to
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reduce tumour colonization potential, as well as increase the sensitivity of the
neoplasm to other agents.237 A combination of glucosidase and endomannosidase
inhibition could offer an alternative approach to this. Due to their unique – in
human cells – structure of an α-1,3-linked disaccharide (such as GlcDMJ shown in
Figure 1.18), endomannosidase inhibitors can potentially be selectively inhibiting
the endomannosidase activity only.
GlcDMJ
α
3
GH99 
endomannosidase 
inhibitors:
-1,3-linked α
disaccharides
Figure 1.18: The general structure of an endomannosidase inhibitor is an α-1,3-linked
disaccharide. Here, GlcDMJ is shown as an example.
19 types of CDG have been identified but none involving mutations in MANEA or
MANEAL.238 Nothing is known about the effect of the knockdown or knockout of
these genes in living and developing organisms and the only data available comes
from the previously mentioned GWAS (genome-wide association study).
1.6 Project aims and Thesis outline
Inhibition of glucosidases is a potentially universal antiviral therapy, as viruses de-
pend on the cellular machinery to assume the correct fold. They need to hijack the
host protein production systems in order to reproduce. When the system is disrupted,
it is almost certain the host will be negatively affected, but also possible that the viral
reproduction cycle will be severely disturbed. The potential for disruption of viral
proteins is even higher if more than one element of the protein folding machinery
is blocked. As endomannosidase can give some viral glycoproteins a way to mature
in the Golgi even under conditions of glucosidase inhibition, applying inhibitors of
this enzyme could enhance the effectiveness of the intervention. Specific glycan tags
were also detected in cancer cells, and endomannosidase inhibitors may prevent those
structures from forming, if combined with mannosidase or glucosidase inhibition
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regimes. The main aims of the project described in this Thesis are listed below.
• Test the endomannosidase reaction mechanism hypothesis posed by Thompson
et al.148 using synthetic reaction intermediate mimics (Chapter 2).
• Use bacterial GH99s as a platform for testing potential novel inhibitors and mea-
sure their thermodynamic binding parameters (Chapter 3).
• Purify a recombinant version of human endomannosidase and characterize its
Michaelis-Menten kinetics. Chapters 4 and 5 explore results of these efforts for
two human GH99 proteins, MANEA and MANEAL.
• Determine the crystal structure of the human endomannosidase. Produce a
crystal form able to accommodate ligands in its active site; investigate human
endomannosidase in complex with its inhibitors in order to learn about the in-
teractions in the active site and test the conclusions drawn by Thompson et al.148
from the structure of the bacterial GH99. This part is presented in Chapter 4.
• Test the antiviral activity of endomannosidase inhibitors alone and in combina-
tion with glucosidase inhibitors using cells infected by a virus with a glycosy-
lated structural protein (Chapter 5).
A compendium of small molecules that are most relevant to this Thesis can be found
in Appendix A. Appendix B contains an explanation of Cremer–Pople parameters
describing the conformations of furanoses and pyranoses. Published work that
was contributed to but not the focus of this Thesis is presented in Appendix C:
Bibliography. It includes determination of the oligomeric state of Talaromyces
pinophilus GH62 arabino furanosidase and its dissociation constant with AraDNJ
(l-arabinodeoxynojirimycin) and crystallization experiments on Bacteroides ovatus
GH43B protein. The appendices are followed by List of Abbreviations that were
used in the Thesis. The list of references is in the last section, entitled References.
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Chapter 2
The endo-α-mannosidase and
endo-α-mannanase mechanism
2.1 Abstract
The knowledge of a reaction mechanism that an enzyme uses is key to understand-
ing its biochemistry. It can guide rational design of inhibitors, as well as reveal
unique chemical transitions. The mechanism of GH99 endo-α-1,2-mannosidase has
been a puzzle since the first structures with inhibitors bound in the  – 2/– 1 subsites
were published. The Koshland double displacement mechanism that many retain-
ing mannosidases follow was not likely: none of the residues around the – 1 sugar
were good candidates for a nucleophile. In this chapter, data supporting hypothe-
sis of an alternative, neighbouring group participation reaction mechanism are pre-
sented. Mimics of the proposed reaction intermediate and related compounds were
synthesized by collaborators and tested with the enzyme and its mutants. Only one
such compound, which resembled the α-1,2-anhydrosugar intermediate most closely,
was a substrate for the bacterial endomannosidase (endomannanase). 3-dimensional
structures of the wildtype enzyme and its mutants with the mimic were obtained
and supported the kinetic data, as well as structures with the minimal substrate and
the product. QM/MM calculations suggest the overall conformational itinerary is:
4C1→2H3→[E3]‡→4E→[E3]‡→4C1. This mechanism is unique among mannosidases
and enzymes in general. These insights are a crucial addition to the understanding
of the process of N-glycosylation.
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2.2 Introduction
Bacterial endo-α-1,2-mannanases have been used as a model for mammalian endo-α-
1,2-mannosidase due to the ease at which they are expressed in E. coli and because
they offer a high likelihood of crystallization. Other factors include belonging to the
same CAZy family (GH99) and therefore an increased likelihood of a similar mode of
action. In a 2012 paper,148 Andrew Thompson et al. suggested that the reaction mech-
anism of this enzyme is not a canonical retaining mannosidase double-displacement
mechanism proposed by Koshland in 195384 (Figure 2.1A) and true for many pre-
viously characterized retaining α-mannosidases. The reaction intermediate in the
proposed reaction mechanism for GH99 endomannosidases would be a disaccharide
with a 1,2-β-anhydrosugar in the – 1 subsite (Figure 2.1B).
A
B
Enz.
Enz.
Enz.
Enz.Enz.Enz.
Bx GH99
numbering
Figure 2.1: Possible mechanisms for endo-α-1,2-mannosidase and endo-α-1,2-
mannanase. (A) General double displacement, retaining mechanism proposed
by Koshland84 for glycoside hydrolases (GH). (B) Mechanism involving a 1,2-β-
anhydrosugar reaction intermediate proposed by Thompson et al148 (BxGH99 num-
bering of the catalytic residues).
The reasoning behind this suggestion came from an observation that in a complex
with a classical GH99 inhibitor,153 GlcDMJ, none of the hydroxyl groups of the
catalytic glutamate residues, E333 and E336, were within 2.6–2.8 Å of the pseu-
doanomeric atom (PDB code 4AD3). The same observation was made for a GH99
inhibitor whose synthesis was first reported in the 2012 paper, α-Glc-1,3-isofagomine
(GlcIFG, PDB code 4AD2). Additionally, the inhibitor was not distorted from the
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relaxed 4C1 chair conformation when bound to the enzyme. Through soaking
of the crystals with both the inhibitor disaccharide and α-1,2-mannobiose, four
subsites, from – 2 to +2, were defined for the enzyme (PDB codes: 4AD4, 4AD5, see
Figure 2.2A).
–2
A CB
–1
+1
+2
R295
E156
Y46
Y252E336
E333
–2
–1
R295
E156
Y46
Y252E336
Q333
GlcIFG + -1,2-mannobioseα
complex with WT BxGH99
ManManMUF
Michaelis-like complex
with BxGH99 E333Q
Comparison of A and B
Figure 2.2: Position and conformation of ligands in the binding site of BxGH99 and
amino acid residues around the – 1 subsite. (A) Structure of WT BxGH99 in complex
with GlcIFG and α-1,2-mannobiose (PDB code 4AD4). Coral – carbons of the small
molecules, green – polypeptide carbons. Subsites and aa residues are annotated. (B)
Structure of E333Q BxGH99 in complex with ManManMUF (PDB code 4V28). Note
E336 exists in two conformations. Grey – carbons of the small molecules, yellow –
polypeptide carbons. Subsites and aa residues are annotated. (C) Comparison of
A and B with major atomic position diffrences highlighted using arrows. Coloured
as previously. Subsite and residue annotations omitted for clarity. Assembled in
ccp4mg.204
BtGH99 mutants E154A and E329A had zero activity, and mutant E332A was 50 ×
slower than the WT. These residues are equivalent to E156, E333 and E336 in BxGH99.
A Michaelis-like complex of the E333Q BxGH99 mutant with ManManMUF was pub-
lished in 2015.159 However, ManManMUF is a remarkably poor substrate for the en-
domannanase and the structure (PDB code 4V28) provides some clues why. The – 2
sugar of the ligand appears bound in an unorthodox position (Figure 2.2BC). Notably,
the OH6 of the – 2 sugar does not form a hydrogen bond with E336 OH – an interac-
tion which was observed in all other structures of BxGH99 with ligands occupying
the  – 2/– 1 subsites (interatomic distance 6.8 Å instead of 2.6–2.8 Å for others). MUF
is also situated in the active site less ideally than the natural + 1/+ 2 leaving group,
α-1,2-mannobiose. In the same article, an endomannanase inhibitor with the best
affinity to the enzyme (ManIFG, PDB code 4V27) was reported. The 4.5-fold increase
in affinity over GlcIFG was achieved by changing the – 2 sugar moiety from Glc to
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Man, supporting the claim that the enzyme has been evolutionarily tuned for yeast
mannan, rather than mammalian N-glycans.
A neighbouring group participation reaction mechanism was observed for hex-
osaminidases from families GH20,239–241 and GH18,242 as well as humanO-GlcNAcase
from family GH84,243–246 GH56247 and GH85.248 In 2016, Spencer Williams’ group149
presented kinetic isotope effect (KIE) evidence that the OH-catalyzed hydrolysis of
1-pNP-α-d-mannopyranoside (1-paranitrophenyl-α-d-mannopyranoside) consistent
with the transition state being a 1,2-anhydrosaccharide (see Figure 2.3). The reaction
intermediate for NaOH-catalyzed solvolysis of α-d-mannosyl fluoride is known to
be the same compound.249
Figure 2.3: Alkaline hydrolysis of 1-pNP-α-d-mannopyranoside. Figure from Ref.
149.
The KIE is defined as the ratio of the reaction rate on a compound with the light iso-
tope to that on the compound with the heavy isotope.250 The change in reaction rate is
caused, in theory, by vibrational differences between the atoms due to their slightly
different mass.251 In general, two types of kinetic isotope effects are measured: pri-
mary and secondary. Primary isotope effects are measured for atoms that directly
participate in a reaction by forming or breaking bonds and secondary isotope effects
for atoms that do not.250 As these KIEs stem from very minimal changes to the nat-
ural substrate, they offer insights into the identity of the generally unobservable TS
(transition state) that are not available through other methods. For example, the mag-
nitude of a KIE can provide information about the bonding environment around the
labelled atom: if it is more than 1 (normal) it is less restricted in the TS and if it is less
than 1 (an inverse KIE) it is more restricted and the compound containing the heavy
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isotope reacts more quickly than the light one.252
That none of the – 1 sugars are distorted when bound to the enzyme is significant.
In α-d-mannose, the OH2 group is in the axial position when mannose is in a 4C1
conformation. This causes an effect destabilizing the sugar conformation when a
nucleophilic attack at the anomeric carbon is attempted – collectively called the Δ2
effect.253 α-Mannosidases need to overcome this effect in order to hydrolyze the gly-
cosidic bond, which is usually accomplished by distorting the conformation of the
– 1 sugar. For inverting α-mannosidases, the observed conformational itineraries are:
OS2→[B2,5]‡→1S5 (GH125)254 and 3S1→[3H4]‡→1C4 (GH47)29,255. These enzymes are
exo-acting and the inhibitors used to elucidate their reaction mechanism are pseudo-
monosaccharides like kifunensine or nojirimycin. Swainsonine256 is a powerful in-
hibitor of glycoprotein processing, acting on Golgi α-mannosidase II and lysosomal
α-mannosidase.257 Fleetamine (α-Glc-1,3-swainsonine) was proposed in 1993154 as a
potentially tightly-binding inhibitor of endo-α-mannosidase, and its synthesis was
published almost two decades later158. However, neither ITC, nor soaking experi-
ments on BxGH99 showed any binding of Fleetamine to the enzyme. Taken together,
these observations about GH99 show this enzyme has unusual features: its active site,
and possibly the mechanism of action is unlike that of other mannosidases. But they
do not provide direct evidence that would prove or disprove the hypothesized GH99
mechanism. Notably, the lack of a “true” Michaelis complex has been problematic in
ascertaining how GH99 works. In this chapter I will present snapshots of the GH99
reaction mechanism at the point of substrate binding, reaction intermediate and the
product. Additionally, data on the activity of four variants of the enzyme on various
intermediate mimics with correct and incorrect stereochemistry at C1 and C2 will be
shown and interpreted.
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2.3 Materials and methods
2.3.1 Gene expression
Genes encoding GH99 endomannosidase from Bacteroides thetaiotaomicron (UniProt ID:
Q8A109) and Bacteroides xylanisolvens XB1A (UniProt ID: D6D1V7) were expressed in
E. coli BL21(DE3) cells (Agilent). The gene encoding BtGH99 was cloned into pET-
YSBL3C vector, which is a pET28a(+) vector modified by the addition of a 3C pro-
tease cleavage site. Cloning of BtGH99 was done by Dr Tracey Gloster before the
commencement of this Thesis work. The gene encoding BxGH99 was cloned into a
canonical pET28a(+) vector (between NdeI and XhoI restriction endonuclease sites).
Cloning of BxGH99, as well as mutagenesis of BxGH99 in order to produce genes en-
coding BxGH99 E333Q and E336Q was done by Dr Andrew Thompson before this
Thesis work was commenced. Competent cells were made using a modified one-
step protocol258 where LB (lysogeny broth) media in TSS (transformation and storage
solution) was substituted with MQ (ultrapure) H2O. The competent cells were trans-
formed with the DNA plasmids using a traditional 45 s at 42 °C heat-shock method
with subsequent 1 h recovery in SOC (super-optimal broth with catabolite repres-
sion) media259 and plating on LB agar containing 50 mg ml-1 kanamycin (Kan). After
overnight incubation at 37 °C, single colonies were selected from the plate and shaken
at 180 RPM (revolutions per minute) in 4 × 8 ml Kan+ LB media overnight at 37 °C in
order to grow starter cultures. The following morning, the 8 ml starter culture was
added to 750 ml of Kan+ (with a working concentration of kanamycin added) LB me-
dia in 2 l flasks. A total of 3 l (4 × 750 ml) media was used at this stage. The cultures
were shaken at 180 RPM and 37 °C until the OD600 (optical density at 600 nm) was
0.8–2, at which point expression was induced by adding sterile IPTG (isopropyl β-
d-1-thiogalactopyranoside) solution up to a concentration of 0.2 mm. After this step,
the cultures were shaken at 180 RPM at 16 °C overnight. Cells were harvested by
centrifugation for 20–30 min at >5000 × g (multiples of gravitational acceleration on
the Earth’s surface) and frozen at -80 °C. BxGH99 mutants: E333Q and E336Q were
produced using the same protocol.
The cell pellet was resuspended in buffer A (25 mm HEPES pH 7.0, 300 mm NaCl,
20 mm imidazole, 1 mm DTT) until homogeneity and then cells were disrupted by
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sonication on ice. The solution for the next step was darker and more viscous. It was
centrifuged at ~3900 × g for 10 min and loaded onto a 5 ml HisTrap FF Crude column
(GE) preequilibrated with buffer A. The column was washed with 30 ml of buffer A,
and then the bound protein was eluted using an imidazole gradient through mix-
ing in buffer B (25 mm HEPES pH 7.0, 300 mm NaCl, 500 mm imidazole, 1 mm DTT).
Fractions containing the protein of interest were collected and concentrated using an
AMICON 30 kDa cut-off ultrafiltration device. The resulting solution was loaded
onto a 120 ml Superdex S75 16/60 gel filtration column, preequilibrated with pro-
tein storage buffer (25 mm HEPES pH 7.0, 100 mm NaCl, 1 mm DTT). The fractions
containing pure protein were combined and concentrated using an identical ultrafil-
tration device. The final concentration was 30–50 mg ml-1. The protein solution was
divided into 50 µl aliquots in 1.5 ml eppendorf tubes, flash frozen in liquid nitrogen
and stored at -80 °C.
2.3.2 Chemicals, assays and mass spectrometry
The compounds used in the study were synthesized by Dan Lu and Sha Zhu
in Matthieu Sollogoub’s laboratory at UPMC, Paris, France and Pearl Fernan-
des, Marija Petricevic, Dr Zalihe Hakki and Dr Gaetano Speciale in Spencer J.
Williams’ laboratory at University of Melbourne, Parkville, Australia. Spencer
Williams’ laboratory provided α-Man-1,3-noeuromycin (ManNOE), α-Man-1,3-
d-glucal (Man-d-glucal), α-Man-1,3-dideoxymannose (ManddMan), α-Man-1,3-
2-aminodeoxynojimycin (ManADMJ), α-Man-1,3-mannoimidazole (ManManIm)
and α-Man-1,3-α-Man-1,2-α-Man-1,2-α-1-methyl-Man (Man4OMe). For struc-
tures, see Figure 2.4A. Matthieu Sollogoub’s laboratory provided α-Glc-1,3-
α/β-epoxide (Glc-α-epoxide/Glc-β-epoxide), α-Glc-1,3-α/β-aziridine (Glc-α-
aziridine/Glc-β-aziridine) and α-Glc-1,3-cyclohexene (Glc-cyclohexene), depicted in
Figure 2.4B. α-1,2-Mannobiose and α-1,3-mannobiose were purchased from Sigma.
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Figure 2.4: Compounds used in the study. (A) Chemicals synthesized in Spencer
J. Williams’ lab: ManNOE, Man-d-Glucal, Man-ddMan, ManADMJ, ManManIm,
Man4OMe. (B) Chemicals synthesized in Matthieu Sollogoub’s lab: Glc-β-epoxide,
Glc-α-epoxide, Glc-β-aziridine, Glc-α-aziridine, Glc-cyclohexene.
Experiments which required quantification of small molecules using mass spectrome-
try, which involved the use of the five compounds from Matthieu Sollogoub’s labora-
tory, were conducted by me on a visit to UPMC, Paris, France. The conditions for each
reaction were: 37 °C in 1.25 mm HEPES pH 7.0, 5 mm NaCl and the total volume var-
ied between 20 and 40 µm. The compounds were incubated in separate reaction tubes
with 1 µm of WT BtGH99, WT BxGH99, BxGH99 E333Q, BxGH99 E336Q; 20 µm of WT
BtGH99; or buffer only. All five compounds were tested. Each reaction was followed
by taking samples after 20 min, 60 min and overnight (after 17–22 h). Each reaction
was quenched by mixing 10 µl reaction mixture with 100 µl methanol. Mass spectra
were obtained using a Bruker microTOF spectrometer using electrospray ionization
(ESI). All compounds were used at a starting concentration of 1 mm with correction
factors from calculations applied later. The peaks corresponding to the [M+Na]+ ions
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were integrated in Origin software260. The concentration of the compounds was esti-
mated as follows: the areas of the peaks corresponding to unreacted epoxide or aziri-
dine and their ring-opened forms in each mass spectrum, were added and assumed
to sum up to 1 mm. The proportion of the area of each peak was divided by the total
area and this was converted into a concentration. In the case of the Glc-β-epoxide, ex-
tended digestion with enzyme revealed that a portion of the substrate peak was not
processed by the enzyme, and were most likely traces of Glc-α-epoxide. This amount
was subtracted from the total calculated Glc-β-epoxide concentration. Glc-β-epoxide
and Glc-β-aziridine were not stable in the buffer used. This can be seen in the reac-
tion graph the case of Glc-β-aziridine, which was the least stable and about 15% of
the aziridine ring was hydrolyzed in 1 h.
NMR of open Glc-β-epoxide was performed by Sha Zhu in D2O using a 600 MHz
Bruker Avance magnet.
2.3.3 Crystallization, crystal handling and structure solution
BxGH99 crystals were grown in droplets containing a 1:1 ratio (1 µl each) of protein
(34 mg ml-1 in 25 mm HEPES pH 7.0, 100 mm NaCl, 1 mm DTT) to reservoir solution
(3 m sodium acetate pH 6.4–7.4). The droplets were hanging on a siliconized cover
slip above 500 µl of the precipitant at 19 °C in darkness. The 24-well plates used for
crystallization were obtained from Greiner Bio-one. The contact surface between the
cover slip and the plate was sealed using high vacuum grease. Crystals were fished
from the droplets using nylon cryoloops. Crystals were soaked with the ligand at var-
ious concentrations, ranging from 1 to ~40 mm. Cryoprotection briefly submerging
the crystal in the reservoir solution with ethylene glycol added up to 20% was applied
when fishing the initial crystals soaked with ManddMan and Man-d-glucal, but was
omitted for subsequent crystals due to no obvious benefits. Data were collected re-
motely at beamlines I02, I04 and I04-1 at Diamond Light Source using a wavelength
of 0.979 Å.
Diffraction was integrated using Xia2261 or DIALS262 and scaled in Aimless.263 The
resolution of the data was cut according to guidelines from Ref. 263, with CC(1/2) be-
ing the most important factor (the cut-off was 0.3). The model used for direct refine-
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ment with each dataset listed in Table 2.2 was BxGH99 with ManddMan with water
molecules and the ligand removed from the pdb file (PDB code 5M17). The details
creating the initial model are in Section 3.3.2, where the BxGH99 + ManddMan struc-
ture is discussed in context of other inhibitors. Refinement was done in Refmac5264
and model modifications were made in Coot.265 Waters were added to the models
when the protein chain was refined as well as possible in real space. The model and
its agreement with electron density was validated using Coot tools and the wwPDB
validation software. CCP4i2 was used for the majority of the process.266
2.4 Results and discussion
2.4.1 Structural snapshots of the endomannanase mechanism and
the conformation of sugars in the – 1 subsite
In order to adequately characterize the GH99 mechanism, a number of BxGH99 com-
plexes with different ligands were solved. An attempt at placing the structures on the
conformational itinerary was then made. A 4C1→[4E]‡→4H5 itinerary was proposed
for the enzyme in a 2014 review267 based on the structural analysis of the available
complex structures, in all of which the – 1 subsite ligand was seen in a 4C1 conforma-
tion, including the Michaelis-like complex with ManManMUF. In the current work,
the structure of a more biologically relevant Michaelis complex (BxGH99 E333Q with
Man4OMe, Figure 2.5A) is reported, as well as the product complex with both α-1,3-
and α-1,2-mannobiose (Figure 2.5C). Structures with reaction intermediate mimics
were solved as well: BxGH99 E333Q with Glc-β-epoxide (as shown in Figure 2.9) and
WT with Glc-β-aziridine (Figure 2.5B). A summary of the conformations of various
compounds in complex with BxGH99 is presented in Table 2.1. The significance of
these results will be presented in the discussion of each structure.
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Figure 2.5: Structural snapshots along the endomannanase reaction coordinate with
residues surrounding the ligand shown. All electron density maps are 2mFo-DFc
syntheses contoured at 0.8 e–/Å3 (A) The BxGH99 E333Q Michaelis complex with
Man4OMe. (B) Complex of WT BxGH99 with a mimic of the reaction intermediate
Glc-β-aziridine. Note the double conformation of the + 1 sugar leading to multiple
possible hydrogen bonds with residues 289, 298 and 336. (C) E333Q product com-
plex with α-1,2-mannobiose and α-1,3-mannobiose. (D) Movement of the + 1 man-
nose moiety as the reaction progresses (models – white: A, grey: B, dark grey: C).
Assembled in ccp4mg.204
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Table 2.1: Conformations of different ligands as determined from refinement to elec-
tron density inside the BxGH99 active site. For views of ManNOE, Man-d-glucal,
ManddMan, ManADMJ, ManManIm and Glc-α-aziridine, see Section 3.4.2.
– 1 sugar
conformation Sugar or sugar analog
4C1 ManNOE, ManddMan, ManADMJ, Man4OMe, open
Glc-β-epoxide, GlcDMJ, ManDMJ, ManManMUF,
α-1,3-mannobiose
4H5 Man-d-glucal, Glc-α-aziridine, Glc-cyclohexene
4E Glc-β-epoxide, Glc-β-aziridine
2H3 / E3 ManManIm
The 4H5 conformation for the anhydrosugar intermediate was proposed due to this
half-chair being the apparent lowest energy conformation of the – 1 anhydrosugar (as
calculated using Marvin).268 4E envelope was deduced as the conformation of the TS
from the principle of least nuclear motion. Transitioning from a 4C1 to 4H5 requires
a larger conformational change than 4C1 to 4E. These crystallographic data suggest a
more simple itinerary of 4C1→4E. Both Glc-β-epoxide and Glc-β-aziridine were found
to bind to the enzyme in a 4E conformation, and the theoretical lowest energy confor-
mation for them is also 4H5. Another possible explanation is that the compounds act
as mimics of the proposed TS, and the reaction intermediate is a 4H5 half-chair. This
seems less likely, as both compounds closely resemble the reaction intermediate. A
third possibility is that the difference between 4E and 4H5 is not large in terms of the
necessary conformational change, and it may be superfluous to explain reaction dy-
namics by it. In the QM/MM calculations which are presented later in this chapter,
conformation 4H5 does not appear. It was observed it in BxGH99 structures in com-
plex with Man-d-glucal, Glc-α-aziridine and Glc-cyclohexene. The calculated lowest
energy conformation for these compounds is also 4H5, but 4E is also energetically
accessible.269
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The Michaelis complex (with Man4OMe, Figure 2.5A, Figure 2.6) shows that BxGH99
is an anti protonating enzyme. The +1C2-–1O1-C1-O5 dihedral angle is 63°, which
serves to position the + 1 sugar on the opposite side to the acid/base E336. The –1O5-
C1-O1-E336Oε angle is 172°, close to 180°, which is optimal for anti protonating en-
zymes. The 4C1 chair of the – 1 sugar is slightly distorted: its θ and ϕ angles are,
respectively, 19.7° and 120.1°. If the θ angle was larger than 22.5° its conformation
would be closer to 2E than 4C1. Such a conformation is caused by strong binding
of the +1/+2 sugars which may serve to kink the mean sugar plane “up” with re-
spect to E336 Oε, positioning the glutamate oxygen slightly below the plane. This
makes the endomannanase an anti-B (below) enzyme according to nomenclature by
Nerinckx.270 The anti position of the acid/base was known since the first structural
study of GH99,148 but the Michaelis complex was essential to determine whether it
acts from above or below the plane. Carbohydrates in other subsites are all relaxed
4C1 chairs. The hydroxyl group of Tyr252 is poised to interact with the – 1 sugar ring
oxygen, but in the Michaelis complex the atom is pulled away from it, making the in-
teratomic distance 3.35 Å. For complexes with Man-d-glucal, ManddMan and α-1,3-
mannobiose this distance is 2.9–3 Å, suggesting the interaction might be important
in the later stages of the reaction.
63°
172°
E336
E336
Q333
Q333
–2
–1
+2
distorted
4C
1
A B
–2
–1
+1
+2
Figure 2.6: Geometry of the BxGH99 E333Q complex with Man4OMe with respect
to the – 1 sugar and with the catalytic residues shown. (A) View from the top with
dihedral angles of interest marked. (B) View from the front, showing the distortion
of the 4C1 conformation. Assembled in ccp4mg.204
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Complexes mimicking the reaction intermediate can offer an intimate look into re-
action dynamics. Perhaps the most relevant for the current analysis is the tertiary
complex of BxGH99 with Glc-β-aziridine and α-1,2-mannobiose, which was solved
at a near-atomic resolution of 1.04 Å (Figure 2.5B, Figure 2.7A for the – 2/– 1 subsites).
E333 clearly stands out as an important residue, making a strong 2.58 Å hydrogen
bond with the aziridine nitrogen but leaving the three-membered ring intact (Fig-
ure 2.7A). The Cδ…Oε1 linkage (see Figure 2.7A for nomenclature) is 0.04 Å shorter
than Cδ…Oε2, and the electron density suggests more of a double-bond like charac-
ter for it. Oε1 is an acceptor of a hydrogen from the H335 backbone nitrogen (distance
2.84 Å) and, more weakly, from the H336 backbone nitrogen (3.02 Å) (Figure 2.7A).
Such a hydrogen bonding pattern causes the E333 side chain to be an uncommon
rotamer: Coot suggests the probability of such a rotamer is 0, but this is the confor-
mation is observed in all BxGH99 structures. The E333 Oε2…C1 distance is 3.49 Å,
much longer than required for a nucleophilic attack (2.6–2.8 Å). When mutated to
an asparagine, Q333 Oε1 assumes a position opposite the – 1 ligand (Figure 2.5) and
Q333 Nε1 faces the ligand. Thus, there is strong preference for the mutant to replicate
the hydrogen bonding pattern with the polypeptide backbone and this requires the
the oxygen atom does not face the solvent or the ligand. Taken together, this supports
the hypothesis that the role of the residue in the reaction is to be a crucial acid/base.
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Figure 2.7: The environment around the side chain of the BxGH99 catalytic residue
333. Interatomic distances that vary significantly between different structures are in
bold (all distances in Ångstroms). α-1,2-Mannobiose in the +1/+2 subsites hidden for
clarity. (A) The complex of WT BxGH99 with Glc-β-aziridine and α-1,2-mannobiose.
2mFo-DFc synthesis contoured at 2 e–/Å3. (B) WT BxGH99 product complex (with
α-1,2-mannobiose and α-1,3-mannobiose). 2mFo-DFc synthesis contoured at 2 e–/Å3.
(C)BxGH99 E333Q product complex (with α-1,2-mannobiose and α-1,3-mannobiose).
2mFo-DFc synthesis contoured at 1 e–/Å3. Assembled in ccp4mg.204
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The product complexes, BxGH99 with α-1,3-mannobiose and with or without α-1,2-
mannobiose, were solved for the WT and E333Q mutant. A minor, but consistent
difference between the binding of the – 1 sugar by these variants exists: the WT
E333 Oε2…OH2 distance is 2.66–2.69 Å and the mutant Nε1…OH2 distance is
2.79–2.81 Å (Figure 2.7BC). A similar bonding pattern is replicated in the structure of
the Michaelis complex, where the Nε1…OH2 distance is 2.79 Å. For the complexes
with intermediate mimics, it also seems to hold true: the hydrogen bond is 2.58 Å
long in the WT structure containing Glc-β-aziridine and 2.78 Å long for E333Q with
Glc-β-epoxide. In WT and E336Q structures with open Glc-β-epoxide (“product
mimic complexes”) this distance is, accordingly, 2.66 and 2.58 Å. These measure-
ments suggest this distance in the WT enzyme-intermediate complex is 2.6–2.7 Å.
For consistency, in Figure 2.5 the Michaelis complex was compared directly with
the E333Q product complex. The crucial difference between the complex with the
substrate and with the products is the positioning of the + 1 sugar with respect to
the – 1 sugar. After the bond is cleaved, the + 1 sugar moves away from the – 1 sugar
O1 while still being transiently bound to the enzyme. That movement can be seen
when saccharide structures along the reaction coordinate are directly compared, as
in Figure 2.5D.
One residue, Y198, was consistently observed in structures with α-1,3-mannobiose to
assume a single conformation and making a hydrogen bond with the OH4 group of
the + 2 mannose, and in two conformations when this subsite is not occupied. Perhaps
Y198 is responsible for dragging the sugar out of the binding pocket after the reaction
occurs. The OH1 group of the + 2 sugar projects outside of the binding pocket into
the solvent, as this is where the rest of the yeast mannan or N-linked glycan would
be located. Due to a higher resolution (1.08 Å) of data, the two conformations of
the + 1 mannose can be seen for the WT product complex, and only one in the lower-
resolution structure with E333Q (1.65 Å). The data collection and model refinement
statistics for the structures presented in this chapter can be found in Table 2.2.
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2.4.2 Activity of GH99 towards novel substrates
The activity of BtGH99 and BxGH99 WT, E333Q and E336Q against compounds
shown in Figure 2.4B was tested. During the course of the experiments, compounds
Glc-β-epoxide and Glc-β-aziridine decomposed in the aqueous buffer solution
used, which was controlled for by performing simultaneous incubations without
the enzyme. Activity was observed only for WT Bt and Bx enzyme, and only for
Glc-β-epoxide (Figure 2.8D). The buffer-induced decomposition of Glc-β-aziridine
proceeded at a faster rate than that of Glc-β-epoxide (compare the controls in
Figure 2.8 C and D).
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Figure 2.8: MS (Mass spectrometry) quantification of the amount of closed or open
potential substrates of GH99 present after incubation with or without the enzyme.
Overnight measurements omitted in all but C in order to preserve graph clarity. (A)
Concentration of closed Glc-α-aziridine over time. Note the Y scale starts at 800 µm.
(B) Concentration of closed Glc-α-epoxide over time. Note the Y scale starts at 800 µm.
(C) Concentration of closed (descending lines) and open (ascending lines) Glc-β-
aziridine over time. (D) Concentration of open Glc-β-epoxide over time. (E) Area
of the MS peak corresponding to closed Glc-cyclohexene over time.
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The results shown in Figure 2.8D were corroborated by the crystal structures obtained
by soaking crystals of BxGH99 WT, E333Q and E336Q with Glc-β-epoxide. In the
structures of WT and the E336Q mutant the epoxide ring is open and the pseudo-
sugar occupying the – 1 subsite resembles α-d-mannopyranose. When bound to the
E333Q mutant, the epoxide ring remains closed, signifying that E333 is crucial to the
activity of the enzyme. The ligand in the WT structure was best explained by setting
the atom occupancy at 75%, which is likely due to its active turnover by the enzyme.
The β-epoxide ring is also seen as open in the structure of E336Q mutant, apparently
contradicting the MS kinetic data. BxGH99 E336Q is roughly equivalent to BtGH99
E332A which was shown previously148 to have residual activity that was about 50-
fold lower than the WT. The MS experiment might have not been sensitive enough to
detect the small amounts of the open epoxide generated by the BxGH99 E336Q vari-
ant. Glc-β-aziridine was observed bound in the active site of BxGH99 WT, as shown
earlier in Figure 2.5. The β-aziridine ring remained closed, suggesting the enzyme is
not active towards compounds with this ring, however, this cannot be asserted with
certainty when looking at the results presented in Figure 2.8C due to the fast decom-
position of the Glc-β-aziridine. This means that the endomannanase is not tuned for
opening the β-aziridine ring. What is also clear is that the compounds with an α-
configured three-membered ring are not substrates for the enzyme, which provides
indirect evidence supporting the hypothesis about the GH99 mechanism shown in
Figure 2.1. It might be argued that the α-configured compounds are unstable and
likely to open on their own, but these results suggest otherwise.
The open Glc-β-epoxide (α-Glc-1,3-α-carbamannose) cannot undergo mutarotation
due to possessing a cyclohexane ring, rather than the pyranose ring: mutarotation
necessitates that the ring can be transiently opened. After incubation of a larger
amount of the compound with BtGH99, an NMR experiment confirmed that the
product is indeed α-configured. Figure 2.9 shows the reaction catalyzed by GH99.
This result is a strong indication that GH99 can open the epoxide ring only when it
resembles the proposed reaction intermediate.
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Figure 2.9: Catalysis of ring opening of Glc-β-epoxide by BxGH99. (A) Structures
of the closed Glc-β-epoxide bound in the active site of BxGH99 E333Q variant (left,
2mFo-DFc synthesis contoured at 0.8 e–/Å3) and open Glc-β-epoxide in the active site
of WT BxGH99 (right, 2mFo-DFc synthesis contoured at 0.5 e–/Å3). Hydrogen bonds
between the catalytic residues and the sugars are shown. (B) Chemical reaction equa-
tion.
2.4.3 Quantum mechanics/molecular mechanics
Important corroborating data were generated by our collaborator Professor Carme
Rovira and Dr Lluis Raich. QM/MM metadynamics simulations on the Michaelis and
intermediate complexes that aimed at replicating the reaction as it happens revealed
the likely conformational itinerary is 2H3→[E3]‡→4E→[E3]‡→4C1 (see Figure 2.10).
The mannose residue in the – 1 subsite of the Michaelis complex (BxGH9 E333Q with
Man4OMe) was a 2E-slanted 4C1, not the 2H3 conformer. It might be that due to the
mutation at residue 333, the enzyme was incapable of fully deforming the substrate
in order to catalyze the reaction, which would require that the substrate assumes a
2H3 conformation. Possibly the difference between the length of the E333-substrate
O2 hydrogen bond (discussed earlier in Section 2.4.1) is responsible for this change.
A fortuitous finding of a weakly binding inhibitor whose – 1 pseudosugar (ManIm)
bound as 2H3 / E3 signifies the enzyme can accommodate such conformers, however,
the binding of ManManIm was undetectable (see Figure 3.7 on page 81).
With the data presented so far at hand, it is possible to form a more informed guess
about the position of the catalytic water. The analysis is presented in Figure 2.11.
Comparison of structures with the intermediate mimic Glc-β-epoxide narrows the
search down to two water molecules that are close to the anomeric carbon and below
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Figure 2.10: Schematic representations of the conformational changes during cataly-
sis of reaction by GH99 endo-α-mannanase. (A) Stoddart projection of the first part of
the reaction. (B) Structural changes during the whole reaction. The asterisk points to
the anomeric carbon.
the – 1 sugar plane (Figure 2.11A). In the structure of WT enzyme with Glc-β-epoxide,
the electron density for the O1 was found to be elongated (Figure 2.11B). This was
accurately explained by adding a water molecule (water 1) in an alternative (B) con-
formation at an occupancy of 0.25 (open Glc-β-epoxide occupancy 0.75, conformation
A). The distance between the refined water 1 position and the carbasugar anomeric
carbon is only 2.9 Å and the water is positioned below the projected plane of the E3
transition state, ideal for a nucleophilic SN2 attack (Figure 2.11D). The equivalent wa-
ter molecule in the structure of Glc-β-epoxide with BxGH99 E333Q mutant is 3.9 Å
away from the anomeric carbon of the modified anhydrosugar ring of Glc-β-epoxide
(Figure 2.11A). However, there is no indication of either of these water molecules in
the structure of Glc-β-epoxide with the slow E336Q mutant (Figure 2.11C). Instead,
even after modelling in the opened intermediate, residual positive difference electron
density remains in the space around O1 (Figure 2.11C). Thus, this result might mean
that both are important in hydrolyzing the reaction intermediate.
64
2.9
3.3
3.9 3.3
A B C
Water 1 Water 2
Water 1
Water 2
O1 O1
85°
D
Water 1 Water 1
4C
1
projected transition
state E
3
102°
Figure 2.11: Differences between the water molecules around the scissile bond posi-
tion in intermediate mimic structures. Distances to water molecules nearest to the
anomeric carbon are shown as dashed lines and labelled with length in Å. (A) Glc-β-
epoxide (occupancy of 1) with the inactive E333Q mutant. 2mFo-DFc synthesis con-
toured at 1 e–/Å3. (B) Glc-β-epoxide (occupancy of 0.75) with WT BxGH99. 2mFo-DFc
synthesis contoured at 0.3 e–/Å3. (C) Glc-β-epoxide (occupancy of 1) with the slow
BxGH99 mutant E336Q. 2mFo-DFc synthesis contoured at 0.5 e–/Å3 and positive mFo-
DFc around the O1 atom at 0.25 e–/Å3. (D) Left: a view of the carbammannose from
the structure of Glc-β-epoxide with WT BxGH99 (the chair conformation plane high-
lighted). Right: the transition state E3 conformation as projected from the carbaman-
nose. Note that both of the angles shown are close to 90°.
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2.5 Conclusions
The structural and kinetic data presented above support the hypothesized
neighbouring-group mechanism for bacterial endo-α-1,2-mannanases. To date,
no other enzymes have been shown to use a 1,2-anhydrosugar “epoxide” interme-
diate during their catalysis. The synthesis of unprotected 1,2-anhydrosugars was
reported recently271 and the compounds were unstable: 29% of 1,2-anhydroglucose
decomposed at -10 °C in 1 hour in 1:1 D2O/acetonitrile mixture. At room tempera-
ture, these compounds are likely to decompose extremely fast. Our result showing
that GH99 is active only towards the β- and not α- form of the 1,2-anhydrosugar
suggests the enzyme is unique in using this structure to circumvent the steric
barriers imposed by the internal α-mannosidic bond of its substrate. Furthermore,
the enzyme did not catalyze the hydrolysis of the aziridine ring, but only the epoxide
ring.
GH99 endomannanases overcome the unfavourable steric interactions at the axial
OH2 group by taking advantage of the presence of these potential clashes. It forms
an easily hydrolyzable reaction intermediate, which would decompose on its own in
solution, but the enzyme evolved to catalyze this process as well, probably because if
it was not broken down, the anhydrosugar would stay bound to the enzyme and in-
hibit it. It is the first instance of data being consistent with the creation of an epoxide
ring during hydrolysis. What is needed as an ultimate proof of the mechanism are
measurements of KIEs of substrates synthesized with heavy carbon, hydrogen and
oxygen isotopes around the scissile bond. KIEs have recently been used to elucidate
the mechanism of hydrolysis of a compound highly structurally related to the GH99
reaction intermediate.149 Measurements of KIEs for the GH99-catalyzed reaction have
been undertaken by the Andrew Bennett’s group (see Figure 2.12) but the results are
not available yet.
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Figure 2.12: Sites of GH99 KIE measurements. Primary isotope effect measurement
sites are at C1 and H1, and secondary at C2 and O2.
Knowing the mechanism by which a reaction proceeds is important in designing en-
zyme inhibitors. Conformationally restricted compounds that mimic the transition
state often bind with excellent affinity, outcompeting the substrate in the active site
and inhibiting catalysis. However, the electrostatic interactions and hydrogen bonds
between GH99 and an inhibitor can only form if a compound has appropriate charge.
In the next chapter, data about shape and charge mimicry in inhibiting GH99 will be
presented and interpreted.
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Chapter 3
Shape and charge of GH99 inhibitors*
3.1 Abstract
The design of enzyme inhibitors is a process which benefits from the knowledge of
ligand-protein interactions. One of the most direct methods for investigating these
interactions is X-ray crystallography, which enables the observation of interatomic
distances and sometimes also the protonation states. This chapter outlines studies on
novel GH99 inhibitor designs. Man- or Glc-linked, conformationally restricted and
unrestricted – 1 subsite warheads were surveyed. Of all of these, the tightest-binding
BxGH99 inhibitor was ManNOE. Its affinity to BtGH99 expressed as the dissociation
constant KD was 30 nm, and 13 nm for BxGH99. This was 5–20 × tighter (depending on
the protein) than the previously known tightest binder, ManIFG. KD values of other
inhibitors were above 1 µm. 3-dimensional structures of BxGH99 with all of the tested
ligands were obtained and helped to explain some surprising findings, namely the
lack of measurable binding of Man-mannoimidazole and the poor affinity of Man-
aminoDNJ. The results presented in this chapter inform future directions in GH99
inhibition, as well as provide additional data pertaining to the mechanism of this
enzyme. Inhibition of endomannosidase is a potential antiviral therapy and the large
arsenal of its inhibitors will be useful in possible future medical applications.
*Some of the work described in this chapter has been published in: Petricevic et al., Contribution
of Shape and Charge to the Inhibition of a Family GH99 endo-α-1,2-Mannanase. J. Am. Chem. Soc.
139, 1089–1097 (2017) and in Fernandes et al., Exploration of Strategies for Mechanism-Based Inhibitor
Design for Family GH99 endo-α-1,2-mannanases. Chem. Eur. J. 24, 7464–7473 (2018).
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3.2 Introduction
Inhibition of endomannosidase can potentially enhance the antiviral activity of glu-
cosidase inhibitors such as NB-DNJ. This therapy can also be antiviral on its own. At
the time when this project was commenced, the most potent known inhibitor of this
enzyme was GlcIFG.148 ManIFG was subsequently synthesized and determined to be
a better inhibitor of the GH99 endomannanase than GlcIFG. As the natural substrate
of the bacterial GH99 is yeast mannan, that was an expected result.159 The obvious ap-
proach for creating a GH99 inhibitor is linking Man or Glc with a previously known
exomannosidase inhibitor in order to obtain the analog of the  – 2/– 1 ligand. The ef-
fects of these compounds on GH99 vary from excellent inhibition (as with GlcDMJ153
and GlcIFG)148 to poor or no binding (as with GlcSW, dubbed Fleetamine).158 Struc-
tures of proposed GH99 inhibitors are presented in Figure 3.1A and inhibitors whose
structure in complex with BxGH99 was solved are presented in Figure 3.1B.
E333
E336
K
D
 ( M): GlcDMJ: 24µ GlcIFG: 0.625 ManIFG: 0.14
E333
E336
E333
E336
A
B
GlcDMJ GlcIFG ManIFG
Fleetamine
Figure 3.1: Proposed GH99 inhibitors with a history of attempts at characterizing
their structure when bound to BxGH99. (A) Chemical structures of the compounds.
(B) Views of the structures of inhibitors bound to BxGH99 and their dissociation con-
stants KD. Extracted from PDBs (left to right): 4AD3, 4AD4, 4V27. The models were
aligned using main chain atoms of residues 333 to 336 in ccp4mg.204
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Conformationally restricted inhibitors are of interest, as many enzymes depend on
deforming the – 1 sugar in order to catalyze hydrolysis.27 This is especially signifi-
cant for mannosidases, which have to overcome steric clashes due to the presence
of the axial OH group at C2.272 Mannoimidazole and noeuromycin are excellent in-
hibitors of GH47 α-mannosidases30 (KDs on the GH47 from Caulobacter strain K31,
accordingly: 47 nm and 99 nm) and moderate inhibitors of GH2 β-mannosidase273
(KDs on BtMan2A: 1.4 µm and approximately 1 µm). Of these two good inhibitors,
mannoimidazole mimics the conformation of the transition state: 3H4 for GH47 and
B2,5 on GH2, and noeuromycin mimics the carbocation. Kifunensine, a specific GH47
inhibitor is observed with these enzymes in a 1C4 conformation, which is reminiscent
of the product of the reaction but not the transition states.29 KIF is structurally sim-
ilar to mannoimidazole but its five-membered ring is not aromatic (see Figure 3.2),
which makes the ring pucker – this property allows the pseudopyranose ring sample
conformational space different to that of ManIm.
mannoimidazole kifunensine
Figure 3.2: Examples of pseudopyranose mannosidase inhibitors with a fused five-
membered ring.
In this chapter, novel designs of GH99 inhibitors will be discussed and their binding
constants measured. Structures of compounds whose – 1 conformation is restrained
will be shown in complex with BxGH99. The relative affinity of various types of
GH99 inhibitors will be assessed. The influence of inhibitor binding on the solvent
molecules observed around the – 1 binding site will be examined. Finally, suggestions
about possible future directions will be made.
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3.3 Materials and methods
3.3.1 Gene expression and protein production
The same stocks of unlabelled Bx and BtGH99 as described in Section 2.3.1 were used.
15N-labelled BtGH99 WT and BxGH99 WT, E333Q and E336Q were produced in M9
media with 1 g l-1 of 15NH4Cl as the sole source of nitrogen. A procedure for expres-
sion and purification identical as with unlabelled proteins expressed in LB media was
used. For each purification, a freshly stripped and recharged or brand new 5 ml His-
Trap FF column was used. This was done in order to prevent cross-contamination by
traces of any unlabelled protein, as well as contamination of each protein variant by a
different one. Gel filtration chromatography was performed in 25 mm HEPES pH 7.0,
100 mm NaCl, 1 mm DTT. In order to perform NMR experiments, the proteins were
buffer-exchanged into 50 mm potassium phosphate pH 7.0, 50 mm KCl buffer with no
loss of material.
3.3.2 Crystallization and structure solution of BxGH99 complexes
with inhibitors
Crystallization conditions were previously described in Section 2.3.3.
Diffraction data reduction were integrated using Xia2261 and DIALS,262 and scaled
in Aimless.263 The Rfree-flagged reflections were kept identical between the iso-
morphous datasets in order to prevent model bias. For the first, high-resolution
structure (BxGH99 with ManddMan) the direct refinement starting model was 4AD4
(PDB code). An improved model obtained after building and refinement of this
structure (polypeptide chain only) was used as the starting model in all subsequent
datasets from crystals soaked with inhibitors. Reciprocal space refinement was
done in Refmac5264 and model modifications were made in Coot.265 Dictionary
files needed for refinement were made in JLigand.274 Waters were added to the
models when the protein chain was refined as well as possible in real space. The
model and its agreement with electron density was validated using Coot tools and
wwPDB validation software. CCP4i2 was used for the majority of the process.266 The
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compounds used were presented in Figure 2.4 in Section 2.3.2 (page 51).
3.3.3 NMR experiments with unlabelled and 15N-labelled Bt and
BxGH99
Initial 1D NMR experiments, which did not yield usable data, were performed in-
house with the help of John Darby. The presented NMR was performed by me during
a visit to CIC bioGUNE in Derio, Basque Country, Spain with the kind help of Os-
car Millet, Sivanadam Veeramuthu Natarajan, Ganeko Bernardo-Seisdedos and Jesús
Jiménez-Barbero. 2D NMR spectra: 1H-15N SOFAST-HMQC were recorded at 298 K
for 1 h each on a Bruker AVANCE III 800 MHz spectrometer with cryoprobe. Spectra
of the unliganded protein and protein mixed with ligands at various concentrations
were prepared in order to measure the binding constants. The signal corresponding
to Nε-Hε correlation of residue R295 served as a reporter for establishing the fraction
of protein that was bound with the ligand: the chemical shift was changing in slow
exchange regime. Peak intensities were used to establish the bound and unbound lig-
and fractions. The exact protein concentration was measured using UV280 absorbance
of stocks used to prepare the samples for titration, which were treated with 6 m guani-
dinium chloride in order to expose all absorbing residues. The exact ligand concen-
tration values were determined by recording their spectra and comparing 1H peaks
to an internal standard, 3-(trimethylsilyl)propionic-2,2,3,3-D4 (Sigma-Aldrich). For
detailed calculation procedures refer to Ref. 269.
3.3.4 ITC experiments with Bt and BxGH99 and their inhibitors
Isothermal titration calorimetry was performed using a MicroCal Auto-ITC200
(GE/Malvern Instruments). The protein was present in the cell and inhibitors
in the syringe. Inhibitor and protein concentration were varied according to the
requirements of each experiment: c-values were taken into account. Care was taken
to perform experiments at a c-value of 5–1000.275 (c=[Protein]/KD (dimensionless)).
For example, for ManNOE, the concentration of Bt and BxGH99 was 5 µm and
the ligand concentration was 50 µm. In case of poorly binding ligands such as
Man-aminoDMJ, 117 µm protein and 6 mm inhibitor was used and stoichiometry
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was fixed at a known value of 1 in order to improve the fit.276 The KD values were
calculated using a modified version of Origin program with ITC200 adjustments and
MicroCal PEAQ-ITC Analysis Software (Malvern Instruments).
3.4 Results and discussion
3.4.1 Inhibitor binding studies
A study of binding constants of several potential GH99 inhibitors was conducted. α-
1,3-Man-substituted versions of ddMan and d-glucal, whose Glc-versions were first
tested in 1993,153 were revisited as the authors of these studies reported only IC50
values and KDs are more useful. The binding of these compounds could not be de-
tected using ITC for reasons that were not uncovered. An alternative approach was
pursued, in which 15N-labelled protein was produced and a search for peaks that
change in presence of a ligand in 2D NMR spectra was performed. Such peaks were
found, and they corresponded to Nε-Hε correlation in residue Arg295 (BxGH99, vis-
ible in Figure 2.2 on page 46 and Figure 2.5 on page 54) or Arg292 (BtGH99). The
bound and unbound fraction could be directly calculated from the peak intensity, as
the chemical shift was perturbed in slow exchange regime. The alternative peak po-
sition signifying binding was almost the same for Man-d-glucal and ManddMan (see
Figure 3.3). Upon binding of these compounds, the reporting hydrogen atoms were
more shielded (lower 1H ppm), and when binding the Glc-α- and β-aziridine, they
were more deshielded (higher 1H ppm). As chemical shift changes depend on a myr-
iad of contributions, it is difficult to say what factors caused these particular changes.
The curves obtained from the NMR experiments are presented in Figure 3.4, and the
results of the ITC experiments in Figure 3.5. The KD values are summarized in Ta-
ble 3.1.
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Figure 3.3: 1H-15N SOFAST-HMQC spectra of BtGH99 (left) and BxGH99 (right)
recorded in absence or presence of large excesses of different ligands. Refer to the
picture for the colour legend.
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Figure 3.4: NMR titration curves for all measurements. The protein, the inhibitor and
the value of the dissociation constant noted next to or on each graph. Figures were
prepared using MATLAB by Ganeko Bernardo-Seisdedos.
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Figure 3.5: Results of isothermal titration calorimetry for ligands whose KDs were
determined using this technique. (A) ManNOE binding to BtGH99. (B) ManNOE
binding to BxGH99. (C) ManADMJ binding to BtGH99. DP: differential power N:
number of sites, ΔH: change in enthalpy, – TΔS: the additive inverse of the change in
entropy multiplied by the absolute temperature. Graph in C has a different layout
because data were analyzed using upgraded software.
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Table 3.1: Dissociation constants of various inhibitors, sorted from weakest to best-
binding. *Asterisks denote publications that use data also reported in this Thesis.
– 2 – 1 KD BtGH99 (µm) KD BxGH99 (µm) Method Ref.
Man ManIm undetectable no data ITC 277*
Glc cyclohexene undetectable no data ITC/NMR 269*
Man aminoDMJ 97.7 ± 4.9 no data ITC 277*
Man ddMan 53 ± 5 221 ± 11 NMR 269*
Glc DMJ 24 no data ITC 148
Glc β-aziridine 17.7 ± 1.3 157 ± 12 NMR –
Man d-glucal 15 ± 1.9 111 ± 11 NMR 269*
Glc α-aziridine 11.5 ± 0.9 no data NMR –
Glc IFG 0.625 no data ITC 148
Man IFG 0.14 ± 0.016 0.27 ITC 159
Man NOE 0.03 ± 0.01 0.013 ± 0.002 ITC 269*
d-Glucal, which was restricted to a 4H5 conformation, turned out to be 2–3.5 times bet-
ter binding than ddMan. This result is concordant with the IC50 data from Hiraizumi
et al.,153 who found that GlcddMan was 1.6 times less effective than Glc-d-glucal at
inhibiting rat endomannosidase (see Figure 1.13). ManDMJ was never synthesized,
but if the KD ratio between GlcIFG and ManIFG was taken as a benchmark, its KD
on BtGH99 would be about 5 µm, which suggests tighter binding than that of Man-
d-glucal. It is important to note that the presence of the endocyclic oxygen atom is
crucial for this inhibitor to bind; Glc-cyclohexene binding could not be detected by
ITC or NMR. At the time of the synthesis of these compounds, the 4H5 conformation
was thought to be present at the transition state; in fact, it is E3, as elaborated in Sec-
tion 2.4.3 (page 63). Therefore, this compound likely does not mimic the conformation
of the TS.
The reaction intermediate mimic described in Chapter 2, Glc-β-aziridine, binds to
both Bt and BxGH99 with a KD close to that of Man-d-glucal. This means that Man-
substituted β-aziridine would bind about 3 × more tightly than Man-d-glucal, (KD on
BtGH99 of about 4 µm). Interestingly, Glc-α-aziridine is a marginally better ligand
than Glc-β-aziridine. Neither of these compounds, however, is particularly effective
as an inhibitor, as the dissociation constant of the ligand that was previously known
to be the tightest binder, ManIFG, was an order of magnitude lower. ManNOE was
found to be an even more potent inhibitor than ManIFG, with a KD in the range of
tens of nm. The structure of Man-configured noeuromycin combines both the pseu-
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doanomeric nitrogen of IFG and the axial OH2 group of DMJ. This result signifies the
importance of hydrogen bonds and polar contacts in designing GH99 ligands: the
aliphatic – 1 subsite warheads with only hydrogen atoms at their C1 and C2 could not
form them with the catalytic residues, and were not binding tightly (see Section 3.4.2).
Another unsuccessful avenue of GH99 inhibitor development were compounds Man-
aminoDMJ and Man-mannoimidazole. ManADMJ binds with a modestKD of 97.7 µm
and binding of ManManIm is undetectable. The result for ManADMJ was initially
puzzling, as it is structurally very similar to GlcDMJ and the hope was to achieve
better affinity by exchanging OH2 for NH2, which could possibly strengthen the
interaction between E333 Oε3 and the NH2 group in the inhibitor, relative to the
Oε2…OH2 interaction with DMJ. This did not happen. The likely explanation for
this phenomenon is that E333 protonates the NH2 and the inhibitor fails to mimic the
oxocarbenium ion. Such a loss of affinity after introduction of an additional amino
group to an inhibitor has been observed previously when a second amino group was
introduced to apramycin, resulting in a 100-fold loss of affinity for the ribosome.278
As for ManManIm, its poor binding can only be explained after looking at its struc-
ture (Figure 3.6D), which was obtained through soaking of crystals, in spite of the
undetectable binding by ITC.
After correcting for the effect of the – 2 sugar, the GH99 – 1 subsite “warheads”, listed
from worst-binding to best-binding, are as follows: ADMJ, ddMan, d-glucal, DMJ,
β-aziridine, α-aziridine, IFG, NOE.
3.4.2 Crystal structures of BxGH99 complexes
Crystal structures ofBxGH99 complexed with all the inhibitors mentioned in Table 3.1
were determined, and ternary complexes with the inhibitor and α-1,2-mannobiose
were also solved for ManNOE, Man-d-glucal, ManddMan, Glc-β-aziridine and Glc-α-
aziridine. The data collection and refinement statistics are presented in Table 3.2 The
binary complexes are shown in Figure 3.6. The occupancy of the ligands was 1, with
one exception of ManManIm, for which the highest obtained occupancy was 0.8. Only
crystals of the inactive E333Q mutant yielded a dataset in which Glc-cyclohexene was
seen. Glc-cyclohexene could not be observed in the active site of WT BxGH99, despite
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prolonged soaking and repeated data collections. In contrast, Glc-β-aziridine was
observed only when complexed with the WT enzyme. This is not surprising, as the
hydrogen bond between Q333 Nε and aziridine NH2 is extremely unlikely to form.
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Figure 3.6: Views of the – 1 subsite of BxGH99 when complexed with novel inhibitors.
Catalytic residues E333 and E336 (and an active site residue Y252 shown when inter-
acting with the endocyclic oxygen) are coloured green, the ligand is coloured grey.
Hydrogen bonds/close polar contacts are marked with dashed lines. ABCDF com-
pounds are Man-linked and GHI are Glc-linked. The contour level of 2mFo-DFc syn-
theses adjusted in order to show size of the electron density on individual atoms (the
contour level details are below). One or two water molecules between the – 1 and + 1
subsites can be seen at the bottom of each panel (numbering as in Figure 2.11, W: wa-
ter). (A) Noeuromycin, 1.2 e–/Å3; (B) 2-amino-DMJ, 1.2 e–/Å3; (C) dideoxymannose,
1.7 e–/Å3; (D) mannoimidazole, 0.5 e–/Å3; (E) Unliganded – 1 subsite from PDB code
4AD1, 1.0 e–/Å3; (F) d-glucal, 1.5 e–/Å3; (G) α-aziridine, 1.5 e–/Å3; (H) β-aziridine,
0.9 e–/Å3; (I) 1,2-cyclohexene, 1.4 e–/Å3.
In the active site of the unliganded BxGH99, residues E333 and E336 form hydrogen
bonds with water molecules positioned roughly where the – 1 Man OH2 group and
the anomeric carbon would otherwise be (Figure 3.6E). The structure with NOE repli-
cates these interactions while not introducing any steric clashes, which makes it a
very good inhibitor. DMJ, β-aziridine and ADMJ both mimic the E333-OH2 interac-
tion only. Their KD values are comparable, but β-aziridine binds slightly more tightly.
The binding of aminoDMJ is poorer probably due to from the amino group protona-
tion problem, explained earlier. Cyclohexene, ddMan and d-glucal do not mimic any
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of these hydrogen bonds and their binding is quite poor, although d-glucal is the best
of the three. This is likely because of the combined effect of less steric clashes with
aliphatic atoms owing to its 4H5 conformation, and the presence of the endocyclic
oxygen. The aziridine NH group of α-aziridine mimics the interation with E336 in
a unique way: by replicating an interaction between E336 Oε and water 4, observed
in the unliganded structure. Mannoimidazole seems to mimic interactions with both
catalytic residues just like ManNOE, but the imidazole nitrogen atom being at a close
distance to both E336 Oε atoms is unfavourable (as shown in Figure 3.6D). Its confor-
mation is 2H3 / E3, which brings about costs in terms of conformational free energy.
The relative size of the electron density peak corresponding to water 1 and water 2
found between the – 1 and + 1 subsites seems to depend on the inhibitor bound. Water
2 peak is larger in the structure with the carbocation mimic NOE and in the structure
with β-aziridine (Figure 3.6AH). The peak is larger for water 1 in complexes with
oxocarbenium ion mimics: ADMJ, ddMan and d-glucal (Figure 3.6BCF). Fittingly, the
sizes are the same in the structure with the cyclohexene (Figure 3.6I). In the structure
of WT with open Glc-β-epoxide (Figure 2.11B, page 65) the electron density peak if
water 2 was more pronounced, implying that the molecule that is being turned over
has a carbocation-like charge. Both of the water molecules around the epoxide in
Figure 2.11A have similar electron density peaks. This might mean that the E333Q
mutation prevents the formation of a carbocation.
Figure 3.7 offers a closer look at the binding pose of mannoimidazole with BxGH99.
The C1-C2 bond in the bound mannoimidazole and the – 1 mannoside residue in the
Michaelis complex are exactly parallel (Figure 3.7AC), which is not the case for any
other GH99 inhibitor structures. Comparison of the Michaelis complex and the struc-
ture with α-1,3-mannobiose shows the C1-C2 bond in the disaccharide is not parallel
to the one in the tetrasaccharide (Figure 3.7BD). Mannobiose sits deep in the  – 2/– 1
binding sites and its position is more reminiscent of that of ManNOE. The rat en-
domannosidase was inhibited by GlcMan disaccharide with a very modest IC50 of
220 µm. ITC experiments with α-1,3-mannobiose and BtGH99 indicated binding but
the KD was unmeasurable by this method (over 2 mm). These values suggest that
GH99 endomannosidases are not significantly affected by product inhibition.
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E/Q333
E336
E/Q333
E336
1.4
2.2
A B
C D
facing C3 facing C1
W2 W2
W2 W2
Figure 3.7: Mannoimidazole bound in the – 1 subsite mimics the TS. Projected dis-
tance between water 2 molecule and the glycosidic oxygen in the aligned model of
the Michaelis complex is shown. (AB) Comparison between the Michaelis complex
(green) and ManManIm complex (grey). Arrowhead points to the C1-C2 bond. (CD)
Comparison between the Michaelis complex (green) and the complex with α-1,3-
mannobiose only (yellow). AC show the species bound in the – 1 subsite facing the C3
and BD facing the C1. Models were aligned using the main chain atoms of residues
333 to 336 in ccp4mg.204
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The best affinity for GH99 is achieved by azasugars with a pseudoanomeric nitrogen.
These are thought to mimic the carbocation, as opposed to ligands with the endocyclic
oxygen swapped to a nitrogen which mimic the oxocarbenium ion. Despite its poor
affinity, ManADMJ binds in exactly the same position as GlcDMJ (Figure 3.8B) and
the crystal structure does not make it obvious why the affinity is lost. With ManNOE
vs. ManIFG the reason for a 4–20 × (depending on the protein) better affinity is clear:
the addition of the OH2 group allows for another hydrogen bond with the enzyme
to form in comparison to IFG. However, ManNOE, due to its hemiaminal functional
group at C2, is predicted to not be a particularly stable molecule in the sometimes
oxidizing conditions inside living cells. Indeed, in solution NOE exists in a 1:2 res-
onance of manno- and gluco-forms.279 ITC experiments with ManNOE with Bt and
BxGH99 needed an unusually long time period (240 s) between injections in order for
the DP to return to baseline (see Figure 3.5AB), which might have been caused by part
of the compound “mutarotating” from the gluco-form to the manno-form and binding
to the enzyme only then. This is in contrast to IFG which is a stable compound, and
unlikely to be hydrolyzed. GlcIFG seems more useful in clinical applications, even if
the binding of GlcNOE to the eukaryotic endomannosidase is probably tighter.
A B
E333
E336
E333
E336ManNOE
ManIFG
ManADMJ
GlcDMJ
Figure 3.8: Comparison of the binding poses of structurally similar GH99 inhibitors
that were published previously (with BxGH99). (A) ManNOE (yellow) vs. ManIFG
(grey). (B) ManADMJ (green) vs. GlcDMJ (grey). Models were aligned using main
chain atoms of residues 333 to 336 in ccp4mg.204
82
3.5 Conclusions
The data presented in this chapter in context with the literature paint a picture of a
unique enzyme. Two molecules that are excellent inhibitors of many mannosidases,
swainsonine and mannoimidazole, do not bind when adapted to act as GH99 in-
hibitors. Carbocation-mimicking agents like ManNOE and ManIFG are the tightest
GH99 inhibitors and it is difficult to think of ways to improve on this rather minimalis-
tic design. It is possible that swapping the pseudoanomeric nitrogen for an atom that
carries an even larger positive charge could improve affinity. At this point, however,
ManIFG and GlcIFG seem like the best compromise between stability and affinity,
and they are also amenable to be modified at other sites for increased stability. Man-
2-amino-NOE could be one possible solution to the instability problem, but it is likely
to lose its affinity due to the vicinal amino group problem.
Interestingly, the “wrong” (α-configured) aziridine is a marginally stronger-binding
molecule than the β-configured aziridine. Only the latter closely resembles the struc-
ture of the reaction intermediate. The shape of the molecule is not likely to be the
factor that makes a good GH99 ligand, and seems to be secondary to the charge-
charge interactions and hydrogen bonds inside the active site. As long as the active
site can accommodate the inhibitor with few steric clashes, which is not the case for
compunds such as ManManIm, a compound is worth trying with the enzyme.
The research presented in Chapters 2 and 3 was done on the bacterial forms of GH99:
BtGH99 and BxGH99. The later part of this thesis will concentrate on a protein which
is clinically more relevant, the human endo-α-mannosidase. Their structural similar-
ity will validate that the results obtained for the bacterial enzyme are meaningful, but
differences between these proteins will also be discussed, as well as the significance
of these differences.
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Chapter 4
Gene cloning, protein production and
structure determination of human
endo-α-mannosidase: MANEA
4.1 Abstract
Structural research into endo-α-mannosidase had originally concentrated on bacterial
GH99 endo-α-mannanases, which are homologs of the human enzyme. The relative
difficulty of the studies on the human endo-α-mannosidase stems from it being a trans-
membrane protein that needs the presence of a detergent to be solubilized,176 which
usually means crystallization of such proteins is challenging. Folding of proteins ex-
pressed recombinantly in E. coli can also be impaired. In this chapter I will describe
how these obstacles were overcome, culminating in obtaining the crystal structure of
the catalytic domain of the human protein MANEA. The overall fold of the protein
is similar to that of the endomannanases whose structures had already been solved.
The main differences between the active site of the endomannanase and the endo-
mannosidase are: a tyrosine residue coordinating a water that hydrogen bonds with
the – 2 sugar in place of a tryptophan in the endomannanase, and the presence of a
loop making contacts with the – 2 sugar. The active site environment around the – 1
and + 1 subsites was conserved, which validates the use of endo-α-1,2-mannanases as
models for studying the reaction mechanism of the endo-α-1,2-mannosidase. The re-
sults presented below fill in a gap in the knowledge of N-glycan-processing enzymes
and provide leads for further structural and functional studies on this enzyme.
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4.2 Introduction
The Homo sapiens genome harbors two genes that encode proteins categorized in
CAZy glycoside hydrolase family 99: MANEA and MANEAL.280 MANEA is located
on chromosome 6 and MANEAL on chromosome 1.281 The MANEA gene has one
isoform whose protein product is 462 aa long. MANEAL has three splice forms, the
protein product of one of which (isoform 3) is of approximately the same length as
MANEA protein (457 aa). The two others – isoforms 1 and 2 – give rise to comple-
mentarily truncated N-terminal and C-terminal fragments of isoform 3. The GH99
domain is fully present in isoform 3 and split in half in the two shorter isoforms.
The short isoforms of MANEAL are expressed at a level that is about 1/2 of the long
isoform expression level.282 Comparison of RNA expression levels on all currently
listed human tissues using Metabolic gEne RApid Visualizer (MERAV)283 suggests
they are weakly anticorrelated (MANEA/MANEAL CC=–0.27). Interestingly, data
from the same source indicate that their expression levels in primary tumours
(CC=0.01) and cancer cell lines (CC=0.09) are not correlated. A close look at the data
reveals that MANEAL is expressed predominantly in the brain, while MANEA in all
other tissues, including non-CNS (non-central nervous system) nerves (Figure 4.1).
Provocatively, a 1989 study by Tulsiani et al.161 looked at endomannosidase activity
isolated from the rat brain tissue before MANEAL was understood to be a separate
gene. This might have been the first, inadvertent look at MANEAL, the activity of
which has not been confirmed.
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Figure 4.1: Comparison of RNA-seq data forMANEA andMANEAL from two sources:
(A) the Human Protein Atlas284,285 and (B) the Genotype-Tissue Expression database
(GTEx).282 The data cover expression in various human tissues, and the GTEx dataset
is extended by transformed cell lines. Note the enhanced expression of MANEAL in
the CNS. TPM: transcripts per million.
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Functional studies have shown MANEA is a type II membrane protein.195 It is highly
likely that MANEAL has the same overall fold as MANEA. MANEA was known to
be localized to the Golgi membrane since its discovery in 1987130 – it was first iso-
lated from rat Golgi membranes – but there were no studies targeting MANEAL. Hu-
man Protein Atlas286 provides a recent (2017), direct piece of evidence showing the
Golgi localization of MANEAL: a micrograph of immunostained cells (Figure 4.2).
It is also likely that MANEAL has the same enzymatic activity as MANEA, but it
is localized to the CNS only, and the expression of MANEAL is likely cell-specific,
just like MANEA expression.177 MANEA from rat liver was observed to be specifi-
cally inhibited by HEPES and HEPPS146 but not MES or MOPSO buffers. HEPES and
HEPPS were uniquely affecting the endomannosidase and not α-glucosidase or exo-
α-mannosidase. Tris abolished the activity of all of these enzymes.
Figure 4.2: Immunofluorescence images showing that both MANEA (left panel) and
MANEAL (right panel) are localized to the Golgi apparatus. U-251 cells are derived
from human malignant glioblastoma and SiHa from human cervix. Data from the
Human Protein Atlas.284,285
Until the 2012 study by Thompson et al.148 there have been no attempts at character-
izing the fold of GH99 proteins. In the article they show that the Bacteroides thetaio-
taomicron and Bacteroides xylanisolvens GH99 fold is a modified (β/α)8 barrel and find
that it can catalyze the same reaction as the human GH99 endo-α-1,2-mannosidase
(EC 3.2.1.130) with overall retention of anomeric conformation. In a later article, it
was found that the primary activity of these GH99 proteins is a selfish mechanism
by which human gut bacteria utilize yeast mannan.207 Since the 2015 publication by
Hakki et al.159 the bacterial GH99s have been referred to as endo-α-1,2-mannanases.
Endo-α-1,2-mannanase activity does not have an EC number assigned at the time of
writing and therefore is referred to as EC 3.2.1.- (although it still correct to refer to
these enzymes as EC 3.2.1.130, because they can catalyze the same reaction as the
87
human enzyme).
The primary amino acid sequence of MANEA shares 39% identity to both Bt and
BxGH99s proteins, with 45% identity when only the catalytic domain is considered
in the alignment. Figure 4.3 shows a global sequence alignment of the GH99 pro-
teins considered in this passage. The main difference between the proteins is that a
tyrosine residue conserved for all endo-α-1,2-mannosidases, Y189 (HsMANEA num-
bering), is a tryptophan residue in all endo-α-1,2-mannanases (W126 according to
BxGH99 numbering). The residues that interact directly with the bound substrate
are also conserved in the MANEAL protein, with a minor but consistent difference:
HsMANEA E224 is a Q226 in HsMANEAL. The significance of this difference is not
known. The analysis of the MANEAL primary sequence, aligned with HsMANEAL,
BtGH99 and BxGH99 in Figure 4.3, corroborates the view that MANEAL has the same
overall transmembrane topology as MANEA.
The efforts in this part of the project were a continuation of Dr Andrew Thompson’s
attempts at producing a folded version of MANEA. He established that the Δ34, His-
tagged version of the protein, when produced in E. coli BL21(DE3) cells, does not fold
properly and is instead deposited in inclusion bodies. The protein was amenable to
isolation from the insoluble fraction, but did not refold. The same truncation but
with an additional N-terminal His-tag and a C-terminal EGFP-tag (enhanced GFP),
was determined by Dr Andrew Thompson to be soluble and active. However, with
this large tag present, the kinetic data were not reliable, and removing it proved to
be difficult. Here I will describe how these problems were overcome and present the
results that were obtained from various crystallization efforts of the human enzyme.
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Figure 4.3: Alignment of the primary sequences of human and Bacteroides GH99s.
The differences between residues conserved within a specific protein family are high-
lighted with the orange rectangle. Residues close to the substrate are marked in blue,
the catalytic residues in red. The endomannosidase catalytic domain corresponds to
the MANEA-Δ98 truncation less 8 C-terminal aa. Amino acid symbols are shaded
according to conservation (BLOSUM62 score matrix200 with a similarity threshold of
1, black background: 100% similar, dark grey: 80–100% similar, light grey: 60–80%
similar, white: less than 60% similar). Figure made in Geneious201; sequences aligned
using the MUSCLE algorithm.202
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4.3 Materials and methods
4.3.1 Methods overview
The following experimental section will start with a commentary on the methods
used and the methods will be presented subsequently. The first attempts at MANEA
expression were made using pGEn1- and pGEn2-MANEA constructs obtained
from the GlycoEnzymes repository.287 The gene in pGEn1-MANEA DNA encodes
for MANEA protein which is N-terminally tagged with a signal sequence for
extracellular secretion, an octahistidine tag, and a StrepII tag (for affinity purification
using Strep-tactin). The gene in pGEn2-MANEA DNA encodes for MANEA protein
which is N-terminally tagged with the same signal sequence, the octahistidine tag,
an Avi tag (for affinity purification) and a superfolder GFP (GFP whose fold is more
stable than the fold of wild-type GFP). The strains used for mammalian expression
were CHO-K1 (ATCC) and HEK-293T (ATCC). This approach was chosen due to
the lack of success by Dr Andrew Thompson in purification of soluble human
endo-α-mannosidase from E. coli. After numerous attempts (transient transfection of
the cells or stable transfection and selection of best-expressing clones), that spanned
about 18 months, no protein was obtained. This prompted a reconsideration of
bacterial expression methods.
Gene expression was performed in BL21(DE3) cells (Agilent) that were made com-
petent using a modified version of a one-step protocol258 where LB media in TSS
(transformation and storage solution) was substituted with MQ H2O. Constructs con-
taining four N-terminal truncations of the MANEA gene (optimized for expression
in Escherichia coli) at positions 60, 71, 83 and 98 fused to a C-terminal EGFP tag were
cloned using restriction enzymes into the pET-28a(+) vector. The MANEA gene was
truncated in the stem domain as shown in Figure 4.4. After expression the genes en-
coding the EGFP fusion proteins, the amount of proteins was checked and the results
indicated presence of protein in the soluble fraction, with a larger amount of soluble
protein in the longer truncations. This was likely only due to the larger protein be-
ing stained by more dye and not a difference in molar concentration or its mRNA
level (expression level). Cell-free expression systems have been used to produce cor-
rectly folded, full-length MANEA195 but the yield of such techniques is usually not
90
high enough to enable structural studies. The publication of a study describing a rel-
atively simple method of producing soluble MANEA in E. coli164 led me to adopt an
approach of co-overexpression of MANEA with the genes encoding the GroEL molec-
ular chaperone. This became the method of choice for producing large amounts of
pure MANEA.
Figure 4.4: Full, annotated sequence of MANEA protein with truncations shown. The
GlycoEnzymes clone refers to the sequence present in pGEn1 and pGEn2-MANEA
constructs. Major structural motifs are highlighted. Residues making close contacts
to the substrate and the active site residues are annotated based on alignment with
BxGH99 structures. Putative phosphorylation (Ph), O-glycosylation and ubiquitiny-
lation (Ub) sites were found using PhosphoSitePlus203, additional ubiquitinylation
from UbiSite288 and ESA-UbiSite.289 The amino acid residues are coloured by type.
Figure made in Geneious.201
Truncation MANEA-Δ98 was selected, based on the sequence alignment with Bt and
BxGH99, as the most likely to contain the folded domain only and therefore most crys-
tallizable, and the pCold-I construct was used for expression. After initial screening,
it became apparent that GroEL was produced in large amounts, but was not soluble
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and therefore not helpful as a molecular chaperone. An experiment by Claire Fowler
revealed that adding 20 mm MgCl2 to the growth media stabilized GroEL. After this
was included in the protocol, another problem with initial large-scale expression ex-
periments was encountered: the protein yield was poor, 0.35 mgprotein per litre of
culture. This was rectified by using TB (Terrific Broth) media (modified from 4 to 8 g
glycerol per litre of media), which increased the yield 7–8-fold.
4.3.2 Truncated MANEA gene cloning and subcloning
Q5 High-Fidelity DNA Polymerase (New England Biolabs, Inc.) was used for all PCR
(polymerase chain reaction) experiments. Eight PCR experiments were set up, each
with a total volume of 20 µl and the following ingredients: 500 pg template DNA
(HsMANEA optimized for E. coli cloned into pET28a(+), generated before the start
of this Thesis work by Dr Andrew Thompson), 10 mm dNTPs (deoxiribonucleotide
triphosphates), 10 µm forward primer, 10 µm reverse primer and 0.02 units µl-1 Q5
High-Fidelity DNA Polymerase (0.2 µl in each reaction mixture). The components
were mixed in 0.2 ml PCR tubes. The PCR cycler (BioER LifeTouch) was preheated
to 98 °C before putting the tubes inside and the hot lid was used in order to prevent
condensation on the tube lid. The tubes were put inside the cycler, incubated at 98 °C
for 30 s and thermocycled 35 times. The denaturation step was 10 s at 98 °C, the
annealing step was 30 s at 60 °C and the extension step was 40 s at 72 °C. After 35 cycles
were complete, the mixtures were incubated for 2 min at 72 °C for a final extension
step and the temperature was lowered to 10 °C for storage until later use. The primers
used in the PCR reactions are presented in Table 4.1. The forward primers used for
the amplification of each truncated version of MANEA were combined with a reverse
primer that added an EcoRI cleavage site (for C-terminal EGFP fusions) or a reverse
primer that added an XhoI cleavage site (for cloning into the MCS (multiple cloning
site) of empty pET28a(+) vector).
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Table 4.1: Primers used for PCR amplification of the genes encoding truncated
MANEA. The italicized sequence adds a 5’ overhang improving the efficiency of diges-
tion by restriction enzymes. The underlined sequence is the palindromic restriction
site. The region in bold is complementary to the template DNA.
Primer sequence Primer name
GATCAGCATATGGACTTTCAGAAATCAGATCGTA HsMANEA Δ60 forward
GATCAGCATATGACCAACACGAAAAATCTGAA HsMANEA Δ71 forward
GATCAGCATATGAAACCGTCGAAAGCAAG HsMANEA Δ83 forward
GATCAGCATATGCCGCTGAACAATTACCTGCA HsMANEA Δ98 forward
GATCAGGAATTCGGAGACCGGCAGTTGAC HsMANEA EcoRI reverse
GATCAGCTCGAGTCAGGAGACCGG HsMANEA XhoI reverse
Agarose gel (0.7% w/v) electrophoresis was performed on all of the thermocycled
PCR mixtures. The electrophoresis grade agarose was obtained from Melford Labo-
ratories, Ltd. When the DNA was resolved well enough to confirm that the size of
the PCR product was correct, the electrophoresis was stopped and the band corre-
sponding to each product was cut out from the agarose gel using a scalpel. The agent
that visualized the DNA under near-UV light was SYBR Safe Stain (Invitrogen). Sub-
sequently, the DNA was extracted from the bands using NucleoSpin Gel and PCR
Cleanup kit (Macherey-Nagel) and dissolved in Buffer NE (5 mm Tris/HCl, pH 8.5)
supplied with the kit.
The extracted PCR products (20 µl of each) were double digested with NdeI and EcoRI
(in case of DNA used for C-terminal EGFP fusions) in EcoRI buffer + BSA (bovine
serum albumin) or NdeI and XhoI in NEBuffer 4 + BSA. All enzymes and buffers were
obtained from New England Biolabs, Inc. 1 µg of each of the vectors: pET28a(+) vec-
tor containing an EGFP tag (generated by Dr Andrew Thompson before the start of
this Thesis work) and empty pET28a(+) were double digested using the same proto-
col. The digestion mixture was incubated at 37 °C for 75 min and subsequently ran
on 0.7% agarose gel electrophoresis. When resolved, the bands were extracted from
the gel as explained above. The insert and the vector DNA were mixed in a 3:1 molar
ratio and ligated using T4 DNA ligase for 15 min at RT (room temperature) (20 µl total
ligation mixture volume, 1 µl enzyme used). After the ligation, 2 µl of each ligation
mixture was used for transformation of DH5α competent cells (New England Biolabs,
Inc.). Transformation of the competent cells with the ligated DNA was achieved by
incubating the cells (~10 µl) for 15–30 min on ice in 1.5 ml Eppendorf tube with the
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ligation mixture added, followed by a heat shock at 42 °C for 45 s and 2 min recovery
on ice. After this, SOC media was added to each tube up to a total volume of 500 µl
and the cells were shaken at 37 °C and 180 RPM for 1 h. 1–10% of the total cell culture
volume was used to plate on LB agar plates with 50 mg ml-1 kanamycin added. The
plates were incubated at 37 °C overnight and stored at 4 °C. At the end of the same
day, cells from single colony forming units (CFU, 2 from each transformation plate)
were used to start a 5 ml liquid Kan+ LB culture, which was shaken overnight at 37 °C.
2 ml of each culture was used for plasmid DNA extraction, which was performed us-
ing QIAprep Spin Miniprep Kit (QIAGEN). The coding sequence region in each plas-
mid (8 in total) was sequenced using the following primers: T7 (sequence: TAAT-
ACGACTCACTATAGGG) and pET-RP (sequence: CTAGTTATTGCTCAGCGG). Se-
quencing was done by GATC Biotech (SUPREMERUN service). In case of ambiguous
or wrong sequencing result, DNA extracted from the second CFU was resequenced.
This was sufficient to confirm that the sequences were correct.
In order to subclone MANEA truncations into pCold‑I vector (obtained from TaKaRa
Bio, Inc.), 1 µg of pET28a(+) containing truncated, optimized MANEA truncations
were double digested with NdeI and XhoI as above, and the empty pCold-I vector was
linearized in the same way. The digestion products were resolved using 0.7% agarose
gel and extracted as above. Each of the four DNA fragments encoding truncated
MANEA was ligated in 3:1 molar ratio with the linearized pCold-I vector as described
earlier. The selective agent used for culturing cells harbouring the pCold-I vector was
ampicillin (Amp) at 100 µg ml-1. Sequencing of truncated genes encoding MANEA
subcloned into the pCold-I vector was not performed. The details of the design of
pCold-I vector can be found in Ref. 290.
Chaperone competent cells were made from BL21(DE3) cells that were transformed
with each of the five vectors from Chaperone Plasmid Set (TaKaRa Bio, Inc.). The
same protocol as referred to previously (published in Ref. 258) was used, with one
difference: the cells were cultured in liquid media in presence of chloramphenicol
(Cam) at 20 µg ml-1. Each of the plasmids from the Chaperone Plasmid Set carries a
chloramphenicol resistance gene. The plasmids are: pG-KJE8, pGro7, pKJE7, pGTf2
and pTf16. Transformation of these cells with pColdI-HsMANEA-Δ98 was achieved
by using the same protocol as used for the transformation of DH5α cells. Maps of
pCold-I-HsMANEA-Δ98 and the pGro7 plasmid are shown in Figure 4.5.
94
pGro7
Cmr
ara C
pACYC ori
gro EL
gro ES
ara B
5.4 kbp
Figure 4.5: The expression system used to produce HsMANEA-Δ98. Left: pCold-I-
HsMANEA-Δ98, right: pGro7 vector harbouring the groEL and groES genes. GroEL
and groES are inducible by l-arabinose. Cmr: chloramphenicol resistance gene, cspA:
cold shock protein CspA gene.
In some cases, glycerol stocks of BL21(DE3) cells transformed with plasmids contain-
ing the genes to be expressed were made in order to facilitate subsequent expres-
sion experiments. To make a glycerol stock, cells from a single CFU were cultured
overnight in 2–5 ml LB media with selective agents (Amp, Cam or Kan) added. 250 µl
of the culture was pipetted into a 2 ml cryotube, followed by adding 250 ml of 50%
v/v glycerol solution. The components were mixed with a pipette, the tubes were
flash-frozen in liquid nitrogen and stored at -80 °C. In order to use the stock, it was
removed from the -80 °C storage, the surface of the cells was scraped with a pipette
tip, and the tip was then briefly dipped in selective media to inoculate the media.
4.3.3 Production and purification of soluble MANEA and its E404Q
variant
Final protocol: starter cultures were grown overnight in LB supplemented with Amp
at 100 µg ml-1 and Cam at 20 µg ml-1. Modified Amp+/Cam+ TB media with 20 mm
MgCl2 and 0.5 g l-1 l-arabinose was inoculated with 1% v/v of the starter culture.
Cells were shaken in 2 l plastic flasks at 220 RPM until the OD600 was at least 0.8. At
this point, cells were cold-shocked in an ice-water slurry for 5 min and stood at 15 °C
for the next 30 min. Subsequently, IPTG was added to a final concentration of 0.2 mm.
The cultures were then shaken overnight at 15 °C. The cell pellet was harvested by
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centrifugation of the cell culture and then frozen at -80 °C.
The protein was purified in two steps: nickel affinity chromatography and cation ex-
change chromatography. Firstly, the cell pellet was thawed and 50-150 ml of Buffer
A1 (50 mm potassium phosphate pH 7.0, 260 mm KCl, 20 mm MgCl2, 20 mm imidazole)
or buffer A2 (25 mm HEPES pH 7.0, 260 mm NaCl, 20 mm MgCl2) was added to the pel-
let. The cells were resuspended and transferred to a suitable container, then sonicated
on ice until the solution became darker and more viscous. Cell debris was separated
by centrifugation in 30 ml spin tubes at 41600×g for 30 min at 4 °C. The supernatant
was loaded onto a 5 ml Ni-NTA HisTrap FF column (GE) preloaded with Co2+ ions
instead of Ni2+ and preequilibrated with buffer A1 or A2. The column was washed
with 5 volumes of buffer A1 or A2 and the protein was eluted in gradient of, respec-
tively, buffer B1 (50 mm potassium phosphate pH 7.0, 300 mm KCl, 500 mm imidazole)
or B2 (25 mm HEPES pH 7.0, 300 mm NaCl, 500 mm imidazole). Two peaks were seen
in the chromatogram (see Figure 4.7 in the Results and discussion Section) and frac-
tions collected from the peak that eluted at a higher concentration of imidazole was
collected and buffer-exchanged into buffer SP A (50 mm potassium phosphate pH 7.0,
50 mm KCl). The solution was loaded onto a 5 ml HiTrap SP FF column (GE). The
SP column is packed with a strong cation exchange resin - Sepharose functionalized
with -CH2CH2CH2SO3- groups. FF relates to the flowrate the column can withstand
with no damage (Fast Flow). The difference between the isoelectric point of MANEA
(9.2) and GroEL (4.5) was used to separate the chaperone molecule. A 50→500 mm
KCl gradient was applied. HsMANEA eluted around 185-200 mm salt, separate from
GroEL. Finally, the fractions of interest were concentrated using an Amicon 30,000
Da ultrafiltration device, buffer-exchanged on the filter into storage buffer 1 (50 mm
potassium phosphate pH 7.0, 185 mm KCl) or storage buffer 2 (25 mm HEPES pH 7.0,
200 mm NaCl), aliquoted and flash-frozen in liquid nitrogen. The maximal yield was
~3 mg protein per litre of culture and the protein was stable up to a concentration of
15-18 mg ml-1.
The pCold-I-HsMANEA-Δ98 construct was mutated at two sites, encoding residues
E404 and E407. These are equivalent to the BxGH99 catalytic residues E333
(base/acid) and E336 (acid/base), respectively. The mutagenesis was performed
using of Q5 Site-Directed Mutagenesis Kit (NEB). Mutagenic primers, containing
two base changes per codon, were designed using the NEBaseChanger tool (see
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Table 4.2). Three mutants: two single and one double (all E→Q), were generated.
MANEA E404Q mutant was produced and purified in exactly the same way as
the WT, with an additional gel filtration step using a HiLoad Superdex 16/600
S75 column in storage buffer 2 in an attempt to remove an insignificant amount of
high-molecular weight impurities (three bands with apparent MWs of 70, 75 and
82 kDa). The same impurities were also present in the WT enzyme (best visible in
Figure 4.7 on page 102 as the bands above GroEL in the collected fractions from
the cobalt column). In case of the WT protein they were not removed, because
they were observed during a purification procedure performed after a successful
crystallization attempt and it was assumed they do not interfere with the process
of crystallization. The gel filtration chromatography was performed after cation
exchange purification. The amount of the impurity appeared to be reduced only
slightly, but it constituted less than 1% of the total protein mass in the sample and
was unlikely to affect any subsequent experiments.
Table 4.2: Primers used in the mutagenesis of the pCold-I-HsMANEA-Δ98 construct.
The bases shown in bold are the mutation site.
Primer sequence Primer name
CCATTCGTTAAAGGAGGTGATACTAATC HsMANEA 404 WT
CCACTGGTTAAAGGAGGTGATACTAATC HsMANEA E404Q
CATGAAGGCACGCAAATTGAAAAAG HsMANEA 407 WT
CATCAGGGCACGCAAATTGAAAAAG HsMANEA E407Q
4.3.4 Crystallization and crystal handling
A number of crystal forms of HsMANEA were obtained. The conditions and proto-
cols common to all of them, unless indicated otherwise when describing each crystal
form, are presented in this paragraph. The crystals were grown at 19 °C. The robot
used to set up crystallization screens was Mosquito LCP (TTP Labtech). 54 µl of the
reservoir solution was transferred in parallel from a crystal screen aliquoted in a 96-
well deep well block to all the wells of standard 96-well MRC sitting drop crystal-
lization plates using Hydra 96 robot (Robbins Scientific). This was the final volume
of the reservoir solution. The final volume of the droplets in 96-well crystallization
screens was 300 nl. Crystal fishing was performed using a nylon cryoloop adapted
to the crystal size and the diffraction quality was checked using an in-house X-ray
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source (Rigaku MicroMax 007HF with a RAXIS IV++ detector). No cryoprotection
was used.
Crystal form 1: The first crystal form of HsMANEA WT was obtained in PACT pre-
mier™ Screen (Molecular Dimensions Ltd) well B3. The crystallization condition con-
tained 100 mm MIB (malonate/imidazole/boric acid) buffer, pH 6.0 (crystals of dif-
ferent quality were observed at pHs between 4 and 7). The protein at a concentration
of 5.5 mg ml-1 was kept in 50 mm potassium phosphate, 50 mm KCl (storage buffer
1). Crystals suitable for fishing appeared after about one month. The dataset used to
solve the MANEA structure was collected using Diamond Light Source (DLS) beam-
line I03. The space group was P21212. The crystal diffracted to a resolution of 2.25 Å.
Crystal form 2: HsMANEA crystallized in 100 mm sodium citrate pH 5.5 and 20-
32.5% w/v PEG 3350 (protein solution:reservoir ratio 1:1 or 1:2, HsMANEA concen-
tration 10 mg ml-1). The protein was in this case kept in storage buffer 2 (25 mm HEPES
pH 7.0, 200 mm NaCl). The crystals appeared after 2 days but their morphology was
not adequate for fishing and X-ray crystallography.
Crystal form 3: HsMANEA crystallized in 1 m sodium succinate pH 7.0, 1% w/v
PEG-MME 2000 (JCSG+ Screen, well F11). The protein solution:reservoir ratio 1:1 or
1:2, HsMANEA concentration 10 mg ml-1 (in storage buffer 2). The crystal was fished
and yielded a dataset collected on DLS beamline I04. The space group was P43212.
The crystal diffracted to a resolution of 2.25 Å.
Crystal form 4: An attempt at crystallizing the protein with an additive Ander-
son−Evans polyoxotungstate [TeW6O24]6− (TEW) was made in order to find a crystal
form that would allow the structure solution from high resolution data and would
allow ligands to bind in the active site. TEW (shown in Figure 4.6) is a compound
that can act as a crosslinker between protein molecules, enabling the otherwise
often disordered residues (e.g. Lys or Glu) that hamper the crystallization process
to participate in crystal contacts291. Only four crystal structures with this agent are
currently deposited in the PDB and they comprise three proteins: hen egg white
lysozyme292, a plant aurone synthase293 and a mushroom tyrosinase.294 The crystal
form of tyrosinase is unusual, as it is an example of heterologous crystallization of
the latent and and active forms of the enzyme.
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Figure 4.6: The structure of Anderson−Evans polyoxotungstate (TEW). (A) Polyhe-
dral representation of the molecule (B) Ball and stick representation with coordi-
nation modes of oxygen atoms assigned. The molecule carries a –6 charge. Figure
adapted from Ref. 291.
XP Screen (Jena Bioscience), which contains 1 mm TEW in each condition, was used
in screening for HsMANEA co-crystallization with TEW and the experiment resulted
in finding a novel crystal form in well B5 (condition: 100 mm HEPES pH 7.5, 200 mm
MgCl2, 30% w/v PEG 400, 1 mm TEW). The protein concentration was 9.2 mg ml-1
(in storage buffer 2). The crystals appeared after 8 days in wells with protein solu-
tion:reservoir ratio of 1:1 and 1:2 but the crystals were larger in the droplet with a 1:1
ratio. Some of the crystals were fished and a dataset was collected on DLS beamline
I03. After this, the crystals from crystal form 4 were soaked overnight with ~20 mM
GlcIFG and subsequently ~40 mM α-1,2-mannobiose to obtain complexes with these
compounds. Fishing was performed after each soaking experiment. Structures of a
binary complex with of HsMANEA with GlcIFG and a ternary complex with GlcIFG
and α-1,2-mannobiose were obtained from data collected on DLS beamline I03. The
space group was P62. These crystals diffracted to a resolution of 1.8–2.0 Å.
Co-crystallization with compounds known to form a complex with MANEA: Co-
crystallization experiments of HsMANEA WT and E404Q mutants were performed.
For the WT protein, the first co-crystallization was attempted by screening 4 mg ml-1
HsMANEA containing a 20 × molar excess of GlcIFG (kept in storage buffer 1). This
returned no droplets that contained protein crystals. A second attempt was made
with 10 mg ml-1 HsMANEA containing a 10 × molar excess of both GlcIFG and α-1,2-
mannobiose (in storage buffer 2). The aim of the experiment was to obtain a ternary
complex with – 2 to + 2 sites occupied, but this was unsuccessful as well.
Crystal form 5: The E404Q inactive mutant was co-crystallized with GlcMan4OMe
synthesized by Pearl Fernandes in Spencer Williams’ laboratory. Numerous hits were
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obtained with the protein. Crystals in Crystal Screen HT (Hampton Research) well
F1 were observed after 1 day. The initial conditions were: 100 mm sodium acetate
pH 4.6, 200 mm ammonium sulfate, 30% w/v PEG-MME 2000. These condition was
later optimized and the crystal used for structure solution was fished from a well
with a precipitant containing 100 mm sodium acetate pH 4.6, 200 mm ammonium
sulfate and 12.8% w/v PEG-MME 2000. In this case, the plate was kept at 6 °C, the
protein solution:reservoir ratio was 1:1 and 500 nl of each was used. The experiment
was done on a 48-well MRC Maxi sitting drop crystallization plate. The data were
collected on DLS beamline I03, and the space group was P21. The crystal diffracted
to a resolution of 1.1 Å.
4.3.5 Structure determination
The images containing diffraction data were indexed, integrated and merged using
DIALS software262 integrated into Xia2 pipeline for automatic data processing.261
Data reduction was done in Aimless.263 5% of reflections were not used in refinement
in order to cross-validate the refinement statistics through the use of Rfree. A new ran-
dom Rfree set of reflections was generated for each crystal form. The initial molecular
replacement (MR) model was created from a model with PDB code 5M17 (wild-
type BxGH99 in complex with 1,2-dideoxymannose269) using CHAINSAW295 (the
polypeptide chain only). The amino acid identity between BxGH99 and HsMANEA
was 42%. MR was done using PHASER.296 After refinement of the initial model to
the first HsMANEA dataset the Rwork/Rfree values were 0.35/0.38. Subsequently, the
model was rebuilt manually using Coot265 and refined in Refmac5.264 Hydrogens
were added in riding positions during refinement for all structures, except the crystal
form 3, for which they did not improve statistics. Water molecules were added to
the model after the protein chain was as complete as possible. After the first round
of refinement with waters present, difference map peaks were looked at in order to
find more water molecules. Agreement between the model and the electron density
was periodically checked using edstats.297 Dictionary files needed for refinement
were made in JLigand,274 with the exception of the dictionary file for TEW, which
was made by Dr Jon Agirre in Libcheck. NCS restraints were used in the refinement
of crystal form 3 form, which was the only one with non-crystallographic symmetry
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(3 molecules in the asymmetric unit). Anisotropic B factors (Debye-Waller factors)
were used in the refinement of crystal form 5 because of a relatively high resolution
of the data (1.1 Å).
Chain A from crystal form 3 was used as the search model for subsequent molecu-
lar replacement procedures. Isomorphous structures (complexed with saccharides)
of the P62 crystal form with ligands were solved by matching the HKL index of the
solution to the first solution (with HEPES bound in the active site) in Aimless and sub-
sequent direct refinement (in Refmac5) of a pdb file containing only the polypeptide
chain of the WT + HEPES structure.
4.3.6 Circular dichroism
Circular dichroism experiments were performed at York Technology Facility using a
Jasco J810 CD Spectrophotometer with a prism monochromator. The samples were
kept in a 1 mm quartz cuvette. HsMANEA at 0.2 mg ml-1 was stable in low salt condi-
tions (2.2 mm KCl). Ellipticity data were collected every 0.5 nm for wavelengths from
190 to 260 nm. Before data analysis, the buffer signal was subtracted from the sample
signals. Data were analyzed using the CAPITO web server.298
4.3.7 Homology modelling of HsMANEAL
The refined model of crystal form 3 of MANEA (chain A, Figure 4.10B) was used as a
template for I‑TASSER299–301 to model MANEAL. All the previously published, bacte-
rial GH99 models were excluded from the modelling job. Only the part of MANEAL
that was homologous to MANEA was modelled (aa 95–457).
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4.4 Results and discussion
4.4.1 Overview of results
HsMANEA was purified to a high degree of homogeneity. The results of the purifi-
cation of HsMANEA WT are presented in Figure 4.7.
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Figure 4.7: Purification of HsMANEA WT from BL21(DE3) cells. Cobalt affinity col-
umn (FF crude) was used in the first step, followed by SP cation exchange chromatog-
raphy. The blue line represents the Abs280 (absorbance at 280 nm)) signal (mAU),
and the orange line the concentration of buffer B (arbitrary 0-100% scale). The col-
lected fractions are tinted green on the 12% reducing SDS-PAGE gel image and the
corresponding chromatogram, the discarded fractions are tinted red. The molecular
weight of ladder bands are in kDa. The hatched box represents all fractions that were
collected for later use. †GroEL chaperone, *N-terminally His-tagged HsMANEA.
HsMANEA crystallized in 5 crystal forms, 4 of which were solved. Crystal form 1 was
the first one to be solved. Knowing the crystal structures of bacterial GH99s would
prove indispensable for phasing the data, a trimmed and mutated model of BxGH99
was used as a search model in MR. An unambiguous solution was found, with one
molecule in the asymmetric unit (ASU) and space group P21212 (unit cell dimensions
(Å): a=38.5, b=86.5, c=135.9, α=β=γ=90°). The diffraction data were usable up to a
resolution of 2.25 Å. After model building and refinement it became apparent that the
structure, while informative about the protein fold, would not permit ligand binding
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analysis. N-terminal His residues from the His-tag and His residues from the active
site participated in coordinating a metal ion (of unknown identity, possibly Ni2+ that
leached from the nickel column used for purification: cobalt affinity columns were
used only in later purification runs). Moreover, the integrity of the crystal seemed to
be provided by the ion: the crystal contacts between proteins were mediated through
it (see Figure 4.8).
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Figure 4.8: Views of the packing of HsMANEA crystal form 1 around the nickel ion.
The molecule which coordinates the ion with an N-terminal H residue is shown in
green, and the molecule coordinating the metal ion with the active site H residues
is shown in gold. (A) Packing of adjacent molecules in the crystal. (B) The residues
around the metal ion. H(96) is present in the sequence because of the way it was
cloned. It is encoded by the first three bases of theNdeI restriction site. The saccharide
shown in yellow comes from structural alignment (in ccp4mg)204 of HsGH99 shown
in gold with PDB code 5M17. H(96) and the metal ion block the – 2 subsite.
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A search for a different crystal form was commenced. Attempts at cleaving off the
N-terminal His-tag with the aim of reducing the strength of the chelation did not
produce usable crystals. Performing crystallization screening again with protein in
25 mm HEPES buffer instead of 50 mm potassium phosphate yielded conditions that
permitted growth of a different crystal form (crystal form 3). Its space group was
P43212 with cubic tendencies (c almost equal to a and b: a=144.2, b=144.2, c=139.7).
The collected data were of lower resolution (3 Å), and it was possible to solve the
structure using MR with the initial model from the first solution. HsMANEA in crys-
tal form 3 appeared to be in a more ordered state. In the first solution, a particular
loop region (residues 131–141), was not visible in the electron density. The crystal
form 3 allowed for this to be built. More importantly, the metal ion was not present
in the active site, but electron density not belonging to the protein was observed there
and it was accurately explained by modelling in HEPES, the buffering agent that was
found to inhibit the rat endomannosidase enzyme three decades before.146 Crystal
form 4 was found by using the polyoxometalate TEW (see Figure 4.6) as an additive.
The structure from this crystal, which diffracted to a resolution of 2.0 Å was solved
with MR using a truncated model from crystal form 3 (protein chain A only). The data
collection and refinement statistics for HsMANEA structures not in complex with sac-
charides can be found in Table 4.3. The same initial model was used in MR to solve
crystal form 5, HsGH99 E404Q mutant structure obtained from its co-crystallization
with substrate GlcMan4OMe (the crystal diffracted to a resolution of 1.1 Å). No metal
ions likely to be functionally important were found in any HsMANEA models, as was
the case for Bx and BtGH99.148
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Table 4.3: Data collection and model refinement statistics of HsMANEA crystal struc-
tures without saccharides bound. *Values in parentheses represent the highest reso-
lution shell.
Crystal form 1 3 4
HsMANEA variant WT WT WT
In complex with Ni2+ HEPES HEPES + TEW
Data collection
Space group P21212 P43212 P62
Cell dimensions
a, b, c (Å) 38.5 86.5 135.9 144.2, 144.2, 139.7 129.0, 129.0, 48.8
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 120
Resolution (Å) 135.92–2.25
(2.33–2.25)*
102.00–3.00
(3.16–3.00)
64.48–2.00
(2.05–2.00)
Rmerge 0.200 (1.872) 0.596 (1.175) 0.126 (0.739)
Rpim 0.083 (1.002) 0.135 (0.265) 0.078 (0.450)
CC(1/2) 0.994 (0.345) 0.974 (0.253) 0.992 (0.411)
<I / σI> 7.0 (0.9) 5.0 (2.9) 6.2 (1.5)
Completeness (%) 98.1 (84.5) 100 (99.8) 99.6 (98.3)
Redundancy 11.4 (6.9) 20.3 (20.5) 3.5 (3.5)
Refinement
Resolution (Å) 73.10–2.25 102.2–3.00 111.69–2.00
No. reflections
all / free 21817 / 1106 30099 / 1429 31481 / 1554
Rwork / Rfree 0.18 / 0.22 0.21 / 0.27 0.20 / 0.24
No. atoms
Protein 2906 8853 2998
Ligand/ion 1 45 140
Water 185 140 165
B-factors (Å2)
Protein 51 49 34
Ligand / ion 88 53 76
Water 51 36 36
RMSD
Bond lengths (Å) 0.011 0.010 0.011
Bond angles (°) 1.4 1.5 1.6
PDB code – – –
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The results of the circular dichroism experiment were of limited usefulness. The es-
timates of the secondary structure content in HsMANEA at 20 °C were: 7–10% α-
helix, 37–44% β-sheet and 46-56% irregular residues (curve most similar to that of
β-crystallin B2). The actual values for the solved, truncated structure with uncleaved
polyhistidine tags are: 27.5% α-helix, 16.5% β-sheet and 56% irregular. A thermal un-
folding experiment (Figure 4.9) reveals that the point at which MANEA loses 50% of
its secondary structure lies at about 50 °C. Interestingly, when MANEA is unfolded,
its position on the [θ]222 vs [θ]200 graph* is closer to that of pre-molten globules, rather
than the fully unfolded proteins.
HsMANEA thermal unfolding
20 C°
40 C°
45 C°
50 C°
55 C°
60 C°
65 C°
70 C°
75 C°
20 C°
40 C°
45 C°
50 C°
55 C°
60 C°
65 C°
70 C°
75 C°
A
B
Figure 4.9: Analysis of circular dichroism experiments of MANEA. (A) A graph of
molar ellipticity [θ] vs wavelength at different temperatures. (B) Comparison of [θ]222
vs [θ]200 of MANEA at different temperatures and the values for other proteins.302,303
Figure made using CAPITO web server298.
4.4.2 Comparison with other GH99 structures
The structure of BxGH99 is by far the best studied GH99 structure to date. The models
of BxGH99 and HsMANEA are very similar (see Figure 4.10). The overall fold is the
same, with even short β-strands that form the core replicated in both proteins.
*[θ]222 vs [θ]200 graph is useful for assessing the folding state of a protein. Unfolded proteins have
a comparatively low ellipticity at 222 nm (usually below 0) and around 0 at 200 nm.302 Folded and
partially folded proteins usually differ from unfolded proteins in ellipticity at these wavelengths.
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C D
TEW
(spheres)
HEPES
(cylinders
Figure 4.10: Comparison of the structures of GH99 proteins. (A) Crystal form 1. The
Ni2+ ion is shown as a grey sphere. (B) Chain A of crystal form 3 with HEPES shown
as cylinders. (C) Crystal form 4 with HEPES and TEW shown. (D)BxGH99 with Man-
NOE and α-1,2-mannobiose (PDB code 5M03). Note the extended loop, not modelled
in crystal form 1 (A) because of disorder, appears to be ordered in crystal form 3 (B),
despite the lower resolution of the data collected from the crystal used to solve the
structure of the protein forming crystal form 3. Assembled using ccp4mg.204
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Only in loop areas significant differences can be found. The extended loop compris-
ing residues 125 to 143 (BxGH99 63 to 80, see Figure 4.11) differs in conformation
between the two enzymes, but does not appear important in protein-substrate inter-
actions. Another region that does not participate in interactions with the ligand, but
has a different structure in these proteins is the short β-structure at residues 252–262
(Figure 4.11). In HsMANEA it is a pair of antiparallel β-strands (distorted in crystal
form 4 due to the proximity of the additive TEW), while in BxGH99 it is a 4-residue
turn (aa 186–189). In crystal form 5 the region could not be modelled. It does not
form a part of the core fold, and can be seen at the bottom of the proteins in Fig-
ure 4.10AB and in Figure 4.11. The region has a highly basic charge and forms a part
of the MANEA basic patch, which will be discussed in Section 4.4.5.
HsMANEA:
125-143
BxGH99:
63-80
HsMANEA:
190-203
BxGH99:
127-134
HsMANEA: 252-262
BxGH99: 184-189
Figure 4.11: Structure of HsMANEA crystal form 3 chain A overlapped with the
structure of BxGH99 with ManNOE and α-1,2-mannobiose (PDB code 5M03). The
polypeptide chains are shown as well as HEPES which is in complex with HsMANEA
in crystal form 3. The parts of the protein which do not differ significantly are shown
as transparent (and coloured by the secondary structure). The parts that differ are
non-transparent. The mainchain trace in HsMANEA is coloured according to its sec-
ondary structure (grey: none, red: helices, blue: strands, pink/tan/coral: turns) and
the parts of BxGH99 with different three dimensional structure are coloured green.
Assembled in ccp4mg.204
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Perhaps the most interesting feature is the conformation of HsMANEA residues 191–
201. This loop is absent from BxGH99, where in its place there is a short sequence
linking a core barrel β-strand to an α-helix (see Figure 4.11). In crystal form 1, this
loop does not appear close to the ligand binding pocket. In both crystals forms with
HEPES bound (2 and 4), the sulfo group seems to stabilize the loop in a position closer
to the projected space where the – 2 sugar would bind. It is probably the case that the
protein co-crystallized with HEPES because it helped stabilize the conformation of
this loop. D195 is poised to interact with the – 2 sugar OH3 group. This residue is
conserved in species that possess endo-α-1,2-mannosidases (see Figure 4.12), which
also points to its probable importance in enzyme function. However, the presence of
HEPES is inconvenient experimentally due to the – 2 and – 1 subsites being occupied
by the buffer molecule. These structures explain why, at high concentrations, the
buffer acts as an inhibitor of the enzyme.
135
144
161β-strand turn α-helix
Figure 4.12: An excerpt of an alignment of endomannosidase proteins from various
eukaryotes showing the 191–201 loop and neighbouring residues. Numbering in the
original sequences is given above each sequence. Secondary structure features from
the human enzyme are annotated on top of the sequences. Only the residues that
are 100% conserved are highlighted, and the colour of the highlighting reflects the
residue type.
The discussion above related to the overall 3-dimensional structure of HsMANEA.
However, of particular interest is the binding pose of HsMANEA inhibitors and nat-
ural substrates/products. In the next Section, this topic will be discussed.
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4.4.3 MANEA ligand binding
A structure of HsMANEA E404Q in complex with α-1,2-Man-O1-α-methylmannose
(crystal form 5) was fortuitously obtained from a co-crystallization experiment in
which the protein was crystallized in the presence of a tenfold molar excess of its
substrate: GlcMan3OMe. The initial aim of the experiment was to see the mode of
binding of the whole substrate – to obtain the so-called Michaelis complex. In the
experimentally determined structure, the ligand is seen only in the +1/+2 sites with
an occupancy of 0.75. Owing to the high quality of the data, the structure of the alter-
native conformation, in which water molecules were present in the active site at an
occupancy of 0.25, could also be resolved. The ligand sits exactly in the position that
was predicted from structural alignment with the BxGH99 product complex (PDB
code 6FWP). The structural similarity goes beyond that: Y271, a residue homologous
to BxGH99 Y198, exists in two conformations. In the bacterial protein, this residue is
disordered in structures where the + 2 subsite is not fully occupied, and is in a stable
conformation when it is occupied. As in the human protein structure the ligand is
at 75% occupancy, what is observed in HsMANEA seems to be the same effect. It is
tempting to explain this remarkable similarity by convergent evolution, but it is not
clear whether this is the reason for it.
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Table 4.4: Data collection and model refinement statistics of HsMANEA crystal struc-
tures with saccharides bound. *Values in parentheses represent the highest resolu-
tion shell. RMSD: root mean square difference.
Crystal form 5 4 4
HsMANEA variant E404Q WT WT
In complex with α-1,2-Man-
ManOMe
GlcIFG GlcIFG +
α-1,2-mannobiose
Data collection
Space group P21 P62 P62
Cell dimensions
a, b, c (Å) 42.7, 81.7, 53.0 127.9 127.9 48.8 127.9 127.9 48.4
α, β, γ (°) 90, 92.93, 90 90, 90, 120 90, 90, 120
Resolution (Å) 52.92–1.10
(1.12–1.10)*
31.97–1.90
(1.94–1.90)
110.76–1.80
(1.84–1.80)
Rmerge 0.054 (0.223) 0.203 (3.430) 0.148 (0.939)
Rpim 0.029 (0.150) 0.050 (0.843) 0.038 (0.237)
CC(1/2) 0.998 (0.944) 0.998 (0.546) 0.999 (0.782)
<I / σI> 11.9 (3.3) 10.5 (1.0) 13.4 (2.9)
Completeness (%) 97.6 (71.3) 100.0 (99.8) 100.0 (100.0)
Redundancy 3.7 (2.6) 17.6 (17.4) 16.5 (16.6)
Refinement
Resolution (Å) 52.98–1.10 110.73–1.90 110.76–1.80
No. reflections
all / free 143263 / 7225 36184 / 1779 42104 / 2094
Rwork / Rfree 0.11 / 0.13 0.19 / 0.22 0.18 / 0.22
No. atoms
Protein 3220 2961 2974
Ligand/ion 24/5 130 164
Water 491 113 137
B-factors (Å2)
Protein 15 32 26
Ligand / ion 19 / 21 66 47
Water 30 32 30
RMSD
Bond lengths (Å) 0.014 0.013 0.014
Bond angles (°) 1.7 1.74 1.9
PDB code – – –
+1/+2 subsites: A comparison with aligned structures of E404Q + α-1,2-Man-
ManOMe and the product complex of BxGH99 reveals an essentially identical
arrangement of the conserved residues and the hydrogen bonds around the +1/+2
subsites (Figure 4.13C).
– 1/– 2 subsites: The aa 191–201 loop seems to be stabilized through the hydrogen bond
that HEPES sulfo group forms with a backbone nitrogen of E196 (Figure 4.13D). The
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R366
E407
W368
D362
Y360
N369
Y268
Y271
V304
T330
D269
F329
Y189
P225
E224 Y268
H222
Y323
Y108
W110
E196
D195
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F324
–2
–1
E224
E196
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Y271
D269
Y360
+1 +2
E407
Figure 4.13: HsMANEA ligand binding pocket. (A) α-1,2-Man-ManOMe in the
+1/+2 subsites of the E404Q mutant (crystal form 5). 2mFo-DFc electron density map
around the ligand shown at 0.5 e–/Å3. (B) HEPES in the active site of the WT co-
crystallized with TEW (crystal form 4). 2mFo-DFc electron density map around the
molecule is contoured at 0.8 e–/Å3. Residues making close contacts to the bound
molecules are shown and labelled. (C) Comparison of the binding pose of α-1,2-
Man-ManOMe (grey) in complex with HsMANEA E404Q (green) with the BxGH99
product complex structure (with α-1,2-mannobiose and α-1,3-mannobiose, only α-
1,2-mannobiose is shown (in yellow)). (D) Comparison of the binding pose of HEPES
(grey) in complex with HsMANEA WT (green) with the BxGH99 product complex
structure (with α-1,2-mannobiose and α-1,3-mannobiose, only α-1,2-mannobiose is
shown (in yellow)). In (CD), hydrogen bonds for MANEA are shown, and only the
residues forming them with the compounds bound in the pocket are labelled. Subsite
nomenclature as in Ref. 304. Assembled in ccp4mg.204
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hydroxyethyl group of HEPES mimics the C5-C6-OH6 atoms of the – 1 sugar, forming
a hydrogen bond with E224 and a hydrophobic interaction with Y195.
Soaking the crystals of crystal form 4 with GlcIFG and subsequently α-1,2-
mannobiose revealed the binding poses of ligands in subsites – 2 to +2 (HEPES
was outcompeted by GlcIFG in the – 2/– 1 subsites). The binding position and
conformation of both compounds almost exactly mimics their position when bound
to BxGH99 (see Figure 4.14). Like in the structure of BxGH99 with GlcIFG and
α-1,2-mannobiose (PDB code 4AD4), isofagomine binds in a 4C1 conformation
(see Figure 4.14AC). The crystallization condition of this crystal form contained
100 mm HEPES at pH 7.5. The protein most likely cocrystallized with HEPES, which
primed the 191–200 loop for reception of the inhibitor into the  – 2/– 1 subsites. The
loop envelops the inhibitor: residue E196 participates in stabilizing the – 2 glucose
residue by making close (~3.05 Å) polar contacts with its OH2. Side chains of
D195 and N197 form hydrogen bonds with the OH3 group. The conserved D195
Oδ…OH3 interaction is particularly strong (2.55 Å). Y189, by homology to BxGH99
W126 thought to be forming a hydrogen bond with the – 2 Glc OH2, is actually
coordinating one of the two water molecules that form hydrogen bonds with the
OH2 group (Figure 4.14A). In BxGH99, this water molecule cannot be seen in the
electron density map – it would cause a steric clash with the tryptophan side chain.
A tantalizing proposition is that the protein is employing the flexible loop close to
the – 2 sugar OH3 in order to allow interactions with precursor glycans with two or
three terminal glucose molecules still attached, the first of which would be bound
to the – 2 Glc via an α-1,3-glycosidic bond. It has been shown that rat MANEA can
cleave Glc3-1Man from Glc3-1Man9GlcNAc2, although the activity towards the longer
glycans is only 7–8% of that towards Glc1Man9GlcNAc2.146 A different situation,
however, is more likely. The loop structure is not present in the bacterial enzymes,
whose primary substrate is the yeast mannan.207 The GH99 endomannanase takes
care of cleaving the terminal α-1,3-mannobiose from the polysaccharide, which
exposes the backbone. It is possible mannans with these branches extended exist. In
such a case, selection pressure in the bacterial enzyme would then act to minimize
any steric clashes at the – 2 subsite, so that it can be cleaved efficiently with no regard
to additional sugars being present. Conversely, the endomannosidase might have
evolved specifically to prevent the longer glycans from binding, and the 7–8% activity
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might represent “leakage”. In this scenario, the function of the enzyme would be to
discriminate against glycans that did not undergo the cleavage by α-glucosidase I
and the first cleavage by α-glucosidase II, which usually are fast processes.81,86
Cell culture studies demonstrated that the predominant product of the enzyme in
glucosidase II-deficient mouse cells is Glc2Man.150 In normal conditions the two
first glucoses are not decorating the glycan, but the last glucose is much more likely
to be carried over from the ER due to the presence of UGGT. Therefore, it would
make sense for the enzyme to evolve a high affinity towards the terminal GlcMan
disaccharide only, and not the longer structures. Kinetic studies are in support of
this: bovine MANEA does not cleave glycans that have more than one glucose on
the A branch. Figure 4.14C demonstrates the different observed conformations of
the loop in question. A “closed” conformation (green) is visible in structures with
HEPES or GlcIFG in the  – 2/– 1 subsites (crystal forms 3 and 4). Two conformations
of the 191–201 loop can be seen in the high-resolution structure of the E404Q mutant
(crystal form 5, yellow) and one in the structure with Ni2+ ion (crystal form 1, red).
Exactly how the loop behaves in the presence of a –3 ligand remains unknown.
The + 1 mannose in the structure of the tertiary complex is visible in two conforma-
tions at 50% occupancy each. This is analogous to how it appears in high resolution
structures of BxGH99, as shown in Chapter 2. This speaks to an extremely high sim-
ilarity between the binding site topography and the mode of action of bacterial and
mammalian GH99 endomannosidases.
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Figure 4.14: HsMANEA binding of GlcIFG, α-1,2-mannobiose and conformational
changes of the 191–201 loop. (A) Side chains of residues around the  – 2/– 1 subsites
and GlcIFG electron density (2mFo-DFc electron density map around the inhibitor
shown at 0.5 e–/Å3). Close polar contacts and hydrogen bonds are shown as dashed
lines. (B) Electrostatic surface of HsMANEA with GlcIFG and α-1,2-mannobiose
binding pose shown (crystal form 4). (C) Worm representation of residues 189–203
in different HsMANEA models and 127–135 in BxGH99 PDB code 4AD4. Green: WT
in complex with GlcIFG and α-1,2-mannobiose (crystal form 4); yellow: E404Q in
complex with α-1,2-Man-ManOMe (crystal form 5); red: WT with Ni2+ (crystal form
1); blue: PDB code 4AD4. Subsite nomenclature as above. Assembled in ccp4mg.204
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4.4.4 Analysis of MANEA mutations in context of the structure
The models of the human MANEA protein permit answering long-standing ques-
tions about the structure of GH99 enzymes. For example, CHO cells have been known
not to possess any detectable endomannosidase activity153,168 and this is due to a mu-
tation in their MANEA protein, described in a 2007 article by Torossi et al.197 This was
discussed in Section 1.4.5.4: see Figure 1.15 on page 37 and the associated text. Two
residues were selected for studying the cause of this lack of activity: residue 177 and
188. In the human MANEA and MANEA proteins encoded in the genomes of many
other mammals, these residues are R177 and W188. The wild-type Chinese hamster
MANEA features an unusual cysteine residue in position 177, and MANEA in CHO
cells contains a W188C mutation. While R177 is not fully conserved – being a cysteine
in WT Chinese hamster and a histidine in Otolemur garnettii (northern greater galago)
– W188 is conserved across the animal kingdom, as well as in the bacterial GH99
enzymes. It was found197 that the W188C mutation causes the protein to be mislo-
calized away from the Golgi and to the ER. This is mediated by the formation of an
intramolecular disulfide bridge. The authors propose two hypotheses as to why this
mutation has such an effect: either R188 forms hydrogen bonds with the substrate, or
it participates in the stabilization of tertiary structure. The MANEA crystal structure
points to the second explanation – with some truth in the first. R188 is a residue that
plays many roles: it is a part of a core β-strand and stabilizes the structure against the
outside α-helix. It also directly precedes Y189, which coordinates a water molecule
that forms a hydrogen bond with the – 2 sugar OH2 (see Figure 4.14A). With R188 mu-
tated to C, both the protein tertiary structure and its ligand binding propensity would
be disturbed, and this effect would probably be exacerbated by the formation of the
disulfide bridge. The appearance of this enzyme variant raises questions about the
utility of not having endomannosidase activity for CHO cell survival: the point mu-
tation at this locus seems to be ideal for compromising the endomannosidase, and
might have been selected for. An interesting experiment would be to see whether
CHO cells with restored MANEA activity are indeed outcompeted by those lacking
it in culture. An answer to this question would have implications for research into
immortalized cell lines, which translates to insights into biology of cancer.
Kukushkin et al. speculated that an S to K substitution at position 227 may be respon-
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sible for the more narrow specificity of bovine MANEA towards monoglucosylated
N-glycans, as opposed to a more relaxed specificity of human MANEA. They thought
it might occlude access of longer structures to the active site.169 It is indeed quite pos-
sible that the lysine makes an H-bond with the spatially close 191–201 loop E196 side
chain or N194 main chain oxygen, which stabilizes the loop. This question can only
be resolved by further structural studies.
A number of somatic point mutations were discovered in the endomannosidase gene
and deposited to publicly available databases. These are summarized in Table 4.5 and
with the structural information at hand, their functional impact on the protein can be
assessed. Of the 89 considered mutations (82 excluding the metastases), there were
five found in more than one sample (at residues 57, 111, 248, 319 and 366). Only two
of these – K57E and G319E – were found in multiple samples that were not clones
of the same tumour. R→C and Y→C variants seem to be prevalent, making up 11%
of non-metastatic missense mutations. This is notable because MANEA proteins, in
general, have low cysteine content (usually 1, rarely 2 in the lumen-resident region).
As discussed earlier, a cysteine in the wrong place can lead to formation of a spurious
disulfide bridge, compromising the activity of the enzyme. However this might not
be significant since the total content of R and Y residues in the MANEA sequence is
12% and the background mutation rate for the protein is not known (11% and 12%
are numbers that are not far apart). The catalytic domain makes up 357 of the 462
MANEA residues (77% of the sequence length; residues 98-454) and 81% (54/67) of
the mutations burden affects the catalytic domain. As such, there seems to be no
preference for mutations to occur within this region. 50% of the mutations within the
catalytic domain affected residues that are conserved between MANEA, MANEAL
and bacterial GH99 endomannanases.
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Table 4.5: Somatic mutations found in the human MANEA. Only the protein variants
are shown. Silent mutations were omitted. Variants of particular interest written in
bold, the mutations resulting in an additional cysteine residue emphasized in italics.
If multiple synonymous missense mutations were observed, the number in parenthe-
ses is the number of patients in whom they occurred. Data taken from the COSMIC
database.305,306
Mutation Count Mutation Count Mutation Count
F4V 1 V219F 1 D318H 1
M23V 1 H222Y 1 D318Y 1
G37E 1 I223R 1 G319E 2 (2)
H49R 1 R229* 1 Y323* 1
R51Q 1 K244N 1 N327S 1
K57E 3 (3) H248Y 4 (1) Y331C 1
N58I 1 A250V 1 S334L 1
D60E 1 Y252* 1 C345Ffs*6 1
D65V 1 A261V 1 Y348C 1
E70* 1 L262V 1 G359A 1
K74N 1 S270F 1 T363I 1
K77E 1 T273A 1 R366C 3 (1)
S78I 1 P275H 1 R366H 1
M83V 1 A279T 1 W368C 1
H104N 1 L281M 1 R376* 1
F106S 1 T283I 1 R376Q 1
Y111C 3 (1) S287F 1 Y381C 1
N113K 1 R288Q 1 R393H 1
P114L 1 N292Y 1 E407A 1
K137R 1 P294L 1 A414Lfs*12 1
G142E 1 L302P 1 V415L 1
Y155C 1 E306* 1 P416S 1
P156S 1 K307N 1 R428C 1
M173V 1 H308R 1 L434F 1
M176I 1 K309T 1 R440H 1
R177H 1 S315I 1 A454V 1
K218N 1
Only one MANEA missense mutation, K57E, was found in tumour samples from
three separate patients. This lysine residue is a part of the stem domain of MANEA,
which is a spacer between the short N-terminal transmembrane helix and the catalytic
domain. It is not predicted to be acetylated307 but is predicted to be ubiquitinylated by
UbiSite288 and ESA-UbiSite289 servers. As it is not within the sequence of the solved
catalytic domain structure, the model cannot inform the assessment of the mutation.
As K57 is a predicted ubiquitinylation site, it suggests there might be some selection
in tumours towards survival of the protein – ubiquitinylation is a marker for degra-
dation by the proteasome. The G319E variant is found in the MANEA sequence from
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two patients. G319 is a residue conserved across vertebrate and bacterial GH99s and
a part of the core β-structure: it can be said with a high degree of confidence that this
change would prevent the protein from folding properly. D318H and D318Y, each
found in one patient, also affects a universally conserved, neighbouring residue and
would have a similar effect. Mutations R366C, R366H and E407A change residues
that form hydrogen bonds with the substrate/product. E407 is the acid/base residue
and an E→A mutation of a homologous glutamate in BtGH99 (E332A) resulted in
activity being reduced by approximately a factor of 50.148 Variant Y111C affects a
tyrosine residue that is conserved and neighbours Y110 which forms hydrophobic
interactions with the pyranose rings of the – 2 and – 1 sugars – it is likely to disrupt
these interactions.
No definite conclusions can be drawn from the mutational analysis. One one hand,
the MANEA variant present in CHO cells, and the relative multiplicity of X→C amino
acid changes suggest the immortalized cells that lack the endomannosidase function
might have a selective advantage over other phenotypes. On the other hand, the most
commonly found mutation was K57E. If the ubiquitinylation prediction software is
correct, it might be a site that – if mutated – could decrease the propensity of MANEA
to be degraded by the proteasome. Perhaps the individual characteristics of each
tumour or cell line favour different levels of MANEA activity. It should be also kept in
mind that somatic mammalian cells are diploid and the other allele could compensate
for the mutation.
4.4.5 MANEA and MANEAL structural features
As MANEA is the first eukaryotic GH99 to have been solved, the possibility of looking
at related proteins was opened. MANEAL is the obvious candidate for such investi-
gation. The MANEAL catalytic domain modelled on the MANEA template revealed
a highly similar protein, with structural alignment containing no gaps, as in the pri-
mary sequence alignment (Figure 4.3). Only one model was generated and it had a
high confidence score (1.76 on a scale from -5 to 2) and a low RMSD (3.1 ± 2.2 Å).
By visual examination, the modelling of the chains is likely not correct, especially
the residues in the active site, which are likely to assume a low-probability rotamer
to which the modelling software is blind. The backbone of the protein, however, is
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identical, and the differences in the primary sequence seem to stem from a series of
functionally neutral changes, with one exception: Q226 (mentioned in Section 4.2),
which is aligned with MANEA E224 (as expected). The interaction that E224 makes
with GlcIFG can be seen in Figure 4.14A on page 115.
A positively charged patch was found upon examination of the electrostatic surface of
MANEA. Such patches have been found in proteins that interact with DNA, but also
in proteins that do not form such interactions.308 The presence of positively charged
patches is correlated with difficulty in production of soluble proteins,309 which might
explain the need for chaperone in order to produce active MANEA in bacteria. The
patch can be seen for both the structure of the WT (Figure 4.15A) and the E404Q mu-
tant (Figure 4.15B). It is more pronounced in the WT structure due to a loop containing
basic residues being present in the model. Interestingly, the MANEAL I-TASSER ho-
mology model does not seem to have such a patch (Figure 4.15C), nor does BxGH99
(D).
A B C   D
Figure 4.15: Electrostatic surface of the models of various GH99 proteins. Top: view
from the active site side, bottom: view from the back of the active site (180° rota-
tion about the Y axis). Red signifies negative charge, and blue positive charge. The
positively charge patch is circled. (A) Crystal form 3 form with HEPES visible; (B)
crystal form 5 with α-1,2-Man-ManOMe visible; (C) HsMANEAL homology model
(modelled afterHsMANEA crystal form 2 chain A); (D)BxGH99 with all four subsites
occupied (by ManNOE and α-1,2-mannobiose, PDB code 5M03). Surface charges cal-
culated using ccp4mg204. Charge scale: ≤-0.5: red, >-0.5 and <0: shades of red, 0:
white, >0 and <0.5: shades of blue, ≥0.5: blue
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4.5 Conclusions
The solution of the crystal structure of human endo-α-mannosidase represents a ma-
jor step in understanding of this enzyme. The remarkable similarity in the binding
of the sugars around the scissile bond validates the mechanistic conclusions drawn
from studying the bacterial homolog of the enzyme. Description of subsites – 2 to + 2
opened new areas of investigation of the enzyme. Three residues surrounding the lig-
and around the – 2 subsite were discovered, and they form a part of a loop that is not
present in bacteria. Two of these residues are highly conserved in eukaryotic endo-
mannosidases. In the process, a method for production of high amounts of human
MANEA in bacteria was refined, and the boundaries of the catalytic domain were
established. Analysis of somatic mutations revealed that the role of MANEA in can-
cer is not easy to predict, and probably depends on the individual characteristics of
each condition. As some mutations that were found are likely to make cells produce
more of the enzyme than in healthy cells, there is therapeutic potential for targeted
inhibition of the enzyme. Answering the questions of when, how and if to intervene
with endomannosidase activity would require more research, but the protocols de-
veloped here may serve to make the process easier. It is also a step forward towards
a structural picture of the whole N-glycosylation pathway. Structures of numerous
eukaryotic ER and Golgi glucosidases and mannosidases from various eukaryotic
sources are available, and the endomannosidase represented a gap in our knowledge
which is now filled.
The human GH99 fold is reasonably stable. The 191–201 loop becoming ordered
when the  – 2/– 1 disaccharide or HEPES (and probably HEPPS, as its structure and
effect on the enzyme are similar) binds is the largest conformational change that hap-
pens in the protein. An interesting avenue of research might be studying the changes
in the loop using NMR. This would require assigning the protein, which with an
enzyme of this length is likely to be cumbersome (2H, 13C and 15N triply labelled
protein is necessary). It would, however, be a good method for uncovering the ob-
served specificity differences that occur between endomannosidases from different
mammals (bovine MANEA is specific towards monoglucosylated glycans only, as dis-
cussed above).169 A conformational change might be observed in rat/human MANEA
upon binding of the longer substrates, but not in bovine MANEA, or it might require
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a higher concentration of the ligand. Understanding of these processes in a larger
sample of endomannosidases will uncover the evolutionary identity of this enzyme.
The path to the solution of HsMANEA structure with saccharides occupying four
subsites reveals that the use of a weakly binding ligand may be a good strategy for
obtaining multiple crystal forms. HEPES was an ideal ligand for this: it binds to the
protein with low affinity and stabilizes an otherwise disordered loop, priming it to re-
ceive the inhibitor. It is well known that using a molecule which binds to the protein
often stabilizes its conformation. Researchers take advantage of this effect by per-
forming thermal shift assays with different molecules present as a way to screen for
potentially binding compounds. A higher melting temperature in comparison to that
of the protein alone often means that the compound is a ligand. If a compound of in-
terest is in limited supply, preventing co-crystallization, and no suitable crystal form
was obtained with the protein alone, trying different buffer molecules can be helpful.
Glycoside hydrolases, glycosyltransferases and lectins are especially suitable for this,
as their binding pocket is tuned to capture ligands with multiple hydroxyl groups,
and biologically useful aqueous buffers often contain those. Additionally, only by
the use of a polyoxometalate TEW as an additive, a crystal form suitable for studies
of the four subsites,  from – 2 to + 2, was obtained. There are only four structures with
this compound in the PDB, even though it has been available for some time already
(the first structure with it was published in 2014).292
Production of soluble, stable protein enabled the characterization of MANEA ligand
binding thermodynamics and studies on its reaction kinetics. In the following chap-
ter, which will close this thesis, data pertaining to these topics, as well as cell cul-
ture experiments, will be presented. In addition, efforts with an aim to produce the
MANEA sister protein – MANEAL – will be described.
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Chapter 5
Kinetic and biochemical
characterization of human GH99s
5.1 Abstract
The human genome contains genes encoding two proteins predicted to have a GH99
domain: MANEA and MANEAL. Previously reported research concentrated on the
MANEA gene and its protein product. Here, an attempt at expression of a truncated
version of the MANEAL gene is presented. The catalytic domains of MANEA and
MANEAL were produced, but only MANEA showed activity on the native substrate
GlcMan9GlcNAc2. The yield of MANEAL was extremely poor, the protein was not
stable in the buffer used for MANEA and likely was misfolded. The binding constants
of isofagomine-type GH99 inhibitors were measured. GlcIFG binds to MANEA with
a KD of 19.6 ± 5.6 nm and binding of ManIFG is roughly 10 times weaker. A novel
inhibitor, “blocked” GlcIFG, binds with a KD of 929 ± 52 nm. The compound is pre-
dicted to be more stable than GlcIFG in vivo. TheKD values obtained for the inhibitors
support previous conclusions about the human enzyme derived from the data ob-
tained from experiments with the bacterial enzyme, namely the preference of the hu-
man enzyme towards Glc-substituted ligands. Michaelis-Menten kinetics of MANEA
activity on a tetrasaccharide substrate analogue GlcMan3OMe were established. Al-
ternative approaches to MANEAL production have to be developed in order to char-
acterize this enzyme. It is possible that by omission of this enzyme, crucial aspects in
the story of the endomannosidase pathway are not understood.
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5.2 Introduction
Production of the other GH99 protein encoded by the human genome, MANEAL, has
never been reported. The success in MANEA purification prompted trying a similar
approach for MANEAL. The activity of this protein is unknown, but as shown in the
previous chapter in Figure 4.2, it is localized to the Golgi and therefore is likely to
play the same role as MANEA but in different tissues or cell types. The expression of
MANEAL mRNA is higher in the tissue depleted in MANEA – the brain (Figure 4.1).
The protein sequence identity of MANEA and MANEAL is 57% and there is one
consistent difference between these proteins: MANEA E224 is Q226 in MANEAL.
This chapter will include a discussion of the results of the protein prodution efforts,
as well as characterization of the activity of both enzymes.
As discussed in Chapter 1, inhibition of endomannosidase is an attractive, potentially
general antiviral therapy. The enzyme offers a pathway of N-glycan maturation in
regimes of glucosidase inhibition. Results from the Terry Butters group (from Dr Do-
minic Alonzi) suggested that the GH99 inhibitor GlcIFG was antiviral against bovine
viral diarrhea virus (BVDV). They are summarized in Figure 5.1. With increasing Gl-
cIFG concentration, the infectivity of BVDV was decreasing. The inhibitor had an
effect on the glycosylation of the viral envelope protein that was distinctly different
from that of an ER glucosidase II inhibitor NAP-DNJ. When used together, these com-
pounds had an additive effect on decreasing infectivity. These data prompted an in-
vestigation into the effect on the infectivity of other viruses that affect humans, whose
results will be presented in this chapter.
A B C
(1 mM)
1 mM
1 Mµ
Figure 5.1: Results of BVDV assay in cell line MDBK. (A) Percentage of FFU (focus-
forming units) relative to untreated cells at different concentrations of GlcIFG at a
MOI (multiplicity of infection) of 1. (B) Effect of endomannosidase inhibition (GlcIFG)
and ER glucosidase II inhibition (NAP-DNJ) on susceptibility of glycans on the BVDV
E1/E2 protein to cleavage by endoH. (C) Effects of NAP-DNJ and GlcIFG on BVDV
infectivity are additive. Figures from the Terry Butters’ group.
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5.3 Materials and methods
5.3.1 Gene subcloning and protein production
A CDS (coding DNA sequence) encoding MANEAL which lacked the 95 N-terminal
amino acids (the stem domain) was optimized for expression in Escherichia coli and
ordered from Genscript Biotech. The gene was subcloned into pET28a(+) and pCold-
I vectors using restriction sites NdeI and XhoI, similarly to MANEA. The gene was co-
expressed with groEL/groES from the pCold-I construct and the protein was purified
from BL21(DE3) cells using the same protocol as HsMANEA (Section 4.3.3). As the
isoelectric point of MANEAL is considerably lower (6.9 vs. 9.2 for MANEA), the pH
of the buffer used for cation exchange was modified from 7.0 to 6.0. An additional gel
filtration step using an S75 16/600 HiLoad Superdex column was performed in 50 mm
potassium phosphate pH 7.0, 185 mm KCl in order to remove residual chaperone. The
protein migrated on the gel as a single band corresponding to a Mw of 42–43 kDa (the
actual Mw of the purified protein was 43963 Da). The yield was extremely low (0.15–
0.2 mg protein per litre of culture). The buffer used to store HsMANEAL was 50 mm
potassium phosphate pH 6.0, 250 mm KCl.
5.3.2 Chemicals and enzymology
MANEA activity on its natural substrate was confirmed by performing an extended
assay. This method was chosen in order to make the results of the assay comparable
with the results of a similar assay performed by Dr Andrew Thompson with BtGH99
and described in his PhD Thesis.310 The protein, at a concentration of 100 nm, was
incubated with 24.5 µm GlcMan8GlcNAc2 oligosaccharide (DEXTRA) (total substrate
amount: 1 µg) for 19 h at 4 °C, 14 h at RT, then 12 h 30 min at 37 °C. The buffer used was
50 mm potassium phosphate pH 7.0, 185 mm KCl. A negative control containing the
oligosaccharide but no enzyme was subjected to the same incubation process. The to-
tal volume of each sample was 20 µl. For MS analysis the enzyme was removed using
an ion exchange column and the resultant carbohydrate samples were dried. Perme-
thylation of the carbohydrates was achieved using a procedure described in Ref. 311.
The samples were analysed using MALDI-MS. Enzyme removal, permethylation, MS
data collection and analysis were performed by York Technology Facility staff.
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Comparison of the activity of HsMANEA and MANEAL was done using a similar
incubation procedure. In this case, all reactions were performed in MANEAL stor-
age buffer: 50 mm potassium phosphate pH 6.0, 250 mm KCl. 4 µl of reaction mixture
containing 500 nm enzyme or no enzyme control and 1 µg GlcMan8GlcNAc2 were
incubated for 67 h at 5 °C, 12 h at RT and 12 h 30 min at 37 °C. The contents of the re-
sulting mixture were analyzed using thin layer chromatography (TLC). The samples
were transferred in 1 µl droplets onto SUPELCO silica gel on TLC Al foils (SIGMA-
ALDRICH). Each droplet was allowed to dry before adding the next droplet. β-1,4-
Xylobiose was used as a standard indicator of Mw (282.24 g mol-1). TLC was per-
formed in a preequilibrated chamber using 50% v/v N-butanol, 25% v/v acetic acid,
25% v/v H2O as the running buffer. When the buffer reached 75% of the plate height,
the plate was taken out of the chamber, dried and put back again. The buffer was
allowed to reach 75% of the plate height again, at which point the migration was ter-
minated. After drying, the samples were visualized by applying a staining solution
(3% v/v sulfuric acid, 75% v/v ethanol, 0.1% orcinol monohydrate). The spots ap-
peared after the plate was dried and subsequently heated on a hot plate (70–100 °C).
Blocked GlcIFG (BGlcIFG) was synthesized in Spencer J. Williams’ laboratory at the
University of Melbourne, Parkville, Australia by Dr Zalihe Hakki and GlcMan3OMe
by Pearl Fernandes from the same group. The structures of these compunds are
shown in Figure 5.2. Endomannosidase activity assay was performed by a linked
assay method, published earlier.159,207 The assay involves the use of BT3990, a GH92
α-mannosidase prepared by Dr Michael Suits, which specifically cleaves the α-1,2-
mannosidic bond in the reaction product α-1,2-Man-ManOMe. The non-methylated
mannose residue was then detected using d-Mannose/d-Fructose/d-Glucose Assay
kit (Megazyme, Inc.). The samples were pre-heated to 37 °C before adding the en-
zymes (GH99 to a final concentration of 1 µm and GH92 to a final concentration of
100 nm). The initial reaction rate was measured at 7–9 min after addition of the en-
zymes as the rate of increase of absorbance at 340 nm. All samples were kept in quartz
cuvettes. Abs340 (absorbance at 340 nm) was directly proportional to the amount of
mannose present in the solution: 160.8 µm mannose per 1 unit of absorbance. The
reactions were performed in 50 mm potassium phosphate pH 7.0, 50 mm KCl. KM
and kcat values were calculated using a non-linear curve fit (Michaelis-Menten fit) in
Origin 9. Additional reactions with mannose standards were performed in order to
standarize the substrate concentration.
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Methylcyclohexanyl-3-
-Glc-1,3-isofagomineα
-Glc-1,3- -Man-1,2- -Man-α α α
1,2- -1-methyl-Manα
Figure 5.2: Compounds used for studies presented in this chapter. Left:
methylcyclohexanyl-3-α-Glc-1,3-isofagomine (BGlcIFG), right: α-Glc-1,3-α-Man-1,2-
α-Man-1,2-α-1-methyl-Man (GlcMan3OMe).
5.3.3 ITC
Isothermal titration calorimetry was done in 50 mm potassium phosphate pH 7.0,
50 mm KCl in the case of HsMANEA and 25 mm HEPES pH 7.0, 100 mm NaCl for
BtGH99. Protein and ligand concentration was varied in order to optimize the c-
value. Details of the ITC hardware and software are explained in Section 3.3.4. The
ITC experiment in the presence of α-1,2-mannobiose were performed with 44 µm of
HsMANEA in cell, 608 µm of GlcIFG in syringe and 1 mm of α-1,2-mannobiose in
both. The details of protein concentration in the calorimeter cell and the inhibitor
concentration in the syringe are explained in the discussion. The protein concentra-
tion in the sample was double-checked by unfolding the protein in 6 m guanidinium
hydrochloride to expose all aromatic residues and measuring Abs280 using an Eppen-
dorf BioPhotometer. The extinction coefficient of HsMANEAL used for calculations
of protein concentration was 95230 m-1 cm-1.
5.3.4 Protein thermal unfolding
Thermal unfolding was done using an Agilent Technologies Mx3005P qPCR system.
The proteins were kept in their respective phosphate storage buffers. The final con-
centration of HsMANEA was 1 mg ml-1 and of HsMANEAL was 0.83 mg ml-1. Tem-
perature was increased from 25 to 95 °C in 1 degree increments of 30 s each. The
reporter molecule was SYPRO Orange (fluorescence measured at 570 nm). The re-
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porter was used at a final concentration of 2.5 × (1/2000 of the 5000 × concentrated
stock – this is the concentration at which it is sold). The measurements were done in
triplicate with single buffer controls.
5.4 Viral infectivity assay
The Level III procedures in the hepatitis C (HepC) activity assay and the immunos-
taining were performed at the University of Birmingham by Scott Davies and Dr
Zania Stamataki. Huh7 cells (human hepatocyte cellular carcinoma cell line) were
grown in 96-well plates for 2 d. After this, the media was exchanged into a 2 × solu-
tion of the tested GH99 inhibitor (GlcIFG, GlcDMJ, BGlcIFG or Glc-β-aziridine) with
or without a 2 × solution of NB-DNJ, in which the cells were incubated for 1 h. The fi-
nal concentration of the GH99 inhibitor was varied (using serial dilutions) from 2 mm
to 3.9 µm. The final concentration of NB-DNJ was varied from 8 mm to 500 µm depend-
ing on the experiment (it is discussed and presented in the Results and discussion
subsection 5.5.4). Then, 50 µl media containing HepC was added to each well, di-
luting the GH99 inhibitor and NB-DNJ to the desired concentration. Experiments
were done in triplicate for samples with NB-DNJ and untreated controls, and in sin-
gle samples for GH99 inhibitors only. The infected cells were then grown for 2 d and
killed using methanol. This inactivated the virus and made the cells safe to handle
outside the Level III facility. The plates were then stained with an anti-NS5A* anti-
body and a secondary antibody conjugated to a red-fluorescent probe. They were
then transported to York, where the cells were stained with the nuclear stain DAPI
(4￿,6-diamidino-2-phenylindole). After staining, all of the wells containing relevant
samples were imaged in the red and blue channel using a Zeiss LSM 780 microscope
with a fully open pinhole. The image data were processed using TissueQuest soft-
ware (TissueGnostics imaging solutions). About 60% of each image was used, and
areas with damaged cells were masked from the analysis. Cells were counted using
the DAPI staining and the infected cells by anti-NS5A staining.
*NS5A (non-structural protein 5A) is a zinc-binding protein essential for HCV (hepatitis C virus)
RNA replication and virion morphogenesis. The protein exists as a number of phosphorylated species.
See Ref. 312 for a more detailed characterization of the protein.
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5.5 Results and discussion
5.5.1 HsMANEAL gene expression, protein purification and unfold-
ing
The truncated HsMANEAL was produced in and purified from E. coli, but the yield
was very low and most of the protein was in the insoluble fraction, even when co-
produced with the GroEL chaperone. The protein seemed to purify in a similar way
toHsMANEA: two peaks were observed when eluting from the nickel affinity column
with an imidazole gradient with a higher concentration of GroEL than HsMANEAL
in the first peak, and three peaks during cation exchange chromatography on an SP
column (see Figure 5.3). The protein was difficult to solubilize at pH 7.0 and 185 mm
salt, the HsMANEA buffer. By changing the pH to 6.0 it was possible to concentrate
the protein up to 1.7 mg ml-1.
Thermal unfolding experiments showed that both proteins are folded – the initial flu-
orescence is stable at 0 at lower temperatures (25–35 °C), which also means that the
fluorescence change (differential) is around 0 when the protein is heated at these tem-
peratures (the fluorescence change is the Y axis in Figure 5.4). MANEA unfolds with
a Tm of 50.3 °C (concordant with the value obtained from CD spectra in Figure 4.9),
while MANEAL exhibits two melting points: 48.7 °C and 60.0 °C (Figure 5.4). All
three replicates gave similar results.
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Figure 5.3: Purification of HsMANEAL WT from BL21(DE3) cells. Nickel affinity col-
umn (FF crude) was used in the first step, followed by SP cation exchange chromatog-
raphy and size exclusion chromatography. The blue line represents the Abs280 signal
(mAU), and the orange line the concentration of buffer B (arbitrary 0-100% scale). The
collected fractions are tinted green on the 12% reducing SDS-PAGE gel image and the
corresponding chromatogram, the discarded fractions are tinted red. The molecular
weight of ladder bands are in kDa. The hatched box represents all fractions that were
collected for later use. †GroEL chaperone, *N-terminally His-tagged HsMANEAL.
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Figure 5.4: First derivative melting plot of HsMANEAL (green lines) and HsMANEA
(red lines). The peaks correspond to inflection points of the melting curves, which
establish the Tm.
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5.5.2 Enzymology of MANEA and MANEAL
The truncated variant of HsMANEA is catalytically active towards its natural sub-
strate GlcMan9GlcNAc2. It releases α-Glc-1,3-Man and Man8GlcNAc2: the presence
of the latter was confirmed by mass spectrometry. Some of the initial substrate was
uncleaved even after prolonged incubation with the enzyme (see Figure 5.5). This
result confirms that the 97 N-terminal amino acids in MANEA are not essential for
its activity.
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Figure 5.5: Mass spectra of carbohydrates present in solution of GlcMan9GlcNAc2
after incubation with (top) or without (bottom) HsMANEA. The peaks correspond to
m/z of [M+Na]+ permethylated derivatives of the oligosaccharides.
MANEA exhibited considerable activity towards GlcMan3OMe. The KM value with
this substrate was 426 ± 33 µm and kcat 27.7 ± 1.0 min-1 (kcat/KM of 65 mm-1 min-1). The
Michaelis-Menten curve fit is presented in Figure 5.6. MANEA catalytic efficiency
is almost identical to that of BtGH99 on the Man4OMe substrate:207 (KM = 2.6 mm,
kcat = 180 min-1, kcat/KM = 69 mm-1 min-1). The 6 × lower KM of the human enzyme
also comes with about 6.5 × lower kcat. The similar values of kcat/KM for these enzymes,
which likely emerged and evolved independently, suggest there is little room for im-
provement in catalytic efficiency. It is possible that the trade-off for the improved
substrate affinity expressed by the lower KM value is a slower process of dissociation
of the products, which reduces the kcat. These values also reflect the environments
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in which the enzymes operate: it is more important that no N-glycans are left unpro-
cessed in the ERGIC/Golgi, even if their concentration is quite low. In contrast, yeast
mannan may reach high concentrations around the cell of a Bacteroides species, and in
this situation what matters is the velocity at which the enzyme can process the sugars.
There was no measurable activity when the substrate was incubated with HsMANEA
E404Q mutant.
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Figure 5.6: Michaelis-Menten kinetics of the catalytic domain of HsMANEA with
GlcMan3OMe as its substrate. The data points at around 49 µm and 111 µm
[GlcMan3OMe] done in triplicate and for higher concentrations in duplicate. A sin-
gle measurement was also takes at 56 µm [GlcMan3OMe]. The error values shown are
standard errors as reported by the fitting software. Due to the precious nature of the
substrate, experiments at higher [GlcMan3OMe] concentrations were not attempted
at this point – the value of Vmax might be corrected in the future. Figure created using
Origin software.
The purified version of HsMANEAL was not active when assessed by thin-layer chro-
matography (see Figure 5.7). While HsMANEA left no detectable GlcMan9GlcNAc2
substrate, releasing GlcMan and Man8GlcNAc2, the contents of the mixture contain-
ing HsMANEAL and the oligosaccharide were not different from those of the nega-
tive control. Together with the thermal unfolding data, this suggests that the protein
might be misfolded. However, the limited amount of the protein prevented analysis
by CD. Attempts at crystallization with various screens produced no hits.
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Figure 5.7: Results of MANEAL activity assay. The tailing at the Xyl2 lane is an arte-
fact of overloading and does not affect the migration of the neighbouring sample.
Contrast around the GlcMan spot was enhanced due to a low amount of the species.
5.5.3 MANEA and MANEAL inhibitor binding
Isothermal titration calorimetry experiments with the human GH99 were problem-
atic. In case of GlcIFG and ManIFG, the number of sites as measured by the inflec-
tion point of the isotherm was larger than 1 (2.3–2.4), even though the shape of the
curve was entirely consistent with a single binding mode. Parallel experiments with
BtGH99 were run in order to measure the ligand concentration using ITC, as it was
known that BtGH99 has one binding site for ManIFG and GlcIFG. These experiments
reduced the discrepancy to 1.7–1.8, which was unsatisfactory. In order to exclude the
possibility of a secondary binding site and saturate the +1/+2 subsites, titration ex-
periments with a large excess (1 mm, 23 × protein concentration) of α-1,2-mannobiose
in the cell and the syringe were run. α-1,2-Mannobiose is the disaccharide that binds
in the +1/+2 subsites, and they were considered as possible culprits changing the
binding mode. In this experiment, the apparent number of sites was was 1.1.
The possibility that the protein concentration having not been measured correctly,
which would skew the apparent N, was considered. The protein concentration was
tested with folded and unfolded HsMANEA and the results were identical. If a part
of the protein was unfolded or inactive, the apparent number of binding sites would
be lower than 1, not higher than 1, as the inhibitor would saturate the protein at a
lower concentration.
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When data from the ITC experiments done in presence or without α-1,2-mannobiose
were analyzed (assuming that N=1 in both cases) and the syringe (inhibitor) concen-
tration, instead of the N, was left to refine freely, the obtained ΔH and KD values
were similar. This led to a tentative conclusion that the the apparent stoichiometry
of 1.7–1.8 was an experimental artefact. If the additional binding site had been real,
there would have been a difference between the ΔH and KD values obtained from
experiments with or without α-1,2-mannobiose. In the ITC curves presented in Fig-
ure 5.8AB, data processing was done with an assumption of a single binding site, and
the syringe concentration was left to refine freely. The experimental N for BGlcIFG
(Figure 5.8C) was 1.
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Figure 5.8: ITC curves for various ligands titrated into cell containing a solution of
HsMANEA. (A) GlcIFG, (B) ManIFG, (C) BGlcIFG.
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The results of ITC experiments are in good agreement with the differences between
the bacterial and the human GH99 enzymes revealed by the kinetic data (see Table 5.1
for a comparison). The overall affinity of the human enzyme to the inhibitors is higher,
which is concordant with its lower KM value on its preferred substrate. Compari-
son of ΔH and -TΔS values obtained from the ITC experiments on HsMANEA with
GlcIFG, ManIFG and BGlcIFG reveals that with increasing inhibitor affinity, the en-
thalpy change (negative – release of heat) has a larger magnitude, as well as the en-
tropy change (a decrease in entropy). The decrease in entropy for BGlcIFG is 13 ×
smaller than for GlcIFG – the most extreme change. This may reflect that the 191–201
loop in HsMANEA remains unstructured upon the binding of BGlcIFG. Structural
studies are needed to resolve this question.
Table 5.1: Comparison of dissociation constants for isofagomine-type ligands with
HsMANEA and BtGH99. *The error is not known, as the value was taken from liter-
ature (as reported in Ref. 148). The KD value of ManIFG with BtGH99 is taken from
Ref. 159.
Compound KD HsMANEA (nm) KD BtGH99 (nm)
BGlcIFG 929 ± 52 –
ManIFG 170 ± 32 140 ± 16
GlcIFG 19.6 ± 5.6 625*
ITC experiments with ManNOE were also attempted. In this case, it was not possible
to interpret the curve using standard fitting software. The reported number of sites
was 2.2–2.3. The curve had an unusual shape: initial injection points indicated weak
binding, and when the number of sites reached about 2, the binding became tight
and the protein saturated almost instantly. The unusual behaviour observed might
indicate cooperative binding or that both the gluco- and manno- forms of ManNOE
bind to the enzyme. One indicator of this is that the time interval for the DP to return
to baseline forHsMANEA is not long, as it was in the case of Bt and BxGH99 (compare
to Figure 3.5 on page 75). In Figure 5.9 the result of the titration is presented. If the
binding was weak, one would expect the curve to not show signs of saturation near
the end of the titration. If the binding was strong, all of the injected ligand would
initially bind after each injection, producing a curve similar to those in Figure 5.8AB.
The ManNOE binding isotherm has characteristics of both. Alternative models were
tried (two set of sites, two sequential binding sites), but due to no knowledge of the
initial parameters, no reasonable results were obtained. Figure 5.9 represents only an
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attempt at fitting a curve that would partly explain the ITC result – a more satisfactory
answer needs to be arrived at, which requires ITC experiments in presence of α-1,2-
mannobiose or displacement titrations, where ManNOE would outcompete a weaker
inhibitor in the – 2/– 1 subsites. Further structural might shed light on the question of
what process gives rise to this behaviour.
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Figure 5.9: ITC traces of ManNOE titrated into a solution of HsMANEA at 38.5 µm
(ligand concentration 714 µm). Filled dots represent points used to fit the curve and
empty dots have been excluded from the fit. The isotherm was fitted using the model
for a single set of sites. The reported KD, ΔH and -TΔS values are likely incorrect, as
the model assumed does not explain the shape of the whole curve.
5.5.4 Hepatitis C infectivity assay
An assay of the effect of incubation of cells infected with HepC with four GH99
ligands and NB-DNJ was performed. The GH99 inhibitors (at 10 concentrations from
4 µm to 2 mm) were used either with or without the glucosidase inhibitor. The 2 mm
concentration of NB-DNJ was chosen so as to achieve full glucosidase inhibition:
0.5 mm is nearly fully inhibiting313 and it was increased four-fold. Multiple images
similar to the one in Figure 5.10 were collected and analyzed in silico.
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Figure 5.10: An example of DAPI (blue)/anti-NS5A (red) staining of HepC-infected
cells. This is a small fragment of the whole image, hundreds of which were used in
the numerical analysis.
The results of this experiment, presented in Figure 5.11 were surprising: onlyNB-DNJ
reduced the percentage of infected cells. None of the GH99 inhibitors had such an
effect, with an exception of Glc-β-aziridine, which was cytotoxic when added to the
media (this could also be caused by a change in the media pH it induced). The initial
goal of the experiment was to probe HepC infectivity. This would be measured more
directly by a change in the average number of cells in the foci, but it would also have
an effect on the percentage of cells that were infected. The latter parameter was used
as a proxy measure of this effect, and if it had changed, the average number of cells
in the foci would have been counted. As no proxy effect was observed, calculations
of the direct measure of infectivity were not performed.
It is possible that this underwhelming result was produced by the experimental de-
sign. The concentration of NB-DNJ used might have been too high: at this concen-
tration, both ER glucosidase I and II are likely to be inhibited. In such conditions,
the relevance of GH99 activity might be lower (although this would be more of an is-
sue for bovine MANEA). The experiment would benefit from repeating in a different
cell line (for example HepG2) and at different concentrations of NB-DNJ. This was
not done because of time constraints and difficulty in procuring access to Level III
laboratories.
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Figure 5.11: Results of the experiment investigating antiviral properties of endoman-
nosidase inhibitors. The NB-DNJ-containing samples are triplicates (error bars: stan-
dard deviation) and samples with endomannosidase inhibitors only are not repli-
cated. The arrowhead points to the concentration of NB-DNJ used in conjuntion with
the GH99 inhibitors. Cell density and the number of infected cells were calculated
using TissueQuest software.
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5.6 Conclusions
GlcIFG is a potent inhibitor of endomannosidase. The affinity of the novel BGlcIFG
is 50 × lower. Blocked-GlcIFG was synthesized in order to prevent ER glucosidase II-
mediated breakdown of GlcIFG (the process was first reported in 1993153 for GlcDMJ).
In order to achieve this, ManIFG is a better candidate: it will be resistant to break-
down by the glucosidase and it has intermediate affinity to HsMANEA (9 × lower
than GlcIFG). The only non-lysosomal enzyme able to cleave α-1,3-mannosidic bonds
is Golgi mannosidase II, but it is unlikely to break down this structure, as its recog-
nition site needs a larger molecule with a GlcNAc branch. Therefore, the results pre-
sented here add to the knowledge about potential therapeutics acting on the endo-
mannosidase. Results of the experiment that probed the antiviral properties of GH99
inhibitors against HepC were negative, but they do not conclusively rule out this po-
tential therapy, as the effect might be obvious only at doses of glucosidase inhibitor
that are lower than the one used.
The expressed version of HsMANEAL was not active. This may mean that its natural
substrate is not identical to that of MANEA (which would be a surprising result), or
that it was not folded properly. Incorrect folding seems to be a more parsimonious
explanation. A substantiating result was that all attempts at its crystallization failed,
and the thermal unfolding showed two peaks. More research is needed to check
the activity of this protein and characterize its structure, including its differences to
MANEA.
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Chapter 6
Conclusions and future perspectives
Knowledge of key cellular processes is key to understanding health and disease. Anal-
ysis of three-dimensional structures of proteins involved in these processes offers an
in-depth look into their mechanism and opens avenues of research that were not con-
sidered before. Endo-α-1,2-mannosidase is a component of a process encountered
widely in various life-forms: N-glycosylation. In particular, it is conserved in the Eu-
metazoa clade of animals, and in essentially all vertebrates. As such, its function is not
dispensable for humans and organisms most closely related to humans. Glycoside
hydrolases have been of interest for their involvement in viral replication, infectiv-
ity, cancer biology and congenital disorders of glycosylation (CDGs), which occur
because of their abnormal function. In the following, short section, the origin of the
genes encoding GH99 endomannosidases in view of the 3-dimensional structures
that were obtained in this Thesis will be discussed.
6.1 The evolutionary origins of MANEA and MANEAL
In 1997, Dairaku and Spiro conducted a phylogenetic analysis in which they argued
that the endo-α-1,2-mannosidase is present in chordates and not in insects.185 The re-
cent explosion of available genome sequences made it possible to re-evaluate their
conclusions. While it is true that some insects seem to have lost the MANEA gene
with the canonical active site sequence EWHE, they ofter harbor a GH99-like protein:
for example CG14015 in Drosophila melanogaster. The canonical MANEA gene is found
in the genome of Cryptotermes secundus, a species of termite. One of the results dis-
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cussed in 1997 was a chance occurrence: the insect species surveyed just happened to
lack the endomannosidase activity. The only species of sea cucumber that was stud-
ied was Cucumaria frondosa. Today, a protein predicted to be an endomannosidase
was found using BLAST in a different sea cucumber species, Apostichopus japonicus.
This is the only species of sea cucumber whose genome has been sequenced so far.314
No endomannosidase was detected in protozoans Tetrahymena, Trypanosoma or Leish-
mania, confirming previous findings.184,185 NCBI resource HomoloGene315 claims that
MANEA is conserved inBilateria andMANEAL inEuteleostomi. This was also evaluated
against new data and is presented in Figure 6.1A. No GH99 could be found in Metazoa
(animals) sister group, Choanoflagellata. It also was not present in Porifera (sponges), a
sister group to Eumetazoa. It was, however, present in Placozoa and Cnidaria, which
are sister groups to Bilateria and daughter to Eumetazoa.316,317 In Bilateria, the gene was
found in all subgroups except Ctenophora (comb jellies). The last universal common
ancestor (LUCA) of all animals lived 650 million years ago.318 Sponges and Trichoplax
diverged 600-620 My (megayears) ago. LUCA of comb jellies (Ctenophora) lived 550 My
ago and no endomannosidase was detected in them. The endomannosidase, there-
fore, arose between 600–650 My ago in a population of metazoans that did not evolve
into sponges or comb jellies.
A curious finding is the presence of an endomannosidase-like protein in Blastocystis,
which is a heterokont (Stramenopiles) but not a metazoan. The common ancestor of
metazoans and heterokonts lived about 1.5 Gy (gigayears) ago, which suggests that
the origin of the endomannosidase could be in the more distant past. The primary
protein sequence of the heterokont GH99 does feature the 191–201 loop region that
all metazoan endomannosidase sequences have, but within it, a highly conserved
glycine (HsMANEA G198) is an alanine. Such a change would probably not alter
the enzyme activity. Prokaryotic enzymes of similar activity were also surveyed. Es-
sential differences between bacterial endo-α-1,2-mannanases and the eukaryotic endo-
α-1,2-mannosidases are that in prokaryotes, a tryptophan is close to the – 2 sugar
instead of a tyrosine, and the 191–201 loop is absent. All of the surveyed bacterial
endo-α-1,2-mannanases featured the tryptophan, suggesting their core substrate was
yeast mannan (or their endogenous mannans). The heterokont GH99 has a tyrosine
in that position, suggesting it has a better affinity towards Glu, rather than Man, in
the – 2 subsite, similar to metazoan endomannosidases.
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Figure 6.1: Phylogenetic analysis of endo-α-1,2-mannosidases. (A) A phylogenetic
tree of endomannosidase evolution. In green taxa genes encoding endomannosidase
were detected, in red no proteins predicted to have this activity exist. (B) PhyML319
maximum-likelihood phylogenetic tree of a collection of endomannosidase proteins
(catalytic domain only). The scale bar refers to calculated patristic distances. The
unique placing of proteins from cartilaginous fishes (Chondrichthyes) is highlighted,
as well as the sequences that are unambiguously MANEA and MANEAL.
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What has never been investigated is at which point the gene duplication that gave
rise to MANEA and MANEAL had occured. Using the publically available data it
was straightforward to answer. Gnathostomata is the clade to which bony vertebrates
and cartilaginous fishes like sharks belong. The genomes of sharks and rays (Chon-
drichthyes) do not encode any MANEAL proteins, but the Teleostomi clade, bony verte-
brates, usually haveMANEA andMANEAL genes. Both daughter groups in Teleostomi,
Actinopterygii and Sarcopterygii, have these two genes. Therefore, the gene duplication
must have occured after cartilaginous fishes diverged (460 million years ago) and be-
fore the LUCA of Teleostomi lived, which is 430 million years ago. This is supported
by the phylogenetic tree analysis (see Figure 6.1B) and sequence identity analysis:
MANEAL has the highest identity to the endomannosidase from cartilaginous fishes.
Early evolution of eukaryotes is the subject of academic debate and all dates given
here should be treated as very provisional. Differences in residue conservation in
MANEA vs. the “ancestral” endo-α-mannosidases are visualized in Figure 6.2.
Figure 6.2: Conservation of the endo-α-mannosidase visualized using the structure of
human MANEA with GlcIFG and α-1,2-mannobiose. Identity colour-coded on the
calculated protein surface. Green: residues conserved in all endo-α-mannosidase
genes including Cnidaria and Placozoa; yellow: residues conserved in MANEA pro-
teins (Asp/Asn and Leu/Ile variations treated as conserved); red: non-conserved
residues.
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6.2 Synopsis
The research presented in this thesis contributed to the molecular understanding
of the mechanism of GH99 endomannosidases/endomannanases. In Chapter
2, mechanistic and structural data entirely consistent with the enzyme using a
1,2-anhydrosugar disaccharide as the reaction intermediate were presented. The
α-mannosidic bond is particularly inaccessible and α-mannosidases have to deform
the conformation of the – 1 sugar in order to catalyze its hydrolysis. This is achieved
through various conformational itineraries, many of which involve half-chair
and boat conformations, but none seem to use neighbouring-group participation
mechanisms.27,267 Interestingly, all of the exo-α-mannosidases involved in processing
of N-glycans use divalent cations as cofactors. The endomannosidase does not
need any metals in solution to work. It is therefore maybe not surprising that its
mechanism is different. Through a combination of structural and computational
approaches, the full itinerary for GH99 was assigned: 2H3→[E3]‡→4E→[E3]‡→4C1.
The mechanistic data support the hypothesis, but the ultimate proof will come from
the kinetic isotope effects studies that are underway.
In Chapter 3, various approaches to GH99 inhibitor design were investigated and
evaluated. As usual with this enzyme, there were surprises: Man-mannoimidazole,
a potentially excellent inhibitor, was seen to bind only when forced into the  – 2/– 1
subsite after prolonged soaking at a high concentration. On the other hand, Man-
NOE was found to be the tightest endomannanase inhibitor ever studied. Classical
isofagomine-type inhibitors were tested with human GH99 and found to be bind-
ing moderately tightly (even ManIFG, which has the “wrong” – 2 sugar). These com-
pounds, which mimic the carbocation, had in all cases better affinities than the reac-
tion intermediate mimic Glc-β-aziridine or the oxocarbenium ion mimics.
The linkages in the N-glycan likely evolved under pressure that kept them unique
and difficult to cleave. Similarly, yeast mannan is notoriously difficult to break down,
but some bacteria manage to live on it.207 These independent evolutionary pressures
led to development of enzymes with a remarkably similar active site and virtually
identical fold, which was shown in Chapter 4. The mechanistic data from bacterial
endomannanase are directly transferable to human endomannosidase and their sub-
strate binding is the same down to minute details, such as the double conformation
of the mannose in the + 1 position. Crucial, structural differences were also found.
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In the eukaryotic GH99s a loop, disordered when the ligand is not bound, becomes
ordered and envelops the – 2 subsite from the “rear end” of the sugar. This loop is not
present in the bacterial enzymes, making the binding cleft more open. To arrive at
this point of understanding, difficulties with the crystal packing of HsMANEA had
to be overcome. Only co-crystallization with HEPES buffer and a polyoxotungstate
molecule TEW yielded a crystal form suitable for inhibition studies. One structure,
although not useful for characterization of inhibitors and saccharides occupying the
 – 2/– 1 subsites, was solved at a resolution of 1.1 Å. Such a near-atomic resolution of-
fers a detailed structural view of the enzyme. The multiplicity of crystal forms helped
establish that this loop becomes ordered upon binding of the  – 2/– 1 ligand.
Crystal form 4 of HsMANEA which was reproducible and able to accommodate the  –
 2/– 1 inhibitor was obtained rather late in the project. If this had been achieved sooner,
mutagenesis of the 191–201 loop would have been performed in order to investigate
its contribution to reaction kinetics and substrate specificity. For example, excision
of the loop (or changing it to the sequence present in bacterial GH99s) may restore
full endomannosidase activity in the presence of di- or triglucosylated forms of N-
glycan. These studies would provide the structural basis for restricted processing of
N-glycans by this enzyme, observed earlier.169 Mutating Asp195 which is conserved
in all eukaryotic GH99s and makes close contacts with the substrate would show the
contribution of the loop to ligand affinity. The knowledge of this contact might also
inform the design of novel inhibitors: it may be the case that changing the OH3 or
OH4 group of the – 2 sugar to an amino group may improve binding.
In Chapter 5 the kinetics of the endomannosidase reaction were discussed, as well as
attempts at production of its paralog, MANEAL. The protein had the correct size on
the gel and it was possible to purify it using a similar protocol to the one used for re-
combinantly expressed MANEA. However, it was not active, possibly due to misfold-
ing (but an unfolding experiment suggested it was folded when in solution). The pro-
tein requires further investigation as it seems to have been overlooked in the research
looking at N-glycosylation. The dissociation constants of isofagomine-type inhibitors
were measured, including the novel BGlcIFG, which was found to bind somewhat
less tightly than others. Finally, experiments with GH99 inhibitors in HepC-infected
cells showed no effect, a result that is surprising given that initial data from another
laboratory found that GlcIFG was antiviral. What might be responsible for this are
the differences in methodology. Future work should concentrate on, first, replicating
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the result obtained by Dr Dominic Alonzi and, second, investigating the properties
of Man-substituted compounds such as ManIFG, which have the advantage of not
being substrates of ER glucosidase II.
6.3 Perspectives for the field
In recent years, the field of glycoscience has immensely benefited from advances in
analytical techniques. Mass spectrometry has become the tool of choice for describ-
ing the proteome of whole organisms and performing in-depth analyses of glycans on
single proteins. Glycan MS can be supplemented by chemical modifications, which
label certain features of the glycan.320 Over 95% of the sites on PhosphoSitePlus, a
database of PTMs, came from MS.203 The glycan shield of the HIV envelope was de-
scribed by mass spectrometry, and these insights may contribute to the development
of one of the holy grails of medicine, a vaccine against HIV.212 The question of how
many proteoforms exist in humans is, however, still difficult to answer, as there is
a multitude of PTMs which one protein can be subjected to. The current estimates
are in the range of 6 million, but these are based on rough calculations.321 Knowledge
of glycosylation states in health and disease can be crucial in reversing an undesired
process: for example, in heart failure, the glycosylation state of LDL protein is di-
rectly implicated in disease progression.322 This also makes glycan profiles useful as
biomarkers aiding diagnoses, especially in various types of cancer.323,324
The relevance of the endomannosidase activity to human (and, more generally, ani-
mal) health is still largely unclear. Given the substantial amount of knowledge about
its structure and mechanism, part of which was contributed by the research pre-
sented in this Thesis, this topic warrants investigation. The glycan profiles from or-
ganisms with altered endomannosidase function are obscure. It would be of interest
to knock down or knock out mouse or ratManea orManeal and observe the differences
from WT in the resulting phenotype and patterns of glycosylation. It is possible that
endomannosidase-related CDGs exist in humans but have not been diagnosed be-
cause of their ambiguous presentation. If the research into antiviral properties of
GH99 inhibitors proves they are of value, further studies on animal models, and then
clinical trials, will be needed to establish the safety of these interventions.
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Appendix A
Compendium of compounds discussed
at most length in the Thesis
R= Man or Glc:α α
R-dideoxymannose 
(RddMan)
R-1-deoxymannojirimycin
(RDMJ)
R- -glucal (ᴅ Rglucal)
R-isofagomine (RIFG)
Glc in the 2 GH99 subsite:–
blocked Glc-isofagomine
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Man in the 2 –
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Man-aminoDNJ
(ManADMJ)
Man-mannoimidazole 
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GH99 reaction 
intermediate mimics:
Glc- -aziridineα
Glc- -epoxideα
Glc- -aziridineβ
Glc- -epoxideβ
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Exoglycosidase inhibitors:
pseudopyranose numbering
on fused ring inhibitors
Castanospermine (CST)
Inhibits ER glucosidases I and II
Kifunensine (KIF)
Inhibits GH47 mannosidases
Mannoiminazole (ManIm)
Inhibits GH47 and other
mannosidases
Noeuromycin (NOE)
Inhibits various glycosidases
Nojirimycin-type
Swainsonine (SW)
Inhibits Golgi mannosidase II and
lysosomal -mannosidaseα
1
2
4
3
5
6
1
2
4
3
5
6
1
2
4
3
5
6
23
4
R
2
R'
2
R
N
Compound Abbreviation Inhibits
OH H H 1-deoxynojirimycin DNJ glucosidases
OH H C
4
H
9
N-butyl-deoxynojirimycin NB-DNJ glucosidases
H OH H 1-deoxymannojirimycin DMJ GH47 mannosidases
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Appendix B
Explanation of Cremer–Pople
parameters describing the
conformations of furanoses and
pyranoses
The IUPAC nomenclature for sugar conformations (“the (approximate) arrangement
of the rind atoms of a monosaccharide in the cyclic form”)325 recommends using a
single, capital, italic letter. These letters are: B for the boat conformation, C for the
chair conformation, E for the envelope conformation, H for the half-chair conforma-
tion, S for the skew-boat conformation and T for the twist conformation. The defined
conformations of furanoses (sugars with a five-membered ring) are E and T, and of
pyranoses (sugars with a six-membered ring) are B, C, E, H and S. These conforma-
tions are shown in Figure B.1CD. To decide on what the conformation of a particular
ring is, a plane of reference is needed. In case of pyranoses, either three (in case of
the twist conformation) or four (in case of the envelope conformation) atoms define
the plane. In case of furanoses, it is either four atoms (conformations B, C, H and
S) or five (the envelope conformation) roughly coplanar atoms define the plane. In
1975, Cremer and Pople26 defined three parameters that are sufficient to describe the
conformation of atoms in a closed ring. This concise approach has become the de facto
standard applied when describing the conformation of furanoses and pyranoses. For
furanoses, two parameters are needed: the angle ϕ and the scalar Q, also called the
total puckering amplitude. For pyranoses, the parameters are two angles ϕ and θ, as
well as the scalar Q. The meaning of these angles and the Q parameter is graphically
presented in Figure B.1AB and explained below.
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Figure B.1: Conformations of pyranoses and furanoses, their interconversions and the
Cremer–Pople sphere. (A) The conformation of a furanose depending on the value of
ϕ. (B) The Cremer–Pople sphere showing the meaning of angles ϕ, θ and the Q coor-
dinate, as well as some conformations (ϕ=0° for 3,OB and 180° for B3,O). The value of ϕ
increases clockwise. (C) The sugar planes and the interconversions between furanose
conformations 4T3 and 4E. (D) Interconversions between various pyranose conforma-
tions and their mean planes. Figure adapted from Ref. 326.
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In case of furanoses, there are 10 possible twist conformations and 10 possible en-
velope conformations (see Figure B.1A). In pyranoses, 2 C conformations, 6 B and
S conformations and 12 E and H distinct conformations are possible. The Cremer–
Pople parameters are sufficient to define each one. By convention, in furanoses the
conformation assigned a ϕ angle of 0° is OE, an envelope in which the oxygen atom
is above the sugar plane (formed by C1, C2, C3 and C4) when the ring is looked at
so that the carbon atom numbering grows clockwise (Figure B.1A). As the ϕ angle
rises to 18°, the conformation changes to OT1, in which the oxygen atom is above the
sugar plane and C1 is below the plane (formed by C2, C3 and C4). At ϕ=36°, the
conformation of the furanose is E1, and the plane is formed by atoms C2, C3, C4 and
O. Finding the envelope conformation by looking at a structural model is straightfor-
ward, as four atoms always form a distinct plane. In case of the twist conformation,
it requires assessing the structure from all sides coplanar with the possible planes
(because any three atoms can form a plane). The mean sugar plane is the one that
bisects a bond which is directly opposite the central plane atom. For example, when
looked from a direction coplanar with the sugar plane of the conformation OT1 so that
C3 is the closest to the observer, C2 and C4 are equidistant from the observer and O
and C1 are behind them, C3 will be exactly in the middle of the bond between O and
C1. The atom symbol in the superscript is always written before the conformation
letter and refers to the atom above the plane. The subscript is always written after the
conformation letter, and points to the atom below the plane.
In case of six-membered rings such as pyranoses, two angles are needed to describe
the conformation, as the atoms may pucker (wrinkle) around the plane from both
sides of the plane. The angle ϕ still refers to the side of the deformation in refer-
ence to conformations 3,OB, OE and 3E which have a ϕ of 0° (the ϕ angle of the chair
conformations, 4C1 and 1C4 does not affect their conformation, and indeed cannot be
determined, when the θ angle is 0° or 180°). The θ angle helps explain what happens
on both sides of the plane in reference to the position about the ring defined by the ϕ
angle.
An intuitive understanding of the θ angle is quite difficult to attain. The following ex-
ample might be helpful. If a sugar conformation changes from 4C1 to 1C4 (the “poles”
of the sphere, see Figure B.1B and Figure B.2) and ϕ is kept at 0°, it has to go through
OE, 3,OB and 3E and all the intermediate conformations (see Figure B.2, Mercator pro-
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jection). The first change, from 4C1 to OE, requires that atom C3 forms a plane together
with atoms C1, C2, C4 and C5. This involves its upward movement if the sugar is
looked at so that the atom numbering grows clockwise. OE has a θ angle of 45°. The
change from OE to 3,OB involves further upward movement of O. A θ angle of 90° at
a ϕ of 0° means that atoms O and C3 are both above the sugar plane, and at an equal
distance from it. The changes from 3,OB (θ=90°) to 3E (θ=135°) and then from 3E to 1C4
(θ=180°) require a downward movement of atom O with the position of C3 being kept
above the plane. In order to find the mean planes of different conformations, refer to
Figure B.1D.
Figure B.2: The Cremer–Pople sphere projections and the conformations of pyranoses
defined on the projections. Left: the polar (Stoddart) projections, northern hemi-
sphere (4C1 is the pole) and the southern hemisphere (1C4 is the pole). Centre: the
Cremer–Pople sphere. Right: The Mercator projection with all the defined conforma-
tions marked, as well as their corresponding ϕ and θ angles. Figure from Ref. 27.
The Q coordinate describes the total puckering of the sugar: it is a sum of the per-
pendicular distances of the ring atoms from the mean sugar plane. For a completely
planar ring its value would be 0.
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The enzymatic hydrolysis of complex plant biomass is a major societal goal of
the 21st century in order to deliver renewable energy from nonpetroleum and
nonfood sources. One of the major problems in many industrial processes,
including the production of second-generation biofuels from lignocellulose,
is the presence of ‘hemicelluloses’ such as xylans which block access to the
cellulosic biomass. Xylans, with a polymeric -1,4-xylose backbone, are
frequently decorated with acetyl, glucuronyl and arabinofuranosyl ‘side-chain’
substituents, all of which need to be removed for complete degradation of the
xylan. As such, there is interest in side-chain-cleaving enzymes and their action
on polymeric substrates. Here, the 1.25 A˚ resolution structure of the
Talaromyces pinophilus arabinofuranosidase in complex with the inhibitor
AraDNJ, which binds with a Kd of 24  0.4 mM, is reported. Positively charged
iminosugars are generally considered to be potent inhibitors of retaining
glycosidases by virtue of their ability to interact with both acid/base and
nucleophilic carboxylates. Here, AraDNJ shows good inhibition of an inverting
enzyme, allowing further insight into the structural basis for arabinoxylan
recognition and degradation.
1. Introduction
The production of ‘second-generation’ biofuels, i.e. from
nonfood plants, is a major societal goal as we move away from
petroleum-based energy towards secure and renewable
energy. Although the majority of polysaccharide biomass in
plants is cellulose, the cellulose fibres are coated with hemi-
celluloses such as xylan, which render access to the cellulose
more difficult. Enzymatic degradation of xylan is therefore
necessary for the action of cellulase on higher plants, but it is
also an important substrate in itself in that glucose and xylan,
with small quantities of other sugars, are the major substrates
for biofuel generation (discussed in Somerville, 2007). The
enzymatic degradation of hemicelluloses such as xylan is of
major importance in the biofuel industry (reviewed in Pauly &
Keegstra, 2008) and also in diverse industries such as bread
manufacture, animal feed and the pulp and paper industry (for
pulp bleaching). Xylan, which is a major component of the
plant cell wall, consists of a backbone -1,4-linked d-xylosyl
chain, which is decorated with diverse substituents including 2-
and 3-linked arabinofuranosyl moieties (typically in cereal
arabinoxylans) and glucuronic acid (notably in cereal and
hardwood glucuronoxylans). Xylan complexity is further
ISSN 2053-230X
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segmented through ester-linked species such as acetyl and
ferulate species, with the latter potentially linking the xylan to
lignin (Fig. 1a). Degradation of xylan both in natural
environments and in the industrial milieu therefore requires a
plethora of enzymes, with some of the main players including
-xylanases, -xylosidases, -glucuronidases, acetyl and feru-
late esterases and arabinofuranosidases, all of which are
subject to keen academic and industrial study (recently
comprehensively reviewed by Biely et al., 2016).
Arabinoxylans, by virtue of being found in many of the
plants now favoured for biofuel production, are considered to
be a major ‘feedstock’ if we are to attain these societal goals in
terms of renewable and secure energy (for reviews, see, for
example, Lagaert et al., 2014; Pauly & Keegstra, 2008). Given
that arabinoxylan degradation requires a consortium of
enzymes acting in partial synergy, most elegantly emphasized
through Gilbert’s recent work on xylan degradation by the
microbiota (Rogowski et al., 2015), there is much interest in
the structure, mechanism and specificity of xylan-active
enzymes, with a special focus on side-chain-cleaving enzymes
and their potential synergy with backbone-cleaving xylanases.
This potential synergy is further complicated by the differing
capacities of the endoxylanases themselves to accommodate
side chains. Of particular interest are the arabino-
furanosidases, which are capable of removing the arabino-
furanosyl (Araf) substituents from the 2- and 3-positions of
the xylan backbone, thus opening up the xylan backbone for
attack by classical endoxylanases. Arabinofuranosidases are
found in families GH2, GH3, GH43, GH51, GH54 and GH62
of the CAZy sequence-based classification (http://www.cazy.org;
Lombard et al., 2014).
CAZY family GH62 contains many enzymes that act
as arabinoxylan-active arabinofuranosidases (extensively
reviewed in Wilkens et al., 2017). The first three-dimensional
structures of GH62 enzymes appeared in 2014, with structures
reported from the bacteria Streptomyces coelicolor (Maehara
et al., 2014) and S. thermoviolaceus (Wang et al., 2014) and of
two fungal enzymes from Ustilago maydis and Podospora
anserina (Siguier et al., 2014). The three-dimensional struc-
tures share a common five-bladed -propeller fold with an
active centre consistent with hydrolysis with inversion of
anomeric configuration, with conserved Glu and Asp residues
acting as the catalytic acid and catalytic base, respectively, in
the single-displacement mechanism (Fig. 1b). GH62 enzymes
have been reviewed in CAZYpedia (for a review, see The
CAZypedia Consortium, 2018).
Here, we present the three-dimensional structure of a
fungal GH62 arabinofuranosidase from Talaromyces pino-
philus refined at 1.25 A˚ resolution in complex with the
bespoke iminosugar arabinofuranosidase inhibitor 1,4-
dideoxy-l,4-imino-l-arabinitol (AraDNJ). The complex sheds
light on the active site and, in light of previously published
data, allows analysis of how the enzyme interacts with
arabinoxylan substrates, serving to remove these side chains
from the xylan backbone.
2. Materials and methods
2.1. Macromolecule production and small-molecule synthesis
The enzyme (a single-module GH62 arabinofuranosidase
with no predicted N-glycosylation sites; GenBank MG656406)
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Figure 1
Xylans and their degradation. (a) The structure of a generic xylan, colour-coded by chemical group. Arrows indicate the positions of cleavage by
arabinoxylan-active arabinofuranosidases. (b) The reaction scheme for an inverting arabinofuranosidase, which requires the presence of both Brønsted
acid and base residues.
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was cloned and expressed by standard heterologous expres-
sion at Novozymes A/S using Aspergillus oryzae as the
expression host, essentially as discussed in Biely et al. (2014).
A novel band of about 35 kDa was observed in cultures of
transformants that was not observed in cultures of the
untransformed production strain. The expression level was
investigated using SDS–PAGE for several transformants that
appeared to express the recombinant arabinofuranosidase.
After expression of the transformant with the highest
expression level in a 1 l bioreactor, the culture broth was
sterile-filtered to remove the mycelia. The filtrated broth was
brought to 1.8 M ammonium sulfate, and after filtration
(0.22 mm PES filter; Nalge Nunc International, Nalgene
labware catalogue No. 595-4520) the filtrate was loaded onto a
Phenyl Sepharose 6 Fast Flow column (high sub; GE
Healthcare, Piscataway, New Jersey, USA) equilibrated with
25 mM HEPES pH 7.0 with 1.8 M ammonium sulfate; the
column was washed with three column volumes of 25 mM
HEPES pH 7.0, 1.0 M ammonium sulfate and bound proteins
were eluted with 25 mM HEPES pH 7.0. The fractions were
pooled and applied onto a Sephadex G-25 column (GE
Healthcare) equilibrated with 25 mM HEPES pH 7.5. The
fractions were applied onto a SOURCE 15Q column (GE
Healthcare) equilibrated with 25 mM HEPES pH 7.5 and the
bound proteins were eluted with a linear gradient from 0 to
1000 mM sodium chloride over ten column volumes. Fractions
were analyzed by SDS–PAGE and those containing the
arabinofuranosidase were combined.
The synthesis of AraDNJ was carried out using literature
procedures (Jones et al., 1985; Naleway et al., 1988).
2.2. Crystallization
Crystallization screening was carried out by sitting-drop
vapour diffusion with drops set up using a Mosquito Crystal
liquid-handling robot (TTP Labtech, England) with 150 nl
protein solution plus 150 nl reservoir solution in 96-well
format plates (MRC 2-well crystallization microplates, Swissci,
Switzerland) equilibrated against 54 ml reservoir solution.
Experiments were carried out at room temperature using
several commercial screens.
Extensive screening was carried out with no promising hits.
As a final resort, the sample was subjected to shallow-gradient
ion exchange in Tris–HCl pH 8.5. The resultant peak was
asymmetric and the conditions of the run were adjusted to
optimize the separation of different regions of the peak
(whole gradient 0–1 M NaCl, peak separation at 10–20% of
elution buffer). Fractions for these regions were pooled
separately and concentrated. Crystallization was set up with
protein fractions from the beginning of the peak. Crystal-
lizations were performed both with and without the inhibitor
AraDNJ which, when used, was mixed with the protein to give
a final concentration of 5 mM. The best hit was obtained for
protein in complex with the inhibitor from Crystal Screen HT
condition G3 (0.01 M zinc sulfate, 0.1 M MES pH 6.5, 25%
PEG 550 MME); this was chosen to make a seeding stock for
further optimizations.
The seeding stock was prepared and microseed matrix
screening (MMS; for a recent review, see D’Arcy et al., 2014)
was carried out using an Oryx robot (Douglas Instruments)
according to the published protocols (Shaw Stewart et al.,
2011; Shah et al., 2005) with two screens, Crystal Screen HT
and JCSG, as well as a number of optimizations of the hit
conditions. Diffraction-quality crystals were obtained from
JCSG screen conditions B2, G7 and G10. That used for data
collection was obtained from condition G10, i.e. 30% PEG 2K
MME, 0.2 M KBr. The crystals were cryoprotected by adding
PEG 3350 to the mother liquor in a 1:2 ratio (3 ml PEG + 6 ml
mother liquor), which corresponded to 16.6% PEG 3350 and
20% PEG 2K in the final cryoprotectant solution. Crystal-
lization conditions are shown in Table 1.
2.3. Data collection and processing
All computations were carried out using programs from the
CCP4 suite (Winn et al., 2011) unless otherwise stated. The
data were collected on beamline I04-1 at Diamond Light
Source (DLS) to 1.2 A˚ resolution and were processed with
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Table 1
Crystallization.
Method Vapour diffusion, sitting drop; MMS
Plate type MRC 2-well crystallization microplate,
Swissci, Switzerland
Temperature (K) 293
Protein concentration (mg ml1) 25
Buffer composition of protein
solution
20 mM Tris–HCl pH 8.5, 150 mM NaCl
Composition of reservoir solution 30% PEG 2K MME, 0.2 M KBr
Volume and ratio of drop 300 nl total, 1:1 ratio
Volume of reservoir (ml) 54
Table 2
Data-collection statistics.
Values in parentheses are for the outer shell.
Diffraction source I04-1, DLS
Wavelength (A˚) 0.93
Temperature (K) 100
Detector PILATUS 6M-F
Crystal-to-detector distance (mm) 254.2
Rotation range per image () 0.1
Total rotation range () 180
Exposure time per image (s) 0.0375
Space group P21
a, b, c (A˚) 43.83, 88.97, 72.66
, ,  () 90, 95.22, 90
Mosaicity () 0.11
Resolution range (A˚) 33.52–1.25 (1.27–1.25)
Total No. of reflections 457639 (14559)
No. of unique reflections 149344 (6813)
Completeness (%) 98 (91)
CC1/2† 0.998 (0.79)
Multiplicity 3.1 (2.1)
hI/(I)i 13.1 (2.9)
Rmerge 0.044 (0.28)
Rr.i.m.‡ 0.052 (0.34)
Overall B factor from Wilson plot (A˚2) 5.1
† CC1/2 values for Imean are calculated by splitting the data randomly into two half data
sets. ‡ Estimated Rr.i.m. = Rmerge[N/(N  1)]1/2, where N is the data multiplicity, and
Rmerge is defined as
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where I(hkl) is the
intensity of the reflection.
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xia2 (Winter et al., 2013). Data-collection and processing
statistics are given in Table 2.
2.4. Structure solution and refinement
The structure was solved by MOLREP (Vagin & Teplyakov,
2010) using S. coelicolor -l-arabinofuranosidase (PDB entry
3wmy; Maehara et al., 2014) as the search model. Chain tracing
used Buccaneer, and the structure was refined with REFMAC
(Murshudov et al., 2011) iterated with manual model correc-
tion using Coot (Emsley et al., 2010). The quality of the final
model was validated using MolProbity (Chen et al., 2010) as
part of the PHENIX package (Adams et al., 2011). The final
refinement statistics are given in Table 3. The structure has
been deposited in the PDB as entry 6f1j.
2.5. Isothermal titration calorimetry
Ligand affinity was measured using isothermal titration
calorimetry (ITC). ITC was performed at 25C in 25 mM
HEPES pH 7.0, 100 mM NaCl using a Malvern MacroCal
Auto-iTC200 calorimeter. The ligand in the syringe was at
1.8 mM and was titrated into a cell containing a 112 mM
solution of the enzyme. Assays were performed in duplicate.
The dissociation constant was calculated using the PEAQ-ITC
Analysis software (Malvern).
3. Results and discussion
The structure (PDB entry 6f1j) was solved and refined at
1.25 A˚ resolution (Table 3). The protein chain can be traced
from residues 25 through to 325 and contains both structural
calcium and zinc ions. The five-bladed -propeller structure
(Fig. 2a) bears a strong similarity to those of previously
published GH62 enzymes, notably those from S. coelicolor
(Maehara et al., 2014) and S. thermoviolaceus (Wang et al.,
2014); 300 residues align with 72 and 69% sequence identity
and r.m.s. C deviations of 0.58 and 0.68 A˚, respectively, as
reflected by high PDBeFold (Krissinel & Henrick, 2004) Q
scores of 0.95 and 0.94, respectively. There are two subunits in
the asymmetric unit with high structural similarity (r.m.s.d. of
0.22 A˚), with some conformational differences on the outer
surfaces, in particular in the region of crystal contacts.
Of the two metal ions, the Ca2+ ion is located essentially as
reported previously, for example in the S. coelicolor enzyme
(Maehara et al., 2014). However, this structural Ca2+ ion
(which is close to, but does not impinge on, the active centre)
is coordinated by six water molecules and a carboxylate O
atom from Glu215. This is different to previous structures, in
which the Ca2+ ion was coordinated by a His and Gln pair,
which are replaced here by a water molecule hydrogen-
bonded to Ser278 (in place of the His) and directly to Glu215
(in place of the Gln observed previously). In the T. pinophilus
enzyme there are additional Zn2+ ions derived from the
‘seeding stock’ (see above) element of the crystallization
conditions. One of those bridges the A and B molecules in the
lattice, presumably aiding lattice formation, with coordination
from His180 from molecule A and the amino-terminal NH2
and carbonyl groups of Ser24 and the side chain of Glu220
from molecule B. Another Zn2+ ion is coordinated by Glu88
from molecule B, His180 from the symmetry-related molecule
B and three waters.
The structure of the T. pinophilus GH62 arabino-
furanosidase was determined in the presence of the putative
arabinofuranosidase inhibitor AraDNJ (Fig. 2b), which allows
further confirmation of the catalytic apparatus. This
compound has found use in studies of other arabino-
furanosidases (Axamawaty et al., 1990; Hemsworth et al., 2016)
as well as as a scaffold for developing inhibitors of other
glycosidases (Siguier et al., 2014; Mena-Barraga´n et al., 2016).
Azasugars and iminosugars are generally considered to be
good inhibitors of retaining glycoside hydrolases by virtue of
their endocyclic N atom, which can be protonated, thus
mimicking the putative positive charge that is thought to exist
in the transition state(s) during glycoside hydrolysis. In addi-
tion, the N atom provides adventitious interactions with both
the acid/base and the nucleophile in the active sites of these
enzymes (see, for example, Gloster et al., 2007). GH62
enzymes are inverting and thus do not have a suitably posi-
tioned nucleophile. It was therefore surprising to us that
AraDNJ acted as an inhibitor with well resolved density. The
binding constant for AraDNJ was therefore determined by
isothermal titration calorimetry (Fig. 2c), revealing a surpris-
ingly tight Kd of 24  0.4 mM. It is rare in glycosidases that
iminosugars bind so well to the glycosidase active site without
research communications
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Table 3
Structure solution and refinement.
Resolution range (A˚) 33.52–1.25
Completeness (%) 97.8
No. of reflections
Working set 141792
Test set 7088
Final Rcryst 0.120
Final Rfree 0.136
Cruickshank DPI 0.037
No. of subunits in the asymmetric unit 2
R.m.s. C deviation between subunits (A˚) 0.221
No. of non-H atoms
Protein 4698
Ion 4
Ligand 18
Water 658
Total 5378
R.m.s. deviations
Bonds (A˚) 0.014 (0.020)
Angles () 1.5 (1.9)
Average B factors (A˚2)
Protein
Chain A 7.3
Chain B 7.7
Ions
Ca2+ 3.3
Zn2+ (1st) 8.8
Zn2+ (2nd) 8.4
Ligand 6.7
Water 18.8
Ramachandran plot†
Favoured (%) 96.4
Outliers (%) 0.33
MolProbity score 0.85
† Ramachandran plot analysis was carried out by MolProbity (Chen et al., 2010).
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a close enzyme-derived nucleophilic interaction, but other
examples include CAZY family GH6, where cellobio-derived
isofagomines have been used to good effect, even reporting on
the substrate distortions involved in catalysis (Gloster et al.,
2007). Here, AraDNJ binds in a potentially transition-state-
mimicking 4E conformation. As might be expected, AraDNJ
binds in the same location as observed for Araf itself (see, for
example, PDB entry 4o8o; Wang et al., 2014), making similar
hydrogen bonds from O2 and O3 to Asp160, from O3 to
Gln120 and from O56 to Asp52. There is also a potential
hydrophobic contact with the side chain of Ile159. There is no
direct interaction of the positively charged N atom (here
replacing the endocyclic O atom of arabinose), but the
structure reveals a water molecule poised 3.1 A˚ ‘below’ the
furanose ring, where it hydrogen-bonds to Asp52, the putative
catalytic base, consistent with previous studies (Maehara et al.,
2014; Wang et al., 2014) and the inverting mechanism (Fig. 1b).
Glu212, the putative acid, is placed for lateral anti protonation
of any departing group (Fig. 2d). Notably, the positively
charged N atom lies exactly where the positively charged N
atom of published Tris complexes of homologues sits (see, for
example, PDB entry 3wn2, the S. coelicolor GH62 enzyme;
Maehara et al., 2014), highlighting that these enzymes have
evolved to stabilize the positively charged transition state,
even without the aid of the direct charge–charge interactions
available to retaining enzymes.
The T. pinophilus GH62 enzyme in complex with AraDNJ,
viewed in light of past work on xylooligosaccharide complexes
of GH62 enzymes, provides further insight into the mechan-
isms by which GH62 enzymes remove the arabinofuranoside
research communications
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Figure 2
Three-dimensional structure and ligand binding of the T. pinophilus GH62 arabinofuranosidase in complex with the inhibitor AraDNJ. (a) Three-
dimensional structure colour-ramped from the N-terminus (blue) to the C-terminus (red). Metal ions are shown as shaded spheres and AraDNJ as a CPK
model. (b) The chemical structure of AraDNJ. (c) ITC data for AraDNJ binding (Kd of 24  0.4 mM). (d) Observed electron density for AraDNJ bound
to GH62, 2Fo  Fc (maximum-likelihood/A-weighted) at 1.25 A˚ contoured at 1. The catalytic acid Glu212 and base Asp52 are shown, along with a
water molecule poised for nucleophilic attack. (e) Partial overlay of the T. pinophilus GH62 arabinofuranosidase (brown with AraDNJ in green) with the
S. coelicolor GH62 arabinofuranosidase (PDB entry 3wn2; pale blue with xylopentaose in green), highlighting the highly conserved binding centre and
the recognition apparatus for the arabinoxylan chain. Structural figures were drawn with CCP4mg (McNicholas et al., 2011).
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decorations from arabinoxylan. An overlay with the xylo-
pentaose complex (PDB entry 3wn2) of the S. coelicolor
GH62 enzyme (Maehara et al., 2014; Fig. 2e) shows how the
interacting surface for the xylan chain is highly conserved
between the two enzymes, with both aromatic platforms
(Phe211, Tyr312 and Trp121) and some hydrogen-bonding
interactions (Arg237, Asn313 and Asp177) being invariant,
suggesting that ligand recognition is similar. Indeed, C1 of the
AraDNJ complex lies 1.9 A˚ from the O3 atom of the ‘second’
(from the reducing end) xylose moiety in PDB entry 3wn2,
highlighting how the T. pinophilus GH62 enzyme could act as
an arabinofuranosidase that is active on O3-substituted xylans,
as was proposed originally for the S. coelicolor GH62 enzyme
(Maehara et al., 2014), although it is possible to also consider
action at the O2 position should the xylan chain occasionally
be reversed through the active site (which is possible with
xylans given their internal pseudo-symmetry).
The T. pinophilus GH62 enzyme thus adds to the growing
literature surrounding these key players in natural and
industrial arabinoxylan degradation. It demonstrates how
arabinofuranoside mimics lie in the active site of the enzyme
and how the enzyme recognizes and cleaves arabinoxylan.
Furthermore, the nonclassical application of an iminosugar-
based glycosidase inhibitor to study inverting-enzyme struc-
ture and function should encourage the further non-intuitive
application of such compounds in the future.
Acknowledgements
The authors would like to thank Novozymes A/S for partially
funding this work. GJD is a Royal Society Ken Murray
Research Fellow. KAS thanks the Australian Research
Council and TC thanks the Australian Government, the
University of Western Australia (UWA) and the Centre for
Microscopy, Characterization and Analysis at UWA. The
authors would also like to thank Diamond Light Source for
beamtime (proposal mx13587) and the staff of beamline I04
for assistance with crystal testing and data collection.
References
Adams, P. D. et al. (2011). Methods, 55, 94–106.
Axamawaty, M. T., Fleet, G. W., Hannah, K. A., Namgoong, S. K. &
Sinnott, M. L. (1990). Biochem. J. 266, 245–249.
Biely, P., Puchart, V., Stringer, M. A. & Mørkeberg Krogh, K. B. R.
(2014). FEBS J. 281, 3894–3903.
Biely, P., Singh, S. & Puchart, V. (2016). Biotechnol. Adv. 34, 1260–
1274.
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino,
R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson,
D. C. (2010). Acta Cryst. D66, 12–21.
D’Arcy, A., Bergfors, T., Cowan-Jacob, S. W. & Marsh, M. (2014).
Acta Cryst. F70, 1117–1126.
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta
Cryst. D66, 486–501.
Gloster, T. M., Meloncelli, P., Stick, R., Zechel, D., Vasella, A. &
Davies, G. J. (2007). J. Am. Chem. Soc. 129, 2345–2354.
Jones, D. W. C., Nash, R. J., Bell, E. A. & Williams, J. M. (1985).
Tetrahedron Lett. 26, 3125–3126.
Hemsworth, G. R., Thompson, A. J., Stepper, J., Sobala, Ł. F., Coyle,
T., Larsbrink, J., Spadiut, O., Goddard-Borger, E. D., Stubbs, K. A.,
Brumer, H. & Davies, G. J. (2016). Open Biol. 6, 160142.
Krissinel, E. & Henrick, K. (2004). Acta Cryst. D60, 2256–2268.
Lagaert, S., Pollet, A., Courtin, C. M. & Volckaert, G. (2014).
Biotechnol. Adv. 32, 316–332.
Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M. &
Henrissat, B. (2014). Nucleic Acids Res. 42, D490–D495.
Maehara, T., Fujimoto, Z., Ichinose, H., Michikawa, M., Harazono, K.
& Kaneko, S. (2014). J. Biol. Chem. 289, 7962–7972.
McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011).
Acta Cryst. D67, 386–394.
Mena-Barraga´n, T., Garcı´a-Moreno, M. I., Nanba, E., Higaki, K.,
Concia, A. L., Clape´s, P., Garcı´a Ferna´ndez, J. M. & Ortiz Mellet, C.
(2016). Eur. J. Med. Chem. 121, 880–891.
Murshudov, G. N., Skuba´k, P., Lebedev, A. A., Pannu, N. S., Steiner,
R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011).
Acta Cryst. D67, 355–367.
Naleway, J. J., Raetz, C. R. & Anderson, L. (1988). Carbohydr. Res.
179, 199–209.
Pauly, M. & Keegstra, K. (2008). Plant J. 54, 559–568.
Rogowski, A. et al. (2015). Nature Commun. 6, 7481.
Shah, A. K., Liu, Z.-J., Stewart, P. D., Schubot, F. D., Rose, J. P.,
Newton, M. G. & Wang, B.-C. (2005). Acta Cryst. D61, 123–129.
Shaw Stewart, P. D., Kolek, S. A., Briggs, A. R., Chayen, N. E. &
Baldock, P. F. M. (2011). Cryst. Growth Des. 11, 3432–3441.
Siguier, B., Haon, M., Nahoum, V., Marcellin, M., Burlet-Schiltz, O.,
Coutinho, P. M., Henrissat, B., Mourey, L., O’Donohue, M. J.,
Berrin, J.-G., Tranier, S. & Dumon, C. (2014). J. Biol. Chem. 289,
5261–5273.
Somerville, C. (2007). Curr. Biol. 17, R115–R119.
The CAZypedia Consortium (2018). Glycobiology, 28, 3–8.
Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25.
Wang, W., Mai-Gisondi, G., Stogios, P. J., Kaur, A., Xu, X., Cui, H.,
Turunen, O., Savchenko, A. & Master, E. R. (2014). Appl. Environ.
Microbiol. 80, 5317–5329.
Wilkens, C., Andersen, S., Dumon, C., Berrin, J.-G. & Svensson, B.
(2017). Biotechnol. Adv. 35, 792–804.
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
Winter, G., Lobley, C. M. C. & Prince, S. M. (2013). Acta Cryst. D69,
1260–1273.
research communications
6 of 6 Moroz et al.  Talaromyces pinophilus GH62 arabinofuranosidase Acta Cryst. (2018). F74
162
& Biochemistry
Spiro-epoxyglycosides as Activity-Based Probes for Glycoside
Hydrolase Family 99 Endomannosidase/Endomannanase
Sybrin P. Schrçder,[a] Wouter W. Kallemeijn,[b] Marjoke F. Debets,[a] Thomas Hansen,[a]
Lukasz F. Sobala,[c] Zalihe Hakki,[d] Spencer J. Williams,[d] Thomas J. M. Beenakker,[a]
Johannes M. F. G. Aerts,[b] Gijsbert A. van der Marel,[a] Jeroen D. C. Cod8e,[a]
Gideon J. Davies,*[c] and Herman S. Overkleeft*[a]
Abstract: N-Glycans direct protein function, stability, folding
and targeting, and influence immunogenicity. While most
glycosidases that process N-glycans cleave a single sugar
residue at a time, enzymes from glycoside hydrolase family
99 are endo-acting enzymes that cleave within complex N-
glycans. Eukaryotic Golgi endo-1,2-a-mannosidase cleaves
glucose-substituted mannose within immature glucosylated
high-mannose N-glycans in the secretory pathway. Certain
bacteria within the human gut microbiota produce endo-1,2-
a-mannanase, which cleaves related structures within fungal
mannan, as part of nutrient acquisition. An unconventional
mechanism of catalysis was proposed for enzymes of this
family, hinted at by crystal structures of imino/azasugars
complexed within the active site. Based on this mechanism,
we developed the synthesis of two glycosides bearing a
spiro-epoxide at C-2 as electrophilic trap, to covalently bind
a mechanistically important, conserved GH99 catalytic resi-
due. The spiro-epoxyglycosides are equipped with a fluores-
cent tag, and following incubation with recombinant
enzyme, allow concentration, time and pH dependent visual-
ization of the bound enzyme using gel electrophoresis.
Introduction
N-Linked glycans are complex oligosaccharides linked to aspar-
agine (Asn) residues in eukaryotic proteins.[1] They play impor-
tant roles in protein function, stability, folding and targeting
and are essential for a range of cellular functions.[2] Erroneous
N-glycan composition is associated with various diseases in-
cluding viral infections, Alzheimer’s disease and metastatic
cancer.[3–5] Assembly of the N-glycan commences in the endo-
plasmic reticulum (ER) where the 14-mer polysaccharide
Glc3Man9GlcNAc2-diphosphodolichol is coupled to the Asn resi-
due of the target protein by the enzyme oligosaccharyl trans-
ferase. The glycan undergoes stepwise “trimming” of the non-
reducing end glucoside residues by a-glucosidase I and II, after
which a-mannosidase I truncates the resulting oligomanno-
side.[6] The resulting Man5GlcNAc2 structure is redecorated to
yield complex N-glycans. Because a-glucosidases I and II play
important roles in the early stages of glycan maturation, these
enzymes were investigated as therapeutic targets to control
diseases involving incorrect N-glycosylation.[7–10] However, in-
hibition of these enzymes did not block N-glycosylation:
mouse lymphoma cells inhibited with the a-glucosidase inhibi-
tor castanospermine as well as mutant cell lines lacking a-glu-
cosidase II retained up to 80% of normal N-glycan matura-
tion.[11–13] Spiro and co-workers identified endo-1,2-a-mannosi-
dase,[14, 15] (later classified as a member of glucoside hydrolase
family 99 (GH99); see http://cazypedia.org),[16] residing in the
Golgi apparatus, which circumvents inhibition of ER a-glucosi-
dase I and II. The enzyme cleaves glucose-substituted mannose
from the A-branch of ER escaped immature N-glycoproteins
bearing Glc1–3Man9GlcNAc2, releasing Glc1-3Man. The resulting
Man8GlcNAc2 glycoprotein subsequently re-enters the normal
processing route in the Golgi apparatus.
Bacterial GH99 orthologs including Bacteroides thetaiotaomi-
cron (Bt) and Bacteroides xylanisolvens (Bx) enzymes possess
endo-1,2-a-mannosidase activity, but are more appropriately
described as endo-1,2-a-mannanases, as they act on yeast
[a] Dr. S. P. Schrçder, Dr. M. F. Debets, T. Hansen, Dr. T. J. M. Beenakker,
Prof. Dr. G. A. van der Marel, Dr. J. D. C. Cod8e, Prof. Dr. H. S. Overkleeft
Department of Bioorganic Chemistry, Leiden Institute of Chemistry
Einsteinweg 55, 2333 CC Leiden (The Netherlands)
E-mail : h.s.overkleeft@chem.leidenuniv.nl
[b] Dr. W. W. Kallemeijn, Prof. Dr. J. M. F. G. Aerts
Department of Medical Biochemistry, Leiden Institute of Chemistry
Einsteinweg 55, 2333 CC Leiden (The Netherlands)
[c] L. F. Sobala, Prof. Dr. G. J. Davies
Department of Chemistry, York Structural Biology Laboratory
University of York, Heslington, York, YO10 5DD (UK)
E-mail : gideon.davies@york.ac.uk
[d] Dr. Z. Hakki, Prof. Dr. S. J. Williams
School of Chemistry and Bio21 Molecular Science and
Biotechnology Institute, University of Melbourne
Parkville, Victoria (Australia)
Supporting information and the ORCID identification numbers for the
authors of this article can be found under:
https://doi.org/10.1002/chem.201801902.
T 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of Creative Commons Attri-
bution NonCommercial-NoDerivs License, which permits use and distribu-
tion in any medium, provided the original work is properly cited, the use is
non-commercial and no modifications or adaptations are made.
Chem. Eur. J. 2018, 24, 9983 – 9992 T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim9983
Full PaperDOI: 10.1002/chem.201801902
163
mannan[17] and exhibit a tenfold preference for mannan-based
substrates versus the equivalent glucose-substituted man-
nans.[18] Several imino/azasugar inhibitors for GH99 endoman-
nosidase have been developed, including a-glucopyranosyl-
1,3-isofagomine (GlcIFG, 1, Figure 1) and a-mannopyranosyl-
1,3-isofagomine (ManIFG, 2). Due to a preference for a manno-
pyranosyl residue in subsite @2 GH99 endo-1,2-a-mannanases
show a greater affinity for 2 than for 1.[18] Recently, mannoeur-
omycin (ManNOE, 3), which features a 2-hydroxyl allowing in-
teraction with the proposed general base/acid residue, has
been reported as the most potent endo-1,2-a-mannanase in-
hibitor for bacterial GH99 enzymes with KD values in the low
nanomolar range.[19] Additionally, fluorescent[20] and fluorogen-
ic[18,21] substrates have been developed for monitoring endo-
1,2-a-mannosidase/mannanase activity.
Family GH99 endo-1,2-a-mannosidases/mannanases cleave
their substrate glycosides with retention of anomeric stereo-
chemistry; however, instead of the classical Koshland double-
displacement mechanism for retaining enzymes,[22] an unusual
neighboring group participation hydrolytic mechanism was
proposed in which a glutamate residue (Glu333 in BxGH99) acts
as a general base assisting OH-2 to displace the aglycon via a
1,2-anhydro sugar that is subsequently hydrolyzed by water
(Figure 1B).[23] In order to study enzyme function in biological
settings, screen for inhibitors, as well as to further illuminate
the catalytic reaction mechanism, the development of a mech-
anism-based irreversible inhibitor would be of interest. Here,
the synthesis is described of two putative covalent inhibitors 4
and 5, designed to, respectively inhibit eukaryotic GH99 endo-
1,2-a-mannosidases and bacterial endo-1,2-a-mannanases and
which vary in the nature of the pyranoside at the non-reducing
end (Figure 1A, right). Both compounds contain a spiro-epox-
ide at position C-2 to serve as an electrophile to trap the gen-
eral base residue. Inspection of the crystal structures of
BxGH99 suggests that the general base will be situated close
to the methylene group of the spiro-epoxide, where it may
open the ring via nucleophilic attack resulting in a covalent in-
termediate (Figure 1C).[23] The compounds are also equipped
with a reporter tag, allowing active enzyme labeling by activi-
ty-based protein profiling (ABPP)[24] protocols, the efficiency of
which is reported as well.
Results
Acceptor 7 was synthesized by 4,6-silylidene protection of
compound 6,[25] followed by formation of the 2,3-orthoben-
zoate and final treatment with acid (Scheme 1).[26] Glucopyra-
noside donor 9 was synthesized from thiophenyl b-glucopyra-
noside 8.[27] While 4,6-silylidene protection proceeded smooth-
ly, elevated temperatures were required to install the TBS-
Figure 1. (A) Known GH99 endo-1,2-a-mannosidase inhibitors (1–3) and fluorescent spiro-epoxyglycosides 4 and 5 subject of this study. KD values are for B.
thetaiotaomicron endo-1,2-a-mannosidase (BtGH99). (B) The proposed catalytic mechanism for GH99 enzyme (amino acid numbering for B. xylanisolvens endo-
1,2-a-mannosidase (BxGH99)). (C) Anticipated covalent inhibition mechanism of GH99 enzymes.
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groups onto both secondary hydroxyl groups, presumably due
to steric hindrance. Using a similar approach, thiophenyl a-
mannopyranoside 10[28] was converted to protected thioman-
noside donor 11.
Glycosylation of acceptor 7 by 9 or 11 was achieved in an N-
iodosuccinimide (NIS)/trimethylsilyl triflate (TMSOTf) mediated
coupling at low temperature, affording 12g or 12m, respec-
tively. Both glycosylations proceeded in excellent yield and ste-
reoselectivity. Pedersen, Bols and co-workers[29] recently report-
ed that silylidene-protected mannosyl donors can be used for
stereoselective b-mannosylation. The contrasting selectivity ob-
tained here is likely the result of the steric buttressing effect of
the large silyl ether protecting groups at the C-2- and C-3-hy-
droxyls of 7, consistent with the steric effects that large pro-
tecting groups and functionalities have in glycosylations of
otherwise b-selective benzylidene-protected mannosyl
donors.[30] Thus, the b-face of mannosyl donor 11 is shielded
from attack by the incoming nucleophile. The glycosylation
stereoselectivity of glucosyl donor 9 can be rationalized by its
high reactivity. The “arming” silyl protecting groups allow this
donor to readily form an oxocarbenium ion, which will likely
take up a 4H3-like conformation, which is preferentially at-
tacked from the a-face to provide the 1,2-cis-linked prod-
uct.[31,32] Next, the benzoyl groups were deprotected under
Zempl8n conditions affording compounds 13g and 13m. The
alcohols were then oxidized with Dess–Martin periodinane
(DMP) to ketones 14g and 14m, which appeared to be in
equilibrium with the corresponding hydrates.
Transformation of ketones 14 into their corresponding spiro-
epoxides was explored next (Table 1). Reaction of 14g with di-
azomethane as methylenating agent[33] resulted in the forma-
tion of the equatorial (15g) and axial (16g) methylenes in a
1:1 ratio and in good yields (entry 1). Their absolute configura-
tion was determined by 1D-NOE difference experiments (see
Supplementary Information). Reaction of 14m with diazome-
thane also resulted in a mixture of 15m and 16m, in a 3:1
ratio, in favor of the equatorial methylene group in almost
quantitative yield (entry 2). We anticipated that a Corey–Chay-
kovsky epoxidation[34] using stabilized dimethylsulfoxonium
methylide would favor the formation of the equatorial methyl-
enes 15g and 15m. Indeed, also in these cases both isomers
were obtained, however the formation of axial methylenes was
still favored in both cases (entries 3 and 4). Finally, using the
more reactive dimethylsulfonium methylide, only the kinetical-
ly favored axial methylenes 16g and 16m were formed, albeit
in moderate yields (entries 5 and 6). With spiro-epoxides 16g
and 16m in hand, global deprotection was accomplished by
reaction with tetrabutylammonium fluoride (TBAF). Finally, a
fluorescent Cy5 tag was installed at the azide handle using
copper(I) catalyzed click chemistry, which after HPLC purifica-
tion afforded spiro-epoxyglycosides 4 and 5.
The ability of 4 and 5 to label recombinant Bt- and BxGH99
endo-1,2-a-mannanase was evaluated (Figure 2A). The com-
pounds label both enzymes in a concentration-dependent
manner, at concentrations as low as 100 nm. Previous studies
indicated a preference for a mannosyl residue at the @2 sub-
site of both enzymes.[18] However, no difference in potency of
labeling was observed. Studies on the effect of the pH de-
pendence on labeling revealed that both spiro-epoxyglyco-
sides label the enzymes maximally at pH 6–8, corresponding to
Scheme 1. Synthesis of fluorescent spiro-epoxyglycosides 4 and 5. Reagents and conditions: a) tBu2Si(OTf)2, 2,6-lutidine, DMF, @50 8C; b) PhC(OMe)3, CSA, 2 h,
then AcOH, H2O, 16 h, 57% over 2 steps; c) TBSOTf, DMAP, pyridine, 60 8C, 16 h, yield 9 : 85% over 2 steps; yield 11: 81% over 2 steps; d) donor 9 or 11, NIS,
TMSOTf, DCM, 4 a MS, @40 8C, 1 h, yield 12g : 92%; yield 12m : 88%; e) NaOMe, MeOH, DCM, yield 13g : 95%; yield 13m : 86%; f) DMP, DCM, yield 14g : 98%;
yield 14m : 96%; g) TBAF, THF, 5 days, yield 17: 97%; yield 18 : 74%; h) Cy5-alkyne,[47] CuSO4·5H2O, sodium ascorbate, DMF, rt, 16 h, yield 4 : 32%; yield 5 : 34%.
Table 1. Transformation of ketones 14g and 14m into their correspond-
ing spiro-epoxides.
Entry s.m. Conditions 15 :16 Yield [%][a]
1 14g
CH2N2, EtOH, 0 8C
1:1 78
2 14m 3:1 97
3 14g
SOMe3I, nBuLi, THF, 60 8C
1:5 83
4 14m 1:2 85
5 14g
SMe3I, NaH, DMSO, THF, @10 8C 0:1 506 14m 0:1 53
[a] Combined yield after column chromatography. s.m.= starting material.
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the pH optimum of GH99 enzymatic activity (Figure 2B).[23] No-
tably, more than one band is evident, suggesting enzyme deg-
radation under reducing SDS-PAGE conditions or alternatively
that multiple labelling events may be occurring. Next, labeling
of wild-type (WT) BxGH99 was compared to analo-
gous active-site mutants (Figure 2C). While WT
enzyme is labeled by spiro-epoxyglycosides 4 and 5
within 5 minutes, the general base mutant E333Q
and the catalytic acid mutant E336Q were not la-
beled in the same time period with these com-
pounds, suggesting that labeling is indeed activity-
based, and is consistent with reaction occurring in a
mechanism-based manner. However, incubation for
longer times resulted in labeling of the mutant en-
zymes, indicating that either the spiro-epoxide is sus-
ceptible to ring opening by the mutant catalytic resi-
dues, or that other residues may also be involved in
covalent labelling. Denaturation of BtGH99 and
BxGH99 completely abrogated labeling by spiro-ep-
oxyglycosides 4 and 5, indicating that labeling re-
quires the natively folded enzyme (Figure 2D).
To further evaluate whether covalent inhibition of
BtGH99 and BxGH99 is activity-based, the processing
of human a-galactosidase A (GLA) by these enzymes
was investigated (Figure 3A). GLA contains three N-
glycosylation sites, of which two are decorated with
oligo-mannose structures, and one contains complex
oligosaccharides low in mannose content.[35,36] We
have previously demonstrated that fluorescent a-gal-
acto-cyclophellitol aziridines such as TB340 covalent-
ly label GLA in activity-based manner.[37] Here, GLA
was pre-labeled with TB340 to enable fluorescent de-
tection on gel. Without additives, GLA gives a dis-
tinct major band at &50 kDa (Figure 3B, lane 1). In-
cubation of GLA with BtGH99 results in demannosyl-
ation of the two high-mannose N-glycans of GLA, re-
sulting in a shift of the GLA band into lower bands
at &42 kDa (lane 2). This shift in molecular weight is
similar to the shift observed when GLA is incubated with
Endo-H (lane 4), which causes demannosylation of high-man-
nose N-glycans by cleaving within the chitobiosyl core leaving
a residual GlcNAc on Asn. Treatment of GLA with PNGase-F
Figure 2. Fluorescent labeling of GH99 endomannanases. (A) Detection limit of Bt and Bx GH99 endomannanases (left and right, respectively), labeled with
various concentrations of fluorescent spiro-epoxyglycosides 4 or 5. (B) Effect of pH on labeling of Bt and Bx GH99 enzymes with 4 or 5. (C) Labeling of wild-
type and mutant BxGH99 with 4 or 5 (left or right, respectively) for 5, 15 or 30 minutes. (D) Effect of denaturation with 1% (w/v) SDS and boiling on labeling
of Bt and Bx GH99 enzymes (left and right, respectively) with 4 or 5. The marker is annotated with an asterisk (*).
Figure 3. (A) Schematic representation of processing of human a-galactosidase GLA by
GH99 endomannosidase. GLA is pre-labeled by fluorescent TB340, and contains high-
mannose N-glycans which can be truncated by endomannosidase, resulting in a decrease
in GLA molecular weight. Activity-based labeling of endomannosidase by spiro-epoxygly-
cosides 4 or 5 (prior to incubation with GLA) blocks its activity, and is therefore unable
to process GLA. (B) BtGH99 wild-type demannosylates GLA, causing a shift in molecular
weight for the protein bands. Pre-labeling BtGH99 wild-type with 4 or 5 abrogates GLA
demannosylation. Endo-H cleaves high-mannose structures, PNGase-F cleaves full N-
linked glycan (leaving Asp-GlcNAc). (C) BxGH99 wild-type demannosylates GLA, while
BxGH99 pre-labeled with 4 or 5 is unable to do so. BxGH99 active-site mutants E333Q
and E3336Q are unable to process GLA. (D) Fluorescent labeling of BtGH99 (top) and
BxGH99 (bottom) by 4 or 5 competed by different concentrations of 17, 18, ManIFG (2)
and yeast mannan. The marker is annotated with an asterisk (*).
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(lane 5), which cleaves most N-glycans leaving Asn, results in a
band of a lower molecular weight, most likely as a result of
complete deglycosylation of all three N-glycans. When BtGH99
was pre-incubated with 4 or 5, demannosylation of TB340-la-
beled GLA was mostly inhibited (lane 3), indicating that bind-
ing of 4 and 5 occurs in the BtGH99 active site. An identical ex-
periment was conducted with BxGH99 wildtype and the E333Q
and E336Q mutant enzymes (Figure 3C). Similar to BtGH99,
wildtype BxGH99 is able to process the N-glycans decorating
the surface of the enzyme, giving rise to a shift in molecular
weight (lane 2), similar to processing by Endo-H (lane 8). Pre-
incubation of WT BxGH99 by 4 or 5, prior to consecutive incu-
bation with TB340-labeled GLA resulted in an observed ab-
sence of glycan processing (lane 3), indicating that binding of
4 and 5 abrogates enzymatic activity. Interestingly, while mu-
tants E333Q and E336Q are labeled by spiro-epoxyglycosides 4
and 5 after prolonged reaction times, they are evidently
unable to process TB340-labeled GLA (lanes 4–7).
Finally, the inhibitory potencies of 2, 17, 18 and yeast
mannan from S. cerevisiae (an a-1,6-linked mannose backbone
branched with a-1,2 and a-1,3 mannoses)[38] towards BtGH99
were investigated using spiro-epoxyglycoside 5 as fluorescent
read-out (Figure 3D). The enzyme was first pre-incubated with
the competitor for 30 min at 37 8C, followed by labeling with
1 mm 5. Compounds 17 and 18 both show a concentration-de-
pendent competition of fluorescent labeling in the range of
10-1,000 mm, although full competition with labeling could not
be achieved under these conditions. Similarly, the azasugar
ManIFG (2) gave concentration-dependent competition but
again full competition was not achieved. However, pre-incuba-
tion by yeast mannan achieved full competition with labeling,
suggesting that processing of spiro-epoxyglycoside 5 by
BtGH99 endomannanase is specific and activity based. A similar
competition experiment was performed for BxGH99, and it was
shown that while pre-incubation with 17 did not fully abrogate
labeling, pre-incubation with 1000 mm of 18 provided full com-
petition, possibly hinting at a slight preference for a mannosyl
residue in subsite @2. Additionally, yeast mannan showed con-
centration dependent (albeit incomplete) competition, and
azasugar 2 fully competed with labeling at 1,000 mm, suggest-
ing that processing of spiro-epoxyglycoside 5 by BxGH99 is
specific and activity-based.
Discussion
Epoxide-based probes have been investigated as mechanism-
based inhibitors of a range of glycosidases. Early work led to
the development of epoxyalkyl glycosides,[39] which were ini-
tially proposed as reagents that could specifically label the nu-
cleophile of retaining glycosidases, however X-ray crystallogra-
phy later revealed labelling of both acid/base and nucleophile
residues.[40] In one classic study, conduritol C epoxide, which
was originally believed to label the nucleophile of E. coli LacZ
b-galactosidase, was subsequently shown to covalently label
the acid/base catalyst.[41] Work from our laboratory has investi-
gated related pyranose-mimicking cyclophellitol epoxides and
aziridines and shown that these typically exhibit excellent se-
lectivity for labelling the nucleophile of assorted a- and b-gly-
cosidases.[42] We have shown that introduction of a reporter
tag (e.g. biotin or a fluorescent dye) onto these small molecule
inhibitors affords chemical probes that enable quantification of
activity,[43,44] and have distinct advantages over techniques
such as transcription analysis and antibody-based detection.
We report here the first activity-based probes for detection of
GH99 enzymes, which were designed based on the proposed
mechanism of this enzyme. In this proposed mechanism a 1,2-
anhydro-epoxide intermediate is formed by general base as-
sisted deprotonation of O2 by a carboxylate residue.[23] Our
design strategy includes a reactive C2 spiro-epoxide that can
potentially covalently label the general base (acting as a nucle-
ophile), and includes a fluorescent label for visualization. Gel-
based analysis of labelled bacterial GH99 endo-1,2-a-mannan-
ases demonstrated concentration dependent labelling which
occurs in a pH dependent manner consistent with the pH opti-
mum of enzyme activity. Labelling could be competed by vari-
ous substrates and inhibitors, providing evidence that it is
active-site directed. While mutation of the key general base
and general acid residues inactivated the enzyme towards
processing of natural substrate N-glycans in GLA, the mutants
could be labelled with the spiro-epoxyglycosides, albeit with
reduced potency. Collectively, our data suggests that these
spiro-epoxides do result in labelling at the active site,
presumeably through the catalytic general base. However, the
high reactivity of the primary epoxide means that labelling is
most likely not exclusive at a single residue. While endo-1,2-a-
mannanase has a preference for mannosyl residues at the @2
binding subsite, there was minimal differences in the efficiency
of labelling for spiro-epoxides bearing either a mannosyl or
glucosyl residue. We believe these compounds represent an
important first step in devising probes that take advantage of
the unique mechanism proposed for this family. Future studies
will seek to better understand the mode of labelling by identi-
fying the covalently labelled residue(s) by X-ray crystallography
or MS based techniques. By analogy to previously described
irreversible cyclophellitol activity-based probes,[43] we propose
these fluorescent spiro-epoxyglycosides could ultimately lead
to chemical tools for functional investigation of GH99 endo-
1,2-a-mannosidase/mannanases, both as isolated species and
in tissue extracts.
Experimental Section
Chemicals were purchased from Acros, Sigma Aldrich, Biosolve,
VWR, Fluka, Merck and Fisher Scientific and used as received
unless stated otherwise. Tetrahydrofuran (THF), N,N-dimethylform-
amide (DMF) and toluene were stored over molecular sieves
before use. All reactions were performed under an argon atmos-
phere unless stated otherwise. TLC analysis was conducted using
Merck aluminum sheets (Silica gel 60 F254) with detection by UV ab-
sorption (254 nm), by spraying with a solution of
(NH4)6Mo7O24·4H2O (25 gL
@1) and (NH4)4Ce(SO4)4·2H2O (10 gL
@1) in
10% sulfuric acid, followed by charring at &150 8C. Column chro-
matography was performed using Screening Device b.v. silica gel
(particle size of 40–63 mm, pore diameter of 60 a) with the indicat-
ed eluents. For reversed-phase HPLC purifications an Agilent Tech-
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nologies 1200 series instrument equipped with a semi-preparative
column (Gemini C18, 250V10 mm, 5 mm particle size, Phenomen-
ex) was used. 1H NMR and 13C NMR spectra were recorded on a
Breker AV-400 (400 and 101 MHz, respectively) or a Breker DMX-
600 (600 and 151 MHz, respectively) spectrometer in the given sol-
vent. Chemical shifts are given in ppm (d) relative to the residual
solvent peak or tetramethylsilane (0 ppm) as internal standard.
High-resolution mass spectrometry (HRMS) analysis was performed
with a LTQ Orbitrap mass spectrometer (Thermo Finnigan),
equipped with an electronspray ion source in positive mode
(source voltage 3.5 kV, sheath gas flow 10 mLmin@1, capillary tem-
perature 250 8C) with resolution R=60000 at m/z 400 (mass range
m/z 150–2000) and dioctyl phthalate (m/z 391.28428) as lock mass.
The high-resolution mass spectrometer was calibrated prior to
measurements with a calibration mixture (Thermo Finnigan).
ManIFG was prepared as previously reported.[18] Recombinant ex-
pression of B. thetaiotaomicron (Bt) and B. xylanisolvens (Bx) GH99
was achieved as previously described.[23] Recombinant a-galactosi-
dase (GLA) was purchased from Genzyme (Cambridge, MA, USA).
The a-galactosidase ABP TB340 was synthesized as described earli-
er.[37] Yeast mannan from S. cerevisiae was purchased from Sigma.
Synthesis and characterization
(4aR,6S,7S,8R,8aS)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-hy-
droxyhexahydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (7):
Compound 6[45] (1.00 g, 3.80 mmol) was co-evaporated with dry
toluene and dissolved in dry DMF (38 mL). The resulting solution
was cooled to @50 8C and SitBu2(OTf)2 (1.11 mL, 3.42 mmol, 0.9 EQ)
and 2,6-lutidine (0.44 mL, 3.80 mmol) were added. The reaction
was stirred at @50 8C for 30 minutes and subsequently quenched
with brine (400 mL). The aqueous layer was extracted with Et2O
(4V100 mL). The combined organic layers were washed with 1m
aqueous HCl (2V100 mL), H2O (100 mL), and brine and dried over
Na2SO4. The solvents were removed under reduced pressure and
the crude product was purified by gradient column chromatogra-
phy (EtOAc/pentane, 1:4 to 1:2). The 4,6-silydene product was ob-
tained as white solid (970 mg, 70%). 1H NMR (400 MHz, CDCl3): d=
4.81 (d, J=1.4 Hz, 1H), 4.11 (dd, J=10.0, 5.0 Hz, 1H), 4.07–4.00 (m,
2H), 3.96 (t, J=10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.69 (td, J=10.0,
5.0 Hz, 1H), 3.50 (ddd, J=10.0, 6.3, 5.2 Hz, 1H), 3.40 (td, J=6.6,
2.0 Hz, 2H), 1.94–1.82 (m, 2H), 1.06 (s, 9H), 1.00 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=166.0, 133.4, 129.9, 129.7, 128.5,
98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8,
20.0 ppm. IR (neat): n˜=3524, 2934, 2886, 2097, 1732, 1717, 1558,
1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm@1. [a]20D (c 0.1,
DCM): @16. HRMS (ESI) m/z : [M+Na]+ calcd for C24H37N3O7SiNa
530.22930, found 530.22907. The 4,-6-silydene compound (889 mg,
2.20 mmol) was dissolved in trimethyl orthobenzoate (5.7 mL) and
CSA (102 mg, 0.44 mmol) was added. The reaction was stirred for
2 hours at room temperature and cooled to 0 8C. Aqueous AcOH
(50%, 20 mL) was added and the mixture was stirred overnight
while the cooling bath was allowed to reach room temperature.
The solution was poured into saturated aqueous NaHCO3 (50 mL)
and the water layer was extracted with CH2Cl2 (3V50 mL). The
combined organic layers were washed with NaHCO3 (50 mL) and
dried over MgSO4. The solvents were removed under reduced pres-
sure and the crude product was purified by gradient column chro-
matography (EtOAc/pentane, 1:99 to 1:10). The title product was
obtained as colorless oil (922 mg, 82%). 1H NMR (400 MHz, CDCl3):
d=8.15–7.98 (m, 2H), 7.63–7.54 (m, 1H), 7.51–7.41 (m, 2H), 5.42
(dd, J=3.4, 1.6 Hz, 1H), 4.88 (d, J=1.4 Hz, 1H), 4.23–4.06 (m, 3H),
3.99 (t, J=10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.59–3.49 (m, 1H), 3.43
(t, J=6.6 Hz, 2H), 1.99–1.81 (m, 2H), 1.09 (s, 9H), 1.02 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=166.0, 133.4, 129.9, 129.7, 128.5,
98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8,
20.0 ppm. IR (neat): n˜=3524, 2934, 2886, 2097, 1732, 1717, 1558,
1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm@1. [a]20D (c 0.1,
DCM): @16. HRMS (ESI) m/z : [M+Na]+ calcd for C24H37N3O7SiNa
530.22930, found 530.22907.
(4aR,6S,7R,8S,8aR)-2,2-Di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)-6-(phenylthio)hexahydropyrano[3,2-d][1,3,2]dioxasiline
(9): Compound 8[27] (2.6 g, 9.5 mmol) was dissolved in dry DMF
(100 mL) under Ar-atmosphere. The mixture was cooled to @50 8C
and 2,6-lutidine (3.3 mL, 28.5 mmol) and SitBu2(OTf)2 (3.4 mL,
10.5 mmol) was added. The reaction was stirred for 2 hours at
@50 8C and subsequently quenched with H2O (100 mL). The water
layer was extracted with EtOAc (3V100 mL). The organic layers
were combined and washed with H2O (2V200 mL) and brine
(200 mL) and dried over MgSO4. The solvents were removed under
reduced pressure and the crude product was purified by gradient
column chromatography (EtOAc/pentane, 1:4 to 1:2). The 4,6-sily-
dene product was obtained as a white solid (3.58 g, 91%). 1H NMR
(400 MHz, CDCl3): d=7.57–7.46 (m, 2H), 7.38–7.28 (m, 3H), 4.60 (d,
J=9.7 Hz, 1H), 4.21 (dd, J=10.2, 5.1 Hz, 1H), 3.90 (t, J=10.2 Hz,
1H), 3.68 (t, J=9.0 Hz, 1H), 3.60 (t, J=8.7 Hz, 1H), 3.51–3.37 (m,
2H), 2.92 (s, 1H), 2.77 (s, 1H), 1.04 (s, 9H), 0.98 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=132.9, 131.7, 129.1, 128.3, 88.6, 77.8,
76.4, 74.5, 71.8, 66.1, 27.4, 27.0, 22.7, 19.9. IR (neat): n˜=3241, 2932,
2858, 1695, 1471, 1058 cm@1. [a]20D (c 0.06, DCM): @57.0. HRMS (ESI)
m/z : [M+Na]+ calcd for C20H32O5SSiNa 435.16319, found
435.16315. The 4,6-silydene product (1.0 g, 2.42 mmol) was co-
evaporated with toluene (3V), dissolved in dry pyridine (5 mL) and
cooled to 0 8C. DMAP (30 mg, 0.24 mmol) and TBSOTf (3.33 mL,
14.5 mmol) were added and the mixture was heated to 60 8C and
stirred overnight. The mixture was carefully diluted with water
(25 mL) and extracted with DCM (3V 50 mL). The combined organ-
ic layers were washed with aq. 1m HCl (3V25 mL) and brine, dried
over Na2SO4, filtrated and concentrated. The crude product was
purified by gradient column chromatography (pentane/EtOAc,
400:1 to 200:1), affording the title product as a white solid (1.44 g,
93%). Analytical data were in accordance with those reported in
literature.[46]
(4aR,6R,7S,8S,8aR)-2,2-Di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)-6-(phenylthio)hexahydropyrano[3,2-d][1,3,2]dioxasiline
(11): The 4,6-silydene compound was prepared from 10[28] (4.9 g,
18 mmol) as described for the preparation of 9 to afford the prod-
uct (6.6 g, 89%) as a white solid. 1H NMR (400 MHz, CDCl3): d=7.52
@7.20 (m, 5H), 5.53 (s, 1H), 4.30 (d, J=3.1 Hz, 1H), 4.24 (td, J=
10.0, 5.0 Hz, 1H), 4.15–4.08 (t, J=9.4 Hz, 1H), 4.05 (dd, J=10.0,
5.0 Hz, 1H), 3.96 (t, J=10.1 Hz, 1H), 3.87 (dd, J=9.1, 3.3 Hz, 1H),
2.67 (brs, 2xOH), 1.05 (s, 9H), 1.03 ppm (s, 9H). 13C NMR (101 MHz,
CDCl3): d=133.9, 131.5, 129.3, 127.7, 87.8, 75.0, 72.4, 72.1, 67.9,
66.2, 27.6, 27.2, 22.8, 20.2 ppm. IR (neat): n˜=3384, 2932, 2858,
1474, 1064 cm@1. [a]20D (c 0.4, DCM): +227. HRMS (ESI) m/z : [M+
Na]+ calcd for C20H32O5SSiNa 435.16319, found 435.16301. The title
product was prepared from the 4,6-silydene compound (6.6 g,
16 mmol) as described for the preparation of 9 to afford the prod-
uct (9.3 g, 91%) as a pale yellow oil which crystallized at @20 8C.
1H NMR (400 MHz, CDCl3): d=7.48–7.25 (m, 5H), 5.29 (d, J=1.5 Hz,
1H), 4.28 (t, J=9.0 Hz, 1H), 4.19 (m, 1H), 4.17–4.11 (m, 1H), 4.11–
4.08 (m, 1H), 3.96 (t, J=9.7 Hz, 1H), 3.87 (dd, J=8.9, 2.5 Hz, 1H),
1.09 (s, 9H), 1.07 (s, 9H), 0.99 (s, 9H), 0.92 (s, 9H), 0.21 (s, 3H), 0.18
(s, 3H), 0.14 (s, 3H), 0.07 ppm (s, 3H). 13C NMR (101 MHz, CDCl3):
d=134.9, 131.3, 129.3, 127.4, 89.9, 75.0, 74.6, 73.0, 69.6, 67.1, 27.8,
27.3, 26.3, 25.8, 22.9, 20.2, 18.5, 18.2, @3.9, @4.1, @4.4, @4.4 ppm.
IR (neat): n˜=2931, 2857, 1471, 1250, 1096 cm@1. [a]20D (c 1.0, DCM):
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+91. HRMS (ESI) m/z : [M+H]+ calcd for C32H61O5SSi3 641.35420,
found 641.36460.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (12g): Com-
pound 9 (2.00 g, 3.12 mmol) and compound 7 (1.58 g, 3.12 mmol)
were combined and co-evaporated with toluene (3V). The mixture
was dissolved in dry CH2Cl2 (20 mL) and stirred with activated 4A
MS for 30 minutes at room temperature. The reaction was cooled
to @50 8C and NIS (842 mg, 3.74 mmol) and TMSOTf (68 mL,
0.37 mmol) were added. The reaction mixture was warmed to
@40 8C, stirred for 1 hour and subsequently neutralized with NEt3
(2 mL). The mixture was diluted with CH2Cl2 (200 mL) and washed
with saturated aqueous Na2SO3 (2V100 mL), H2O (100 mL) and
subsequently dried over MgSO4. The solvents were removed under
reduced pressure and the crude product was purified by gradient
column chromatography (EtOAc/pentane, 1:50 to 1:40). The title
product was obtained as a white foam (2.98 g, 92%). 1H NMR
(400 MHz, CDCl3): d=8.08 (d, J=7.3 Hz, 2H), 7.59 (t, J=7.4 Hz, 1H),
7.47 (t, J=7.7 Hz, 2H), 5.49 (s, 1H), 5.16 (d, J=2.9 Hz, 1H, H-1
“donor”), 4.86 (s, 1H, H-1 “acceptor”), 4.44 (t, J=9.4 Hz, 1H), 4.22–
4.15 (m, 2H, H-3), 4.04 (t, J=10.2 Hz, 1H), 3.95–3.79 (m, 3H), 3.75–
3.66 (m, 2H), 3.61 (t, J=8.4 Hz, 1H), 3.54 (dt, J=10.2, 5.7 Hz, 1H),
3.49–3.41 (m, 2H), 1.91 (dq, J=13.5, 6.9 Hz, 1H), 1.13 (s, 9H), 1.04
(s, 9H), 1.03 (s, 9H), 0.97 (s, 9H), 0.91 (s, 9H), 0.79 (s, 9H), 0.17 (s,
3H), 0.05 (s, 3H), 0.03 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=
165.4, 133.2, 129.9, 129.6, 128.5, 98.1, 97.9, 78.6, 75.2, 74.3, 73.4,
72.6, 71.1, 67.8, 67.8, 66.9, 66.6, 64.4, 48.1, 28.9, 27.5, 27.1, 27.0,
26.4, 26.2, 22.7, 22.7, 20.0, 20.0, 18.1, 18.0, @3.2, @3.5, @3.6,
@4.4 ppm. 13C-HMBC-GATED NMR (101 MHz, CDCl3): d=98.1
(JC1,H1=170.6 Hz, C1 “donor”), 97.9 (JC1,H1=172.1 Hz, C1 “acceptor”).
IR (neat): n˜=2966, 2859, 2093, 1732, 1472, 1260, 1096, 1069, 1045,
827 cm@1. [a]20D (c 0.1, DCM): +20. HRMS (ESI) m/z : [M+Na]
+ calcd
for C50H91N3O12Si4+Na 1060.55720, found 1060.55694.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (12m): This
compound was prepared from 11 (378 mg, 0.59 mmol) and 7
(299 mg, 0.59 mmol) as described for the preparation of 12g, to
afford the title product (538 mg, 88%) as a pale yellow oil. 1H NMR
(400 MHz, CDCl3): d=8.02 (m, 2H), 7.62–7.53 (m, 1H), 7.45 (t, J=
7.7 Hz, 2H), 5.34 (dd, J=3.5, 1.6 Hz, 1H), 4.96 (d, J=1.9 Hz, 1H),
4.82 (d, J=1.4 Hz, 1H), 4.28 (t, J=9.5 Hz, 1H), 4.15 (m, 3H), 4.08
(dd, J=9.4, 3.6 Hz, 1H), 4.02–3.93 (t, J=10.3 Hz, 1H), 3.90–3.77 (m,
4H), 3.77–3.67 (m, 2H), 3.57–3.37 (m, 3H), 2.02–1.77 (m, 2H), 1.09
(s, 9H), 1.04–1.00 (s, 9H), 1.00 (s, 9H), 0.95–0.89 (m, 9H), 0.87–0.82
(m, 9H), 0.82–0.76 (m, 9H), 0.07 (s, 3H), 0.00 (s, 3H), @0.13 (s, 3H),
@0.17 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=165.5, 133.4,
130.0, 129.7, 128.6, 103.4, 98.2, 75.2, 75.1, 74.0, 73.6, 72.4, 71.8,
69.5, 67.7, 67.5, 67.1, 64.8, 48.4, 29.0, 27.9, 27.7, 27.2, 27.2, 26.2,
25.8, 22.9, 22.9, 20.1, 19.9, 18.4, 18.2, @4.3, @4.4, @4.4, @4.7 ppm.
13C-HMBC-GATED NMR (101 MHz, CDCl3): d=103.4 (JC1,H1=172.1 Hz,
C1 “donor”), 98.2 ppm (JC1,H1=172.5 Hz, C1 “acceptor”). IR (neat):
n˜=2931, 2858, 20998, 1729, 1472, 1226, 1096, 1068 cm@1. [a]20D (c
0.4, DCM): +1. HRMS (ESI) m/z : [M+H]+ calcd for C50H92N3O12Si4
1038.57526, found 1038.57587.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-ol (13g): Compound 12g
(610 mg, 0.59 mmol) was co-evaporated with toluene (3V) and dis-
solved in a mixture of DCM/MeOH (9 mL, 1:1). NaOMe (30 wt%,
560 mL) was added and the reaction mixture was stirred for 24 h.
The reaction was neutralized with AcOH and the solvents were re-
moved under reduced pressure. The crude product was purified by
gradient column chromatography (EtOAc/pentane, 1:11 to 1:8).
The title product was obtained as a white foam (519 mg, 95%).
1H NMR (400 MHz, CDCl3): d=5.34 (d, J=3.1 Hz, 1H), 4.81 (d, J=
0.7 Hz, 1H), 4.29 (t, J=9.3 Hz, 1H), 4.10–4.02 (m, 2H), 3.98 (t, J=
10.3 Hz, 1H), 3.95 (s, 1H), 3.88 (dd, J=9.2, 3.3 Hz, 1H), 3.86–3.76
(m, 3H), 3.76–3.66 (m, 3H), 3.58 (dd, J=8.2, 3.1 Hz, 1H), 3.54–3.47
(m, 1H), 3.38 (td, J=6.5, 1.7 Hz, 2H), 3.00 (s, 1H, OH), 1.94–1.78 (m,
2H), 1.05 (s, 9H), 1.04 (s, 9H), 1.00 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H),
0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.09 ppm (s, 3H).
13C NMR (101 MHz, CDCl3): d=99.7, 97.4, 78.7, 75.1, 74.6, 74.5, 74.3,
71.1, 67.6, 67.4, 67.0, 66.4, 64.4, 48.4, 29.0, 27.6 (3V), 27.5 (3V), 27.2
(3V), 27.1 (3V), 26.4 (3V), 26.4 (3V), 22.9, 22.7, 20.1, 20.1, 18.3, 18.3,
@3.1, @3.3, @3.4, @3.9 ppm. IR (neat): n˜=2931, 2856, 2099, 1472,
1252, 1132, 1095, 1069, 1043, 868, 827, 772, 654 cm@1. [a]20D (c 0.1,
DCM): +44. HRMS (ESI) m/z : [M+Na]+ calcd for C43H87N3O11Si4+Na
956.53099, found 956.53097.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-ol (13m): This compound
was prepared from 12m (501 mg, 0.48 mmol) as described for the
preparation of 13g to afford the title product (386 mg, 86%) as a
colorless oil. 1H NMR (400 MHz, CDCl3): d=5.00 (d, J=1.9 Hz, 1H),
4.79 (d, J=1.1 Hz, 1H), 4.17 (t, J=9.2 Hz, 1H), 4.11 (m, 3H), 3.99–
3.88 (m, 4H), 3.88–3.82 (m, 2H), 3.82–3.77 (m, 1H), 3.77–3.62 (m,
2H), 3.49 (m, 1H), 3.40 (td, J=6.5, 3.1 Hz, 1H), 2.37–2.03 (brs, OH),
1.97–1.77 (m, 2H), 1.04 (m, 18H), 0.99 (s, 9H), 0.97 (s, 9H), 0.93 (s,
9H), 0.86 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.02 ppm (s,
3H). 13C NMR (101 MHz, CDCl3): d=103.2, 99.6, 77.7, 74.5, 74.1,
73.3, 72.4, 71.5, 69.6, 67.4, 67.33, 66.8, 64.5, 48.4, 28.9, 27.8, 27.6,
27.2, 27.1, 26.3, 25.8, 22.9, 22.7, 20.1, 18.6, 18.2, @3.9, @4.1, @4.3,
@4.6. ppm IR (neat): n˜=2930, 2858, 2098, 1472, 1250, 1096,
1031 cm@1. [a]20D (c 0.4, DCM): +32. HRMS (ESI) m/z : [M+H]
+ calcd
for C43H88N3O11Si4 934.54904, found 934.54959.
(4aR,6S,8S,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydropyrano[3,2-d][1,3,2]dioxasilin-7(6H)-one (14g): Compound
13g (2.20 g, 2.36 mmol) was co-evaporated with dry toluene (3V)
and dissolved in dry CH2Cl2 (65 mL). Dess–Martin periodinane
(2.00 g, 4.71 mmol) was added and the mixture was stirred over-
night. Celite was added and the solvents were removed under re-
duced pressure. The product was purified by gradient column
chromatography (EtOAc/pentane, 1:70 to 1:4). The title product
was obtained as a white foam (2.15 g, 98%). 1H NMR (400 MHz,
CDCl3): d=5.18 (d, J=2.8 Hz, 1H), 4.73–4.72 (m, 2H), 4.24–4.02 (m,
5H), 4.02–3.90 (m, 1H), 3.90–3.73 (m, 3H), 3.67 (t, J=8.6 Hz, 1H),
3.62–3.54 (m, 2H), 3.40 (t, J=6.6 Hz, 2H), 1.94–1.81 (m, 2H), 1.06 (s,
9H), 1.04 (s, 9H), 1.02 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H), 0.92 (s, 9H),
0.17 (s, 3H), 0.12 (s, 3H), 0.11 (s, 3H), 0.08 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=196.2, 100.2, 98.2, 80.0, 78.9, 78.7, 74.9, 73.9,
67.49, 67.45, 67.0, 66.0, 65.3, 48.0, 27.5, 27.4 (3V), 27.1 (3V), 27.0
(3V), 26.5 (3V), 26.41 (3V), 22.7, 22.6, 20.0, 20.0, 18.3, 18.1, @3.0,
@3.5, @3.7, @3.9 ppm. IR (neat): n˜=2932, 2859, 2099, 1757, 1474,
1387, 1362, 1252, 1161, 1093, 1070, 1043, 866, 827, 775, 652 cm@1.
[a]20D (c 0.1, DCM): +50. HRMS (ESI) m/z : [M+Na]
+ calcd for
C43H85N3O11Si4+Na 954.51534, found 954.51535.
(4aR,6S,8S,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
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silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydropyrano[3,2-d][1,3,2]dioxasilin-7(6H)-one (14m): This com-
pound was prepared from 13m (355 mg, 0.38 mmol) as described
for the preparation of 14g to afford the title product (340 mg,
96%) as a yellow oil. 1H NMR (400 MHz, CDCl3): d=4.81 (d, J=
1.9 Hz, 1H), 4.75 (s, 1H), 4.45 (d, J=9.1 Hz, 1H), 4.31–4.19 (m, 2H),
4.18–4.12 (t, J=9.2 Hz, 1H), 4.12–3.98 (m, 4H), 3.97–3.88 (m, 2H),
3.88–3.78 (m, 2H), 3.61–3.52 (dt, J=9.9, 5.4 Hz, 1H), 3.41 (t, J=
6.5 Hz, 2H), 2.00–1.76 (m, 2H), 1.05 (s, 9H), 1.05 (s, 9H), 1.04 (s,
9H), 1.00 (s, 9H), 0.93 (s, 9H), 0.86 (s, 9H), 0.15 (s, 3H), 0.12 (s, 3H),
0.09 (s, 3H), 0.01 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=195.8,
103.4, 100.3, 82.2, 79.5, 74.4, 73.3, 72.1, 68.9, 67.3, 67.1, 66.6, 65.3,
48.0, 28.8, 27.6, 27.4, 27.1, 27.0, 26.2, 25.7, 22.8, 22.7, 20.1, 20.0,
18.4, 18.1, @4.0, @4.2, @4.5, @4.7 ppm. IR (neat): n˜=2933, 2858,
2087, 1755, 1471, 1254, 1155 cm@1. [a]20D (c 0.4, DCM): +47. HRMS
(ESI) m/z : [M+H]+ calcd for C43H86N3O11Si4 932.53339, found
932.53363.
(2S,4a’R,6’S,8’S,8a’R)-6’-(3-Azidopropoxy)-2’,2’-di-tert-butyl-8’-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]dioxasiline]
(15g) and (2R,4a’R,6’S,8’S,8a’R)-6’-(3-azidopropoxy)-2’,2’-di-tert-
butyl-8’-(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyl-
dimethylsilyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-
yl)oxy)tetrahydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]di-
oxasiline] (16g): Method A: dimethyl sulfonium methylide: A 1m
solution of dimsyl-sodium was prepared from sodium hydride
(60 wt%, 200 mg, 5 mmol) in dry DMSO (2.5 mL) and heating this
mixture to 70 8C for 1 h. The olive-green solution was cooled to
room temperature and diluted with dry THF (2.5 mL). A fraction
(0.12 mL, 0.19 mmol) of this mixture was added to a dried flask
and cooled on an ice-salt bath. Then, a solution of trimethylsulfoni-
um iodide (26.3 mg, 0.129 mmol) in dry DMSO (0.43 mL) and dry
THF (0.4 mL) was added drop wise and the mixture was stirred for
5 minutes. Then, compound 14g (100 mg, 0.11 mmol, co-evaporat-
ed with toluene (3V) beforehand) in dry THF (0.64 mL) was added
and the mixture was stirred for 30 minutes. The mixture was dilut-
ed with water (20 mL) and extracted with Et2O/pentane (2:1, 4x
15 mL). The combined organic layers were washed with water
(20 mL), dried over Na2SO4, filtrated and concentrated. The crude
product was purified by gradient column chromatography (pen-
tane/EtOAc, 60:1 to 50:1) to afford solely product 15g (51 mg,
50%) as an oil.
Method B: dimethyl sulfoxonium methylide: Trimethylsulfoxonium
iodide (37.8 mg, 0.172 mmol) was suspended in dry THF (2 mL)
and cooled to 0 8C. nButyllithium (2m in pentane, 80 mL,
0.16 mmol) was added and the mixture was heated to 60 8C. Com-
pound 14g (100 mg, 0.11 mmol) was co-evaporated with toluene
(3V), dissolved in dry THF (1 mL) and added drop wise to the ylide
solution. After 10 minutes, the mixture was cooled to room tem-
perature and quenched with MeOH (0.5 mL). The mixture was
evaporated and the crude product was purified by gradient
column chromatography (pentane/EtOAc, 60:1) to give a mixture
of compounds 15g and 16g (90 mg, ratio 15g :16g 1:5, total yield
88%) as a colorless oil.
Method C: diazomethane: To a glass tube were added aq. KOH
(40%, 5 mL) and Et2O (20 mL) and this mixture was cooled to 0 8C.
Then, 1-methyl-3-nitro-1-nitrosoguanidine (2.9 g, 10 mmol) was
added in portions with swirling. A fraction (2 mL) of the bright
yellow ether layer was added drop-wise to a solution of compound
14g (100 mg, 0.11 mmol) in EtOH (3 mL) at 0 8C. After stirring for
10 minutes, acetic acid (glacial) was added drop wise until the
yellow mixture turned colorless. The mixture was concentrated and
co-evaporated with toluene (3V). The crude products were purified
by column chromatography (pentane/acetone, 150:1), affording
compound 15g and 16g (79 mg, ratio 15g :16g 1:1, total yield
78%). Data for compound 15g (equatorial methylene): 1H NMR
(400 MHz, CDCl3): d=5.33 (d, J=2.9 Hz, 1H), 4.27–4.15 (m, 3H),
4.18 (s, 1H), 4.10–4.01 (m, 2H), 4.00–3.95 (t, J=10.1 Hz, 1H), 3.92–
3.76 (m, 3H), 3.75–3.59 (m, 4H), 3.50–3.35 (m, 3H), 3.15 (d, J=
5.1 Hz, 1H), 2.61 (d, J=5.1 Hz, 1H), 1.86 (quintet, J=6.3 Hz, 2H),
1.04 (s, 9H), 1.04 (s, 9H), 0.98 (s, 18H), 0.91 (s, 9H), 0.90 (s, 9H),
0.13 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=102.5, 97.4, 79.3, 78.5, 76.0, 74.8, 68.7, 67.6,
67.1, 66.3, 64.2, 59.4, 48.3, 46.4, 29.9, 29.1, 27.6, 27.5, 27.2, 27.1,
26.3, 22.9, 22.7, 20.1, 18.4, 18.3, @3.6, @3.6, @4.0 ppm. IR (neat):
n˜=2930, 2858, 2099, 1472, 1252, 1091, 1043 cm@1. [a]20D (c 0.1,
DCM): +54. HRMS (ESI) m/z : [M+Na]+ calcd for C16H27N3O11Na
968.53099, found 968.53089.Data for compound 16g (axial methyl-
ene) 1H NMR (400 MHz, CDCl3): d=5.34 (d, J=3.0 Hz, 1H), 4.40–
4.22 (m, 2H), 4.09 (dd, J=10.4, 5.1 Hz, 2H), 4.04–3.93 (m, 3H),
3.87–3.76 (m, 4H), 3.66 (t, J=8.7 Hz, 1H), 3.56–3.39 (m, 4H), 3.23
(d, J=5.6 Hz, 1H), 2.63 (d, J=5.6 Hz, 1H), 1.89 (q, J=5.7 Hz, 2H),
1.07 (s, 18H), 1.05 (s, 9H), 1.02 (s, 9H), 0.96 (s, 9H), 0.95 (s, 9H),
0.16 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.10 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=101.2, 96.9, 79.7, 78.2, 74.7, 73.8, 67.7, 67.4,
66.9, 66.8, 66.1, 64.4, 58.3, 48.1, 48.0, 29.0, 27.6 (3V), 27.3 (3V), 27.2
(3V), 27.0 (3V), 26.5 (3V), 26.4 (3V), 22.8, 22.5, 20.1, 20.0, 18.2, 18.1,
@3.08, @3.38 (2V), @4.03 ppm. IR (neat): n˜=2934, 2858, 2320,
2094, 1095, 1043, 827, 773 cm@1. [a]20D (c 0.1, DCM): +98 (c 0.1,
DCM). HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4 946.54904,
found 946.54953.
(2S,4a’R,6’S,8’S,8a’R)-6’-(3-Azidopropoxy)-2’,2’-di-tert-butyl-8’-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]dioxasiline]
(15m) and (2R,4a’R,6’S,8’S,8a’R)-6’-(3-azidopropoxy)-2’,2’-di-tert-
butyl-8’-(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyl-
dimethylsilyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-
yl)oxy)tetrahydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]di-
oxasiline] (16m): Compounds 15m and 16m were prepared from
14m as described for the preparation of 15g and 16g, and could
be separated by careful column chromatography. Method A : Start-
ing from compound 14m (100 mg, 0.11 mmol), the product 16m
(54 mg, 53%) was obtained as the single product. Method B : Start-
ing from compound 14m (150 mg, 0.16 mmol), product 15m and
16m were obtained as a mixture (129 mg, 85%, ratio 15m :16m=
1:2). Method C: Starting from compound 14m (265 mg,
0.28 mmol), product 15m and 16m were obtained as a mixture
(263 mg, 98%, ratio 15m :16m=3:1). Data for 15m (equatorial
methylene): 1H NMR (400 MHz, CDCl3): d=5.12 (d, J=2.0 Hz, 1H),
4.28 (d, J=9.4 Hz, 1H), 4.22–4.14 (m, 3H), 4.14–4.05 (m, 2H), 4.00–
3.93 (t, J=10.3 Hz, 1H), 3.93–3.83 (m, 3H), 3.83–3.77 (m, 2H), 3.55–
3.43 (m, 2H), 3.40 (m, 2H), 3.08 (d, J=4.7 Hz, 1H), 2.67 (d, J=
4.7 Hz, 1H), 1.94–1.82 (m, 2H), 1.05 (s, 9H), 1.04 (s, 9H), 1.00 (s,
9H), 0.99 (s, 9H), 0.94–0.90 (m, 9H), 0.84 (s 9H), 0.14 (s, 3H), 0.11
(s, 3H), 0.10 (s, 3H), 0.00 ppm (s, 3H). 13C NMR (101 MHz, CDCl3):
d=102.2, 101.9, 78.2, 74.4, 73.4, 72.1, 70.8, 69.7, 68.2, 67.3, 66.5,
64.2, 58.9, 48.2, 46.6, 28.8, 27.7, 27.5, 27.01, 26.2, 25.6, 22.7, 22.6,
20.0, 19.9, 18.4, 18.1, @4.0, @4.2, @4.2, @4.8 ppm. IR (neat): n˜=
2929, 2098, 1741, 1251, 1161, 1099 cm@1. [a]20D (c 0.05, DCM): +38.
HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4 946.54904, found
946.54940. Data for compound 16m (axial methylene): 1H NMR
(400 MHz, CDCl3): d=4.94 (d, J=2.0 Hz, 1H), 4.28 (s, 1H), 4.25–4.11
(m, 5H), 3.98–3.85 (m, 6H), 3.85–3.75 (m, 3H), 3.48 (m, 3H), 2.98 (d,
J=5.3 Hz, 1H), 2.64 (d, J=5.3 Hz, 1H), 2.02–1.80 (m, 2H), 1.08 (s,
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9H), 1.06 (s, 9H), 1.03 (s, 9H), 1.01 (s, 9H), 0.96 (s, 9H), 0.87 (s, 9H),
0.15 (s, 3H), 0.14 (s, 3H), 0.11 (s, 3H), 0.03 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=102.1, 101.3, 79.0, 74.4, 73.5, 72.6, 68.7, 67.4,
67.2, 66.9, 64.5, 58.3, 48.2, 47.6, 28.9, 27.7, 27.7, 27.2, 27.1, 26.3,
25.7, 22.8, 22.8, 20.2, 20.1, 18.7, 18.2, @4.0, @4.1, @4.3, @4.6 ppm.
IR (neat): n˜=2931, 2098, 1741, 1251, 1159, 1097 cm@1. [a]20D (c 0.05,
DCM): +44. HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4
946.54904, found 946.54933.
(2R,3R,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-Azidopropoxy)-7-hy-
droxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (17): Compound
16g (145 mg, 0.153 mmol) was co-evaporated with toluene (3V)
and dissolved in dry THF (14.5 mL). TBAF (1m in THF, 2.3 mL,
2.3 mmol) was added and the mixture was stirred 5 days at room
temperature. The solution was eluted with THF over a small
Dowex-50WX4-200-Na+ packed column, concentrated and purified
by gradient column chromatography (EtOAc/MeOH, 19:1 to 9:1).
The product was dissolved in water and lyophilized to afford the
title compound as a white solid (64.8 mg, 97%). 1H NMR (400 MHz,
D2O): d=5.23 (d, J=3.8 Hz, 1H), 4.50 (s, 1H), 4.25 (d, J=9.0 Hz,
1H), 3.95–3.68 (m, 8H), 3.63–3.53 (m, 2H), 3.53–3.43 (m, 3H), 3.41–
3.34 (t, J=8 Hz, 1H), 3.17 (d, J=4.5 Hz, 1H), 2.87 (d, J=4.6 Hz, 1H),
1.97–1.85 ppm (m, 2H). 13C NMR (101 MHz, D2O): d=100.0, 99.2,
73.0, 72.9, 72.5, 71.7, 71.5, 70.91, 69.1, 64.8, 60.3, 60.2, 58.7, 48.4,
48.1, 27.8 ppm. IR (neat): n˜=3369, 2927, 2108, 1521, 1026 cm@1.
[a]20D (c 0.1, DCM): +174. HRMS (ESI) m/z : [M+NH4]
+ calcd for
C16H31N4O11 455.19838, found 455.19849.
(2R,3S,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-azidopropoxy)-7-hy-
droxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (18): This com-
pound was prepared from 16m (59 mg, 0.623 mmol) as described
for the preparation of 17 to afford the title product (20 mg, 74%)
as a white solid. 1H NMR (400 MHz, D2O): d=5.05 (d, J=1.6 Hz,
1H), 4.45 (s, 1H), 4.18 (d, J=9.3 Hz, 1H), 3.95 (dd, J=3.2, 1.8 Hz,
1H), 3.77 (m, 6H), 3.64 (m, 3H), 3.57–3.48 (m, 1H), 3.41 (t, J=
6.5 Hz, 2H), 3.10 (d, J=4.5 Hz, 1H), 2.81 (d, J=4.5 Hz, 1H), 1.95–
1.78 ppm (m, 2H). 13C NMR (101 MHz, D2O): d=101.0, 100.0, 73.3,
72.8, 72.5, 70.9, 70.4, 69.9, 66.3, 64.7, 60.8, 60.2, 58.7, 48.3, 48.0,
27.8 ppm. HRMS (ESI) m/z : [M+Na]+ calcd for C16H27N3O11
460.1538, found 460.1544.
1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-
(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-
((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium (4): Compound 17 (4.83 mg, 11.0 mmol) was dis-
solved in DMF (0.5 mL) and placed under Argon. Then the Cy5-
alkyne47 (6.1 mg, 11.0 mmol), aq. CuSO4 (0.1m, 44 mL, 4.4 mmol) and
aq. sodium ascorbate (0.1m, 44 mL, 4.4 mmol) were added and the
mixture was stirred overnight at room temperature. The product
was purified by HPLC (50 mm NH4CO3) to afford the title com-
pound as a blue solid (3.54 mg, 32%). 1H NMR (400 MHz, MeOD):
d=8.24 (t, J=13.0 Hz, 2H), 7.89 (s, 1H), 7.49 (d, J=7.4 Hz, 2H),
7.44–7.38 (m, 2H), 7.32–7.23 (m, 4H), 6.62 (t, J=12.4 Hz, 1H), 6.28
(d, J=13.7 Hz, 2H), 5.14 (d, J=3.8 Hz, 1H), 4.85 (s, 1H), 4.53 (t, J=
6.8 Hz, 2H), 4.42 (s, 2H), 4.32 (s, 1H), 4.16 (d, J=9.1 Hz, 1H), 4.10 (t,
J=7.4 Hz, 2H), 3.84–3.64 (m, 9H), 3.63 (s, 3H), 3.56 (t, J=9.3 Hz,
1H), 3.40 (dd, J=9.7, 3.8 Hz, 1H), 3.37–3.32 (1, 9H), 3.07 (d, J=
5.3 Hz, 1H), 2.70 (d, J=5.4 Hz, 1H), 2.25 (t, J=7.3 Hz, 2H), 2.23–
2.15 (m, 2H), 1.88–1.76 (m, 2H), 1.75–1.67 (m, 17H), 1.51–1.44 ppm
(m, 2H). 13C NMR (101 MHz, MeOD): d=180.3, 175.7, 175.4, 174.7,
155.5, 155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6,
126.3, 126.2, 124.7, 123.4, 123.3, 112.0, 111.9, 104.4, 104.3, 102.4,
101.8, 76.8, 75.1, 74.4, 74.0, 73.9, 73.0, 71.2, 65.3, 62.4, 62.4, 59.8,
50.6, 50.5, 48.4, 44.8, 36.5, 35.6, 31.5, 31.0, 28.1, 27.9, 27.8, 27.3,
26.4 ppm. HRMS (ESI) m/z : [M]+ calcd for C51H69N6O12 957.4968,
found 957.5005.
1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-
(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-
((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium (5): This compound was prepared from 18
(3.72 mg, 8.5 mmol) as described for the preparation of 4 to afford
the product (2.9 mg, 34%) as a blue solid. 1H NMR (600 MHz,
MeOD): d=8.24 (t, J=13.0 Hz, 2H), 7.90 (s, 1H), 7.49 (d, J=7.4 Hz,
2H), 7.44–7.39 (m, 2H), 7.28 (dt, J=16.4, 7.6 Hz, 4H), 6.62 (t, J=
12.4 Hz, 1H), 6.28 (d, J=13.7 Hz, 2H), 5.19 (d, J=1.3 Hz, 1H), 4.85
(s, 1H), 4.54 (t, J=6.8 Hz, 2H), 4.42 (s, 2H), 4.29 (s, 1H), 4.23 (d, J=
9.2 Hz, 1H), 4.10 (t, J=7.4 Hz, 3H), 3.90 (dd, J=3.2, 1.7 Hz, 1H),
3.85–3.68 (m, 9H), 3.66 (d, J=9.5 Hz, 1H), 3.63 (s, 3H), 3.60 (dd, J=
9.5, 3.3 Hz, 1H), 3.57–3.52 (m, 1H), 3.36–3.32 (m, 1H), 3.01 (d, J=
5.3 Hz, 1H), 2.68 (d, J=5.4 Hz, 1H), 2.26 (t, J=7.3 Hz, 2H), 2.20 (dq,
J=13.1, 6.7 Hz, 2H), 1.83 (m, 2H), 1.73 (s, 17H), 1.47 ppm (m, 2H).
13C NMR (150 MHz, MeOD): d=180.3, 175.7, 175.4, 174.7, 155.5,
155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3,
126.2, 124.8, 123.4, 123.3, 112.1, 111.8, 104.4, 104.3, 102.6, 102.4,
74.7, 74.3, 74.1, 73.3, 72.7, 72.1, 68.2, 65.2, 62.7, 62.3, 59.9, 50.6,
50.5, 48.3, 44.8, 36.5, 35.7, 31.5, 31.1, 31.0, 28.1, 28.0, 27.8, 27.3,
26.4 ppm. HRMS (ESI) m/z : [M]+ calcd for C51H69N6O12 957.4968,
found 957.4995.
Labeling of BtGH99 and BxGH99 enzymes
To determine the detection limit, 400 ng recombinant B. thetaiotao-
micron (Bt) and B. xylanisolvens (Bx) GH99 enzymes were labeled in
150 mm McIlvaine buffer, pH 7.0 (citric acid-Na2HPO4) with 0.0001–
10 mm spiro-epoxyglycoside 4 or 5 for 1 h at 37 8C. The samples
were then denatured with 5V Laemmli buffer (50% (v/v) 1m Tris-
HCl, pH 6.8, 50% (v/v) 100% (v/v) glycerol, 10% (w/v) DTT, 10%
(w/v) SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at
100 8C, and separated by electrophoresis on 10% (w/v) SDS-PAGE
gel running continuously at 90 V.[43] Wet slab-gels were scanned on
fluorescence using a Typhoon FLA 9500 (GE Healthcare at lEX
532 nm and lEM 575 nm for ABP TB340; and at lEX 635 nm and lEM
665 nm for 4 and 5. The pH optimum was analyzed using 4 ng
enzyme incubated with 1 mm 4 or 5 dissolved in McIlvaine buffer,
pH 3–8, for 30 min at 37 8C. Time-dependent labeling of BxGH99
wild-type, E333Q and E336Q enzymes was assessed by incubating
400 ng for 5, 15 or 30 min with 1 mm 4 or 5 dissolved in McIlvaine
buffer, pH 7.0. The effect of denaturation was assessed on 4 ng
wild-type BtGH99 and BxGH99 by boiling for 4 min at 100 8C prior
to incubating with 1 mm 4 and 5 for 30 min at 37 8C. Competitive
ABPP assays utilized 4 ng BtGH99 and BxGH99 enzyme that was
pre-incubated with 10–1000 mm 17, 18 or ManIFG, or 0.3–
30 mgmL@1 yeast mannan (S. cerevisiae), at pH 7.0 for 30 min at
37 8C, followed by labeling with 1 mm 4 and 5 for 30 min at 37 8C.
Functional GLA assay
Recombinant a-galactosidase GLA was diluted 1:2 in 50 mm McIl-
vaine buffer, pH 4.6, and pre-labeled with 2 mm TB340 for 1 h at
37 8C. Subsequently, the mixture was diluted to 1:500 in 150 mm
McIlvaine buffer, pH 7.0. In parallel, 400 ng BxGH99 wild-type,
E333Q and E336Q were incubated in the presence or absence of
10 mm 4 or 5, dissolved in 150 mm McIlvaine buffer, pH 7.0, for 1 h
at 37 8C. Subsequently, the BxGH99 mixture (10 mL) was incubated
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with 10 mL TB340-labeled GLA for 8 h at 37 8C. Hereafter, samples
were denatured, separated on SDS-PAGE gel and visualized by fluo-
rescence scanning, as described above (vide supra). As control,
10 mL TB340-labeled GLA was treated by either Endo-H or PNGase-
F, following the manufacturer’s instructions (New England Biolabs).
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& Enzymes
Exploration of Strategies for Mechanism-Based Inhibitor Design
for Family GH99 endo-a-1,2-Mannanases
Pearl Z. Fernandes,[a] Marija Petricevic,[a] Lukasz Sobala,[b] Gideon J. Davies,*[b] and
Spencer J. Williams*[a]
Abstract: endo-a-1,2-Mannosidases and -mannanases, mem-
bers of glycoside hydrolase family 99 (GH99), cleave a-Glc/
Man-1,3-a-Man-OR structures within mammalian N-linked
glycans and fungal a-mannan, respectively. They are pro-
posed to act through a two-step mechanism involving a 1,2-
anhydrosugar “epoxide” intermediate incorporating two
conserved catalytic carboxylates. In the first step, one car-
boxylate acts as a general base to deprotonate the 2-hy-
droxy group adjacent to the fissile glycosidic bond, and the
other provides general acid assistance to the departure of
the aglycon. We report herein the synthesis of two inhibitors
designed to interact with either the general base (a-manno-
syl-1,3-(2-aminodeoxymannojirimycin), Man2NH2DMJ) or the
general acid (a-mannosyl-1,3-mannoimidazole, ManManIm).
Modest affinities were observed for an endo-a-1,2-manna-
nase from Bacteroides thetaiotaomicron. Structural studies re-
vealed that Man2NH2DMJ binds like other iminosugar inhibi-
tors, which suggests that the poor inhibition shown by this
compound is not a result of a failure to achieve the expect-
ed interaction with the general base, but rather the reduc-
tion in basicity of the endocyclic nitrogen caused by intro-
duction of a vicinal, protonated amine at C2. ManManIm
binds with the imidazole headgroup distorted downwards, a
result of an unfavourable interaction with a conserved active
site tyrosine. This study has identified important limitations
associated with mechanism-inspired inhibitor design for
GH99 enzymes.
Introduction
Glycoside hydrolases of the carbohydrate-active enzyme (see
www.cazy.org; www.cazypedia.org)[1,2] family GH99 are endo-
acting mannosidases that cleave a-mannoside linkages within
mammalian high mannose N-glycans (endo-a-1,2-mannosidas-
es)[3–7] and fungal a-mannans (endo-a-1,2-mannanases, Fig-
ure 1A).[8, 9] Inhibitor design for these enzymes is driven by
their potential use to understand glycoprotein biosynthesis
and maturation in the secretory pathway, and to manipulate
fungal mannan degradation processes in the human gut mi-
crobiota. Structural and mechanistic studies of family GH99 en-
zymes suggest that they utilise an unusual mechanism involv-
ing neighbouring group participation by the substrate 2-hy-
droxy to form a 1,2-anhydrosugar intermediate.[10] In this pro-
posed mechanism, a conserved active site residue acts as a
general base to deprotonate the 2-OH group, thereby facilitat-
ing its nucleophilic attack on C1 (Figure 1A). This process has
little biological precedent (for a related proposal see Ref. [11]),
but occurs in the base-promoted solvolysis of a-mannosides.[12]
Efforts to develop inhibitors of GH99 enzymes have relied
upon appending 1,3-linked a-glucosyl (to target mammalian
endo-a-1,2-mannosidases) or 1,3-linked a-mannosyl (to target
bacterial endo-a-1,2-mannanases) groups to various sugar-
shaped heterocycles. Spiro and co-workers reported the dis-
covery of a-glucosyl-1,3-deoxymannojirimycin (GlcDMJ) as an
effective inhibitor of the mammalian enzyme,[13, 14] and follow-
on studies by Fleet and co-workers revealed a-mannosyl-1,3-
deoxymannojirimycin (ManDMJ) to be a slightly weaker inhibi-
tor for this enzyme (Figure 1B).[15] The potency of GlcDMJ
was subsequently exceeded by a-glucosyl-1,3-isofagomine
(GlcIFG).[10, 16] Equivalent results have been noted for bacterial
GH99 enzymes, which led to the development of a-mannosyl-
1,3-isofagomine (ManIFG; dissociation constant, KD=0.14 mm
for Bacteroides thetaiotaomicron GH99).[8] Furthermore, reintro-
duction of the “missing” 2-OH of 1,3-isofagomine (IFG) into
ManIFG gave a-mannosyl-1,3-noeuromycin (ManNOE), which
was shown to be five-fold more potent towards the B. thetaio-
taomicron GH99 enzyme (KD=0.03 mm).
[17] These compounds
bind in a ground-state 4C1 conformation, as seen in complexes
of inactive enzyme with substrate and thus proposed for the
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conformation of substrate within the Michaelis complex (Fig-
ure 1A), which suggests that potent inhibition of GH99 en-
zymes can be achieved simply by mimicry of the charge in the
transition state.[17]
Separately, Spiro and co-workers showed that the neutral
compound GlcGlucal (Figure 1C) was a modest inhibitor of
mammalian GH99 (rat Golgi preparation, IC50=2.3 mm ; for
GlcDMJ IC50=1.7 mm) ;
[14,18] the equivalent molecule targeting
bacterial GH99, ManGlucal, was also a ligand with mildly
potent affinity (KD=15 mm for BtGH99).
[17] Computational free-
energy landscape analysis of the preferred conformation of d-
glucal suggested that the inhibition of the glucal-based inhibi-
tors arises from mimicry of the proposed 4E conformation of
the transition state or the proposed 4H5 conformation of the
1,2-anhydro sugar intermediate, but with no contribution from
charge mimicry owing to the neutral nature of this com-
pound.[17]
We report here our efforts to explore two new inhibitor
design strategies for the inhibition of GH99 enzymes. Consider-
ing the role of the basic residue implicated in the 1,2-anhydro-
sugar mechanism of GH99 enzymes, we speculated that intro-
duction of an amino group into the structure of ManDMJ to
give Man-2NH2DMJ (1; Figure 1E) could promote the formation
of a favourable ionic interaction upon inhibitor binding (Fig-
ure 1D). Separately, the glycoimidazole class of inhibitors were
developed following the discovery of the natural product nag-
statin,[19] and are believed to derive their potency from their
ability to mimic the shape of the oxocarbenium-like transition
state as well as from the ability of the imidazole glycosidic ni-
trogen to engage in a hydrogen bond with an appropriately
situated carboxylate residue in the active site (Figure 1D).[20]
For the present work, this would require the synthesis of Man-
ManIm (2 ; Figure 1E). Thus, we report herein on the synthesis
of these two target inhibitors, the structural characterisation of
their binding modes and measurement of their binding con-
stants.
Results and Discussion
Synthesis of Man2NH2DMJ and ManManIm
Man2NH2DMJ (1) was prepared by substitution of known tosy-
late 3[21] with sodium azide in DMF to afford azide 4
(Scheme 1). Coupling of azide 4 with trichloroacetimidate 5[22]
under the agency of TfOH afforded the disaccharide 6 in a
yield of 83%. The deprotection of 6 was achieved in a stepwise
Figure 1. (A) Proposed mechanism for family GH99 enzymes retaining endomannosidases/endomannanases. Only the first half of the catalytic cycle is shown.
(B) Saturated basic heterocyclic inhibitors for GH99 enzymes mimicking the ground state conformation. (C) Neutral glycal inhibitors for GH99 enzymes mim-
icking the transition state. (D) Two inhibitor design concepts explored herein. (E) Structures of Man2NH2DMJ (1) and ManManIm (2).
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manner, as attempts to perform a global deprotection that in-
volved simultaneous removal of benzyloxycarbonyl (Cbz), ben-
zylidene and benzyl ethers as well as the reduction of the
azide was unsuccessful. Deacetylation of 6 (NaOMe/MeOH) and
then hydrolysis of the benzaldehyde acetal (TFA/H2O) afforded
triol 7. The azide group was reduced with dithiothreitol (DTT)/
pyridine buffer to afford amine 8. Removal of the Cbz and
benzyl groups then proceeded smoothly by using H2 and
Pearlman’s catalyst to afford 1.
ManManIm (2) was synthesised through a sequence involv-
ing the preparation of the protected mannoimidazole alcohol
22, followed by elaboration to the disaccharide (Scheme 2).
The known alcohol 9[23] was treated with 2-naphthylmethyl
bromide (NapBr)/NaH in DMF to afford 10. Hydrolysis of the
thioglycoside with N-iodosuccinimide (NIS) in H2O/acetone
gave the hemiacetal 11, which was oxidised to the lactone 12
under Albright–Goldman conditions.[24] For the conversion of
the lactone 12 to the lactam 17 we followed the protocol de-
veloped by Overkleeft et al. ,[25] which involved aminolysis to
the acyclic amide 13, Albright–Goldman oxidation (!14) and
ring closure promoted by ammonia/MeOH (!15). Reduction
of the hemiaminals 15 with NaCNBH3 afforded a 2:1 mixture of
the d-manno and l-gulo lactams, from which the d-manno
lactam 17 was isolated in a yield of 38%. Conversion of the
lactam to the thionolactam 18 was achieved by using Lawes-
son’s reagent and pyridine in toluene. Annulation of the imida-
zole ring was achieved by following the general approach of
Vasella and co-workers.[26] Reaction of the thionolactam 18
with aminoacetaldehyde dimethyl acetal afforded the amidine
19, and imidazole ring formation was achieved by catalysis
with TsOH to provide a mixture of d-gluco and d-manno imida-
Scheme 1. Reagents and conditions: a) NaN3, DMF, reflux, 74%; b) TfOH,
CH2Cl2, @30 to 0 8C, 87%; c) i. NaOMe, MeOH, ii. 9:1 TFA/H2O, 83%; d) DTT,
pyr, pH 9.2 NaHCO3/Na2CO3, 80%; e) H2, Pd(OH)2/C, aq. HCl, 2:2:1 EtOAc/
MeOH/H2O, 70%.
Scheme 2. A) Preparation of imidazole alcohol 22. Reagents and conditions: a) NapBr, NaH, DMF, 86%; b) NIS, H2O, acetone, 0 8C, 99%; c) DMSO, Ac2O; d) NH3,
THF, reflux; e) DMSO, Ac2O; f) NH3, MeOH, 88% over steps c–f ; g) HCO2H, NaBH3(CN), 38% d-manno, 33% l-gulo ; h) Lawesson’s reagent, pyridine, 4 a molecu-
lar sieves, toluene, 93%; i) H2NCH2CH(OMe)2 ; j) TsOH·H2O, toluene, 60 8C, yields over steps i and j: 42% d-gluco, 32% d-manno ; k) DDQ, CH2Cl2/H2O, 67%.
B) Synthesis of ManManIm (2). Reagents and conditions: l) TfOH, 4 a molecular sieves, toluene, @20 8C, 47%; m) K2CO3/MeOH, 46%; n) H2 (34 bar), Pd(OH)2/C,
AcOH, EtOAc, MeOH, H2O, 48%.
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zoles in a 2:1 ratio, from which the d-manno imidazole 21 was
isolated in a yield of 32% over two steps. The naphthylmethyl
group was removed under the agency of 2,3-dichloro-5,6-di-
cyano-1,4-benzoquinone (DDQ) and CH2Cl2/H2O to afford the
alcohol 22.
Coupling of 22 with trichloroacetimidate 5[22] catalysed by
TfOH afforded the disaccharide 23 in a yield of 47%. Deprotec-
tion was achieved in two steps under conditions chosen to
avoid epimerisation at C2. Treatment of 23 with K2CO3/MeOH
afforded the alcohol 24, and hydrogenation with Pearlman’s
catalyst afforded 2.
Binding affinities and 3D structures
Isothermal titration calorimetry (ITC) was used to assess the
binding of 1 and 2 to a bacterial endomannosidase. Titration
of BtGH99 with Man2NH2DMJ (1) revealed binding with KD=
97.7:4.9 mm (Figure 2), whereas no binding with ManManIm
(2) was evident by ITC. Placed in context, 1 has a poorer bind-
ing affinity towards BtGH99 than GlcDMJ (KD=24 mm) ;
[10] the
equivalent data is not available for ManDMJ, but as this
enzyme prefers to bind Man-configured substrates, the differ-
ence would be expected to be even greater.
Three-dimensional structures were obtained for 1 and 2
bound to the endo-a-1,2-mannanase BxGH99 from Bacteroides
xylanisolvens, which is closely related to BtGH99 but more ame-
nable to complex formation. These complexes diffracted to a
resolution of 1.1 and 1.3 a, respectively (Table 1). Occupancy of
the active site for the complex with 1 was essentially complete,
whereas that with 2, with prolonged soaking, was estimated to
be 80%, likely a consequence of the poor affinity of the com-
pound for the enzyme. As predicted, both compounds bound
in the @2/@1 subsites of the enzyme (sub-site nomenclature
from Ref. [27]) and will be discussed in turn.
Structural analysis of the BxGH99–1 complex (Figure 3A) re-
vealed the piperidine ring in a 4C1 conformation, which match-
es that seen for complexes of the wild-type enzyme with
GlcDMJ and isofagomine-based inhibitors[8, 10, 17] as well as that
of a disabled mutant with substrate.[8] The 2-amino group is
situated appropriately to interact with the E333 residue, that
which is proposed to act as a general base/acid through de-
protonation of the 2-hydroxy group. Overlay of this complex
with that of BxGH99–GlcDMJ reported previously[10] revealed
that the positioning and conformations of the rings in the @1
and @2 sub-sites are essentially identical, and that no amino
acid residues undergo significant movement (Figure 3C). In
particular, the E333···O2 and E333···N2 distances are 2.54 and
2.59 a, respectively. The poor binding affinity of 1 compared
with GlcDMJ therefore does not result from incorrect binding
of the inhibitor, and must instead reflect a failure to fully capi-
talise on the proposed interactions. It is widely acknowledged
that iminosugars such as DMJ (and thus GlcDMJ) achieve inhib-
ition through binding to glycosidases in their protonated
Table 1. Data collection and refinement statistics for the complexes of
BxGH99 with 1 and 2.
BxGH99 complexed
with aminoDMJ (1)
BxGH99 complexed
with ManManIm (2)
Data collection
Space group I4 I4
Cell dimensions
a [a] 108.1 108.6
b [a] 108.1 108.6
c [a] 67.5 67.8
a [8] 90 90
b [8] 90 90
g [8] 90 90
resolution [a] 76.44–1.13 (1.15–1.13)[a] 76.81–1.30 (1.32–1.30)[a]
Rmerge 0.069 (1.501) 0.054 (1.224)
Rpim 0.026 (0.735) 0.020 (0.610)
CC(1/2) 0.999 (0.400) (0.999) 0.486
I/sI 10.2 (1.0) 14.0 (0.9)
completeness [%] 99.1 (86.0) 99.5 (92.7)
redundancy 7.5 (4.8) 7.5 (4.6)
Refinement
resolution [a] 76.44–1.13 76.81–1.30
no. reflections
all/free
143544/7133 96144/4810
Rwork/Rfree 0.122/0.144 0.134/0.162
no. atoms
protein 3188 3146
ligand/ion 22 25
water 467 427
B factors [a2]
protein 17.2 20.5
ligand/ion 20.3 22.4
water 35.1 36.7
r.m.s. deviations
bond lengths [a] 0.0101 0.011
bond angles [8] 1.495 1.497
PDB ID 6FAM 6FAR
[a] Values in parentheses are for the highest-resolution shell.
Figure 2. Isothermal titration calorimetry thermogram showing the binding
of Man2NH2DMJ (1) to Bacteroides thetaiotaomicron endo-a-1,2-mannanase
(BtGH99). DP=differential power. Binding parameters KD=97.7:4.9 mm,
N=1 (fixed) and DH=@5.9:0.1 kcalmol@1.
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form;[28] this is supported by first-principles consideration of
the basicity of these inhibitors and the relevant pKa values of
the catalytic residues, as well as by studies of the pH depend-
ence of inhibition. In the case of 1, there are two basic nitro-
gen residues. However, for vicinal diamines, protonation at one
nitrogen has a profound effect on the pKa value at the second
nitrogen; in acyclic systems this effect has been estimated to
be DpKa=3.6 units for NH3
+ and NR3
+ .[29] Moreover, in cyclic
systems there are stereoelectronic and conformational contri-
butions, notable examples for various diamines (pKa1, pKa2) in-
clude piperazine (9.8, 5.7),[29] cis-1,3-diaminocyclohexane (10.3,
8.3)[30] and trans-1,3-diaminocyclohexane (10.4, 8.5).[30] Finally,
vicinal hydroxy groups can also perturb amine pKa values; in
Man2NH2DMJ, O4 is antiperiplanar with respect to the endocy-
clic nitrogen and would be expected to reduce its basicity by
around 1.3 pKa units.
[30] Collectively, this analysis would suggest
that N2 is protonated by the general acid E333, and that it is
unlikely that the dication is formed, and therefore
Man2NH2DMJ fails to appropriately mimic an oxocarbenium-
like transition state. A related example of this phenomenon
was reported in which introduction of a second amine vicinal
to a pre-existing one in apramycin resulted in a dramatic loss
of binding to a bacterial ribosome of approximately 100-
fold.[31] Additionally, the proposed binding mode of 1 shown in
Figure 1D highlights the fact that the 2-amino group has addi-
tional hydrogen substituents that may cause an energy penalty
upon binding of the inhibitor.
Structural analysis of the BxGH99–2 complex revealed the pi-
peridine ring of the mannoimidazole moiety to be in an un-
usual 2H3/E3 conformation (Figure 3B).
[32] Overlay of the com-
plex with that of BxGH99–GlcDMJ[10] revealed that although
the @2 sugar residues occupy similar positions, the mannoimi-
dazole headgroup is atypically positioned such that the hetero-
cycle projects downward into the active site, below the plane
of the piperidine ring of the GlcDMJ complex (Figure 3D). In
this case the E336···N (imidazole ring) distance is 2.65 a, similar
to that seen in related glycoimidazole complexes.[33] In the
original formulation by Heightman and Vasella, b-equatorial
glycosidases were proposed to perform protonation from the
side, in what was termed “lateral protonation”, with the acid
either on the same side as the endocyclic oxygen (syn) or op-
posed to it (anti).[20] In a subsequent publication Nerinckx et al.
formalised this concept by dividing the space around the @1
sugar into anti and syn hemispheres through a plane defined
by the glycosidic oxygen, C1 and H1 of the sugar residue.[34]
Analysis of complexes of various anti-protonating glycosidases
revealed that the acid/base or acid residues responsible for
protonating the leaving group are in fact not universally locat-
ed lateral to the mean plane of the sugar, but are more com-
monly positioned above or below it, so as to better protonate
the leaving group oxygen. However, this does not prevent gly-
coimidazoles binding in normal orientations and engaging in
hydrogen-bonding interactions with the imidazole nitrogen.
For example, in the case of the retaining GH116 b-glucosidase
from Thermoanaerobacterium xylanolyticum, the acid/base is
positioned above the mean plane of the sugar, but a normal
orientation and conformation of glucoimidazole was ob-
served.[35] Mannoimidazole also binds in the normal fashion to
an inverting GH47 a-mannosidase from Caulibacter sp. in
which the acid is below the mean plane of the inhibitor, but
instead the inhibitor establishes an interaction with another
conserved active site carboxylic acid that lies lateral to the imi-
dazole.[36] BxGH99 is an anti-protonating enzyme with its gen-
eral acid/base Glu336 positioned below the plane of the ring
to facilitate classical anti protonation of the axial glycosidic
oxygen (O5-C1-O1 angle is approximately 608). The distorted
mode of binding of the mannoimidazole moiety of 2 seems to
be a consequence of the imidazole binding to maximise this
interaction with the acid/base. Close examination of the active
site of BxGH99 revealed that if the ManIm moiety were to be
shifted up to the same position as that of the piperidine of
GlcDMJ, a steric interaction would result with Tyr252, a con-
served residue. In fact, the distance between the imidazole C=
C bond and Tyr252 Ce is only 3.2 a, which causes the wwPDB
validation software[37] to report H/H steric clashes in this
region. In fact, a ternary complex of GlcDMJ and a-1,2-manno-
biose highlighted the fact that the active site of the enzyme in-
volves a sharp bend in the @1 and +1 sub-sites. The failure of
2 to bind in a typical position in the @1 sub-site is thus likely a
result of a failure to accommodate the imidazole ring owing to
the location of Tyr252.
Conclusions
We have reported here the design and synthesis of two “mech-
anism-based” inhibitors of family GH99 endomannanases. Al-
though Man2NH2DMJ (1) bound to the bacterial endomanna-
nase BxGH99 in the expected manner, its affinity for BtGH99
did not exceed that seen for GlcDMJ. This appears to be a
result of the perturbing effect of the 2-amino substituent,
which reduces the basicity of the endocyclic nitrogen and its
ability to be protonated in the active site and thereby resem-
ble the oxocarbenium-like transition state. On the other hand,
the binding of ManManIm (2) to BtGH99 could not be detect-
Figure 3. Three-dimensional structures of BtGH99 complexed with
A) Man2NH2DMJ (1) and B) ManManIm (2). Electron density maps are maxi-
mum likelihood/sA weight Fo@Fc difference syntheses contoured at 0.5 and
0.3 ea@3 for panels A and B, respectively, visible before refining the structure
model with the ligand added. (C) Overlay of Man2NH2DMJ (1) with GlcDMJ
(PDB code 4FAM). (D) Overlay of ManManIm (2) with GlcDMJ (PDB code
4FAR).
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ed by ITC and, consistent with this, the X-ray structure of 2
complexed with BxGH99 displayed incomplete occupancy. The
poor binding of this inhibitor appears to be a consequence of
an inability of the active site of BxGH99 to accommodate the
annulated imidazole ring because of an interaction with a con-
served Tyr active-site residue. This study provides important in-
sights that will inform future strategies for the development of
mechanism-inspired and transition-state mimicking inhibitors
of GH99 enzymes.
Experimental Section
General : 1H and 13C NMR spectra were recorded by using 400, 500
or 600 MHz Varian INOVA spectrometers. All signals were refer-
enced to TMS (d=0.00 ppm) or solvent peaks (CDCl3 : d=7.26 ppm
for 1H and 77.16 ppm for 13C; D2O: d=4.80 ppm for
1H and TMS:
d=0.00 ppm for 13C; [D4]MeOH: d=3.49 ppm for
1H and d=
49.0 ppm for 13C). Melting points were obtained by using a Reich-
ert-Jung hot-stage apparatus. TLC analysis was performed with alu-
minium-backed Merck Silica Gel 60 F254 sheets, detection was ach-
ieved by using UV light, 5% H2SO4 in MeOH or ceric ammonium
molybdate (“Hanessian’s stain”) with charring as necessary. Flash
chromatography was performed by using Geduran silica gel ac-
cording to the method of Still et al.[38] Dry CH2Cl2, THF and Et2O
were obtained from a dry solvent apparatus (Glass Contour of SG
Water, Nashua).[39] DMF and DMSO were dried over 4 a molecular
sieves.
2-Azido-4,6-O-benzylidene-N-benzyloxycarbonyl-1,2,5-trideoxy-
1,5-imino-d-mannitol (4): Sodium azide (57.8 mg, 0.890 mmol)
was added to a solution of 4,6-O-[(R)-benzylidene]-N-benzyloxycar-
bonyl-1,5-dideoxy-2-O-(p-toluenesulfony1)-d-glucitol[21] (3 ; 120 mg,
0.222 mmol) in DMF (1 mL). The suspension was heated at reflux
for 18 h, poured into ice, extracted into EtOAc (3V20 mL), washed
with brine (2V20 mL), dried over anhydrous MgSO4 and evaporat-
ed to dryness. Column chromatography (AcOEt/pet. ether 40-60,
1:5) gave the azide 4 (67.7 mg, 74%) as a white solid. [a]24D =@21.9
(c=1.12 in CHCl3) ;
1H NMR (CDCl3, 500 MHz): d=2.74 (s, 1H; NH),
2.82 (dd, J=1.6, 14.5 Hz, 1H; 1-Ha), 3.06 (td, J=4.6, 10.2 Hz, 1H; 5-
H), 3.74 (dd, J=3.8, 9.2 Hz, 1H; 3-H), 3.79–3.93 (m, 2H; 2,4-H), 4.31
(dd, J=3.0, 14.5 Hz, 1H; 1-Hb) 4.46 (t, J=11 Hz, 1H; 6-Ha), 4.66 (dd,
J=4.6, 11.6 Hz, 1H; 6-Hb), 5.01 (d, J=3.1 Hz, 2H; CH2), 5.48 ppm (s,
1H; CH); 13C NMR (CDCl3, 125 MHz): d=48.1, 55.8, 60.1, 67.8, 69.2,
73.6, 78.2 (7C; C1–C6, CH2), 101.8 (1C; CH), 126.3, 128.3, 128.4,
128.5, 128.7, 129.4, 136.0, 137.3 (12C; Ph), 155.0 ppm (1C; C=O);
HRMS (ESI, +ve): m/z calcd for C21H22N4O5 : 411.1663 [M+H]
+ ;
found: 411.1664.
2-O-Acetyl-3,4,6-tri-O-benzyl-a-d-mannopyranosyl-(1!3)-2-
azido-4,6-O-benzylidene-N-benzyloxycarbonyl-1,2,5-trideoxy-1,5-
imino-d-mannitol (6): TfOH (0.043 mL, 0.0049 mmol) was added to
a mixture of acceptor 4 (20 mg, 0.049 mmol) and 2-O-acetyl-3,4,6-
tri-O-benzyl-a-d-mannopyranosyl trichloroacetimidate (5 ;[22] 37 mg,
0.058) in CH2Cl2 over 4 a sieves at @30 8C, The mixture was stirred
for 30 min, warmed to 0 8C and quenched with Et3N (7 mL,
0.05 mmol) and then concentrated under reduced pressure. Flash
chromatography (EtOAc/pet. ether, 25:75) gave the disaccharide 6
(37.4 mg, 87%) as a colourless oil. [a]24D =@4.2 (c=0.89 in CHCl3) ;
1H NMR (CDCl3, 500 MHz): d=2.80 (dd, J1,1=14.4, J1,2=0.9 Hz, 1H;
1-Ha), 3.15 (dt, J=10.1, 4.6 Hz, 1H; 5-H), 3.70–4.00 (m, 6H; 3,4,4’,5’-
H, 6“-Ha, 6’-Hb), 4.03 (dd, J=9.3, 3.4 Hz, 1 H; 3’-H), 4.17–4.20 (m,
1H; 2-H), 4.28 (dd, J=14.5, 2.2 Hz, 1H; 1-Hb), 4.47–4.52 (m, 3H; 3V
CH2Ph), 4.60–4.64 (m, 2H; 6-Ha, CH2Ph), 4.69 (d, J=11 Hz, 1H;
CH2Ph), 4.76 (dd, J=11.6, 4.5 Hz, 1H; 6-Hb), 4.86 (d, J=11 Hz, 1H;
CH2Ph), 5.12 (d, J=3.6 Hz, 2H; CH2), 5.28 (d, J=1.6 Hz, 1H; 1’-H),
5.59 (dd, J=3.3, 1.8 Hz, 1H; 2’-H), 5.64 (s, 1H; CH), 7.17–7.46 ppm
(m, 25H; Ph); 13C NMR (CDCl3, 125 MHz): d=48.3 (1C; C-1), 56.3
(1C; C-5), 60.0, 72.7, 74.4, 77.8 (4C; C-3,4,4’,5), 67.7 (1C; CH2), 68.5
(1C; C-2’), 69.1 (1C; C-6), 69.3 (1C; C-6’), 72.2, 73.6, 75.1 (3C;
CH2Ph), 78.1 (1C; C-2), 78.2 (1C; C-3’), 99.5 (1C; C-1’), 100.90 (1C;
CH), 100.92, 126.0, 127.77, 127.79, 127.83, 127.9, 128.0, 128.2,
128.28, 128.29, 128.41, 128.44, 128.5, 128.7, 128.9 ppm (30C; Ph);
HRMS (ESI, +ve): m/z calcd for C50H52N4O11: 907.3525 [M+Na]
+ ;
found: 907.3544.
3,4,6-Tri-O-benzyl-a-d-mannopyranosyl-(1!3)-2-azido-N-benzyl-
oxycarbonyl-1,2,5-trideoxy-1,5-imino-d-mannitol (7): A solution
of sodium methoxide in methanol (0.1m, 10 mL, 1 mmol) was
added to 6 (60 mg, 0.068 mmol) in methanol (0.5 mL) and the mix-
ture was stirred for 1 h and then concentrated under reduced pres-
sure to give an alcohol, which was used without purification. TFA/
H2O (9:1, 100 mL) was added to the crude alcohol and the mixture
was stirred for 30 min, concentrated and azeotroped with toluene
(3V10 mL). Flash chromatography (EtOAc/pet. ether, 9:1) gave the
triol 7 (42.5 mg, 83%,). [a]25D =44.6 (c=1.03 in MeOH);
1H NMR
(500 MHz, CD3OD): d=2.67–4.20 (13H; 1-Ha–6-Hb, 2’-H–6’-Hb), 4.43–
4.46 (m, 2H; 2VCH2Ph), 4.52 (d, J=12.0 Hz, 1H; CH2Ph), 4.70 (d, J=
12.7 Hz, 1H; CH2Ph), 4.72 (d, J=11.2 Hz, 1H; CH2Ph), 4.89 (d, J=
2.1 Hz, 1H; 1’-H), 5.12 (s, 2H; CH2), 5.15 (app. s, 1H; 1’-H), 7.03–
7.42 ppm (m, 20H; 4VPh); 13C NMR (CDCl3, 125 MHz): d=59.5,
68.0, 68.9, 69.0, 71.9, 72.5, 73.5, 74.2, 74.9, 79.5 (13C; C-
1,2,3,4,5,6,1’,2’,3’,4’,5’,6’, CH2) 127.8, 127.9, 128.0, 128.1, 128.16,
128.19, 128.4, 128.5, 128.6, 128.7, 137.9, 138.0, 138.3 (24C; Ph),
156.5 ppm (1C; C=O); HRMS (ESI, +ve): m/z calcd for C41H46N4O10 :
755.3287 [M+H]+ ; found: 755.3300.
3,4,6-Tri-O-benzyl-a-d-mannopyranosyl-(1!3)-2-amino-N-
benzyloxycarbonyl-1,2,5-trideoxy-1,5-imino-d-mannitol (8): DTT
(51 mg, 0.331 mmol) was added to a solution of azide 7 (25 mg,
0.0331 mmol) in pyridine (1 mL) and NaHCO3/H2CO3 buffer
(0.625 mL, pH 9.16). The mixture was stirred at room temperature
for 4 h, concentrated and azeotroped with toluene (5V10 mL).
Flash chromatography (EtOAc/MeOH/H2O, 94:4:2) gave the
amine 8 (80%, 19.2 mg). 1H NMR (500 MHz, CD3OD): d=2.89 (t, J=
12.4 Hz, 1H; 2-H), 3.21–4.13 (13C; m, 1-Ha, 1-Hb, 3,5-H, 6-Ha, 6-Hb,
1’–6b’-H), 4.36 (t, J=7.8 Hz, 1H; 4-H),4.46–4.54 (m, 2H; 2VCH2Ph),
4.58 (d, J=12.0 Hz, 1H; CH2Ph), 4.66 (d, J=11.8 Hz, 1H; CH2Ph),
4.77–4.81 (m, 2H; 2VCH2Ph), 4.98 (d, J=2.5 Hz, 1H; 1’-H), 5.15 (s,
2H; CH2), 7.16–7.47 ppm (m, 20H; Ph);
13C NMR (CDCl3, 125 MHz):
d=46.8, 59.9, 65.6, 68.5, 69.4, 70.4, 72.6, 73.7, 74.4, 75.4, 75.7, 78.1,
80.1, 100.8 (16C; C-1–6, C1’–6’, 4VCH2), 128.81, 128.84, 129.2,
129.28, 128.30, 129.3, 129.4, 129.5, 138.0, 139.3, 139.5, 139.6 ppm
(24C; Ph); HRMS (ESI, +ve): m/z calcd for C41H48N2O10 : 729.3385
[M+H]+ ; found: 729.3398.
a-d-Mannopyranosyl-(1!3)-2-amino-1,2,5-trideoxy-1,5-imino-d-
mannitol (1): The triol 8 (19.2 mg, 0.0264 mmol) in EtOAc/MeOH/
H2O (2:2:1, 3 mL) and 10% HCl in methanol (0.3 mL) was treated
with Pd(OH)2/C (50 mg) and H2 (20 atm, 18 h). The suspension was
filtered, concentrated and purified with cation and anion resin
(eluted with aqueous NH3) to give ManNH2DMJ (1; 70%, 6.02 mg)
as a colourless oil. [a]25D =17.2 (c=0.08 in H2O);
1H NMR (500 MHz,
D2O): d=2.78–2.84 ( m, 1H; 5-H), 3.09 (dd, J1a,1b=14.0, J1a,2=2.1 Hz,
1H; 1-Ha), 3.25 (dd, J1a,1b=14.0, J1a,2=3.2 Hz, 1H; 1-Hb), 3.62–3.95
(m, 9H; 2,3,4,4’,5’-H, 6-Ha, 6’-Ha, 6-Hb, 6’-Hb), 3.98 (dd, J3’,4’=9.2,
J2’,3’=4.3 Hz, 1H; 3’-H), 4.09 (dd, J2’,3’=3.3, J1’,2’=1.8 Hz, 1H; 2’-H),
5.24 ppm (d, J1’,2’=1.6 Hz, 1H; 1’-H);
13C NMR (125 MHz, D2O): d=
44.5, 50.4, 60.0, 60.8, 61.0, 66.6, 67.3, 69.7, 70.1, 73.7, 77.3,
101.6 ppm; HRMS (ESI, +ve): m/z calcd for C12H24N2O8 : 325.1605
[M+H]+ ; found: 325.1606.
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4-Methylphenyl 2,4,6-tri-O-benzyl-3-O-(2-naphthylmethyl)-1-
thio-a-d-mannopyranoside (10): A dry solution of the alcohol 9[23]
(167 mg, 0.30 mmol) in DMF (5 mL) was cooled to 0 8C. The solu-
tion was charged with NaH (60% dispersion in mineral oil, 36 mg,
0.9 mmol) and the mixture stirred for 30 min. 2-Bromomethylnaph-
thalene (79.6 mg, 0.36 mmol) was added and the mixture stirred
overnight. The mixture was diluted with Et2O (20 mL), poured into
ice/water and washed with water (3V20 mL) and brine (1V20 mL).
The organic extracts were dried (MgSO4), the solvent was removed
under reduced pressure and the resulting residue was subjected to
flash chromatography (EtOAc/pet. ether, 15:85) to give the protect-
ed thioglycoside 10 (179.3 mg, 86%) as a colourless oil. [a]24D = +
65 (c=0.69 in CHCl3) ;
1H NMR (500 MHz, CDCl3): d=2.28 (s, 3H;
TolMe), 3.78 (dd, J5,6a=1.8, J6a,6b=10.9 Hz, 1H; 6-Ha), 3.87 (dd, J5,6b=
5.2, J6a,6b=10.9 Hz, 1H; 6-Hb), 3.97 (dd, J2,3=3.0, J3,4=9.3 Hz, 1H; 3-
H), 4.04 (dd, J1,2=3.0, J2,3=1.8 Hz, 1H; 2-H), 4.11 (m, 1H; 4-H), 4.33
(ddd, J4,5=9.8, J5,6a=5.1, J5,6b=1.6 Hz, 1H; 5-H), 4.49 (d, J=11.9 Hz,
1H; CH2Ph), 4.57–4.67 (m, 3H; 3VCH2Ph), 4.74 (m, 3H; CH2Ph, 2V
CH2Nap), 4.96 (d, J=10.9 Hz, 1H; CH2Ph), 5.58 (d, J1,2=1.5 Hz, 1H;
1-H), 7.02 (app. d, J=7.9 Hz, 2H; Tol), 7.21–7.37 (m, 17H; 3VPh,
Tol), 7.44–7.47 (m, 3H; Nap), 7.74–7.83 ppm (m, 4 H; Nap); 13C NMR
(125 MHz, CDCl3): d=21.2 (1C; TolMe), 69.3 (1C; C-6), 71.9 (1C;
CH2Ph), 72.2 (1C; CH2Nap), 72.8 (1C; C-5), 73.3 (1C; CH2Ph), 75.1
(1C; C-4), 75.2 (1C; CH2Ph), 76.3 (1C; C-2), 80.3 (1C; C-3), 86.1 (1C;
C-1), 125.9–126.5 (4C; Nap), 127.5–128.4 (18C; 3VPh, Nap), 129.8
(2C; Tol), 132.3 (2C; Tol), 133.4, 135.8, 137.6, 138.0, 138.5,
138.6 ppm (6C; Cq) ; HRMS (ESI, +ve): m/z calcd for C45H44O5S:
719.2802 [M+Na]+ ; found: 719.2809.
2,4,6-Tri-O-benzyl-3-O-(2-naphthylmethyl)-a-d-mannopyranose
(11): N-Iodosuccinimide (216 mg, 0.961 mmol) was added to a solu-
tion of the thioglycoside 10 (447 mg, 0.641 mmol) in acetone (1%
aq., 10 mL) at 0 8C and left to stir for 2.5 h. The solution was
quenched with aq. Na2S2O3 (0.5m, 10 mL), diluted with EtOAc
(20 mL) and washed with aq. Na2S2O3 (0.5m, 3V20 mL), NaHCO3
(2V20 mL) and brine (1V20 mL). The organic extracts were dried
(MgSO4), the solvent was removed under reduced pressure and
the resulting residue was subjected to flash chromatography
(EtOAc/pet. ether/Et3N, 30:69.5:0.5) to afford the hemiacetals 11
(344 mg, 91%; a/b 3.3:1) as a white powder. a anomer: 1H NMR
(500 MHz, CDCl3): d=3.69 (dd, J5,6a=6.6, J6a,6b=10.5 Hz, 1H; 6-Ha),
3.74 (dd, J5,6b=2.0, J6a,6b=10.4 Hz, 1H; 6-Hb), 3.83 (dd, J1,2=2.0,
J2,3=2.8 Hz, 1H; 2-H), 3.91 (t, J3,4= J4,5=9.6 Hz, 1H; 4-H), 4.05 (dd,
J2,3=3.0, J3,4=9.4 Hz, 1H; 3-H), 4.10 (ddd, J4,5=8.7, J5,6a=5.8, J5,6b=
1.9 Hz, 1H; 5-H), 4.51–4.59 (m, 3H; 3VCH2Ph), 4.74–4.76 (m, 4H;
2VCH2Ph, 2VCH2Nap), 4.94 (d, J=11.0 Hz, 1H; CH2Ph), 5.27 (d,
J1,2=1.8 Hz, 1H; 1-H), 7.18–7.41 (m, 17H; 3VPh), 7.45–7.47 (m, 3H;
Nap), 7.72–7.83 ppm (m, 4H; Nap); 13C NMR (125 MHz, CDCl3): d=
69.7 (1C; C-6), 71.4 (1C; C-5), 72.2 (1C; CH2Nap), 72.7 (1C; CH2Ph),
73.3 (1C; CH2Ph), 75.1 (1C; CH2Ph), 75.1 (1C; C-2), 75.3 (1C; C-4),
79.8 (1C; C-3), 92.6 (1C; C-1), 125.8–126.3 (4C; Nap), 127.6–128.5
(18C; 3VPh, Nap), 133.0, 133.4, 136.1, 138.0, 138.5 ppm (6C; Cq) ;
HRMS (ESI, +ve): m/z calcd for C38H38O6 : 608.3007 [M+NH4]
+ ;
found: 608.3007.
2,4,6-Tri-O-benzyl-3-O-(2-naphthylmethyl)-d-mannonolactone
(12): A solution of the hemiacetal 11 (742 mg, 1.26 mmol) in acetic
anhydride (6.1 mL) and dry DMSO (6.6 mL) was stirred under N2 for
22 h. The mixture was diluted with EtOAc (20 mL), quenched with
ice and washed with water (3V20 mL) and brine (1V20 mL). The
organic extracts were dried (MgSO4) and the solvent was evaporat-
ed. Azeotropic toluene was used to remove any residual AcOH to
afford the crude lactone 12 (823 mg), which was used directly in
the next step. A portion of 12 obtained from a separate experi-
ment was purified by flash chromatography (EtOAc/pet. ether, 1:9)
to yield analytically pure 12 as a colourless oil. [a]25D = +4.05 (c=
0.44 in CHCl3) ;
1H NMR (500 MHz, CDCl3): d=3.61 (m, 2H; 6-Ha, 6-
Hb), 3.80 (dd, J2,3=1.5, J3,4=7.2 Hz, 1H; 3-H), 4.09 (dd, J1,2=2.6,
J2,3=1.6 Hz, 1H; 2-H), 4.23 (m, 2H; 5-H, 4-H), 4.38 (d, J=2.6 Hz, 1H;
CH2Ph), 4.48 (app. d, 2H; 2VCH2Ph), 4.56 (d, J=11.8 Hz, 1H;
CH2Ph), 4.77 (d, J=12.5 Hz, 1H; CH2Ph), 4.94 (d, J=12.5 Hz, 1H;
CH2Ph), 5.06 (m, 2H; 2VCH2Nap), 6.96–7.45 (m, 18H; 3VPh, Nap),
7.69–7.78 ppm (m, 4H; Nap); 13C NMR (125 MHz, CDCl3): d=69.0
(1C; C-6), 71.6 (1C; C-4), 72.8 (1C; CH2Ph), 72.9 (1C; CH2Nap), 73.3
(1C; CH2Ph), 75.5 (1C; CH2Ph), 75.8 (1C; C-3), 76.5 (1C; C-2), 78.4
(1C; C-5), 125.9–126.1 (3C; Nap), 126.9 (1C; Nap), 127.6–128.9
(18C; 3VPh, Nap), 132.9, 133.0, 135.0, 136.7, 137.3, 137.6 (6C; Cq),
169.3ppm (1C; C=O); HRMS (ESI, +ve): m/z calcd for C38H36O6 :
606.2850 [M+NH4]
+ ; found: 606.2853.
2,4,6-Tri-O-benzyl-3-O-(2-naphthylmethyl)-d-mannonamide (13):
A dry-ice/acetone cold finger cooling trap was used to condense
ammonia (50 mL) into a solution of the crude lactone 12 (823 mg)
in dry THF (30 mL) at @78 8C. The solution was allowed to reflux at
0 8C for 4 h. The mixture was then evaporated to dryness to afford
the crude amide 13 (771 mg), which was used directly in the next
step. A portion obtained from an independent experiment was pu-
rified by flash chromatography (EtOAc/pet. ether, 3:2) to yield ana-
lytically pure 13 as a yellow solid. M.p. 120 8C; [a]25D = +7.21 (c=
0.41 in CHCl3) ;
1H NMR (500 MHz, CDCl3): d=3.20 (d, J5,OH=6.2 Hz,
1H; OH), 3.61 (m, 2H; 6-Ha, 6-Hb), 3.87 (dd, J3,4=5.9, J4,5=7.3 Hz,
1H; 4-H), 3.98 (m, 1H; 5-H), 4.13 (dd, J2,3=3.5, J3,4=5.8 Hz, 1H; 3-
H), 4.33 (d, J2,3=3.5 Hz, 1H; 2-H), 4.43–4.60 (m, 6H; 6VCH2Ph), 4.82
(s, 2H; 2VCH2Nap), 5.50 (br s, 1H; NH), 6.54 (br s, 1H; NH), 7.11–
7.27 (m, 15H; 3VPh), 7.38–7.43 (m, 3H; Nap), 7.68–7.76 ppm (m,
4H; Nap); 13C NMR (125 MHz, CDCl3): d=71.1 (1C; C-5), 71.4 (1C;
C-6), 72.9 (1C; CH2Ph), 73.6 (1C; CH2Ph), 74.6 (1C; CH2Ph), 75.0
(1C; CH2Nap), 79.1 (1C; C-4), 80.2 (1C; C-2), 81.6 (1C; C-3), 126.0–
126.3 (3C; Nap), 126.9 (1C; Nap), 127.8–128.7 (18C; 3VPh, Nap),
133.1, 133.4, 135.7, 137.2, 138.2, 138.4 (6C; Cq), 173.4 ppm (1C; C=
O); HRMS (ESI, +ve): m/z calcd for C38H39NO6 : 606.2844 [M+H]
+ ;
found: 606.2850 ppm.
(3S,4S,5S,6R/S)-3,5-Bis(benzyloxy)-6-(benzyloxymethyl)-6-hy-
droxy-4-(2-naphthylmethoxy)piperidin-2-one (15): A solution of
the crude amide 13 (771 mg) in acetic anhydride (6.1 mL) and dry
DMSO (6.6 mL) was stirred under N2 for 21 h. The reaction mixture
was diluted with EtOAc (20 mL), quenched with ice and washed
with water (3V20 mL) and brine (1V20 mL). The organic extracts
were dried (MgSO4) and the solvent was evaporated to afford the
keto-amide 14 as a white solid. A dry-ice/acetone cold finger was
used to condense ammonia (20 mL) into a solution of the crude
keto-amide in dry methanol (30 mL) at 0 8C. The solution was al-
lowed to warm to room temperature and stirred under N2 for 16 h.
The solvent was removed under reduced pressure and the result-
ing residue was subjected to flash chromatography (EtOAc/pet.
ether, 1:1) to give a separable mixture of the hydroxy-lactams 15
(669 mg, 88% over four steps; d-manno/l-gulo 2.2:1). 1H NMR
(500 MHz, CDCl3), partial spectrum of the mixture of diastereomers:
d=3.38 (d, J=9.8 Hz, 1H; CH2(C6) d-manno), 3.43 (d, J=9.6 Hz,
1H; CH2(C6) l-gulo), 3.47 (d, J=9.8 Hz, 1H; CH2(C6) d-manno), 3.57
(d, J=9.6 Hz, 1H; CH2(C6) l-gulo), 3.72 (br s, 1H; OH), 4.22 (d, J3,4=
3.0 Hz, 1H; 3-H d-manno), 4.26 (d, J3,4=3.1 Hz, 1H; 3-H l-gulo),
4.98 (d, J=12.5 Hz, 1H; CH2Ph d-manno), 5.10 (d, J=12.3 Hz, 1H;
CH2Ph l-gulo), 6.33 (br s, 1H; NH l-gulo), 6.22 ppm (brs, 1H; NH d-
manno) ; 13C NMR (125 MHz, CDCl3): d=74.0 (1C; CH2(C6) d-
manno), 74.5 (1C; C-3 d-manno), 169.6 (1C; C=O d-manno),
170.2 ppm (1C; C=O l-gulo) ; HRMS (ESI, +ve): m/z calcd for
C38H37NO6 : 604.2694 [M+H]
+ ; found: 606.2698 ppm.
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(3S,4S,5S,6R)-3,5-Bis(benzyloxy)-6-(benzyloxymethyl)-4-(2-naph-
thylmethoxy)piperidin-2-one (16) and (3S,4S,5S,6S)-3,5-bis(ben-
zyloxy)-6-(benzyloxymethyl)-4-(2-naphthylmethoxy)piperidin-2-
one (17): Sodium cyanoborohydride (90.4 mg, 1.44 mmol) was
added to a solution of the hydroxy-lactams 15 (86.9 mg,
0.144 mmol) and formic acid (0.52 mL) in dry acetonitrile (3 mL)
and the mixture stirred under N2 for 20 h. Sodium cyanoborohy-
dride (90.4 mg, 1.44 mmol) was added and the reaction mixture
was stirred for a further 24 h when TLC analysis (EtOAc/pet. ether,
1:3) indicated complete consumption of the starting material. The
mixture was diluted with EtOAc (20 mL) and washed with aq. sat.
NaHCO3 (3V20 mL) and brine (1V20 mL). The aqueous extracts
were treated with sodium hypochlorite prior to disposal. The or-
ganic extracts were dried (MgSO4), the solvent was removed under
reduced pressure and the resulting residue was subjected to flash
chromatography (EtOAc/pet. ether, 1:1) to afford the l-gulo lactam
16 (28.2 mg, 33%) and the d-manno lactam 17 (32.5 mg, 38%),
both as colourless oils.
Characterisation for 16 : [a]23D =@57 (c=0.535 in CHCl3) ; 1H NMR
(400 MHz, CDCl3): d=3.36 (dd, J6,6a=4.27, J6a,6b=9.11 Hz, 1H;
CH2(C6)), 3.46 (m, 2H; 6-H, CH2(C6)), 3.57 (m, 1H; 3-H), 3.91 (dd,
J3,4=3.1, J4,5=4.4 Hz, 1H; 4-H), 3.95 (m, 1H; 6-H), 4.08–4.19 (m, 3H;
2VCH2Ph, 5-H), 4.40 (m, 2H; 2VCH2Ph), 4.66 (d, J=12.4 Hz, 1H;
CH2Ph), 4.71 (d, J=12.3 Hz, 1H; CH2Nap), 4.93 (d, J=12.3 Hz, 1H;
CH2Nap), 5.10 (d, J=12.4 Hz, 1H; CH2Ph), 5.83 (br s, 1H; NH), 6.84
(app. d, J=7.05 Hz, 2H; Ph), 7.07–7.45 (m, 16H; Ph, Nap), 7.62 (s,
1H; Nap), 7.72–7.79 ppm (m, 3H; Nap); 13C NMR (100 MHz, CDCl3):
d=52.8 (1C; C-6), 70.3 (1C; CH2(C6)), 72.5 (1C; CH2Nap), 73.6 (1C;
CH2Ph), 73.6 (1C; CH2Ph), 73.7 (1C; CH2Ph), 74.2 (1C; C-5), 74.3
(1C; C-3), 74.8 (1C; C-4), 126.0–126.3 (3C; Nap), 126.8 (1C; Nap),
127.8–128.6 (18C; 3VPh, Nap), 133.2, 133.3, 135.6, 137.0, 137.6,
138.4 (6C; Cq), 171.3 ppm (1C; C=O); HRMS (ESI, +ve): m/z calcd
for C38H37NO5 : 588.2749 [M+H]
+ ; found: 588.2747.
Characterisation for 17: [a]25D =@9.49 (c=0.715 in CHCl3) ; 1H NMR
(400 MHz, CDCl3): d=3.41 (m, 1H; CH2(C6)), 3.54 (m, 2H; 6-H,
CH2(C6)), 3.66 (t, J4,5= J5,6=5.2 Hz, 1H; 5-H), 3.98 (dd, J3,4=2.9, J4,5=
5.0 Hz, 1H; 4-H), 4.18 (d, J3,4=2.9 Hz, 1H; 3-H), 4.38 (d, J=11.6 Hz,
1H; CH2Ph), 4.42–4.49 (m, 2H; 2VCH2Ph), 4.55 (d, J=11.6 Hz, 1H;
CH2Ph), 4.69 (d, J=12.1 Hz, 1H; CH2Ph), 4.74 (d, J=12.2 Hz, 1H;
CH2Nap), 4.88 (d, J=12.2 Hz, 1H; CH2Nap), 5.06 (d, J=12.2 Hz, 1H;
CH2Ph), 5.91 (br s, 1H; NH), 7.08–7.49 (m, 18H; 3VPh, Nap), 7.72–
7.84 ppm (m, 4H; Nap); 13C NMR (100 MHz, CDCl3): d=55.5 (1C; C-
6), 71.5 (1C; CH2(C6)), 72.9 (1C; CH2Nap), 72.9 (1C; CH2Ph), 73.4
(1C; CH2Ph), 73.5 (1C; CH2Ph), 75.0 (1C; C-5), 75.2 (1C; C-3), 77.8
(1C; C-4), 126.1–126.3 (3C; Nap), 127.0 (1C; Nap), 127.8–128.6
(18C; 3VPh, Nap), 133.2, 133.3, 135.5, 137.5, 138.1 (6C; Cq),
169.6 ppm (1C; C=O); HRMS (ESI, +ve): m/z calcd for C38H37NO5 :
588.2744 [M+H]+ ; found: 588.2747.
(3S,4S,5S,6S)-3,5-Bis(benzyloxy)-6-(benzyloxymethyl)-4-(2-naph-
thylmethoxy)piperidin-2-thione (18): Lawesson’s reagent (202 mg,
0.50 mmol) was added to a mixture containing the mannonolac-
tam 17 (98 mg, 0.167 mmol), pyridine (6.7 mL, 0.083 mmol), freshly
activated 4 a molecular sieves and distilled toluene (6 mL) and the
mixture was stirred for 20 h. The mixture was then filtered, stirred
with MeOH (1.68 mL) for 2 h and the solvent removed under re-
duced pressure. The residue obtained was subjected to flash chro-
matography (EtOAc/pet. ether, 20:80) to afford the thionolactam
18 (94 mg, 93%) as a white solid. M.p. 147 8C; [a]23D =@52 (c=
0.215 in CHCl3) ;
1H NMR (400 MHz, CDCl3): d=3.43 (m, 1H;
CH2(C6)), 3.56 (m, 2H; 6-H, CH2(C6)), 3.83 (apt. t, 1H; 5-H), 3.91 (dd,
J3,4=2.6, J4,5=7.2 Hz, 1H; 4-H), 4.42 (d, J3,4=2.5 Hz, 1H; 3-H), 4.44–
4.52 (m, 3H; 3VCH2Ph), 4.68–4.73 (m, 2H; CH2Nap, CH2Ph), 4.79 (d,
J=12.1 Hz, 1H; CH2Nap), 4.83 (d, J=12.0 Hz, 1H; CH2Ph), 5.08 (d,
J=12.1 Hz, 1H; CH2Ph), 7.14–7.52 (m, 18H; 3VPh, Nap), 7.73–7.85
(m, 4H; Nap), 8.13 ppm (br s, 1H; NH); 13C NMR (100 MHz, CDCl3):
d=59.8 (1C; C-6), 70.6 (1C; CH2(C6)), 72.5 (1C; CH2Nap), 73.2 (1C;
CH2Ph), 73.5 (1C; CH2Ph), 73.7 (1C; CH2Ph), 74.2 (1C; C-5), 78.3
(1C; C-4), 79.8 (1C; C-3), 125.9–126.3 (3C; Nap), 126.8 (1C; Nap),
127.8–128.7 (18C; 3VPh, Nap), 133.1, 133.3, 135.4, 137.3, 137.6,
138.0 (6C; Cq), 200.0 ppm (1C; C=O); HRMS (ESI, +ve): m/z calcd
for C38H37NO4S: 604.2516 [M+H]
+ ; found: 604.2524 [] .
(5R,6R,7S,8S)-7-(2-Naphthylmethoxy)-6,8-bis(benzyloxy)-5-(ben-
zyloxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (20) and
(5R,6R,7S,8R)-7-(2-naphthylmethoxy)-6,8-bis(benzyloxy)-5-(ben-
zyloxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (21): Thi-
onolactam 18 (256 mg, 0.424 mmol) was dissolved in aminoacetal-
dehyde dimethyl acetal (0.69 mL, 6.33 mmol) and the mixture
stirred under N2 for 18 h. The mixture was diluted with Et2O
(20 mL) and washed with H2O (2V20 mL) and brine (1V20 mL).
The organic extracts were dried (MgSO4) and the solvent removed
under reduced pressure to afford the amidines 19 as a colourless
residue. p-Toluenesulfonic acid monohydrate (0.14 g, 0.74 mmol)
was added to a solution of the crude amidines in toluene (9.5 mL)
and the mixture was stirred at 60 8C overnight. The mixture was
then diluted with DCM (20 mL) and washed with NaHCO3 (2V
20 mL) and brine (1V20 mL). The organic extracts were dried
(MgSO4), the solvent was removed under reduced pressure and
the residue was subjected to flash chromatography (EtOAc/pet.
ether, 1:1) to afford the glucoimidazole 20 (110 mg, 42% over two
steps) as a colourless oil and the mannoimidazole 21 (83.3 mg,
32% over two steps) as a yellow oil.
Characterisation for 20 : [a]25D = +52 (c=0.315 in CHCl3 ; lit. :
[39] +52
(in CHCl3)) ;
1H NMR (600 MHz, CDCl3): d=3.75 (dd, J5,5a=5.0, J5a,5b=
10.3 Hz, 1H; CH2(C5)), 3.87 (m, 2H; 6-H, CH2(C5)), 4.13 (dd, J6,7=7.5,
J7,8=5.8 Hz, 1H; 7-H), 4.18 (m, 1H; 5-H), 4.45 (app. d, 2H; 2V
CH2Ph), 4.51 (d, J=11.2 Hz, 1H; CH2Ph), 4.78 (d, J7,8=5.8 Hz, 1H; 8-
H), 4.84 (d, J=11.6 Hz, 1H; CH2Ph), 4.86 (d, J=11.2 Hz, 1H; CH2Ph),
4.89 (d, J=11.5 Hz, 1H; CH2Nap), 4.97 (d, J=11.5 Hz, 1H; CH2Ph),
5.19 (d, J=11.5 Hz, 1H; CH2Nap), 7.04 (s, 1H; 2-H), 7.12 (s, 1H; 3-
H), 7.14–7.48 (m, 18H; 3VPh, Nap), 7.68–7.83 ppm (m, 4H; Nap);
13C NMR (125 MHz, CDCl3): d=58.3 (1C; C-5), 68.5 (1C; CH2(C5)),
72.9 (1C; CH2Nap), 73.4 (1C; CH2Ph), 74.3 (1C; CH2Ph), 74.4 (1C;
CH2Ph), 74.5 (1C; C-8), 76.2 (1C; C-6), 82.2 (1C; C-7), 117.4 (1C; C-
2), 126.1–126.9 (3C; Nap), 127.7 (1C; Nap), 127.8–128.6 (18C; 3V
Ph, Nap), 129.5 (1C; C-3), 133.2, 133.4, 135.5, 137.4, 137.7, 138.4
(6C; Cq), 144.2 ppm (Cq, imidazole).
Characterisation for 21: [a]25D =@24 (c=0.24 in CHCl3 : lit. :[39] @20
(in CHCl3)) ;
1H NMR (600 MHz, CDCl3): d=3.57 (dd, J5,5a=7.1, J5a,5b=
10.1 Hz, 1H; CH2(C5)), 3.71 (dd, J5,5a=3.4, J5a,5b=10.1 Hz, 1H;
CH2(C5)), 3.84 (dd, J6,7=9.3, J7,8=3.1 Hz, 1H; 7-H), 4.06 (m, 1H; 5-
H), 4.25 (dd, J5,6=9.3, J6,7=7.2 Hz, 1H; 6-H), 4.39 (m, 2H; 2V
CH2Ph), 4.56–4.66 (m, 3H; 2VCH2Ph, CH2Nap), 4.69 (d, J=12.2 Hz,
1H; CH2Nap), 4.74 (d, J=12.0 Hz, 1H; CH2Ph), 4.78 (d, J7,8=3.0 Hz,
1H; 8-H), 4.96 (d, J=11.2 Hz, 1H; CH2Ph), 6.98 (s, 1H; 3-H), 7.09 (s,
1H; 2-H), 7.17–7.39 (m, 18H; 3VPh, Nap), 7.62–7.74 ppm (m, 4H;
Nap); 13C NMR (125 MHz, CDCl3): d=60.0 (1C; C-5), 68.3 (1C; C8),
70.6 (1C; CH2Nap), 71.2 (1C; CH2(C5)), 71.8 (1C; CH2Ph), 73.3 (1C;
CH2Ph), 74.3 (1C; C-6), 75.0 (1C; CH2Ph), 80.2 (1C; C-3), 119.5 (1C;
C-2), 125.2–126.9 (3C; Nap), 126.7 (1C; Nap), 128.6–127.7 (18C; 3V
Ph, Nap), 129.4 (1C; C-3), 133.2, 133.3, 135.4, 137.6, 138.2, 138.3
(6C; Cq), 143.0 ppm (Cq, imidazole).
(5R,6R,7S,8R)-6,8-Bis(benzyloxy)-5-(benzyloxymethyl)-5,6,7,8-tet-
rahydroimidazo[1,2-a]pyridin-7-ol (22): DDQ (25.2 mg,
0.111 mmol) was added to a solution of the mannoimidazole 21
(22.6 mg, 0.037 mmol) in DCM/H2O (9:1, 1 mL) and the reaction
mixture was stirred at room temperature overnight. DDQ (25 mg,
Chem. Eur. J. 2018, 24, 7464 – 7473 www.chemeurj.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim7471
Full Paper
180
0.11 mmol) was again added and the mixture stirred for 3 days
when TLC analysis (EtOAc/pet. ether, 8:2) indicated complete con-
sumption of the starting material. The mixture was then diluted
with DCM (20 mL), washed with water (3V20 mL) and aq. sat.
NaHCO3 (3V20 mL), dried (MgSO4), filtered and concentrated. The
crude product was purified by flash chromatography (EtOAc/pet.
ether, 80:20 to 100:0) to afford the alcohol 22 (11.7 mg, 67%) as a
yellow oil. [a]24D =@35 (c=0.585 in CHCl3 ; lit. :[40] @6 (in CHCl3)) ;
1H NMR (500 MHz, CDCl3): d=3.64 (dd, J5,5a=5.9, J5a,5b=10.2 Hz,
1H; CH2(C5)), 3.78 (dd, J5,5a=2.5, J5a,5b=10.2 Hz, 1H; CH2(C5)), 4.03
(m, 3H; 7-H, 6-H, 5-H), 4.42 (app. s, 2H; 2VCH2Ph), 4.54 (d, J=
11.2 Hz, 1H; CH2Ph), 4.65 (d, J=11.6 Hz, 1H; CH2Ph), 4.70 (d, J7,8=
3.3 Hz, 1H; 8-H), 4.85 (d, J=11.6 Hz, 1H; CH2Ph), 4.90 (d, J=
11.2 Hz, 1H; CH2Ph), 7.05 (s, 1H; 3-H), 7.13 (s, 1H; 2-H), 7.19–
7.28 ppm (m, 15H; 3VPh); 13C NMR (125 MHz, CDCl3): d=59.1 (1C;
C-5), 70.2 (1C; CH2(C5)), 71.2 (2C; C-8, CH2Ph), 72.4 (1C; C-6), 73.2
(1C; CH2Ph), 74.6 (1C; CH2Ph), 75.3 (1C; C-7), 118.9 (1C; C-2),
127.7–128.5 (15C; 3VPh), 129.6 (1C; C-3), 137.5, 137.7, 137.8 (3C;
Cq), 142.3 ppm (Cq, imidazole).
(5R,6R,7S,8R)-7-(2-O-Acetyl-3,4,6-tri-O-benzyl-a-d-mannopyrano-
syloxy)-6,8-bis(benzyloxy)-5-(benzyloxymethyl)-5,6,7,8-tetrahy-
droimidazo[1,2-a]pyridine (23): A mixture of the alcohol 22
(13.8 mg, 0.029 mmol), 2-O-acetyl-3,4,6-tri-O-benzyl-a-d-mannopyr-
anosyl trichloroacetimidate (5 ;[22] 32.5 mg, 0.051 mmol) and freshly
activated 4 a molecular sieves in toluene (1.5 mL) was stirred at
room temperature for 30 min. Triflic acid (1 mL, 0.011 mmol) was
added to the mixture at @20 8C and the mixture was stirred for
1 h, then at 0 8C for 20 min, and at room temperature for another
20 min, quenched with pyridine (1 drop) and filtered through a
pad of Celite. The solvent was removed under reduced pressure
and the resulting residue was subjected to flash chromatography
(EtOAc/pet. ether/ Et3N 80:19:1) to recover alcohol 26 (6.4 mg) and
afford the disaccharide 23 (12.9 mg, 47%) as a colourless oil.
[a]23D = +7.2 (c=0.175 in CHCl3) ;
1H NMR (600 MHz, CDCl3): d=2.11
(s, 3H; Ac), 3.49 (dd, J5’,5a’=1.7, J5a“,5b’=10.9 Hz, 1H; CH2(C5’)), 3.55
(dd, J5,5a=6.7, J5a,5b=10.2 Hz, 1H; CH2(C5)), 3.63 (dd, J5’,5b’=3.5,
J5a”,5b’=10.8 Hz, 1H; CH2(C5’)), 3.67 (dd, J5,5b=3.2, J5a,5b=10.2 Hz,
1H; CH2(C5)), 3.87 (m, 1H; 5’-H), 3.93 (t, J3’,4’= J4’,5’=9.5 Hz, 1H; 4’-
H), 4.01 (dd, J2’,3’=3.3, J3’,4’=9.5 Hz, 1H; 3’-H), 4.07 (dd, J6,7=9.5,
J7,8=3.1 Hz, 1H; 7-H), 4.13 (1H, m, 5-H), 4.29 (dd, J5,6=7.1, J6,7=
9.5 Hz, 1H; 6-H), 4.41 (m, 2H; 2VCH2Ph), 4.46 (d, J=10.9 Hz, 1H;
CH2Ph), 4.51 (d, J=11.3 Hz, 1H; CH2Ph), 4.54 (d, J=12.0 Hz, 1H;
CH2Ph), 4.57 (d, J=11.3 Hz, 1H; CH2Ph), 4.64 (app. d, 3H, 3V
CH2Ph), 4.81 (d, J2,3=3.1 Hz, 1H; 2-H), 4.84 (m, 2H; 2VCH2Ph), 5.19
(d, J1’,2’=1.6 Hz, 1H; 1’-H), 5.48 (dd, J1’,2’=1.6, J2’,3’=3.3 Hz, 1H; 2’-
H), 7.07 (s, 1H; 3-H), 7.14 (s, 1H; 2-H), 7.08–7.34 ppm (m, 30H; 6V
Ph); 13C NMR (125 MHz, CDCl3): d=21.2 (1C; Me), 60.0 (1C; C-5),
68.5 (1C; C-6’), 69.1 (1C; C-2’), 70.3 (1C; CH2Ph), 70.8 (1C; CH2(C5)),
70.9 (1C; C-8), 72.1 (1C; CH2Ph), 72.4 (1C; C-5’), 73.4 (1C; CH2Ph),
73.7 (1C; CH2Ph), 74.2 (1C; C-4’), 74.4 (1C; C-6), 75.1 (2C; CH2Ph),
78.2 (1C; C-3’), 80.3 (1C; C-7), 100.1 (1C; C-1’), 119.4 (1C; C-2),
127.6–128.7 (30C; 6VPh), 129.5 (1C; C-3), 137.6, 137.7, 137.9,
138.1, 138.2, 138.8 (6C; Cq), 142.6 (Cq, imidazole), 170.4 ppm (1C;
C=O); HRMS (ESI, +ve): m/z calcd for C58H60N2O10 : 945.4321
[M+H]+ ; found: 945.4322.
(5R,6R,7S,8R)-7-(3,4,6-Tri-O-benzyl-a-d-mannopyranosyloxy)-6,8-
bis(benzyloxy)-5-(benzyloxymethyl)-5,6,7,8-tetrahydroimida-
zo[1,2-a]pyridine (24): K2CO3 (1 mg, 0.007 mmol) was added to a
solution of the acetate 23 (13.1 mg, 0.014 mmol) in dry methanol
(0.3 mL) and the resulting suspension was stirred at room tempera-
ture for 6.5 h. The reaction mixture was quenched with acetic acid
(5 mL, 0.087 mmol), the solvent was removed under reduced pres-
sure and the resulting residue was subjected to flash chromatogra-
phy (EtOAc/pet. ether/Et3N 50:49.5:0.5) to afford the alcohol 24
(5.8 mg, 46%) as a colourless oil. [a]24D = +13 (c=0.305 in CHCl3) ;
1H NMR (500 MHz, CDCl3): d=2.40 (d, J2’,OH=2.5 Hz, 1H; OH), 3.49
(dd, J5’,6a’=1.8, J6a“,6b’=10.8 Hz, 1H; 6’-Ha), 3.58 (m, 2H; CH2(C5), 6’-
Hb), 3.70 (dd, J5,5a=3.2, J5a,5b=10.1 Hz, 1H; CH2(C5)), 3.87 (m, 1H;
5’-H), 3.91 (m, 2H; 4’,3’-H), 4.03 (m, 1H; 2’-H), 4.08 (dd, J6,7=9.6,
J7,8=3.1 Hz, 1H; 7-H), 4.13 (1H, m, 5-H), 4.28 (dd, J5,6=7.3, J6,7=
9.6 Hz, 1H; 6-H), 4.40–4.53 (m, 5H; 5VCH2Ph), 4.57–4.68 (m, 5H;
5VCH2Ph), 4.79 (m, 2H; 2VCH2Ph), 4.85 (d, J7,8=3.1 Hz, 1H; 8-H),
5.23 (d, J1’,2’=1.5 Hz, 1H; 1’-H), 7.08 (s, 1H; 3-H), 7.14 (s, 1H; 2-H),
7.11–7.35 ppm (m, 30H; 6VPh); 13C NMR (125 MHz, CDCl3): d=60.0
(1C; C-5), 68.6 (1C; C-6’), 69.0 (1C; C-2’), 70.3 (1C; CH2Ph), 70.7
(1C; C-8), 71.1 (1C; CH2(C5)), 72.0 (1C; C-5’), 72.4 (1C; CH2Ph), 73.4
(1C; CH2Ph), 73.7 (1C; CH2Ph), 74.3 (2C; C-6,3’), 75.1 (2C; CH2Ph),
80.1 (1C; C-4’), 80.4 (1C; C-7), 101.8 (1C; C-1’), 119.3 (1C; C-2),
127.6–128.7 (30C; 6VPh), 129.6 (1C; C-3), 137.6, 137.8, 138.1,
138.3, 138.7 (6C; Cq), 142.7 ppm (Cq, imidazole); HRMS (ESI, +ve):
m/z calcd for C56H58N2O9 : 903.4215 [M+H]
+ ; found: 903.4214.
(5R,6R,7S,8R)-6,8-Dihydroxy-5-(hydroxymethyl)-7-(a-d-manno-
pyranosyloxy)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (2):
Pd(OH)2/C (20%, 24 mg) was added to a solution of the deacety-
lated disaccharide 24 (12.6 mg, 0.014 mol) in EtOAc/MeOH/H2O
(5:17:3, 1.50 mL) and AcOH (0.34 mL). The reaction vessel was filled
with H2 (34 bar) and agitated for 4 days. At this point TLC analysis
(EtOAc/MeOH/H2O, 7:3:2) indicated complete conversion to a
single species along with baseline by-products. The suspension
was filtered through a pad of Celite, the solvent was evaporated
and the resulting residue was subjected to flash chromatography
(EtOAc/MeOH/H2O, 5:2:1) to afford ManManIm (2 ; 2.4 mg, 48%) as
a colourless residue. [a]27D = +13 (c=0.12 in H2O);
1H NMR
(500 MHz, D2O): d=3.57 (t, J3’,4’= J4’,5’=9.8 Hz, 1H; 4’-H), 3.66 (dd,
J5’,6a’=6.3, J6a“,6b’=12.1 Hz, 1H; 6’-Ha), 3.77 (m, 1H; 5’-H), 3.83 (m,
2H; 3’-H, 6’-Hb), 3.91 (m, 1H; 5-H), 3.95 (dd, J5,5a=3.3, J5a,5b=
12.7 Hz, 1H; CH2(C5)), 3.99 (dd, J6,7=10.2, J7,8=3.7 Hz, 1H; 7-H),
4.02 (dd, J1’,2’=3.4, J2’,3’=1.7 Hz, 1H; 2’-H), 4.13 (dd, J5,5b=2.6,
J5a,5b=12.7 Hz, 1H; CH2(C5)), 4.27 (dd, J5,6=8.6, J6,7=10.2 Hz, 1H; 6-
H), 4.97 (d, J7,8=3.7 Hz, 1H; 8-H), 5.23 (d, J1’,2’=1.6 Hz, 1H; 1’-H),
7.01 (s, 1H; 3-H), 7.20 ppm (s, 1H; 2-H); 13C NMR (125 MHz, D2O):
d=59.3 (1C; CH2(C5)), 60.9 (1C; C-5,6’), 63.5 (1C; C-8), 63.9 (1C; C-
6), 66.7 (1C; C-4’), 69.9 (1C; C-2’), 70.3 (2C; C-4,3’), 73.5 (1C; C-5’),
78.1 (1C; C-7), 102.1 (1C; C-1’), 118.3 (1C; C-2), 128.7 (1C; C-3),
144.7 ppm (Cq, imidazole); HRMS (ESI, +ve): m/z calcd for
C14H22N2O9 : 363.1398 [M+H]
+ ; found: 363.1398.
Isothermal titration calorimetry (ITC): The binding affinity of
Man2NH2DMJ (1) to BtGH99 was determined by using a Microcal
iTC200 calorimeter (GE Healthcare/Malvern Instruments). The assay
was carried out at 25 8C with 18V2 mL injections of the inhibitor
(6 mm) titrated into the ITC cell containing 117 mm BtGH99. Owing
to the low affinity of the ligand, which prevented the observation
of a sigmoidal binding isotherm, N was fixed at 1.[41] An initial ITC
experiment was conducted by using 1m inhibitor in the syringe
and 52 mm protein with 24V1.5 mL injections. The dissociation con-
stant (KD), change in enthalpy (DH) and measurement uncertainty
were calculated by using the MicroCal PEAQ-ITC Analysis Software
(Malvern Instruments).
Crystallisation and data collection : BxGH99 protein[10] was crystal-
lised by using the vapour diffusion hanging drop method in 3m
sodium acetate at pH 7.4. Crystals were grown at 19 8C in a 24-well
plate with 500 mL of reservoir solution in each well and sealed with
vacuum grease. The droplet was created by mixing 1 mL of BxGH99
solution (34 mgmL@1 in 25 mm HEPES buffer, pH 7.0, 100 mm NaCl)
with 1 mL of the crystallant solution. Crystals were fished from the
droplet by using a nylon cryoloop, without cryoprotection. Data
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were collected at Diamond Light Source beamline i04 using X-rays
with a wavelength of 0.979 a.
Structure solution and refinement : Images containing diffraction
patterns were indexed and integrated by using DIALS[42] through
xia2.[43] The hkl index of each data set was then matched to a pre-
vious solution in Aimless.[44] Refinement was performed by using
Refmac5[45] and real-space model building in Coot.[46] Model geom-
etry and agreement with electron density were validated in Coot
and Edstats.[47] The quality of the carbohydrates and nitrogen het-
erocycles were verified by using Privateer.[32] The modelling and re-
finement processes were aided by using ccp4i2 interface.[48]
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ABSTRACT: Inhibitor design incorporating features of the
reaction coordinate and transition-state structure has emerged
as a powerful approach for the development of enzyme
inhibitors. Such inhibitors find use as mechanistic probes,
chemical biology tools, and therapeutics. Endo-α-1,2-manno-
sidases and endo-α-1,2-mannanases, members of glycoside
hydrolase family 99 (GH99), are interesting targets for
inhibitor development as they play key roles in N-glycan
maturation and microbiotal yeast mannan degradation, respectively. These enzymes are proposed to act via a 1,2-anhydrosugar
“epoxide” mechanism that proceeds through an unusual conformational itinerary. Here, we explore how shape and charge
contribute to binding of diverse inhibitors of these enzymes. We report the synthesis of neutral dideoxy, glucal and cyclohexenyl
disaccharide inhibitors, their binding to GH99 endo-α-1,2-mannanases, and their structural analysis by X-ray crystallography.
Quantum mechanical calculations of the free energy landscapes reveal how the neutral inhibitors provide shape but not charge
mimicry of the proposed intermediate and transition state structures. Building upon the knowledge of shape and charge
contributions to inhibition of family GH99 enzymes, we design and synthesize α-Man-1,3-noeuromycin, which is revealed to be
the most potent inhibitor (KD 13 nM for Bacteroides xylanisolvens GH99 enzyme) of these enzymes yet reported. This work
reveals how shape and charge mimicry of transition state features can enable the rational design of potent inhibitors.
■ INTRODUCTION
Over 500 000 gene sequences have been discovered encoding
glycoside hydrolases that are grouped into more than 130
families according to the Carbohydrate Active enZyme
classification (CAZy: www.cazy.org).1 Glycoside hydrolases of
family 99 possess two distinct activities: endo-α-1,2-mannosidase
and endo-α-1,2-mannanase. endo-α-1,2-Mannosidases are eu-
karyotic proteins involved in N-linked glycan maturation,
folding, and quality control2−5 and are of clinical significance
as they provide a means for viruses and cancer to evade the effect
of exo-glucosidase inhibitors.5,6 endo-α-1,2-Mannanases are
produced by Bacteroides spp., bacterial residents of the gut
microbiota.7 They facilitate the degradation of dietary yeast
mannan consumed in bread and fermented foods, facilitating the
breakdown of these complex carbohydrates, with beneficial
effects on the gastrointestinal tract and, possibly, mitigating the
symptoms of Crohn’s disease.8 Given the importance of family
GH99 enzymes in N-linked glycan maturation and carbohydrate
processing by the microbiota, the development of inhibitors has
been of particular importance to allow assessment and
manipulation of their roles in these complex processes. In this
work, we investigate several mechanism-inspired inhibitor design
concepts for family GH99 endo-α-1,2-mannanases from the gut
microbiota constituents Bacteroides thetaiotaomicron and Bacter-
oides xylanisolvens; BtGH99 and BxGH99, respectively. Our
results cast light on the importance of structural mimicry of shape
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and charge of species along the reaction coordinate for achieving
potent inhibition of this enzyme family.
Glycosidases that cleave their substrates with retention of
anomeric configuration typically operate through a two-step
mechanism that proceeds via a covalent glycosyl-enzyme
intermediate. Such enzymes utilize enzymatic amino acid
residues that in the first step act as general acid and nucleophile
to assist in departure of the anomeric substituent while
simultaneously substituting the anomeric group; in the second
step the first carboxylate acts as a general base to deprotonate a
nucleophilic water molecule that hydrolyzes the covalent
glycosyl enzyme intermediate (Figure 1A).9,10 Important
exceptions include a range of β-hexosaminidases that perform
catalysis through mechanisms involving neighboring group
participation by the 2-acetamido group of the substrate (Figure
1B).11 These enzymes also operate through a two-step
mechanism: in the first step an amino acid residue acts as a
general acid to assist in departure of the leaving group while the
2-acetamido group performs a nucleophilic attack on the
anomeric center, forming a bicyclic oxazoline/oxazolinium ion
intermediate. In the second step the same amino acid residue acts
as a general base, assisting nucleophilic attack by a water
molecule that opens the oxazolinium ion ring, reforming the 2-
acetamido group and completing the hydrolysis reaction.
Family GH99 enzymes cleave glycosides with an overall
retention of anomeric configuration.12 X-ray structures are
available for GH99 enzymes in complex with a variety of ligands
based on sugar-shaped heterocycles.7,8,12 However, in X-ray
structures of B. xylanisolvens BxGH99 with various substrate-
mimicking ligands, it was not possible to identify an appropriately
positioned enzymatic nucleophile within the typical <3 Å
distance from the reactive anomeric center, leading to the
proposal of a nonclassical mechanism.12 In particular, in
structures of GlcIFG (2) and ManIFG (3) with BxGH99,
there were no close contacts with a likely candidate enzymatic
nucleophile,7,12 at odds with the usual observation of a
carboxylate situated typically 2.6−2.7 Å away in classical
retaining glycosidases. Moreover, in complexes of GlcDMJ (1)
with BxGH99 a conserved carboxyl residue (E333; numbering
refers to BxGH99) was located 2.7 Å from the 2-OH group;12
similar observations extend to the binding of a substrate (α-Man-
1,3-α-ManMU) to the carboxamide mutant BxGH99 E333Q.7
Collectively these data supported the proposal of a two-step
reaction involving in the first step the formation of a bicyclic 1,2-
anhydro sugar intermediate, through E333 acting as a general
base residue to deprotonate the 2-OH and facilitating a
nucleophilic substitution at C1 coincident with departure of
the leaving group, assisted by E336 acting as general acid (Figure
1C).12 In the second step of this proposed mechanism, E333 acts
as a general acid, assisting ring opening of the epoxide, while
E336 acts as a general base, promoting nucleophilic attack by a
water molecule. While such a mechanism lacks precedent in
enzymes, there is strong evidence that the base-catalyzed
solvolysis of 4-nitrophenyl α-D-mannoside and α-mannosyl
fluoride proceed through similar neighboring group participation
mechanisms.13−16 Themost stable conformation of 1,2-anhydro-
β-D-mannose is a 4H5 half-chair; applying the principle of least
nuclear motion, a 4C1→
4E‡→ 4H5 conformational itinerary has
been proposed for the first step of the family GH99 reaction
coordinate.17
Intensive efforts have been invested in the rational develop-
ment of glycosidase inhibitors, and many fundamental principles
have been articulated inspired by our deep mechanistic
understanding of this class of enzyme. Based on pioneering
insights from Pauling18 and Wolfenden,19 it is recognized that a
common principle underpinning catalysis is the selective affinity
of an enzyme for a reaction transition state, relative to the ground
state. Accordingly, inhibitor design by transition state mimicry,
which can take advantage of the high transition state affinity of a
glycosidase, has proven a useful guiding strategy.20 While it is
widely appreciated that perfect transition state mimics are
chemically unstable and thus unattainable, a general design
principle is to develop analogues incorporating features that
mimic the shape and charge of the transition state.20 Three
features have been highlighted for consideration in the
development of effective glycosidase inhibitors: configuration,
conformation and charge.21 Configuration is the simplest to
address and not surprisingly it is usually found that glycosidases
are normally best targeted by inhibitors with stereochemistry
matching that of the substrate. In the case of BxGH99, an enzyme
that has the ability to cleave both α-Glc-1,3-α-Man-OR and α-
Man-1,3-α-Man-OR configured substrates (with a preference for
the latter),7 optimal inhibition is achieved by inhibitors matching
the preferred substrate configuration. Glycosidases typically
operate through transition states with substantial oxocarbenium
ion character, and partial double bond development between O5
and C1, leading to a flattened conformation at the transition
state. Consequently, mimicry of the flattened conformation
expected at the transition state has proven a second effective
strategy, with inhibitors bearing sp2-hybridized atoms at the
anomeric or endocyclic oxygen positions, such as glyconolac-
tones and -lactams, identified as fairly broad spectrum
glycosidase inhibitors. Finally, partial charge development at
C1 and the endocyclic oxygen at the transition state can be
mimicked by the protonated forms of nitrogen-containing
heterocycles, exemplified by deoxymannojirimycin (DMJ) with
Figure 1. (A) Mechanism for a canonical retaining α-glycosidase that
proceeds through a covalent glycosyl-enzyme intermediate. (B)
Mechanism for a retaining β-hexosaminidase involving neighboring
group participation by the 2-acetamido group, via an oxazolinium ion
intermediate. (C) Proposed mechanism for family GH99 α-
mannosidases involving neighboring group participation by the 2-OH
group, via a 1,2-anhydro sugar (epoxide). Numbering is for BxGH99.
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a nitrogen in place of the endocyclic oxygen, and isofagomine
with a nitrogen in place of C1.
Motivated by the unusual mechanism proposed for family
GH99 enzymes and the complexity of their biochemical roles,
our understanding of which should benefit from the develop-
ment of potent inhibitors, we undertook a study of several
inhibitor designs inspired by the concepts of charge and shape
mimicry. GlcDMJ (1), an inhibitor reported by Spiro and co-
workers,22 was the first effective inhibitor of mammalian endo-α-
1,2-mannosidase,6 and was subsequently shown to bind to and
inhibit BxGH99 and BtGH99 (Table 1).12 More potent
inhibition was achieved by GlcIFG (2),12 which also proved to
be a more effective inhibitor than GlcDMJ of mammalian endo-α-
1,2-mannosidase in cell-based studies,23 demonstrating that
varying the position of charge can provide improvements in
potency. Further, upon identification of the Bacteroides spp.
enzymes as preferential endo-α-1,2-mannanases,7,8 we were able
to configurationally match the substrate and develop the
inhibitor ManIFG (3), the most potent inhibitor yet reported
for any GH99 enzyme.7 However, ManIFG and GlcIFG lack the
2-OH group of the substrate and thus cannot benefit from
specific interactions with the putative acid/base E333. Separately,
Spiro and co-workers reported that two other neutral
compounds were almost as effective as GlcDMJ in the inhibition
of mammalian endo-α-1,2-mannosidase, namely, GlcddMan (4)
and GlcGlucal (6).6,24 We were intrigued by these observations
and sought to investigate whether the equivalent configuration-
ally matched species, ManddMan (5) and ManGlucal (7), and
the related cyclohexene derivative (8) were inhibitors of bacterial
GH99 enzymes and to understand how they bind to the enzyme.
■ RESULTS AND DISCUSSION
Synthesis of ManGlucal and ManddMan. ManddMan
(5) and ManGlucal (7) were prepared from α-1,3-mannobiose
(10) (Scheme 1). Acetylation, followed by bromination afforded
mannobiosyl bromide (12), which was converted to the
protected glucal (13) using Zn in MeOH. Zempleń trans-
esterification affordedManGlucal (7). Alternatively, reduction of
13 using H2/Pd−C, followed by Zempleń transesterification
affordedManddMan (5). The preparation of GlcChex (8) will be
described elsewhere.
Binding and 3-D Structural Analyses of Putative
“Shape Mimics”. Dissociation constants for the binding of
compounds 5 and 7 to BtGH99 and BxGH99 were determined
by NMR spectroscopy (Figure S1). The 2D NMR SOFAST-
HMQC spectra of 15N-labeled enzymes determined in the
presence or absence of a saturating amount of the ligands
revealed several H−N peaks that displayed significant chemical
shift perturbations. For instance, new signals for an arginine
residue (assigned as R295 in BxGH99 and R291 in BtGH99 on
the basis of analysis of inter-residue nOes from the 3D-HSQC-
NOESY spectra; see annotation to Figure 4A) appeared during
the titration experiments, which were in slow exchange with the
initial ones in the chemical shift time scale (Figure 2). Therefore,
since the relative intensities of these signals are proportional to
the populations of the bound and unbound forms (see
Experimental Section and Supporting Information (SI)), the
dissociation constants (KD) were readily calculated. The binding
constants are shown in Table 1. No evidence for binding of
GlcChex could be obtained by either NMR or ITC.
In order to analyze the mode of binding of the conformation-
ally restricted compounds, 3-D structures of complexes of
BxGH99 with 7 and 8 were determined by X-ray crystallography
at near atomic (approximately 1.0 Å) resolutions (Table 2, Figure
3A,B). ManGlucal 7 (KD 111 μM) binds to BxGH99 in the −2
and −1 subsites, with the −1 glucal ring intact in a 4H5
conformation. For reasons most likely related to its poor affinity
for the enzyme, we were unable to obtain a complex of GlcChex
with wildtype enzyme, but were serendipitously successful in
obtaining a complex with the catalytically inactive BxGH99
E333Qmutant. In this complex GlcChex 8 also bound in the−2/
−1 subsite with the cyclohexene ring in a 4H5 conformation
(Figure 3B). Relative to ManGlucal, GlcChex suffers both by
replacement of the endocyclic oxygen with methylene and by the
presence of a nonreducing-end glucosyl moiety, the latter of
which is known to reduce binding to the Bacteroides spp. enzymes
by 4−10-fold.7 Owing to the unmeasurable binding of GlcChex,
the synthesis of the mannose analogue was not pursued. The lack
of oxygen atoms within the GlcChex ring means it cannot form
hydrogen bonds with active site residues Y252, E333 or E336.
MS experiments indicated that the compound is not affected by
Table 1. Dissociation Constants for GH99 endo-Mannanase
Inhibitors
KD values (μM)
compd BtGH99 BxGH99 method
1 (GlcDMJ) 24 NDa ITC12
2 (GlcIFG) 0.63 NDa ITC12
3 (ManIFG) 0.14 0.27 ITC6
5 (ManddMan) 53 ± 5 221 ± 11 NMR
7 (ManGlucal) 15 ± 1.9 111 ± 11 NMR
8 (GlcChex) no binding no binding NMR/ITC
9 (ManNOE) 0.03 ± 0.01 0.013 ± 0.002 ITC
aND, not determined.
Scheme 1. Synthesis of ManddMan (5) and ManGlucal (7)
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the enzyme or its variants so the reason for binding to only the
inactive variant is unclear.
Glycals are often effective inhibitors of classical retaining
glycosidases. Inhibition is typically found to be time-dependent,
owing to a chemical reaction in which the conjugate acid of the
nucleophile protonates the enol ether of the glycal, and forms a 2-
deoxy-glycosyl enzyme.25,26 This mode of reactivity has been
exploited to allow the identification of the catalytic nucleophile
by peptide sequencing,25 and the 2-deoxyglycosyl-enzymes are
sufficiently stable to be studied by X-ray crystallography.27 To
date, only two classes of retaining glycosidases have been
identified upon which glycals bind as competitive inhibitors
without exhibiting this mode of reactivity. These are N-
acetylhexosaminidases that use neighboring group participation
and retaining sialidases, and in both cases these enzymes lack a
typical carboxylate nucleophile. Retaining N-acetylhexosamini-
dases use a 2-acetamido group, which is able to catalyze the slow
hydration of the enol ether.30 Retaining sialidases lack a
carboxylate nucleophile capable of protonating the glycal, and
instead use a less acidic tyrosine residue as the catalytic
nucleophile.31 In the case of sialidases, the corresponding glycal
2,3-didehydro-2-deoxy-N-acetylneuraminic acid has been elabo-
rated into the extraordinarily potent inhibitor zanamivir,32 a
clinically used antiinfluenza drug. Despite its potency,
quantitative examination of transition state mimicry by zanamivir
reveals it to be a poor transition state mimic.33 The observation
that ManGlucal binds to BxGH99 without a chemical reaction
despite the retaining mechanism of the enzyme provides further
evidence in favor of the unique neighboring group participation
mechanism proposed for this family.
Binding and 3-D Structural Analyses of ManddMan:
Probing the Role of O2 Interactions. In order to harness the
tighter binding of the bacterial enzymes with a mannoside in the
−2 subsite7 ManddMan (5) was synthesized (Scheme 1). NMR
titration revealed ManddMan to bind to BxGH99 and BtGH99
with KD values of 221 and 53 μM, respectively (Table 1). By
comparison, GlcddMan (4) is an inhibitor for rat endomanno-
sidase6 with an IC50 value of 3.8 μM for inhibition of cleavage of
14C-labeled GlcMan9GlcNAc, only slightly worse than that of
GlcDMJ (1) (IC50 = 1.7 μM). The structure of BxGH99 in
complex with ManddMan was determined at 1.03 Å resolution.
Compound 5 binds in the −2/−1 subsites of the enzyme in an
undistorted 4C1 conformation. This conformation matches that
of the ground state of the substrate, and while this is consistent
with the modest dissociation constant, it is noteworthy that the
tight-binding inhibitor ManIFG 3 also binds in a 4C1 chair.
Design, Synthesis, and Characterization of ManNOE as
a GH99 Inhibitor. As ManIFG (3), ManddMan (5), and
ManGlucal (7) all lack an O2 group, in considering the
contribution of shape and charge to inhibition, it would appear
that the cationic nature ofManIFG contributes most significantly
to inhibition, in spite of its conformational resemblance to the
ground state. We therefore decided that it would be appropriate
to investigate a charged inhibitor based onManIFG that was able
to make the correct O2 interactions, in particular with E333.
Inspired by the work of Bols and co-workers on the development
of noeuromycin, a 2-hydroxy analogue of isofagomine that binds
2−4000 times more tightly than isofagomine to various
glycosidases,34 we therefore synthesized the noeuromycin
derivative, ManNOE. This inhibitor was synthesized by the
regioselective mannosylation of the nitrile diol 1635 by
trichloroacetimidate 15 Scheme 2.36 The sole acetate group of
the glycoside 17 was cleaved by treatment with HCl/MeOH to
afford alcohol 18, and the nitrile group was reduced using BH3·
Me2S, followed by protection as the Boc derivative 19.
Hydrogenolysis of the benzyl ethers of 19 using H2/Pd−C,
and then cleavage of the Boc group with HCl, afforded
ManNOE.HCl (9) [as a mixture of α-hydroxypiperidine and
pyranose isomers (not drawn); see the SI].
Figure 2. Excerpt of the side chain HN ε-arginine region in the 2D
SOFAST-HMQC NMR spectra of 15N-labeled BtGH99 in the absence
(blue) or presence of an excess (top) ofManGlucal (7; red) or (bottom)
ManddMan (5; green). The arrow highlights the chemical shift
perturbation observed for the HN-ε signal corresponding to R295.
Table 2. X-ray Data and Structure Summary
5 (ManddMan) 7 (ManGlucal) 8 (GlcChex) 10 (ManNOE)
10 + M2
(ManNOE + 1,2-α-mannobiose)
resolution (outer
shell) (Å)
76.77−1.03 (1.05−1.03) 76.85−1.07 (1.09−1.07) 39.54−1.2 (1.22−1.2) 76.73−1.14 (1.16−1.14) 57.21−1.05 (1.07−1.05)
Rmerge (outer) 0.052 (0.989) 0.052 (1.748) 0.059 (0.955) 0.051 (1.158) 0.054 (1.314)
Rcryst/Rfree 0.117/0.130 0.124/0.141 0.119/0.137 0.124/0.143 0.115/0.133
rmsd bonds (Å) 0.010 0.011 0.012 0.011 0.013
rmsd angles (deg) 1.53 1.54 1.59 1.50 1.67
PDB code 5M17 5M5D 5MEL 5LYR 5M03
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Isothermal titration calorimetry revealed ManNOE (9) to
bind to BxGH99 with KD = 13 nM, and to BtGH99 with a KD =
30 nM, 17- and 5-fold more tightly than ManIFG (3) to the
respective enzymes, commensurate with improvements seen for
binding of IFG versus NOE for other enzymes,34,37 and
demonstrating that better matching of the substrate by
reinstatement of the 2-OH group absent in the latter compound
provides more effective inhibition (Table 1, Figure S4). 3-D
structures were solved of a binary complex of BxGH99−
ManNOE, and a ternary complex of BxGH99−ManNOE−α-
1,2-mannobiose at resolutions of 1.14 and 1.05 Å, respectively
(Figure 4). The poses of ManNOE in both complexes were
essentially identical and the more informative ternary complex,
with ManNOE in the −2/−1 subsites, and α-1,2-mannobiose in
the +1/+2 subsites will therefore be discussed. The NOE
heterocycle binds in a 4C1 conformation, similar to that seen for
ManIFG with the same enzyme. A close contact with E333 Oδ···
O2 of 2.58 Å is evident, similar to that seen in the complex of
BxGH99 with GlcDMJ (2.54 Å, PDB 4AD3).
Conformational Analyses of Glucal, Chex, ddMan, and
NOE. In order to understand the intrinsic conformational
preferences of the D-glucal, 1,2-dideoxymannose (ddMan),
Chex, and noeuromycin (NOE) inhibitor warheads, so as to help
Figure 3. Stereoview of active site of B. xylanisolvens family GH99 enzyme complexes. (A) BxGH99 with ManGlucal (7), (B) BxGH99-E333Q with
GlcChex (8), and (C) BxGH99 with ManddMan (5). Depicted electron density maps are REFMAC28 maximum-likelihood/σA weighted 2F0 − Fc
syntheses contoured at 1.5σ (0.57, 0.59, and 0.62 eÅ−3, respectively). All panels were assembled using CCP4mg.29
Scheme 2. Synthesis of ManNOE (9)
Figure 4. (A) X-ray structure of ternary complex of BxGH99 with ManNOE (above) and α-1,2-mannobiose (below). The residue used for NMR
titrations, R295, is shown in yellow. 2F0 − Fc map contoured at 1.0 σ (0.42 eÅ−3). The +1 subsite mannose residue electron density is best modeled by
two mannose conformations with 0.6/0.4 occupancy, rotated by about 30° with respect to +2 mannose. (B) Stereoview of ManNOE in the active site.
2F0 − Fc map contoured at 1.5 σ (0.58 eÅ−3). Assembled using CCP4mg.29
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rationalize the conformations observed on-enzyme, we calcu-
lated their conformational free energy landscapes (FELs). FELs
were computed by ab initio metadynamics (see Experimental
Section), and the Cremer−Pople puckering coordinates θ and ϕ
were used as collective variables, yielding a Mercator
representation38 for each inhibitor FEL (Figure 5). The same
procedure has been previously used to analyze the conforma-
tional preferences of related GH inhibitors (mannoimidazole,
glucoimidazole, and IFG).39,40
The FELs of both D-glucal and Chex (Figure 5A,B) exhibit a
main energy minimum centered at 4H5. The free energy well is
quite large and extends through 4E−4H5−E5, with an “arm”
toward B3,O, indicating substantial conformational freedom
around 4H5. There is also a local minimum in the southern
hemisphere, centered at 5H4. However, this is 3 kcal mol
−1 higher
in energy and thus less populated at room temperature.
Interconversion between the two minima is hindered by an 8
kcal mol−1 energy barrier. Therefore, both D-glucal and Chex
display only one main accessible conformation at room
temperature, 4H5, but can readily adopt the nearby
4E
conformation predicted for the transition states leading to and
from the proposed 1,2-anhydrosugar intermediate. These data
suggest that D-glucal and Chex provide good shape mimicry of
the transition state or intermediate for the GH99 catalyzed
reaction.
That both D-glucal and Chex adopt a 4H5 conformation when
complexed to BxGH99 (Table 2 and yellow star in Figure 5A,B)
indicates that the conformational preference of the isolated
molecules are not significantly perturbed on-enzyme. This is also
the case for ddMan, for which the FEL (Figure 5C) is strongly
biased toward the 4C1 chair (the local minima on the equator are
≈8 kcal/mol higher in energy), as observed in the X-ray structure
on-enzyme. However, the FEL of ddMan does not exhibit any
stable minimum around 4H5, thus it cannot be considered a
GH99 transition state shape mimic, and should instead be
considered a mimic of the substrate conformation in the
Michaelis complex.
Figure 5. Conformational free-energy landscapes (FELs, Mercator projection) of isolated D-glucal (A), Chex (B), ddMan (C), and NOE (D),
contoured at 1 kcal mol−1. FELs have been annotated (yellow star) with the inhibitor conformations of ManGlucal 7 (for A), GlcChex 8 (for B),
ManddMan 5 (for C), and ManNOE 9 (for D) that have been observed on-enzyme in this work.
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NOE differs from the other inhibitors considered here as it is a
basic molecule and was therefore considered as both the neutral
(Figure 5D) and protonated species (Figure S5). While the
topographies of the FELs for the two protonation states are
broadly similar, they differ greatly in relative energies, most
importantly for the global and local minima, such that the most
stable state in NOE, a 4C1 chair, becomes the “ring-flipped”
1C4
conformer in protonated NOE. In that case, the two most stable
species, the 1C4 and
1S5 states, are characterized by the presence
of transannular hydrogen bonds between NH2
+ and O6 or O3,
respectively. What then is the most appropriate FEL to consider
in relation to the enzyme-bound state, which is expected to be
protonated, but which in a 4C1 conformation lacks a transannular
hydrogen bond? It is known that in the absence of solvation (in
the gas phase) flexible molecules in low charge states tend to
compensate charge effects by forming stabilizing intramolecular
interactions that do not take place in other environments (e.g., in
solution). For example, low-charge state proteins in the gas phase
tend to adopt more compact structures owing to increased
intramolecular interactions.41 On balance, we consider the FEL
of neutral NOE to be a more relevant representation of the
enzyme-bound conformations, because interactions of the
inhibitor with active site residues prevent the formation of
intramolecular hydrogen bonds that dominate the conforma-
tions of charged species. Accordingly, the FEL displays a wide
main minimum situated close to 4C1 (Figure 5D), and is thus
similar to that of ddMan. TheNOE FEL is also reminiscent of the
one previously computed for the closely related neutral IFG
inhibitor39 (which differs from NOE by the absence of the 2-
hydroxyl group). Interestingly, the transition state region
between the north pole and the equator in NOE (4H3/
4E) is
shifted by 60° in ϕ in ddMan. This is likely due to a vicinal
intramolecular hydrogen bond formed between the 2-OH and
the 3-OH, which stabilizes the 4H3/
4E conformations in NOE;
this interaction is not present in ddMan or IFG as they both lack a
2-OH. Overall, NOEmost closely resembles the conformation of
the substrate in the Michaelis complex and in its protonated state
on-enzyme provides mimicry of an oxocarbenium-ion-like
transition state; it is therefore best considered a “charge”-
mimicking inhibitor with no significant shape mimicry of the
transition state.
■ CONCLUSIONS
The proposed GH family 99 neighboring group participation
mechanism, via a 1,2-anhydro sugar, allows prediction of a 4C1→
4E‡ → 4H5 conformational itinerary for the first step of the
reaction coordinate. The FELs for Glucal and Chex suggest that
when these inhibitor warheads are extended to ManGlucal and
GlcChex, their flattened conformations provide mimicry of the
4E transition state and 4H5 intermediate conformations. Their
nonbasic nature provides shape but not charge mimicry of the
transition state. X-ray structures of these compounds in complex
with BxGH99 revealed them to bind in a 4H5 conformation, most
closely matching the proposed intermediate conformation. The
modest dissociation constant of ManGlucal, and lack of
detectable binding for GlcChex, suggests that shape mimicry of
the intermediate or transition state provides only weak affinity for
the enzyme. On the other hand the FEL for the neutral sugar
ddMan reveals a preference for a 4C1 conformation, and the
corresponding complex of ManddMan with BxGH99 revealed
this compound to bind in the same conformation, albeit with an
affinity relative to ManGlucal 8- or 18-fold worse for Bx or
BtGH99 enzymes, respectively. As ManGlucal, GlcChex and
ManddMan all lack a 2-OH group, these ratios provide an
estimate for the contribution of shape-mimicry of the TS or
intermediate to enzyme binding.
Based on the above analysis, and combined with the previous
discovery that the best inhibitor for GH99 endo-α-mannanases is
ManIFG,7 which provides charge mimicry, but poor transition
state shape mimicry, we were inspired to reinstate the 2-hydroxyl
group missing in this compound. ManNOE was synthesized and
shown to bind to Bx and BtGH99 with KD values of 30 and 13
nM, the most tightly binding ligand for these enzymes yet
reported, and a 20-fold enhancement of affinity relative to
ManIFG. The X-ray structure of ManNOE in complex with
BxGH99 reveals a 4C1 ground-state conformation mimicking the
Michaelis complex, and we conclude that this inhibitor acts
primarily to mimic the charge of the transition state.
■ EXPERIMENTAL SECTION
X-ray Crystallography.Data reduction was performed using xia242
or XDS.43 Data set HKL index was matched to a previous solution using
Aimless44,45 software and FreeR set was generated from BxGH99−
ManddMan data, and then used for every other data set. Initial
polypeptide chain model was obtained from the same previous solution,
refined against BxGH99−ManddMan data and used as starting model
for other structure solutions. Refmac528 with ProSmart was used for
restrained refinement and Coot46 for real-space refinement. During
model rebuilding the Fobs − Fcalc difference map was examined at 3σ.
Validation was performed using Coot and edstats.47 Sugar and
pseudopyranose conformations and density correlation were validated
by Privateer.48,49
Isothermal Titration Calorimetry. ManNOE binding to Bt and
BxGH99 was measured using a MicroCal AutoITC200 instrument
(Malvern Instruments, formerly GE Healthcare) at 25 °C in 25 mM
HEPES pH 7.0, 100 mMNaCl buffer. Protein concentration was kept at
5 μM and ligand concentration at 50 μM. As ManNOE exists as a 5:2
ratio of D-gluco and D-manno NOE isomers; the effective ManNOE
concentration was adjusted accordingly.
2DNMR Titrations.Two-dimensional 1H−15N SOFAST-HMQC50
spectra were recorded at 298 K for 1 h using 15N-labeled BtGH99 and
BxGH99 on a Bruker AVANCE III 800 MHz spectrometer with
cryoprobe. Upon binding of ManGlucal or ManddMan, chemical shift
perturbations were observed in slow exchange regime. A signal
corresponding to Nε-Hε of R295 (numbering based on BxGH99),
and which is close to the enzyme active site, was chosen as binding
reporter. In the case of BxGH99, this signal shifts from δ 7.33, 87.5 ppm
(1H,15N) in the free state to δ 7.41, 87.2 ppm (1H,15N) in the bound
state. Bound and free protein populations at different protein/ligand
ratios were calculated from peak intensities. NMR measurements were
made in 50 mM potassium phosphate pH 7.0, 50 mMKCl with 5%D2O
added. Protein concentration was determined by measuring 280 nmUV
absorbance after denaturing the solution in 6 M guanidinium chloride
(average protein concentration: 58 μM). Ligand concentrations were
cross verified by integrating the 1H peaks against the internal standard
TSP-d4 (Sigma-Aldrich). The NMR data were processed and integrated
using NMRPipe.51 The dissociation constants (KD values) were
estimated using in-house Matlab 2015b scripts, using the following
equation:
=
+ K
[PL]
P
[L]
[L]T D
where L is the free ligand concentration and ([PL]/PT) is the ligand-
bound protein fraction. Duplicate experimental points were used for
error-bar estimation. Errors were propagated using a Monte Carlo
algorithm to estimate the uncertainty in the KD values. A distribution of
KD values (n = 10 000) were obtained from data sets randomly varying
within the error bars, and the standard deviation of was used for the KD
error estimation.
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Quantum Chemical Calculations. To obtain the conformational
free energy landscapes of ddMan, Glucal, Chex, and NOE, quantum
mechanical calculations were performed using density functional theory
basedmolecular dynamics (MD), according to the Car−Parrinello (CP)
method.52 Eachmolecule was enclosed in an isolated cubic box of 12.0 Å
× 12.0 Å × 12.0 Å. A fictitious electron mass of 700 au was used for the
CP Lagrangian and a time step of 0.12 fs was used in all CPMD
simulations. The Kohn−Sham orbitals were expanded in a plane wave
(PW) basis set with a kinetic energy cutoff of 70 Ry. Ab initio
pseudopotentials, generated within the Troullier−Martins scheme, were
employed.53 The Perdew, Burke, and Ernzerhoff generalized gradient-
corrected approximation (PBE)54 was selected in view of its good
performance in previous work on isolated sugars,55 glycosidases,56 and
glycosyltransferases.57
The metadynamics algorithm,58 provided by the Plumed 2 plugin,59
was used to explore the conformational free energy landscape of the
systems, taking as collective variables θ and φ of the puckering
coordinates of Cremer and Pople,60 in the spirit of the pioneering work
by Dowd, French, and Reilly.61 Initially, the height of these Gaussian
terms was set at 0.6 kcal mol−1 and a new Gaussian-like potential was
added every 250 MD steps. Once the whole free energy space was
explored, the height of the Gaussian terms was reduced to half of its
initial value (0.3 kcal·mol−1) and a new Gaussian-like potential was
added every 500 MD steps. The width of the Gaussian terms was set to
0.10 Å. The simulations were stopped when energy differences among
wells remain constant, which was further confirmed by a time-
independent free energy estimator.62 For all molecules, the phase
space was fully explored in less than 60 ps and the simulations were
further extended up to 140 ps for Chex and Glucal, 160 ps for ddMan,
and 240 ps for NOE. The errors in the principal minima, taken as a
standard deviation (SD) from the last 60 ps, are below 0.6 kcal mol−1
(Figure S6).
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The human gastrointestinal tract harbours myriad bacterial species,
collectively termed the microbiota, that strongly influence human health.
Symbiotic members of our microbiota play a pivotal role in the digestion of
complex carbohydrates that are otherwise recalcitrant to assimilation.
Indeed, the intrinsic human polysaccharide-degrading enzyme repertoire is
limited to various starch-based substrates; more complex polysaccharides
demand microbial degradation. Select Bacteroidetes are responsible for the
degradation of the ubiquitous vegetable xyloglucans (XyGs), through the
concerted action of cohorts of enzymes and glycan-binding proteins encoded
by specific xyloglucan utilization loci (XyGULs). Extending recent (meta)
genomic, transcriptomic and biochemical analyses, significant questions
remain regarding the structural biology of the molecular machinery required
for XyG saccharification. Here, we reveal the three-dimensional structures of
an a-xylosidase, a b-glucosidase, and two a-L-arabinofuranosidases from
the Bacteroides ovatusXyGUL. Aided by bespoke ligand synthesis, our analyses
highlight key adaptations in these enzymes that confer individual specificity
for xyloglucan side chains and dictate concerted, stepwise disassembly of
xyloglucan oligosaccharides. In harness with our recent structural characteriz-
ation of the vanguard endo-xyloglucanse and cell-surface glycan-binding
proteins, the present analysis provides a near-complete structural view of
xyloglucan recognition and catalysis by XyGUL proteins.
1. Background
The metabolism of complex carbohydrates in the distal gastrointestinal (GI)
tract is central to human nutrition and health [1,2]. It is widely understood
that a well-balanced human diet consists of a significant proportion of fruits
and vegetables, the cell walls of which are primarily (approx. 90% of the dry
weight) comprised of a structurally diverse array of intrinsically non-digestible
polysaccharides popularly referred to as ‘dietary fibre’ [1–5]. The human
genome is, however, remarkably bereft of genes encoding the enzymes
& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
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necessary to digest the manifold plant polysaccharides we
ingest, with the exception of the a-glucans, amylose and amy-
lopectin, that constitute starch [6]. Even in this case, certain
structurally compact, recalcitrant forms, known as ‘resistant
starches’ (RS), may reach the colon intact [3]. Both RS and the
diverse non-starch polysaccharides (NSP) of plant cell walls
are instead metabolized, to various extents, by our symbiotic
gut microbiota. Microbial fermentation of monosaccharides
in the gut produces short chain fatty acids (SCFAs), which pro-
vide a notable proportion (up to 10%) of our daily caloric
intake. In addition, localized butyrate production is particu-
larly required to maintain a healthy colonic epithelium [7–9].
There is, therefore, intense current research focus on (and con-
siderable popular interest in) potential causal links between
imbalance of the microbiota (dysbiosis) and a wide array of
human diseases, including irritable bowel diseases, persistent
Clostridium difficile infection, metabolic syndrome, diabetes,
atopy and neurological disorders [10–14].
Thus, human health is crucially dependent on the popu-
lation dynamics of the gut ecosystem, which is, in turn,
rooted in the capacity of the microbiota to utilize the complex
carbohydrates that we are otherwise incapable of accessing
[15,16]. Strikingly, many individual microbiotal species,
especially from the phylum Bacteroidetes, possess the genetic
capacity to produce hundreds of predicted carbohydrate-
active enzymes (CAZymes) [6,17]. This tremendous diversity
is directly reflective of the natural structural complexity of
plant, fungal and animal oligosaccharides and polysaccharides
in the human diet [5,16]. Numerous (meta)genomic, tran-
scriptomic and proteomic studies are continuing to provide a
wealth of information on the genetic potential and dynamic
response of the human gutmicrobiomewith regard to complex
carbohydrate catabolism [9,17–22]. However, our functional
understanding of the molecular mechanisms fuelling this eco-
system is currently only in its infancy, due to a comparative
paucity of enzymology and structural biology [23,24].
Indeed, among glycoside hydrolases (GH) from all organisms,
biochemically and structurally characterized examples total
only approximately 5% and 0.5%, respectively, of known
open-reading frames (ORFs) [25]; these values are much
lower for gut bacterial species.
The two dominant phyla in the colon of healthy adult
humans are the Gram-positive Firmicutes and the Gram-nega-
tive Bacteroidetes [26], individual species of which have been
implicated as key contributors to the breakdown of NSP in
the diet [17,19,27,28]. Bacteroidetes are particularly notable
for organizing cohorts of CAZymes and binding, transport
and sensor/regulator proteins into contiguous polysaccharide
utilization loci (PULs) [23,29,30]. Bacteroidetes PUL complex-
ity generally scales with the monosaccharide and linkage
complexity of the cognate substrate, especially with regard to
the number of GHs and polysaccharide lyases (PLs)
[17,19,23]. As such, PULs often encode completemolecular sys-
tems for the specific utilization of individual polysaccharides.
Likewise, intimate coordination of substrate adherence and
initial backbone cleavage at the cell surface, followed by com-
plete oligosaccharide hydrolysis in the confines of the
periplasmic space, represents a particularly elegant evolution-
ary strategy to limit loss of monosaccharides to the competitive
gut environment [31] (figure 1).
Transcending ‘omics’ surveys of the gut microbiota, an
emergingmethodology for the in-depth functional characteriz-
ation of PULs combines bacterial genetics, biochemistry and
enzymology, and structural biology. A growing number of
such system-based approaches have been used to elucidate
the complex molecular details of fructan [36], seaweed por-
phyran [37], yeast mannan [38] and cereal xylan [39]
utilization by symbiotic human gut Bacteroides species. In this
context, we recently reported the characterization of a novel
xyloglucan utilization locus (XyGUL) that confers Bacteroides
ovatus, and species harbouring syntenic XyGULs, with the abil-
ity to utilize this abundant vegetable polysaccharide across
sampled human populations [32]. In this work, the complete
biochemical and crystallographic characterization of the van-
guard endo-xyloglucanase responsible for initiating substrate
backbone cleavage was presented, in addition to biochemical
data revealing the substrate specificity of the six downstream
exo-glycosidases. Together, these data allowed us to outline a
general pathway for dietary xyloglucan saccharification to
monosaccharides for primary metabolism. Until now, how-
ever, molecular-level insight into xyloglucan oligosaccharide
(XyGO) recognition and hydrolysis by these key downstream
enzymes has been lacking. Here, we present the three-
dimensional structures of BoGH31, BoGH43A, BoGH43B and
BoGH3B, expanding our knowledge of the structural determi-
nants required for xyloglucan degradation (figure 1). Our
analyses highlight key adaptations in these enzymes that
confer their specificity for xyloglucan oligosaccharides, while
also providing a rationale for themaintenance of two divergent
genes coding for GH3 enzymes, and similarly two divergent
genes for GH43 family members, within the same PUL.
2. Material and methods
2.1. Cloning, over-expression and structure
determination of BoGH31
For structural characterization, the gene encoding BoGH31 was
recloned from pET21a(GH31) [32] into a modified pET28a
vector (pET-YSBL3C) containing an N-terminal His6-tag for
immobilizedmetal affinitypurification (IMAC)and3C-cleavage
site to allow subsequent removal of the tag [40]. The GH31 ORF
was amplified fromthepET21a(GH31) template and cloned into
linearized pET-YSBL3C using the InFusion-HD cloning kit
(ClonTech), according to the manufacturer’s instructions, to
give pET-YSBL3C(GH31).
Chemically competent Escherichia coli TUNER(DE3) cells
were transformed with the pET-YSBL3C(GH31) vector and
grown in LB medium containing 50 mg ml21 kanamycin at
378C. Once the cells reached an OD600nm of 0.8–1.0, the temp-
erature was lowered to 168C and expression was induced by
the addition of isopropyl b-D-galactopyranoside (IPTG) to a
final concentration of 200 mM and the expression was allowed
to proceed overnight. Cells were harvested by centrifugation at
10 800g for 20 min at 48C. Spent medium was discarded and
the cells were resuspended in 5 volumes of Buffer A
(50 mM HEPES pH 7, 0.3 M NaCl, 10 mM imidazole). Cells
were lysed with four 20 s pulses of sonication at maximum
amplitude in an MSE Soniprep 150 sonicator on ice. Cell
debris was removed by centrifugation at 3900g in a cooled
bench top centrifuge and the cleared lysate was applied
directly to a 5 ml HisTrap FF Crude column (GE Healthcare).
After washing with 5–6 volumes of Buffer A, protein
was eluted with a linear gradient from 0 to 100% Buffer B
(50 mM HEPES pH 7, 0.3 M NaCl, 500 mM imidazole) over
rsob.royalsocietypublishing.org
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20 column volumes, collecting 6 ml fractions. Peak fractions
containing BoGH31 were combined and concentrated to less
than 2 ml using a 50 kDa cut-off Sartorius concentrator
before being applied to a HiTrap 16/60 superdex 200 column
(GE Healthcare), which had been equilibrated with 25 mM
HEPES pH 7, 100 mM NaCl and 1 mM DTT. After a void
volume of 40 ml, 2 ml fractions were collected and those
containing BoGH31 were combined and concentrated using a
BACOVA_RS11515
GH3A GH2 GH31 HTCS-like GH9 SGBP-B SGBP-A(SusD-like)
TBDT
(SusC-like) GH5 GH43A GH43B GH3B
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SGBP-B
SGBP-A
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outer membrane
inner membrane
HTCS-like
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H+
TonB-ExbBD
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( f )
Figure 1. Summary of the xyloglucan saccharification system encoded by the BoXyGUL. (a) Gene organization of the BoXyGUL, coloured with reference to the
proteins shown in subsequent panels. GenBank locus tag numbers are indicated below each gene. (b) endo-Xyloglucanases GH5 (structure from [32]) and GH9
localized to the surface of the cell cleave long xyloglucan polysaccharides into smaller fragments, with glycan capture facilitated by cell-surface glycan-binding
proteins SGBP-A and SGBP-B (structures from [33]). (c) The resulting shorter oligosaccharides are imported into the periplasm via the TonB-dependent transporter
(TBDT) for further processing. (d ) exo-Glycosidases GH31, GH43A, GH43B and GH2 remove pendant xylosyl, arabinofuranosyl and galactosyl side chains. (e) GH3A and
GH3B b-glucosidases act from the non-reducing end liberating individual glucose residues. The oligosaccharides can be further hydrolysed, by these individual
enzymes, into monosaccharides. ( f ) The liberated sugars are imported into the cell and metabolized. See [34] for a detailed summary of XyG side-chain structures;
monosaccharides are represented using standard Consortium of Functional Glycomics symbols [35].
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50 kDa cut-off Sartorius concentrator. Protein concentration
was determined to be 35 mg ml21 as judged by A280nm using
an extinction coefficient of 238735 M21 cm21 and a molecular
weight of 109 815.6 Da.
Crystals ofBoGH31were obtained by hanging drop vapour
diffusion (198C) using 0.2 M potassium thiocyanate, 14–20%
(w/v) PEG-3350 as mother liquor and were used for sub-
sequent structure determination. Crystals were cryo-cooled
for data collection at 100 K by plunging in liquid nitrogen
after a 30 s soak in mother liquor supplemented with 20%
ethylene glycol. Crystals of BoGH31 in complexwith a covalent
inhibitor, 5FIdoF [41,42], were obtained by soaking native crys-
tals in 10 mM (final) 5FIdoF supplemented with mother liquor
for 30 s, immediately prior to cryocooling. Diffraction data for
native BoGH31were collected at Diamond Light Source, beam-
line i04-1 at awavelength of 0.920 A˚, while data for the covalent
5FIdoF complex were collected at beamline i04 (also Diamond
Light Source, l ¼ 0.9795 A˚). All data were indexed and inte-
grated using XDS [43] with all subsequent processing steps
performed using the CCP4 software suite [44]. The structure
was solved by molecular replacement in MOLREP [44] using
the protein chain in PDB entry 2xvg as the search model. An
initial model was generated using ARP-WARP [45] before sub-
sequent model building and refinement were performed in
COOT [46] and REFMAC [47], respectively.
2.2. Cloning, over-expression and structure
determination of BoGH43A
For structural characterization, the gene encoding BoGH43A
was recloned from pET21a [32] into pET28a containing
an N-terminal His6-tag for IMAC. The BoGH43A ORF was
amplified from the pET21a(BoGH43A) template and cloned
into linearized pET28a using the InFusion-HD cloning kit
(ClonTech) according to the manufacturer’s instructions.
Protein expression and purification were performed exactly as
described above for BoGH31. The final BoGH43A sample was
concentrated on a 30 kDa cut-off Sartorius concentrator to
103 mg ml21 as judged byA280nm using an extinction coefficient
of 105 450 M21 cm21 and a molecular weight of 57 965.1 Da.
Crystals of BoGH43A were obtained by hanging drop
vapour diffusion (198C) using 0.1 M Tris pH 7.2–7.8, 0.18 M
magnesium chloride and 12% (w/v) PEG-6000 as mother
liquor and were used for subsequent structure determina-
tion. Crystals were cryo-cooled for data collection at 100 K
by plunging in liquid nitrogen after a 30 s soak in mother
liquor supplemented with 20% ethylene glycol. Crystals of
BoGH43A in complexwithAraDNJandAraLOGwere obtained
by soaking native crystals in 10 mM (final) solutions of respect-
ive compounds supplemented with mother liquor for 60 min,
prior to cryocooling. Diffraction data for native BoGH43A
were collected at Diamond Light Source, beamline i04-1
at a wavelength of 0.920 A˚, while datasets for AraDNJ
and AraLOG complexes were both collected at beamline i03
(l ¼ 0.9795 A˚). All data were indexed and integrated using
XDS [43] with all subsequent processing steps performed
using the CCP4 software suite [44]. The structure was solved
by molecular replacement in PHASER [48] using the protein
chain from previously solved BoGH43B as the search model.
An initial model was generated using BUCCANEER [49,50]
before subsequent model building and refinement were
performed in COOT [46] and REFMAC [47], respectively.
2.3. Over-expression and structure determination
of BoGH43B
Chemically competent E. coli BL21 (DE3) cells were trans-
formed with pET21a(BoGH43B) [32] and grown in LB
medium containing 100 mg ml21 ampicillin at 378C. Once the
cells reached anOD600 of 0.4–0.6, the temperaturewas lowered
to 168C and expression was induced by the addition of IPTG to
a final concentration of 100 mMand the expressionwas allowed
to proceed overnight. Cells were harvested by centrifugation at
10 800g for 20 min at 48C. Spent medium was discarded
and the cells were resuspended in 5 volumes of Buffer A
(50 mM HEPES pH 7, 0.5 M NaCl, 30 mM imidazole). Cells
were lysed with four 20 s pulses of sonication at maximum
amplitude in an MSE Soniprep 150 sonicator on ice. Cell
debriswas removed by centrifugation at 39 000g and the super-
natant was applied directly to a 5 ml HisTrap FF Nickel NTA
column (GE HEalthcare). After washing with five volumes of
Buffer A, protein was eluted with a linear gradient from 0 to
100% Buffer B (50 mMHEPES pH 7, 0.5 M NaCl, 300 mM imi-
dazole) over 20 column volumes, collecting 1.6 ml fractions.
Peak fractions containing BoGH43B were combined and con-
centrated to less than 1 ml using a 30 kDa cut-off Sartorius
concentrator before being applied to a HiTrap 16/60 superdex
200 column (GEHealthcare) which had been equilibrated with
10 mM HEPES pH 7, 250 mM NaCl. After a void volume
of 40 ml, 1.6 ml fractions were collected and those contain-
ing BoGH43B were combined, concentrated and buffer
exchanged with 10 mM HEPES pH 7 on a 30 kDa cut-off
Sartorius concentrator. Protein concentration was determi-
ned to be 10 mg ml21 as judged by A280nm using an
extinction coefficient of 102 790 M21 cm21 and a molecular
weight of 57 243.3 Da.
Crystals of BoGH43B were obtained by hanging drop
vapour diffusion using 0.2 M sodium acetate pH 5, 20–30%
PEG-3350 as mother liquor and they were used for sub-
sequent structure determination. Crystals were cryo-cooled
for data collection at 100 K by plunging in liquid nitrogen
after a 30 s soak in mother liquor supplemented with 20%
ethylene glycol. Diffraction data were collected at Diamond
Light Source, beamline i02 at a wavelength of 0.980 A˚. The
data were indexed and integrated using XDS [43] with all
subsequent processing steps performed using the CCP4 soft-
ware suite [44]. The structure was solved by molecular
replacement in PHASER [48] using the protein chain in
PDB entry 1yrz as the search model. The initial phases
were improved using PARROT [51] and an initial model gen-
erated using BUCCANEER [49,50] before subsequent model
building and refinement were performed in COOT [46] and
REFMAC [47], respectively.
2.4. Over-expression and structure determination
of GH3B
GH3B expression and purification from the pET21a(GH3B)
construct created by Larsbrink et al. [32] was performed as
described above for BoGH43B. The final sample was pre-
pared at 10 mg ml21 as judged by the A280nm using an
extinction coefficient of 142 670 M21 cm21 and a molecular
weight of 86 512.6 Da.
Crystals were obtained by hanging drop vapour diffusion
using 0.2 M sodium acetate and 15–25% PEG-3350 as the
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mother liquor. Crystals were cryo-cooled by plunging in
liquid nitrogen using mother liquor supplemented with 20%
ethylene glycol as the cryo-protectant prior to data collection
at Diamond Light Source, beamline i04-1 at a wavelength of
0.920 A˚. Indexing and integration of diffraction data was per-
formed with XDS [43] with all subsequent data processing
performed using the CCP4 software suite [44]. Data were
phased by molecular replacement in PHASER [48] using the
barley b-glucosidase structure 1ex1 [52] as the search model.
Phase improvement was performed using PARROT [51]
before generation of an initial model using BUCCANEER
[49,50]. Subsequent model building and refinement were
performed in COOT [46] and REFMAC [47], respectively.
TLS refinement using two TLS groups per protein chain was
invoked towards the end of structure refinement.
2.5. Synthesis of arabinofuranosidase inhibitors
2.5.1. General
1H and 13C nuclear magnetic resonance spectra were obtained
on Bruker ARX500 (500 MHz for 1H and 125 MHz for 13C)
or Bruker AV600 (600 MHz for 1H and 150 MHz for 13C)
spectrometers (see the electronic supplementary material).
Mass spectra were recorded with a Waters GCT Premier
spectrometer using electrospray ionization (ES).
2.5.2. (E) and (Z )-2,3,5-Tri-O-acetyl-L-arabinofuranose oxime (2)
Hydroxylamine hydrochloride (240 mg, 3.45 mmol) was
added to a solution of the hemiacetal 1 [53] (610 mg,
2.21 mmol) and pyridine (0.45 ml, 5.5 mmol) in MeOH
(20 ml) and the mixture was stirred at reflux (2 h). Con-
centration of the solution by co-evaporation with toluene
(3  15 ml) followed by flash chromatography of the residue
(6 : 4 EtOAc/hexanes) produced the presumed oxime 2 as a
white solid (575 mg, 94%). Rf 0.40 (7 : 3 EtOAc/hexanes). This
solid was used without further purification.
2.5.3. (Z )-2,3,5-Tri-O-acetyl-L-arabinonhydroximo-1,4-lactone (3)
1,8-Diazabicyclo[5.4.0]undec-7-ene (0.35 ml, 2.3 mmol) was
added to a solution of the oxime 2 (575 mg, 2.08 mmol)
and NCS (305 mg, 2.28 mmol) in CH2Cl2 (21 ml) at 2408C,
in such a way that the temperature did not rise above
2358C, and the resulting mixture was stirred at 2408C for
1 h before being allowed to warm to room temperature over
2 h. The resulting solution was quenched with water and
diluted with CH2Cl2 (20 ml). The organic layer was separated
and washed with water (3  15 ml), brine, dried (MgSO4), fil-
tered and concentrated. Flash chromatography of the residue
(3 : 2 EtOAc/hexanes) yielded the triacetate 3 as a colourless
oil (410 mg, 71%). Rf 0.38 (7 : 3 EtOAc/hexanes).
1H NMR
(500 MHz, CDCl3): d 6.96 (br s, 1H), 5.74 (d, 1H, J ¼
2.8 Hz), 5.22–5.20 (m, 1H), 4.68–4.63 (m, 1H), 4.42 (dd, 1H,
J ¼ 4.5, 12.0 Hz), 4.31 (dd, 1H, J ¼ 6.0, 12.0 Hz), 2.15 (s, 3H),
2.13–2.11 (m, 6H); 13C NMR (125 MHz, CDCl3): d 170.66,
169.89, 169.28, 154.26, 83.37, 74.90, 72.46, 62.39, 20.69, 20.65.
HRMS (ES): m/z ¼ 312.0683; [M þ Na]þ requires 312.0695.
2.5.4. (Z )-L-Arabinonhydroximo-1,4-lactone (AraLOG)
Saturated ammonia in MeOH (5 ml) was added to a solution
of the triacetate 3 (100 mg, 0.346 mmol) in MeOH (5 ml) at
08C and the solution was allowed to stand (08C, 2 h). Concen-
tration of the solution followed by flash chromatography of
the residue (3 : 7 MeOH/EtOAc) yielded the title compound
(39 mg, 68%). Rf 0.37 (3 : 7 MeOH/EtOAc).
1H NMR
(600 MHz, D2O): d 4.70 (d, 1H, J ¼ 7.2 Hz), 4.39–4.33
(m, 1H), 4.20 (dd, 1H, J ¼ 7.2 Hz), 4.00–3.95 (m, 1H), 3.81
(dd, 1H, J¼ 4.8, 13.2 Hz); 13C NMR (150 MHz, D2O): d
159.00, 84.79, 73.95, 73.71, 59.99. HRMS (ES): m/z¼ 164.0551;
[Mþ H]þ requires 164.0559.
2.5.5. (Z )-O-(2,3,5-Tri-O-acetyl-L-arabinosylidene)amino
N-phenylcarbamate (4)
Phenyl isocyanate (50 ml, 0.46 mmol) was added to a solution
of the triacetate 3 (105 mg, 0.363 mmol) and Et3N (0.16 ml,
1.2 mmol) in THF (5 ml) at 08C and the solution was stirred
(08C, 2 h). Concentration followed by flash chromatography
of the residue (1 : 1 EtOAc/hexanes) produced the carbamate
4 as a colourless foam (90 mg, 57%). Rf 0.31 (1 : 1 EtOAc/
hexanes). 1H NMR (500 MHz, CDCl3): d 7.76 (br s, 1H),
7.49–7.44 (m, 2H), 7.36–7.30 (m, 2H), 7.14–7.09 (m, 1H),
5.86 (d, 1H, J ¼ 3.0), 5.24 (dd, 1H, J ¼ 2.5, 3.0 Hz), 4.77–4.74
(m, 1H), 4.46 (dd, 1H, J ¼ 4.5, 12.5 Hz), 4.34 (dd, 1H, J ¼ 6.0,
12.5 Hz), 2.20 (s, 3H), 2.15 (s, 3H), 2.14 (s, 3H); 13C NMR
(125 MHz, CDCl3): d 170.38, 169.70, 168.88, 157.69, 151.21,
137.00, 129.07, 124.14, 119.36, 85.25, 77.16, 74.70, 72.85,
62.02, 20.60, 20.52. HRMS (ES): m/z ¼ 409.1248; [M þ H]þ
requires 409.1247.
2.5.6. (Z )-O-(L-Arabinosylidene)amino N-phenylcarbamate
(AraPUG)
Saturated ammonia inMeOH (5 ml) was added to a solution of
the carbamate 4 (80 mg, 0.20 mmol) inMeOH (5 ml) at 08C and
the solution was allowed to stand (08C, 2 h). The resulting sol-
utionwas concentrated to yield awhite solid. Trituration of the
solid (1 : 4 : 95 H2O/MeOH/EtOAc) yielded the title com-
pound as a white powder (43 mg, 78%). Rf 0.26 (1 : 9 MeOH/
EtOAc). 1H NMR (600 MHz, (CD3)2SO): d 9.78 (br s, 1H),
7.52–7.47 (m, 2H), 7.32–7.26 (m, 2H), 7.03–6.99 (m, 1H),
6.21 (br s, 1H), 5.85 (br s, 1H), 5.14 (br s, 1H), 4.46 (d, 1H, J ¼
4.8 Hz), 4.26–4.22 (m, 1H), 4.01 (m, 1H), 3.71 (m, 1H), 3.58
(m, 1H); 13C NMR (150 MHz, (CD3)2SO): d 163.17, 151.81,
138.71, 128.75, 122.71, 118.58, 88.38, 74.45, 73.77, 59.91.
HRMS (ES): m/z ¼ 283.0928; [M þ H]þ requires 283.0930.
2.6. Binding constant determination for AraF inhibitors
Binding of two arabinofuranosidase inhibitors, AraDNJ and
AraLOG, to BoGH43A and BoGH43B was investigated by iso-
thermal titration calorimetry (ITC) in a MicroCal Auto-
ITC200 system (GE Healthcare/Malvern Instruments).
BoGH43A titrations were performed in 25 mM HEPES pH
7.0, 100 mM NaCl and 1 mM DTT, while BoGH43B titrations
used 25 mM HEPES pH 7.0, 100 mM NaCl. Ligands were
prepared by dilution in the identical buffer as used for
protein sample preparation. AraLOG binding could not be
detected to either BoGH43A or B with titrations performed
in triplicate at 258C, with 1 mM AraLOG titrated into
100 mM pure protein. An interaction between AraDNJ and
both proteins, however, could be detected but appeared to
be weak and so low c-value ITCs were performed to obtain
binding data [54]. Assays were conducted in triplicate at
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258C, with 2 mM AraDNJ titrated into approximately 100 mM
protein (more precise protein concentrations were measured
for each sample immediately before performing the titrations
and these values were used for data fitting in ORIGIN). To
obtain saturation, titrations were split into two runs, the
first consisting of a single 1 ml injection at the start of the
run (discarded during the analysis) followed by 19 2 ml
injections of ligand. At the end of this run 39 ml was removed
from the cell, the syringe was refilled with ligand and the
titration was continued with 20 additional 2 ml injections.
CONCAT32 (MicroCal) was then used to concatenate the
data together into a single titration. To account for heats of
dilution, an additional titration was performed in exactly
the same way, titrating ligand into buffer. These reference
data were then subtracted from all experimental data
which were subsequently used to calculate dissociation
constants (Kd) using the ORIGIN 7 software package by
fixing the N-value at 1.0 during the fitting (MicroCal, see
figure 3d ).
3. Results and discussion
3.1. Structure of the a-xylosidase BoGH31
As with many of the glycoside hydrolase families represented
within the Bo xyloglucan PUL (XyGUL), GH31 forms a large
(currently over 3800 sequences) and functionally diverse col-
lection of enzymes, with many a-glucosidases, a-xylosidases
and a-galactosidases featuring prominently [25]. Within
XyGULs, GH31 a-xylosidases play an essential role removing
xylose from the non-reducing end of processed xyloglucan
oligosaccharides (illustrated in figure 1d ). Such activity per-
mits enzymatic access to the b-1,4-linked glucose moieties
of the XyGO backbone. Indeed, deletion of the gene encoding
GH31 from the XyGUL completely abrogates the ability of
B. ovatus to grow on XyG and XyGOs [32]. Consistent with
this role, the GH31 a-xylosidase present within the Bo XyGUL
(BoGH31) has been shown to be highly active against native
XyGO substrates (XXXG and XLLG, nomenclature according
to [34]), rather than disaccharide-configured activity probes,
such as Xyl-a-PNP [32], despite the presence of optimized
chemical leaving groups requiring little protonic assistance
from the enzyme. These observations suggest substrate binding
by XyGO-active GH31 enzymes to be a both complex and
highly specific process, requiring recognition and occupancy
of multiple sub-sites distal to the catalytic centre.
The crystal structure of BoGH31 was determined to a res-
olution of 1.5 A˚ by molecular replacement using the
coordinates of CjXyl31A, a functional homologue present in
Cellvibrio japonicus (PDB ID: 2xvg, see [55]), as the search
model (for X-ray data collection and refinement statistics,
see the electronic supplementary material, table S1). A struc-
tural comparison of the refined BoGH31 atomic model using
PDBEFOLD [56] revealed close similarity to several other GH31
enzymes, including YicI from E, coli (currently the only other
structurally characterized a-xylosidase [57]). However, by far
the closest structural match to BoGH31 was CjXyl31A (Z
score ¼ 33.1, with RMSD ¼ 1.15 A˚ across 888 matched Ca
positions). As observed for CjXyl31A, BoGH31 presents with
an extensive, modular structure featuring several accessory
domains appended to a well-conserved TIM barrel-like struc-
ture (figure 2a) (for a full description of terms and domain
nomenclature see [55]). The catalytic core of BoGH31 is com-
posed of residues 384 to 758, which form the central (b/a)8
(TIM) barrel fold and harbour the active site (discussed
below). The domains decorating the central catalytic unit
include an N-terminal b-sandwich domain formed by resi-
dues 16 to 213 with additional strands contributed by
residues 363 to 383 when the peptide chain returns from a
PA14 domain (residues 214 to 362). The presence of PA14
has been observed previously for GH31 in CjXyl31A and is
believed to contribute to the recognition and binding of
extended XyGO substrates, as was indicated by NMR spec-
troscopy and molecular docking studies [55,58]. C-terminal
to the central catalytic unit, are two additional domains—the
C-terminal proximal (residues 759–839) and distal (residues
840–954) b-sandwiches. While these accessory regions can
be thought of as distinct subdomains, extensive interactions
and packing of secondary structure elements against the cen-
tral (b/a)8 barrel are strongly suggestive of a low-flexibility,
monolithic structure.
The location of the BoGH31 active site and identity of
the catalytic amino acids were confirmed through analysis
of a covalent enzyme-glycoside intermediate formed bet-
ween crystals of native BoGH31 and a nucleophile-trapping
glycosyl fluoride, 5-fluoro-b-L-idosyl fluoride (5FIdoF)
(figure 2a–c). Within the complex structure, 5FIdoF forms
an a-glycosidic linkage to the side-chain carboxylate of
Asp553 at the centre of the (b/a)8 barrel. 5FIdoF makes
H-bonding interactions to Asp553, Arg613, Asp630 (O2 of
the sugar ring), His709 and a highly coordinated water mol-
ecule positioned between Asp630 and Asp659 (O3) and
Asp441 (O4 and the axially positioned F5 atom). Interest-
ingly, the enzyme-bound 5FIdoF shows significant
distortion away from the 1C4 ground state expected for
L-sugars, appearing in a 1S3 conformation. Such a confor-
mation is also reflected in various other covalent
intermediates with GH31 enzymes, including CjXyl31A in
complex with 5-fluoro-a-D-xylosyl fluoride (5FXylF; also
1S3, see 2xvk [55]) and CjAgd31B, a GH31 a-1,4-transglucosy-
lase, in complex with 5-fluoro-a-D-glucosyl fluoride (5FGlcF;
ligand appears midway between 4C1 and
1S3, see 4ba0 [59]).
The BoGH31 covalent glycosyl-enzyme intermediate struc-
ture lends further support to the role of the PA14 domain in
ligand binding [55]. This domain is in close proximity to the
enzyme-bound 5FIdoF, with the side chain of Trp316 approxi-
mately 6.5 A˚ from the ligand (figure 2d ). Furthermore, a
fortuitously bound HEPES molecule, present in the protein
buffer, can also be observed in the active site pocket below
the plane of the 5FIdoF sugar ring and bridging the gap
between ligand and PA14 (figure 2c). Within xyloglucan
from both dicot and solanaceous species, side-chain xylose
moieties are linked a-1,6 to the glucan backbone. Thus back-
bone sugars occupying the þ1, and other potential positive
sub-sites, would also highly likely be coordinated below the
plane of a21 xyloside, extending across and out of the catalytic
(b/a)8 barrel. The positioning of HEPES therefore appears
prescient, with the piperazine ring of the ligand engaged in a
van der Waals’ stacking interaction with Trp513 (catalytic
domain) from above, and Trp316 of PA14 from below. The
positioning of these aromatic side chains, in addition to numer-
ous other amino acids capable of forming hydrogen bonds,
is highly suggestive of a carbohydrate-binding motif, and
therefore a direct role for PA14 in the coordination of extended
XyGO substrates. A homologous role was proposed for the
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PA14 domain in the structurally similar, XyGO-specific
CjXyl31A from the saprophyte C. japonicus [55,58].
3.2. Structures of the a-L-arabinofuranosidases
BoGH43A and BoGH43B
GH43 is a large and diverse family of CAZymes with mem-
bers identified with b-xylosidase, a-L-arabinofuranosidase,
arabinanase, xylanase, galactan 1,3-b-galactosidase, a-1,2-
L-arabinofuranosidase, exo-a-1,5-L-arabinofuranosidase,
exo-a-1,5-L-arabinanase and b-1,3-xylosidase activities.
There are two GH43 family members represented in the
B. ovatus xyloglucan PUL: BoGH43A and BoGH43B [32].
Both enzymes have demonstrable activity on L-Araf-a-PNP,
though BoGH43A was considerably more active, and both
are thought to be responsible for the removal of pendant arabi-
nofuranoside side chains from solanaceous xyloglucan
substrates, thereby converting S to X for further processing
by the a-xylosidase and other members of the PUL [32].
3.2.1. Synthesis of arabinofuranosidase inhibitors
To aid in the structural characterization of the BoGH43A and
BoGH43B active sites, two new potential inhibitors for these
enzymes were synthesized. The compounds were prepared
incorporating an sp2-hybridized carbon at carbon-1, which
is thought to allow the carbohydrate ring to potentially
adopt a conformation that is similar to the geometry of the
transition state of glycosidase-catalysed reactions [60]. The
synthesis of these inhibitors proceeded from the hemiacetal
1 (scheme 1) [53]. Treatment of the hemiacetal with hydroxy-
lamine hydrochloride yielded the presumed mixture of
oximes 2, which were used without purification and
converted to the hydroximolactone 3 in good overall yield.
The inhibitor AraLOG was then prepared by treating 3 with
saturated ammonia in methanol. Taking the hydroximolac-
tone 3 and treating with phenyl isocyanate furnished the
phenyl carbamate 4. Deprotection of the carbamate 4 under
similar conditions used to prepare AraLOG gave AraPUG
in good yield.
3.2.2. BoGH43A structure
The structure of BoGH43A was determined to be 1.6 A˚ by
molecular replacement using the structure of BoGH43B
described below as the search model (for X-ray data collection
and refinement statistics, see the electronic supplemen-
tary material, table S2). Typical of all GH43s, BoGH43A has
a two-domain architecture, consisting of an N-terminal
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Figure 2. BoGH31 a-xylosidase overall and active site structure. (a) Overall structure of BoGH31 coloured by domain: N-terminal b sandwich in blue, the PA14
domain in purple, TIM barrel domain in gold, C-terminal proximal b-sandwich in green and C-terminal distal b-sandwich in red. The location of the active site
revealed by the covalent glycosyl-enzyme intermediate is shown as sticks coloured by atom type with green carbons. (b) Mechanism of formation of the glycosyl-
enzyme intermediate for the BoGH31–5FIdoF complex. (c) Wall-eyed stereo view of the active site pocket. The active site nucleophile (Asp553) and 5FIdoF are
coloured with green carbon atoms, with the surrounding active site side chains shown with gold carbon atoms. (d ) Wall-eyed stereo view of the wider active site
with the additional fortuitous HEPES molecule (white carbon atoms) shown revealing the likely role of the PA14 domain (purple) in extending the active site pocket
to allow binding of longer xyloglucan oligosaccharides.
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5-bladed b-propeller domain (residues 21 to 321) harbouring
the catalytic active site, and a C-terminal b-sandwich domain
(residues 322 to 522) which is frequently observed, though
can be replaced by carbohydrate binding modules in some
family members (see [61] for example) (figure 3a). Structural
comparisons using PDBEFOLD [56] reveal close overall matches
to other GH43s including XynB from Bacillus subtilis subsp.
subtilis strain 168 (BsXynB, 1yif; Z score ¼ 17.8, with
RMSD ¼ 1.44 A˚ across 478 matched Ca positions) and XynB
from Bacillus halodurans C-125 (BhXynB, 1yrz; Z score ¼ 17.7,
RMSD ¼ 1.45 A˚ across 473 matched Cas), which all share the
same two-domain architecture.
Within the native BoGH43A structure, a TRIS molecule
from the crystallization solution was observed bound in a
shallow, enclosed pocket proposed to form the BoGH43A
21 sub-site. Soaking of native BoGH43A with two putative
inhibitors, AraDNJ [62] and AraLOG, yielded respective
enzyme–ligand complexes, confirming this as the active site
(figure 3b). Disappointingly, no complexes were obtained
with AraPUG, despite the use of high concentrations of
inhibitor. AraDNJ was able to displace TRIS from the 21
sub-site and appeared bound in a low-energy 3E con-
formation typical of iminosugar ‘furanose’ inhibitors. The
side-chain carboxylate of Asp140 (O3 and O4 positions), the
backbone amino group of Ala94 (O4) and the OD2 atom of
Asp34 all directly coordinated the inhibitor (figure 3b).
GH43 members typically contain three highly conserved
acidic residues in their active sites to impart activity [63].
Together with Asp34 as the general base, which activates
water to attack the anomeric carbon, Glu189 is ideally
poised as the general acid, while Asp140 completes the triplet
of residues and is important for modulating the pKa and
orienting the general acid for catalysis. The positions of
these residues are absolutely conserved with other GH43
members.
For the AraLOG complex, repeated soaking at concen-
trations of up to 25 mM AraLOG for several hours failed to
displace TRIS from the 21 sub-site. Rather, AraLOG was
instead observed at the þ1 site, which would normally be
occupied by xylose moieties in the XyGO substrate
(figure 3c). The AraLOG complex therefore highlights key
interactions at this þ1 sub-site, with the inhibitor stacking
against Tyr187 while also H-bonding directly to the side
chains of Glu210 and Glu189. In the light of the inability of
AraLOG to displace TRIS from the active site, ITC (in the
absence of Tris) was used to probe the affinity of both
BoGH43A and BoGH43B (discussed below) for these inhibitors.
AraDNJ binds to BoGH43A with Kd ¼ 35+4 mM (figure 3d),
while AraLOG binding was too weak to be measured using
this technique, consistent with its inability to displace TRIS
during crystal soaking.
3.2.3. BoGH43B structure
Despite significant functional overlap with BoGH43A,
BoGH43B, the second a-L-arabinofuranosidase present in the
BoXyGUL, shares just 41% sequence identity with BoGH43A
and appears to be significantly less active on the substrates
tested [32]. The structure of BoGH43B was determined to
2.3 A˚ resolution by molecular replacement using a b-1,4-
xylosidase from B. halodurans (PDB ID 1yrz) as the search
model (electronic supplementary material, table S3). Remark-
ably, given their apparent differences at the amino acid level,
the structure of BoGH43B appears extremely similar to that of
BoGH43A, which can be superimposed onto BoGH43B, using
GESAMT [44], with an RMSD of 1.24 A˚ over 482 amino acid
residues (figure 4a). Comparison of tertiary folds reveals few
significant differences between the two paralogues, with the
most obvious being the presence of a metal binding site, occu-
pied by calcium, towards the C-terminus of BoGH43B. Such an
equivalent site appears entirely absent within BoGH43A. In
some GH43 members, addition of divalent cations within the
catalytic site has led to increased activity and stability for
these enzymes [64–66]. However, the Ca2þ-binding site in
BoGH43B is located in the C-terminal b-sandwich domain,
on the opposite side of the molecule from the active site, and
similar sites in other family members have not been implicated
in catalysis to date [63].
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Scheme 1. Synthesis of the putative a-L-arabinofuranosidase inhibitors AraLOG and AraPUG as well as the structure of the iminosugar AraDNJ. (a) HONH2.HCl,
C5H5N, MeOH; (b) NCS, DBU, CH2Cl2; (c) NH3/MeOH (d ) PhNCO, Et3N, THF.
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Attempts to obtain structures of BoGH43B in complex
with the same inhibitors used for BoGH43Awere unsuccessful.
ITC was used to determine the affinity of BoGH43B for
AraDNJ and AraLOG. BoGH43B bound AraDNJ with a Kd of
111+6 mM (figure 4c), while the affinity for AraLOG was too
weak to be measured, as observed for BoGH43A. This weaker
binding affinity for AraDNJ also appears consistent with the
lower specific activity of BoGH43B for xyloglucan oligosacchar-
ides when compared to its counterpart [32]. Superposition of
apo-BoGH43B with AraDNJ-BoGH43A reveals that the three
residues implicated in catalysis (Asp38, Asp148 and Glu198
in BoGH43B) are absolutely conserved. The only difference in
the BoGH43B 21 sub-site is the replacement of Phe93
(in BoGH43A) with a tyrosine residue in BoGH43B. The þ1
sub-site occupied by AraLOG in BoGH43A, however, is
considerably different. AraLOG stacks against Tyr187 in
BoGH43A, which is replaced by Ser196 in BoGH43B. This vari-
ation means the active site pocket in BoGH43B is considerably
more open than in its XyGUL paralogue, possibly resulting in
weaker substrate binding affinity and hence lower specific
activity against authentic XyGO substrates. The reasoning that
B. ovatus should harbour two GH43 members in its XyGUL
remainsunclear, but thedifferences in theactive site architecture
away fromthe21 sub-sitemay represent the adaptationof these
enzymes to specific substrate sources, possibly with alternate
Araf structures on XyG branch termini [34].
3.3. Structure of b-glucosidase BoGH3B
GH3 represents a large family of over 8000 sequences in the
CAZy database. Like GH43, there are two GH3 members
(BoGH3A and BoGH3B) present in the Bo XyGUL, both of
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Figure 3. Overall structure and inhibitor binding to BoGH43A a-L-arabinofuranosidase. (a) Overall structure of BoGH43A; the N-terminal catalytic domain is coloured
purple and C-terminal b-sandwich domain is coloured blue. The location of the active site is indicated by the position of AraDNJ shown in stick representation
coloured by atom type with green carbons. (b) Wall-eyed stereo view of the active site in the BoGH43A-AraDNJ complex. The final 2Fo-Fc map for the ligand is
shown contoured at 1s in blue. The hydrogen bonding interactions made by the inhibitor are shown as black dashed lines. (c) Wall-eyed stereo view of the active
site for BoGH43A-AraLOG complex. Binding of the AraLOG inhibitor (yellow carbon atoms) was too weak to displace TRIS (white carbon atoms) from the21 sub-site
and instead occupies þ1, revealing key stacking interactions with Tyr187 and other conserved residues. (d ) ITC thermogram showing the binding of AraDNJ to
BoGH43A in solution giving a Kd of 35+ 4 mM.
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which have been shown to be b-glucosidases with very similar
specific activities. Despite apparently duplicated biochemical
function, the two enzymes appear to have diverged signifi-
cantly, sharing only 27% sequence identity at the amino acid
level [32]. As for the GH43 enzymes, the functional significance
of maintaining two seemingly identical b-glucosidases
remains unclear, and so we aimed to structurally characterize
both orthologues.
While GH3B proved readily amenably to crystallization,
unfortunately, despite intense efforts, a similarly crystalliz-
able form of GH3A could not be produced. The structure of
GH3B was determined to 2.3 A˚ resolution (electronic sup-
plementary material, table S4) by molecular replacement
using the coordinates of barley b-glucosidase (PDB ID:
1ex1, see [52]) as the search model. BoGH3B comprises
a three-domain architecture, consisting of an N-terminal
(TIM) barrel-like domain (residues 26 to 419), a central a/b
sandwich domain (residues 420 to 660) and a fibronectin
type-III (FN-III)-like domain at the C-terminus (residues
661–782) (figure 5a). Structural comparisons using PDBEFOLD
[56] revealed close structural matches to several other GH3
members, the closest match being to a single protomer of a
novel homodimeric GH3 identified in a metagenomic analy-
sis of unnamed soil bacteria (PDBs: 3u48 and 3u4a), with
RMSDs of 1.22 and 1.21 A˚ over 742 and 739 residues, respect-
ively. The dimeric organization of this novel enzyme appears
potentially important for function, with a large, flexible loop
reaching over from one protomer to contact the substrate and
fully assemble the active site of the neighbouring molecule.
There is no suggestion of such a dimerization occurring for
GH3B, which also shows close matches to more typical
monomeric family members including the family 3 b-glucosi-
dases from Thermatoga neapolitana (PDBs: 2x42 and 2x41 with
RMSDs of 1.49 A˚ and 1.50 A˚, respectively, both over 715 resi-
dues) [68] and Hypocrea jecorina/Trichoderma reesei (PDBs: 4i8d
and 3zyz with RMSDs of 1.42 and 1.50 A˚ over 711 and 713
residues, respectively) [69]. All of these structures share the
same three-domain architecture as GH3B, though maximum
identity is no more than 36% at the primary sequence level.
BoGH3B was found to co-purify with glucose in its active
site (figure 5b). This could readily be modelled with a 4C1
chair conformation, highlighting the position of the 21 sub-
site. As is typical for hydrolytic GH3 members, the active
site is formed largely by residues from the core TIM barrel,
with additional interactions further contributed by loops
from the a/b sandwich domain (figure 5b). GH3 members
are well-known to employ the classical Koshland double-dis-
placement, configuration-retaining mechanism [70]. Within
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Figure 4. Structural comparison of BoGH43B with BoGH43A. (a) Overall superposition of BoGH43B (orange) with BoGH43A (purple) revealing a highly conserved
tertiary structure arrangement between the two proteins, even though they share only 41% sequence identity. The largest differences between the two proteins are
restricted to altered positioning of loops linking secondary structure elements. (b) Comparison of the arrangement of the active site residues between BoGH43B
(orange carbons) and BoGH43A (purple carbons). The positions of AraDNJ (green carbons) and AraLOG (yellow carbons) from the BoGH43A structure are shown. The
21 sub-site is mainly conserved between the two proteins, but the þ1 sub-site surrounding the AraLOG ligand is significantly different between BoGH43A and B,
most notably Tyr187, which stacks against AraLOG in BoGH43A, is replaced by Ser196 in BoGH43B. (c) Representative ITC thermogram for the measurement of AraDNJ
binding to BoGH43B. Weaker binding was observed to this enzyme compared to BoGH43A giving a Kd of 111+ 6 mM, providing a rationale for our inability to
obtain a BoGH43B-AraDNJ complex structure.
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Figure 5. Structural analysis of BoGH3B. (a) Overall structure of BoGH3B with the N-terminal TIM-barrel-like domain coloured pink, the a/b sandwich domain
coloured purple and the C-terminal FN-III like domain coloured green. The position of the active site is indicated by the presence of glucose, represented as sticks
with green carbon atoms. (b) Wall-eyed stereo view of the active site in BoGH3B. The final 2Fo-Fc map is shown contoured at 1s as a blue mesh around the glucose
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clipped for clarity. See the electronic supplementary material, figure S1a, for stereo view. (d ) Surface representation of the active site pocket from T. neopolitana GH3
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much more open structure to the active site entrance. See the electronic supplementary material, figure S1b, for stereo view. (e) Structure-based sequence alignment
of BoGH3B with other GH3 family members identified through PDBEFOLD [56]—sections of the alignment have been removed for brevity and breaks are indicated by
diagonal double lines across the alignment (the full sequence alignment can be found in the electronic supplementary material, figure S2). The sequence for
BoGH3A was added to the structural alignment using MAFFT [67]. The secondary structure elements (coloured by domain as previously) and residue numbers
from BoGH3B are indicated along the top of the alignment, with sequence similarity indicated by the shading behind the individual amino acids. Below the aligned
sequences, residues lining the21 sub-site are indicated with green triangles, the catalytic nucleophile and acid/base are indicated by magenta stars and tryptophan
side chains narrowing the active site structure in BoGH3B are shown with orange circles.
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the GH3B active site, putative catalytic nucleophile (Asp314)
and acid/base (Glu534) residues can be observed in close
proximity to the glucose moiety, poised for nucleophilic
attack. Together with residues forming the 21 sub-site, these
interactions appear well conserved, and are maintained in sev-
eral other GH3–glucose complexes [52,68,69]. Away from the
21 sub-site, the exterior surface structure of the GH3B active
pocket deviates from themost closely related homologues, pre-
senting as a more closed structure (figure 5c) similar to that
seen in the distantly related barley b-glucosidase [52]. The
barley enzyme shows quite narrow specificity for b-1,3- and
b-1,4-linked glucans, while closer overall structural matches
to BoGH3B, including the T. neapolitana and H. jecorina
enzymes described above, show much broader activities
against b-1,2-, b-1,3-, b-1,4- and b-1,6-linked disaccharides
[68,69]. Such promiscuous catalytic functionality has been
suggested to result from the more open active site architecture
maintained by this group, allowing diverse linkages and
longer substrates to be accommodated (figure 5d) [68]. GH3B
has significant activity for glucose-only oligosaccharides but
displays far weaker activity on xyloglucan-derived oligos,
which retain their xylose side chains [32]. Similar to barley b-
glucosidase, such observations might suggest that the narrow-
ing of the active site cleft could be responsible for the high
specificity of BoGH3B towards b-1,4-linked glucans.
Analysis of residues forming the GH3B þ1 sub-site
reveals more discernable differences between the two paralo-
gous GH3 members in the BoXyGUL. Sequence analysis
suggests poor conservation of two aromatic residues,
Trp315 and Trp458 (BoGH43B numbering), which through
p-stacking interactions appear to form the narrow GH3B
þ1 sub-site. Although the equivalent to Trp315 is maintained
in GH3A (Trp274), an equivalent to Trp458 appears absent.
We hypothesize therefore that GH3A may present a more
open active site architecture, leading to a similar rationale
in the presence of two GH3 genes to that described above
for the BoXyGUL GH43 paralogues. The closed active site
pocket in GH3B appears to result in higher affinity inter-
actions with longer ‘cello-oligosaccharides’, suggesting that,
as for the two BoGH43 members, subtle differences in the
active site architecture might confer adaptations to specific
substrates. Again, such a proposal would thus provide a
reasonable molecular basis for the maintenance of two
highly similar genes in the same operon.
4. Conclusion
The absence, within the human genome, of genes encoding
enzymes able to metabolize a significant proportion of the
complex polysaccharides present in our own diet has
thrown into sharp relief the importance of our internal
microbial ecosystems [6,71]. The capacity of the gut micro-
biota to utilize these large, intractable molecules dictates
both the composition and correct functioning of this large
non-somatic dietary organ, and as such has a direct and cru-
cial impact upon the health of the human host [72]. Recent
systems biology approaches have highlighted the many
niche roles played by diverse bacteria within the human
microbiota [36–39]. While genomics and metagenomics
initiatives continue apace, generating increasing amounts of
sequence data, further approaches linking sequence data to
biological function are essential to understanding the
adaptations of individual species that allows them to fulfil
their symbiotic role within the human digestive system.
Xyloglucan degradation is a niche occupied primarily by
the Bacteroidetes, and we have previously highlighted the
importance of the specific XyGUL encoded by B. ovatus to
allow this bacterium to compete for nutrients [32]. Central
to this analysis was the tertiary structural characterization
of the vanguard endo-xyloglucanase, BoGH5, that catalyses
the first backbone hydrolysis step required for xyloglucan
polysaccharide metabolism. Recently, we have revealed the
key role that two cell-surface glycan-binding proteins
(SGBPs) encoded by the XyGUL play in XyG utilization
through combined genetic, biophysical and crystallographic
analyses [33].
Here, we have significantly extended our knowledge of the
structural biology of the XyGUL through crystallography of
several exo-glycosidases encoded by the BoXyGUL. This
analysis provided insight into the structural features within
these enzymes that allow them to interact with and degrade
their xyloglucan oligosaccharide substrates. Furthermore,
our analysis highlights differences in the structures of two
GH43 proteins, which display similar biochemical properties
but aremaintainedwithin the operon nonetheless. Such obser-
vations suggest that these paraloguesmayplay subtly different
roles during the degradation of xyloglucans from different
sources, or may function most optimally at different stages in
the catabolism of XyGOs, for example before or after hydroly-
sis of certain side-chain moieties. While we were unable to
determine a structure for BoGH3A, our structural and
sequence analysis of BoGH3B has also allowed us to highlight
further potential differences between these two enzymes
encoded by the operon. Together with existing biochemical
data, our analyses of the three-dimensional structures, andvar-
ious enzyme-inhibitor complexes, of BoGH31, BoGH43A,
BoGH43B and BoGH3B provide molecular-level insight into
the stepwise breakdown of xyloglucan by the BoXyGUL.
Characterization of key adaptions within these enzymes pro-
vides a firm rationale for alternate specificities for XyGOs
that may also allow for more efficient degradation of xyloglu-
can from different sources within the gut.
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2mFo-DFc Maximum likelihood (m, figure of merit)-weighted and
σA(D)-weighted 2Fo-Fc electron density map
aa Amino acid(s)
AA Auxillary activity
Abs280 Absorbance at 280 nm
Abs340 Absorbance at 340 nm
Ac Acetate
ALG5 Asparagine-linked glycosylation 5 homolog
Amp+ With a working concentration of ampicillin added
ASU Asymmetric unit
BCD Bromoconduritol
B factor Debye-Waller factor
BHK Baby hamster kidney
BiP Binding immunoglobulin protein
Bt Bacteroides thetaiotaomicron
BVDV Bovine viral diarrhea virus
Bx Bacteroides xylanisolvens
Cam+ With a working concentration of chloramphenicol added
CBM Carbohydrate-binding module
CC Correlation coefficient
CD4 Cluster of differentiation 4
CDS Coding DNA sequence
CE Carbohydrate esterase
CFU Colony forming unit
Cg Cricetulus griseus
CHO Chinese hamster ovary
CIP Cocaine-induced paranoia
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Cmr Chloramphenicol resistance gene
CNS Central nervous system
CNX Calnexin
COPII Coat protein II
CRT Calreticulin
CspA Cold shock protein CspA
CST Castanospermine
d Deoxy
Da Dalton
DAPI 4’,6-Diamidino-2-phenylindole
dd Dideoxy
DLS Diamond Light Source
DMJ 1-Deoxymannojirimycin
DNA 2-Deoxyribonucleic acid
DNJ 1-Deoxynojirimycin
dNTP Deoxiribonucleotide triphosphate
Dol Dolichol
DOLK Dolichol kinase
DP Differential power
DPAGT1 Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1
DPM Dolichol-P-mannose synthase
DPM1 Dolichyl-phosphate mannosyltransferase subunit 1, catalytic
DTT 1,4-Dithiothreitol
EDEM ER degradation enhancing alpha-mannosidase like protein
EGFP Enhanced green fluorescent protein
Env Envelope
ER Endoplasmic reticulum
ERAD Endoplasmic reticulum-associated degradation
ERGIC ER-Golgi intermediate compartment
ERLEC1 Endoplasmic reticulum lectin 1
ERQC Endoplasmic reticulum quality control
ESI Electrospray ionization
FEL Free energy landscape
FFU Focus forming units
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FOS Free oligosaccharides
fs Frameshift
× g Multiples of gravitational acceleration on the Earth’s surface
Gal d-Galactose
GalNAc N-acetylgalactosamine
GANAB Glucosidase II alpha subunit
GDP Guanosine diphosphate
GF Gel filtration
GH Glycoside hydrolase
Glc d-Glucose
GlcNAc N-acetylglucosamine
GTEx Genotype-Tissue Expression database
GnXMXGn2 GlcNAcXManXGlcNAc2
GXMXGn2 GlcXManXGlcNAc2
GXMX GlcXManX
G protein Glycoprotein (viral protein, not related to G protein coupled to
transmembrane receptors)
GFP Green fluorescent protein
GPI Glycosylphosphatidyinositol
GT Glycosyltransferase
GWAS Genome-wide association study
HepC Hepatitis C
HCV Hepatitis C virus
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
HEPPS 3-[4-(2-Hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid
HIV Human immunodeficiency virus
Hs Homo sapiens
HSP70 70-kDa heat shock protein
HSPA5 Heat shock protein family A member 5
IC50 Inhibitor concentration at which an enzyme catalyzes the reaction at
50% of the rate of the uninhibited reaction
IFG Isofagomine
iGWAS Integrative genome-wide association study
Im Imidazole
208
IPTG Isopropyl β-d-1-thiogalactopyranoside
ITC Isothermal titration calorimetry
IUB International Union of Biochemistry
IUPAC International Union of Pure and Applied Chemistry
Kan Kanamycin
Kan+ With a working concentration of kanamycin added
kd Knockdown
KIE Kinetic isotope effects
KIF Kifunensine
ko Knockout
LB Lysogeny broth
LG Leaving group
LUCA Last universal common ancestor
m Molar
MagT1 Magnesium transporter 1
Man d-Mannose
MAN1A1 mannosidaseGH alpha class 1A member 1
MAN1A2 mannosidase alpha class 1A member 2
MAN1B1 mannosidase alpha class 1B member 1
MAN1C1 mannosidase alpha class 1C member 1
MANEA Mannosidase endo-alpha
MANEAL Mannosidase endo-alpha-like
ManIm Mannoimidazole
MAP1LC3 Microtubule associated protein 1 light chain 3
MCS Multiple cloning site
MDBK Madin-Darby bovine kidney
MDCK Madin-Darby canine kidney
Me Methyl
MES 2-(N-morpholino)ethanesulfonic acid
MGAT1 Mannosyl (alpha-1,3-)-glycoprotein
beta-1,2-N-acetylglucosaminyltransferase
MIB Malonate/imidazole/boric acid (buffer system)
MOGS Mannosyl-oligosaccharide glucosidase
MPDU1 Mannose-P-dolichol utilization defect 1
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MOPSO 2-Hydroxy-3-morpholinopropanesulfonic acid
MQ Ultrapure
MS Mass spectrometry
MUF 4-Methylumbelliferone
Mw Molecular weight
MX ManX
MXGn2 ManXGlcNAc2
N Number of sites (in ITC)
NAD Nicotinamide adenine dinucleotide
NB-DNJ N-butyl-deoxynojirimycin
NCS Non-crystallographic symmetry
ND Not determined
NGS Next-Generation Sequencing
NOE Noeuromycin
NS5A Non-structural protein 5A
OD600 Optical density at 600 nm
ORF Open reading frame
OS9 OS9, endoplasmic reticulum lectin
OST Oligosaccharyltransferase
P Phosphate
PCR Polymerase chain reaction
PDB Protein Data Bank
PL Polysaccharide lyase
PP Pyrophosphate
PEG Polyethylene glycol
PEG-MME Polyethylene glycol monomethyl ether
PNGase Peptide:N-glycosidase
ppm Parts per million
PRKCSH Protein kinase C substrate 80K-H
PtK1 Potorous tridactylus kidney
PTM Post-translational modification
QCV Quality control vesicle
R Radical
Ref. Reference
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RFT1 RFT1 (requiring fifty three 1) homolog
RMS Root mean square
RMSD Root mean square difference or root mean square deviation
RPKM Reads per kilobase per million
RPM Revolutions per minute
RT Room temperature
SARS-CoV Severe acute respiratory syndrome coronavirus
SNP Single-nucleotide polymorphism
SOC Super-optimal broth with catabolite repression
STT3 Catalytic subunit of the oligosaccharyltransferase complex
SW Swainsonine
TEW Anderson−Evans polyoxotungstate [TeW6O24]6−
TGN trans-Golgi network
TLC Thin layer chromatography
TPM Transcripts per million
Tris 2-Amino-2-(hydroxymethyl)propane-1,3-diol
TS Transition state
TSS Transformation and storage solution
Tusc3 Tumor suppressor candidate 3
UDP Uridine diphosphate
UTR Untranslated region
V3 Variable 3
VSV Vesicular stomatitis virus
WT Wild-type
XTP3-B XTP3-transactivated gene B protein
Xyl d-Xylose
y year(s)
ΔH Change in enthalpy
ΔS Change in entropy
Δ# N-terminal truncation before amino acid number #
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